ClinGen Mendelian review progress

Species: human

ClinGen Mendelian review progress

Project and complete gene inventory

Process the nuclear protein-coding Definitive, Strong, Moderate, and Limited tiers
in order, alphabetically within each tier, followed by mitochondrial protein genes,
RNA genes, other HGNC locus types, and undetermined-inheritance follow-ups. Keep
RNA genes in scope and use just fetch-ncrna human SYMBOL (RNAcentral identifiers)
before reviewing their functional literature. The archived HGNC subset records both
locus_group and locus_type: 2,837 protein-coding genes, 35 non-coding RNAs, and
4 other loci (readthrough, immunoglobulin, or T-cell receptor genes).

Existing reviews receive a substantive audit; a COMPLETE status does not certify
assessment against this campaign's current evidence and curation rules. The first
batch already demonstrates the value: AARS1's unconditional monomer claim needed
new disease-mechanism evidence, while AARS2 had untraced propagation judgments and
modeled variant effects presented as measured results. Prioritize new substantive
findings, evidence access, and rule compliance; do not manufacture changes to a
sound review merely to enlarge a PR.

Each gene has one dedicated PR containing its review, supporting research and
references, notes, and session history. Address biological review feedback and
in-scope validation failures on that PR. Mark a gene complete only after the final
review is validated, all actionable PR feedback is addressed, and its PR is merged.
Preserve justified UNDECIDED annotations when evidence remains inaccessible; record
the limitation rather than replacing it with an unsupported decision.

Ownership of shared files

Gene PRs change only the gene, its required cached sources, and gene history.
They do not change this log, the shared inventory, or generated project pages.
The coordinator updates those shared files serially in the project branch after
checking each PR's authoritative state. Only after merge does the coordinator tick
the gene's inventory checkbox and record the merged PR and final validation.
The current concurrency is three gene reviewers, not one worker per inventory row.

Symbol migration checks

Before fetching a gene, check its HGNC ID and both current and historical symbols
against existing review directories. These six source-to-approved mappings are
verified by HGNC prev_symbol, not guessed from aliases:

ClinGen source symbol Approved symbol Existing review at campaign start
BVES POPDC1 Neither symbol has a review
CCDC115 VMA22 Neither symbol has a review
CENPJ CPAP Neither symbol has a review
NAT8L ASPNAT Neither symbol has a review
NDUFA4 COXFA4 genes/human/NDUFA4/NDUFA4-ai-review.yaml
TRAF3IP1 IFT54 Neither symbol has a review

COXFA4 must reuse and migrate the existing NDUFA4 review in its dedicated gene PR;
do not fetch a second review independently under COXFA4. Preserve history through
target.superseded_by as documented in docs/history.md. Recheck the directories
at assignment time because other work may have added or renamed a review.

Human-qualified frontmatter deliberately avoids linking same-symbol reviews in
other species. The initial renderer check demonstrated that bare ALB and CDT1
were ambiguous without a human review, and a symbol found in only one nonhuman
species can be linked there despite the human hint. Missing-human-review warnings
are therefore expected; existing human reviews still link normally.

Completion checkpoint 394 — 2026-10-13 16:34:02 UTC

394 complete / 2,482 remaining in the frozen 2,876-gene catalogue.
This checkpoint adds 44 distinct gene reviews to the merged checkpoint 350.
The cutoff is the final CPT1A merge a9655bc9362c58342ad7a7d077637d13d75a3d49.

The original checkpoint omitted CPAMD8 despite its actual merge at 12:58:43 UTC,
before this cutoff. Its final approval
and detailed review
leave no blocking request. The ordinary merge-group validation
passed before the merge. All 15 approved modes, types and blobs match the merge;
its complete parent delta is exactly those 15 paths. This corrects the omission
without moving the cutoff or counting later merges.

Gene PR Approved head Merge time UTC Merge commit Full PR paths Parent delta
CLN6 #4717 f49f0215585d9810b909d581af9526c39478872a 2026-10-12T17:38:25Z 7d915faa876d 45 45
COL6A3 #4943 ba6811be38e4cc73ebb2dd37b79f3c86e7e06a62 2026-10-12T18:04:09Z e565df36bca8 32 20
CLN3 #4704 9e12ec8e19eec2b044c0531a4395524ef42045af 2026-10-12T18:22:43Z 7daf2acc4586 23 21
CLN8 #4722 7cc52a288ae8cebd9f4df6a09590c2c7ae1b9414 2026-10-12T18:43:29Z dc8bc5b2c884 17 14
CLPP #4733 09926b14b66defe050738f59887c14d26cf26408 2026-10-12T19:05:40Z 8a0bae1506be 8 8
CNTNAP2 #4841 5074fc70da81979f6ef36164659d599a44eedb5c 2026-10-12T19:30:59Z d79d76cb2029 21 21
CNNM4 #4794 7aa3425f439285db4e5a0439afeb6f1f3937bee4 2026-10-12T19:56:02Z 3ebf728a1d03 16 16
COG4 #4872 f65662ed586b956ebb31f3ddafd79196b35c2b5d 2026-10-12T20:13:55Z b22904f4f1d3 16 14
COL7A1 #4944 fa493c4929b48feca35eb4a638911d630bacb90c 2026-10-12T20:35:33Z 3256629f18e0 30 30
COG7 #4912 65c1f800ebbf4ccdff1e839f5e4fa51fb210475c 2026-10-12T20:59:59Z 803eff6ca53b 16 14
COL11A2 #4918 08102d2ca1d0dc0ef6ea79391b63dcc6c0d6125d 2026-10-12T21:24:10Z b59857269769 19 19
CNNM2 #4791 fea62aab7284f228db1e605558f9c98d5108228e 2026-10-12T21:49:22Z 69df7d3a5071 22 19
COL9A1 #4945 81a76e778330d253be6c205b7a104b6e9c36f42e 2026-10-12T22:15:26Z 81a43a71cfc9 19 19
COA8 #4870 201df218220b05783e0056a6a57c9f841846af9a 2026-10-12T22:36:18Z 0325db35893b 16 16
COCH #4871 58ca87ff3e564c7684a6a1cf5694e400ec4061c4 2026-10-12T22:54:22Z ed000cae872f 23 23
COL2A1 #4931 2ada5e144cac4fdea13cb88ffdcd53fab5d7ecc4 2026-10-12T23:13:45Z f1097102f74a 34 29
COL18A1 #4919 a2d6b3f2562ded2bb812b11c6d23292138ee1928 2026-10-12T23:39:25Z c24d195707c7 31 30
COL1A1 #4921 d1d3ae87eff5bb58c2d52e9c891af4afe630fa76 2026-10-13T00:04:36Z 84cdd162363b 47 47
CNGA1 #4746 92905a9d99d85e97c9728c2574f006bc6f7ea5be 2026-10-13T00:31:17Z c494c60261c2 20 11
CLRN1 #4736 a0bc87d865903004de6c52c9c0a5d3d0a34f8187 2026-10-13T00:53:00Z 61ba4c431e43 15 15
COA6 #4857 9398a5da2d1038ffb3752258e1fda2a13c9e450b 2026-10-13T01:11:02Z 1e778d3c04c2 10 10
COL3A1 #4932 bed5cc754e5f5e0f025463389118484cdc091477 2026-10-13T01:36:52Z aa2a8779acf6 41 38
COL10A1 #4916 ac8aaeca977ec833099771024aa3c589075bc5a8 2026-10-13T01:58:34Z 70e5b6140518 16 14
COA7 #4866 16fa6255c3002e5a2bcb518fdf5937ad275a2b01 2026-10-13T02:23:37Z 0ee74dc9812b 10 10
COL9A3 #4946 246a667cd9ec769d6a17c32891e44f290b9009c2 2026-10-13T02:48:51Z 43b6bd2bfe31 14 9
COL4A5 #4936 02d6ec7bad1394e8dee0b0d6baff8088122220a0 2026-10-13T03:11:02Z b15b0e0879c9 20 20
COL4A3 #4934 5f9454f5ea1201dac4686ee0d381a837c824d156 2026-10-13T03:31:57Z 2b4dcaf9c440 28 24
COL5A1 #4937 ef531e3cb41553cdcdb55259518e366a5dd62a02 2026-10-13T03:58:00Z e3fdba00c248 28 24
COL1A2 #4928 f2f01c7e3c1d256f7b70c46522d563e521802557 2026-10-13T04:21:39Z ff03322aaefa 12 11
COL4A4 #4935 e18da0afbb44026347921a93b05ac94e3ad9cfd5 2026-10-13T04:46:58Z 63b613d7142b 19 16
COL5A2 #4938 4711c9d5beb0df208488a18d2f05659e3cf4a97f 2026-10-13T05:07:20Z 1d51d6d60861 22 12
COL4A1 #4933 50af702da83e1714048d0786e56207e73636c2f7 2026-10-13T05:57:31Z b4b1dae2ede9 12 12
CORO1A #4952 ef0febd87a4d4ae888df1ff2bdd911f72fd4ddb3 2026-10-13T07:02:29Z 95c769b1c1cd 31 31
COX10 #4953 2023f325c91b0d9221e0e014363396598a8ab322 2026-10-13T07:27:37Z c1574b6f0d59 9 9
COMP #4951 0725b4c9b97b1dcb3763ef5980ee4244a4658bf4 2026-10-13T07:54:10Z 4d00a6de6693 22 22
COX15 #4956 280c9b4d93a163e226f2a8b801b0a20342ab5aa6 2026-10-13T08:13:10Z a90e9a2afbea 8 8
COX6B1 #4957 b6d6eee9972a97e45df6bf4fab32d52af3804831 2026-10-13T08:31:27Z 233c920c84b2 9 9
COXFA4 #4958 3d79a3ba499e2fee22bbfdd4c766054059a1b8e3 2026-10-13T10:09:26Z 44d5a199822a 17 17
CP #4959 ad2e58fbcefb3f7d3c81cbe4a7c8c0e1b0d1ba5a 2026-10-13T11:29:27Z 4a1c58370745 25 25
CPAMD8 #4961 bae41e46d9198aaed97ef99219318926f6305a14 2026-10-13T12:58:43Z 6e66bd1c2eed 15 15
CPLANE1 #4964 27fb4d6bd9639dceb273d900f93c984775ab12e2 2026-10-13T13:25:46Z a87b3c1a87ed 12 12
CPAP #4963 965cde4fa1039cb92b3fdc59544c84dcea75acf3 2026-10-13T15:43:04Z f44840baae84 23 23
CPOX #4965 ad948941fff6f94a4a50c77a5e23b987c5a0046c 2026-10-13T16:09:26Z df60d6da2141 16 16
CPT1A #4968 c155487423cdd4de0660a760aece8a8ea26ce54e 2026-10-13T16:34:02Z a9655bc9362c 29 29

The complete approved inventories contain 918 path occurrences across these
44 PRs. Each approved path agrees with its actual merged mode, type and blob,
including the confirmed deletion in COXFA4; the 847 parent-relative changes
contain no extra paths. Parent-identical shared paths remain part of the full
inventories but add no integration delta or gene credit. Final approvals and
required checks were verified in the accepted merge evidence for each PR.

COXFA4 is the single catalogue gene HGNC:7687, whose retained ClinGen source
symbol is NDUFA4. PR #4958 removes the obsolete NDUFA4 review path and retains
the COXFA4 review; this is one gene, not two. Its association text is unchanged.

Update 73 appends these 44 genes only. All 72 prior updates, all 235 historical
queue records, all 2,876 catalogue association texts and their order are preserved.
Completed, campaign_audited_merged and the legacy original_merged field are 394;
pending_followups remains zero. Products, follow-up commits and shared sources
do not receive separate credits.

The baseline tracker PR #4962
merged at 2026-10-13 12:31:49 UTC as
fdcbaab48e51,
preserving its approved head 32da3e6e03e8763801f689837ace186af98eba7d. That tracker merge adds no gene credit.
The old checkpoint sections below retain their original observations and wording,
including statuses that were OPEN or QUEUED when recorded.

Publication session history.

Completion checkpoint 350 — 2026-10-12 17:16:33 UTC

350 complete / 2,526 remaining in the frozen 2,876-gene catalog.
CNKSR2 is the sole addition beyond checkpoint 349 and was absent from all 71
prior completion updates. It was unchecked in that preserved proposal.

Gene PR Approved head Approval API merge time UTC Merge commit
CNKSR2 #4781 b7e2e9e807fd9e9467a9a2731ab0daff36b568ac Approved 2026-10-12T17:16:33Z 3f28b1714ba53f3d9173ed69992ac335f7e92c4c

All 12 complete PR paths have identical approved-head and merge blobs. The JSON
completion entry records their hashes and actual parent-relative path accounting.
The later merge is disjoint from every path in the two preceding collagen PRs
and leaves all six published tracker341 preimages unchanged. This is one primary
gene credit, not another credit for either of its genuine history records.

Update 72 adds CNKSR2 alone. Update 71 preserves the separate COL6A1/COL6A2
proofs; all 70 earlier completion updates, all 235 historical queue objects and
all 2,876 association texts remain exact. Completed, campaign_audited_merged and
legacy original_merged are 350; pending_followups remains zero. Tracker #4806's
merge remains recorded in checkpoint349 and adds no gene completion. Earlier
checkpoint observations remain historical; this is the final frozen cutoff for
this proposal.

Publication session history.

Completion checkpoint 349 — 2026-10-12 16:50:16 UTC

349 complete / 2,527 remaining in the frozen 2,876-gene catalog.
COL6A1 and COL6A2 are the only additions beyond frozen checkpoint 347. Both
were unchecked and absent from all 70 prior completion updates.

Gene PR Approved head Approval API merge time UTC Merge commit
COL6A1 #4941 37f1aa9535e07fb7aface73af24c1ca4e44e0044 Approved 2026-10-12T16:33:15Z c5d3421c60bbf6ed470b5c03263ccf70186bcd49
COL6A2 #4942 0d765fa4a87a383ebaa301c913d6f50b79cd2c88 Approved 2026-10-12T16:50:16Z 55a60723b3369503c6b3caaee74208918278cf3d

The complete PR inventories contain 26 COL6A1 paths and 24 COL6A2 paths. Every
approved-head blob equals its merge blob and its blob at the frozen main cutoff.
The JSON completion entry records each Git blob, content hash and parent-relative
delta, including shared caches already identical in a parent. These are two
distinct primary genes; their products, follow-ups and history records add no
separate credit. This checkpoint does not reassess their scientific conclusions.

Update 71 adds both genes. All 70 previous updates remain exact, including the
separate staged checkpoints 343–347. All 235 historical queue objects and all
2,876 association texts remain unchanged. Completed, campaign_audited_merged and
legacy original_merged are 349; pending_followups remains zero.

The previously published checkpoint 341 in tracker #4806 merged at
2026-10-12T16:07:55Z as 6091dffa32318a8f33450bb4c75a240fb5aab07c,
from head 260cf538c0256bcd2d678e45b688d7bffc1cfbfa. Its six publication
files remain exact at the cutoff. Older checkpoint entries retain their original
observations, including the then-queued tracker state. The tracker merge adds no
gene completion. No separate checkpoint348 proposal was created; the first
collagen merge established348 and the second established349.

Publication session history.

Completion checkpoint 347 — 2026-10-12 14:29:11 UTC

347 complete / 2,529 remaining in the frozen 2,876-gene catalog.
COG5 is the sole addition beyond staged checkpoint 346. It was unchecked in
that proposal and absent from all 69 prior completion updates.

Gene PR Approved head Approval API merge time UTC Merge commit
COG5 #4880 e2a1c0cead5759c0e664a98556e5aa4f840ecc6d Approved 2026-10-12T14:29:11Z 5375ac52c3f4c4ab078b8beeec63b11853088bcb

All 14 PR paths have identical approved-head and merge blobs, including the review,
source artifacts and two genuine gene history records. The actual merge delta has
13 paths; PMID_27066481.md was already identical in the parent. The JSON completion
entry retains the exact path/blob/hash evidence. This adds one distinct gene,
not a biological reassessment or separate credits for products or follow-ups.

Update 70 contains COG5 alone. All 69 previous updates remain unchanged, including
update 69 for COG8, update 68 for COG6, update 67 for CNGA3 and update 66 for
CNOT3/CNGB1. All 235 queue objects and 2,876 association texts remain exact; only
COG5's checkbox changes from staged346. Completed, campaign_audited_merged and
legacy original_merged are 347; pending_followups remains zero. Tracker #4806 was
observed queued at 2026-10-12 14:32:13 UTC, at
260cf538c0256bcd2d678e45b688d7bffc1cfbfa; this pending proposal makes no
change to that PR. A genuine session history will be created only at publication.

Publication session history.

Completion checkpoint 346 — 2026-10-12 14:02:20 UTC

346 complete / 2,530 remaining in the frozen 2,876-gene catalog.
COG8 is the sole addition beyond staged checkpoint 345. It was unchecked in
that proposal and absent from all 68 prior completion updates.

Gene PR Approved head Approval API merge time UTC Merge commit
COG8 #4913 cc51fff7d8ccfae688b8d14175ed88311a0a4f49 Approved 2026-10-12T14:02:20Z 1ec0b0b2fed4675003ae94a7684ac6e20296685b

All 15 PR paths have identical approved-head and merge blobs, including the review,
source artifacts and two genuine gene history records. The actual merge delta has
14 paths; PMID_27066481.md was already identical in the parent. The JSON completion
entry retains the exact path/blob/hash evidence. This adds one distinct gene,
not a biological reassessment or separate credits for products or follow-ups.

Update 69 contains COG8 alone. All 68 previous updates remain unchanged, including
update 68 for COG6, update 67 for CNGA3 and update 66 for CNOT3/CNGB1. All 235 queue
objects and 2,876 association texts remain exact; only COG8's checkbox changes from
staged345. Completed, campaign_audited_merged and legacy original_merged are 346;
pending_followups remains zero. Tracker #4806 remains queued at
260cf538c0256bcd2d678e45b688d7bffc1cfbfa; this pending proposal makes no
change to that PR. A genuine session history will be created only at publication.

Publication session history.

Completion checkpoint 345 — 2026-10-12 13:43:54 UTC

345 complete / 2,531 remaining in the frozen 2,876-gene catalog.
COG6 is the sole addition beyond staged checkpoint 344. It was unchecked in
that proposal and absent from all 67 prior completion updates.

Gene PR Approved head Approval API merge time UTC Merge commit
COG6 #4902 8ca06f0e055f23daf52cb9324afb049301091496 Approved 2026-10-12T13:43:54Z 91cea6ec7a9a2f8a77e79ed8636148c65a9ebcf3

All 16 PR paths have identical approved-head and merge blobs, including the review,
source artifacts and two genuine gene history records. The JSON completion entry
retains exact path/blob/hash evidence. This adds one distinct gene completion,
not a biological reassessment or separate credits for products or follow-ups.

Update 68 contains COG6 alone. All 67 previous updates remain unchanged, including
update 67 for CNGA3 and update 66 for CNOT3/CNGB1. All 235 queue objects and 2,876
association texts remain exact; only COG6's checkbox changes from staged344.
Completed, campaign_audited_merged and legacy original_merged are 345;
pending_followups remains zero. Tracker #4806 remains queued at
260cf538c0256bcd2d678e45b688d7bffc1cfbfa; this pending proposal makes no
change to that PR. A genuine session history will be created only at publication.

Publication session history.

Completion checkpoint 344 — 2026-10-12 13:25:41 UTC

344 complete / 2,532 remaining in the frozen 2,876-gene catalog.
CNGA3 is the sole addition beyond staged checkpoint 343. It was unchecked in
that proposal and absent from all 66 prior completion updates.

Gene PR Approved head Approval API merge time UTC Merge commit
CNGA3 #4750 d003c2986007378390e4dcd50d9f57df773d4056 Approved 2026-10-12T13:25:41Z b55d5643c7ba3064cf073f9d7452dadcd6b1ebed

All 26 PR paths have identical approved-head and merge blobs, including the review,
source artifacts and three genuine gene history records. The JSON completion entry
retains their exact path/blob/hash evidence. This adds one distinct gene completion,
not a new biological assessment or credit for each product, follow-up or history.

Update 67 appends CNGA3 while preserving update 66 for CNOT3/CNGB1 verbatim as a
parsed object, all earlier updates, all 235 queue objects and all 2,876 association
texts. Only the CNGA3 checkbox changes relative to the staged343 proposal.
Completed, campaign_audited_merged and legacy original_merged are 344;
pending_followups remains zero. The approved tracker PR #4806 remains queued at
260cf538c0256bcd2d678e45b688d7bffc1cfbfa; this is a pending proposal and does
not alter that PR. A genuine session history will be created only at publication.

Publication session history.

Completion checkpoint 343 — 2026-10-12 01:01:00 UTC

343 complete / 2,533 remaining in the frozen 2,876-gene catalog.
CNOT3 and CNGB1 are the only new completions beyond checkpoint 341. Both were
unchecked in tracker revision 260cf538c0256bcd2d678e45b688d7bffc1cfbfa and absent from its completion additions.

Gene PR Approved head Approval API merge time UTC Merge commit
CNOT3 #4826 69afb67456dff36741d9a7726fae178bad481908 Approved 2026-10-12T00:28:15Z 5d0b91e92a2fb621ceda58b58961b06f8dfdc888
CNGB1 #4772 2e5deeaf8b0738188afee353988fa40e864ad03f Approved 2026-10-12T01:01:00Z d9f82bb33f6e1ee2b9a65520a05263f30d6ddc13

The accepted merge qualifications compare all 24 CNOT3 PR paths and all 29 CNGB1
PR paths with the approved revisions. Sixteen and 27 paths, respectively, were
new integration changes; eight and two shared paths were already identical in
the merge parent. All 31 CNOT3 and 26 CNGB1 cached/local references were checked.
The JSON completion entry retains exact paths, blob identities, hashes, approvals
and successful check receipts. This tracker amendment adds no biological claims.

Exactly two catalog checkboxes change. All 2,876 association texts, frontmatter,
235 queue objects, 65 prior completion entries and previous progress text remain
unchanged. Update 66 is appended to identical JSON mirrors. Completed,
campaign_audited_merged and legacy original_merged are 343; pending_followups is
zero. Existing counter definitions and earlier checkpoint scope remain in force.

Publication session history.

Completion checkpoint 341 — 2026-10-11 23:54:55 UTC

341 complete / 2,535 remaining in the frozen 2,876-gene catalog.
CNOT1 is the sole new completion. It was unchecked at the actual pending tracker
revision 7d5112b980bd82bf7af5eb2e4d99685780df40f0 and absent from its 64 completion additions.

Gene PR Approved head Approval API merge time UTC Merge commit
CNOT1 #4820 3c61cc26ebcf933ee1318ecab60303ed71b426d6 Approved 2026-10-11T23:54:55Z 9ce0404b697131c6465edbea9af026a5a4a00cf5

Approval was submitted at 2026-10-11T18:48:45Z on the final head.
The exact-head approval resolves the earlier blocking review. Remaining suggestions
were explicitly non-blocking. The required test and reviewer workflow both succeeded before merge:

Merge queue integration completed at the API time above. The 27 changed PR paths,
complete six-file gene directory, and all 35 cache/local reference objects (32 PMID
caches, two Reactome entries and the cited source-evidence file) are identical at
the approved head and actual merge. All 27 PR paths are also actual integration changes; none was omitted as already present. Captured main equals that merge. The JSON
completion entry records paths, Git blob IDs and SHA-256 hashes; no scientific
claims or new primary-source readings are added by this tracker update.

Exactly one catalog checkbox changes. All 2,876 association texts, frontmatter,
235 queue objects, 64 earlier completion entries, prior progress text and existing
history records are preserved. Update 65 is appended to identical JSON mirrors.
The counts completed, campaign_audited_merged and legacy original_merged are
341; pending_followups remains zero. Neither pending reviews nor tracker commits
add completions. Existing checkpoint scope and counter definitions remain in force.

Checkpoint 341 session history.

Completion checkpoint 340 — 2026-10-11 23:13:41 UTC

340 complete / 2,536 remaining in the frozen 2,876-gene catalog.
CNGB3 is the sole new completion. It was unchecked at the actual pending tracker
revision 8e0400093727037c8250f2b7ec1c4536ab8ea74b and absent from its 63 completion additions.

Gene PR Approved head Approval API merge time UTC Merge commit
CNGB3 #4768 a040afa672fab99d939b91d24bba1108754fcfb0 Approved 2026-10-11T23:13:41Z f6bb52a1888bb449150cfee7bae168e1e6578570

Approval was submitted at 2026-10-11T18:29:02Z on the final head.
The exact-head approval resolves the earlier blocking review. Remaining suggestions
were explicitly non-blocking. The required test and reviewer workflow both succeeded before merge:

Merge queue integration completed at the API time above. The 18 changed PR paths,
complete six-file gene directory, and 10 referenced PMID caches are identical at
the approved head and actual merge. All 18 PR paths are also actual integration changes; none was omitted as already present. Captured main equals that merge. The JSON
completion entry records paths, Git blob IDs and SHA-256 hashes; no scientific
claims or new primary-source readings are added by this tracker update.

Exactly one catalog checkbox changes. All 2,876 association texts, frontmatter,
235 queue objects, 63 earlier completion entries, prior progress text and existing
history records are preserved. Update 64 is appended to identical JSON mirrors.
The counts completed, campaign_audited_merged and legacy original_merged are
340; pending_followups remains zero. Neither pending reviews nor tracker commits
add completions. Existing checkpoint scope and counter definitions remain in force.

Checkpoint 340 session history.

Completion checkpoint 339 — 2026-10-11 12:44:47 UTC

339 complete / 2,537 remaining in the frozen 2,876-gene catalog.
CNTN2 is the sole new completion. It was unchecked at the actual pending tracker
revision 14a07a782e17fdd094b283f76c0f2824c9c73487 and absent from its 62 completion additions.

Gene PR Approved head Approval API merge time UTC Merge commit
CNTN2 #4830 d6e14551e979eb3200bc214dcc629d6c617e666c Approved 2026-10-11T12:44:47Z eeccfc52335ab3ea5e4f16f9c30daa4eb308405b

Approval was submitted at 2026-10-11T12:21:03Z on the final head.
ROOT read the complete approval and detailed review; remaining suggestions were
optional. The required test and reviewer workflow both succeeded before merge:

Squash merge completed at the API time above. The 26 changed PR paths,
complete six-file gene directory, and 20 referenced PMID caches are identical at
the approved head and actual merge. All 26 PR paths are also actual squash changes; none was omitted as already present. Captured main equals that merge. The JSON
completion entry records paths, Git blob IDs and SHA-256 hashes; no scientific
claims or new primary-source readings are added by this tracker update.

Exactly one catalog checkbox changes. All 2,876 association texts, frontmatter,
235 queue objects, 62 earlier completion entries, prior progress text and existing
history records are preserved. Update 63 is appended to identical JSON mirrors.
The counts completed, campaign_audited_merged and legacy original_merged are
339; pending_followups remains zero. Neither pending reviews nor tracker commits
add completions. Existing checkpoint scope and counter definitions remain in force.

Checkpoint 339 session history.

Completion checkpoint 338 — 2026-10-11 11:03:24 UTC

338 complete / 2,538 remaining in the frozen 2,876-gene catalog.
CLN5 is the sole new completion. It was unchecked at the actual pending tracker
revision b268c1432f697b432dc39b6da1b5b985fc0895e2 and absent from its 61 completion additions.

Gene PR Approved head Approval API merge time UTC Merge commit
CLN5 #4710 c3358f58561a2067a67f4f62a644f1700a4c0cf8 Approved 2026-10-11T11:03:24Z b7934f19c0fc20c5f57601b41a87fc02850082d6

Approval was submitted at 2026-10-11T10:50:13Z on the final head.
ROOT read the complete approval and detailed review; remaining suggestions were
optional. The required test and reviewer workflow both succeeded before merge:

Squash merge completed at the API time above. The 26 changed PR paths,
complete six-file gene directory, and 25 referenced PMID caches are identical at
the approved head and actual merge. All 26 PR paths are also actual squash changes; none was omitted as already present. Captured main equals that merge. The JSON
completion entry records paths, Git blob IDs and SHA-256 hashes; no scientific
claims or new primary-source readings are added by this tracker update.

Exactly one catalog checkbox changes. All 2,876 association texts, frontmatter,
235 queue objects, 61 earlier completion entries, prior progress text and existing
history records are preserved. Update 62 is appended to identical JSON mirrors.
The counts completed, campaign_audited_merged and legacy original_merged are
338; pending_followups remains zero. Neither pending reviews nor tracker commits
add completions. Existing checkpoint scope and counter definitions remain in force.

Checkpoint 338 session history.

Completion checkpoint 337 — 2026-10-11 10:33:02 UTC

337 complete / 2,539 remaining in the frozen 2,876-gene catalog.
CLCN5 is the sole new completion. It was unchecked at the actual pending tracker
revision 0314bf1973a88ddab8c71030db41203b30205dc1 and absent from its 60 completion additions.

Gene PR Approved head Approval API merge time UTC Merge commit
CLCN5 #4686 b44200220f3dd257ea0980f29d22ddcf077f110e Approved 2026-10-11T10:33:02Z d0f37ace6af1e18e19b58afbda935e2f753110a5

Approval was submitted at 2026-10-11T10:09:54Z on the final head.
ROOT read the complete approval and detailed review; remaining suggestions were
optional. The required test and reviewer workflow both succeeded before merge:

Squash merge completed at the API time above. The 18 changed PR paths,
complete six-file gene directory, and 11 referenced PMID caches are identical at
the approved head and actual merge. The squash changes 13 paths; five shared
files were already identical in its parent and are preserved. Captured main equals that merge. The JSON
completion entry records paths, Git blob IDs and SHA-256 hashes; no scientific
claims or new primary-source readings are added by this tracker update.

Exactly one catalog checkbox changes. All 2,876 association texts, frontmatter,
235 queue objects, 60 earlier completion entries, prior progress text and existing
history records are preserved. Update 61 is appended to identical JSON mirrors.
The counts completed, campaign_audited_merged and legacy original_merged are
337; pending_followups remains zero. Neither pending reviews nor tracker commits
add completions. Existing checkpoint scope and counter definitions remain in force.

Checkpoint 337 session history.

Completion checkpoint 336 — 2026-10-11 10:15:33 UTC

336 complete / 2,540 remaining in the frozen 2,876-gene catalog.
CLCN4 is the sole new completion. It was unchecked at the actual pending tracker
revision 4ad06a72170d5ce10eaff72e510491243a21973b and absent from its 59 completion additions.

Gene PR Approved head Approval API merge time UTC Merge commit
CLCN4 #4681 156891895a65241cb02212ab69125151a4b792b3 Approved 2026-10-11T10:15:33Z 38b117f6c544544dd9034bb1fd9ed12f25a08e21

Approval was submitted at 2026-10-11T09:59:49Z on the final head.
ROOT read the complete approval and detailed review; remaining suggestions were
optional. The required test and reviewer workflow both succeeded before merge:

Automatic squash merge completed at the API time above. The 22 changed PR paths,
complete six-file gene directory, and 13 referenced PMID caches are identical at
the approved head and actual merge. Captured main equals that merge. The JSON
completion entry records paths, Git blob IDs and SHA-256 hashes; no scientific
claims or new primary-source readings are added by this tracker update.

Exactly one catalog checkbox changes. All 2,876 association texts, frontmatter,
235 queue objects, 59 earlier completion entries, prior progress text and existing
history records are preserved. Update 60 is appended to identical JSON mirrors.
The counts completed, campaign_audited_merged and legacy original_merged are
336; pending_followups remains zero. Neither pending reviews nor tracker commits
add completions. Existing checkpoint scope and counter definitions remain in force.

Checkpoint 336 session history.

Completion checkpoint 335 — 2026-10-11 08:23:41 UTC

335 complete / 2,541 remaining in the frozen 2,876-gene catalog.
CLDN16 is the sole new qualifying completion. It was unchecked in the actual
pending tracker334 proposal and absent from all 58 prior completion additions.
The two rounds of its gene review count as one audit, with no additional count
for products or justified UNDECIDED decisions.

Gene PR Approved head Approval API merge time UTC Merge commit
CLDN16 #4700 0005e0722bc3720721c81c3fb4384afc655ddc65 Approved 2026-10-11T08:23:41Z 72f77443344b3bdd8f49d54f237b85b4d70fa0a3

The exact-head approval was submitted at 2026-10-11T08:01:10Z.
The reviewer explicitly resolved both mandatory issues and approved the final
source-scoped magnesium and partner-dependent adhesion decisions. Suggestions
about a new term, boolean wording and optional core cargo specificity are nonblocking.
The approval noted that tests were still running; the final gate independently
verified both required checks succeeded before the merge:

The complete final review, detailed comment and empty review-thread set were
read. No actionable objection remains. ROOT's actual merge and publisher-state
receipts are reused without another merge or workflow retry. This checkpoint
makes no new scientific claim or primary-source reading claim.

Exact content and source proof

All 19 changed PR paths have identical approved-head, merge and captured-current-main
blobs, including both gene histories and all added publication caches. The complete
six-file CLDN16 directory is also identical at those three commits. All 11 referenced
PMID cache pairs match; the unchanged source annotations and ancillary reference
identities remain those of the approved gene review. Exact paths, Git object IDs,
SHA-256 hashes and sizes are recorded in queue update 59.

The gene cutoff is 72f77443344b3bdd8f49d54f237b85b4d70fa0a3, API merged at 2026-10-11T08:23:41Z.
Its Git commit time is recorded separately as 2026-10-11T09:23:40+01:00.
The later applicability snapshot f057b5f28fd4eff091a80d1e1bb7a72c1b1136d3 adds no completion.

Pending tracker baseline and preservation

The baseline is the actual open tracker334 #4806
head 68ca45f3b459de78ed4c7ef4326a21993f160030. Its queue is byte-identical to the already verified tracker334 proposal;
the prior 334-gene evidence is reused, not reconstructed from a stale main-branch
page and not recounted. The baseline tracker is pending, not described as merged.
The coordinator will amend that PR only after reviewing this isolated delta.

Exactly one checkbox changes. All 2,876 association texts, frontmatter, 235 queue
objects, 58 prior completion updates, unrelated queue metadata and the complete
prior progress text remain exact. Update 59 is appended and the two JSON mirrors
are identical. The nine existing parent-page session links and all 152 project
history records present at the baseline are preserved. ROOT alone creates and
validates the new session record; this proposal does not rewrite any history.

Counts are 335 for completed, campaign_audited_merged and legacy
original_merged, 0 for pending_followups, and 2,541 remaining.
No other open or newly merged gene is counted by this frozen amendment. In particular,
CLPP and FH remain unchecked under the preserved checkpoint334 scope.

Ordinary frontmatter tests and both project renders compare the baseline and
proposal using the same authenticated current-main renderer and complete gene-review
context. Missing-review availability warnings must remain identical; availability
alone is never completion. Final check counts are recorded in the proposal handoff.

Checkpoint 335 session history.

Completion checkpoint 334 — 2026-10-11 06:08:52 UTC

334 complete / 2,542 remaining in the frozen 2,876-gene catalog.
CHEK2, CHAMP1, CHN1, CIITA, CIB2, CHD3, CHD4, CHRNA1, CHRNA4, CISD2 and CLDN14
are eleven distinct completions beyond checkpoint 323. Every gene was unchecked
in that actual merged tracker and absent from its prior completion additions.
Each counts once after its first qualifying substantive audit; products, repeated
follow-ups, DRAFT status and justified uncertainty add no extra counts or holds.

Gene PR Approved head Approval API merge time UTC Merge commit
CHEK2 #4599 30679cb6be4eadff942500ba2ca7b3f403faeef4 Approved 2026-10-10T23:45:01Z d6a01fd305ee7d7fdc6fbc2d1c7a72eff02c8835
CHAMP1 #4569 8260449b4cc8fa36662f9962d9ab0db92da6a472 Approved 2026-10-11T00:13:02Z 3b771a1473998724cead92201d9c97c2ba2c27f1
CHN1 #4607 3c4842dbfea343d3906067e8134796d9ee7ad8ec Approved 2026-10-11T00:14:03Z 405c9880e95895ba19e80e4c7cdff193ef2c81b6
CIITA #4670 4b7eb79c5400331d0d7da27e0f7bff885adf24df Approved 2026-10-11T01:08:53Z a783a11b511f3591d5e8c65643f0cce5a5ac2ade
CIB2 #4657 c4454c5300ad3ede6d5840b7a4b6abd010df88e2 Approved 2026-10-11T01:30:43Z 272b1676c210ef2b0124d4c443679cad40886796
CHD3 #4587 54454f7071c2a8d594df30a2e4252eab72f31167 Approved 2026-10-11T03:14:30Z f8337fea41c734214bea2c20b927d275a14bddc5
CHD4 #4589 f72a9310a39ddf15b465e423aacbb52ef6818146 Approved 2026-10-11T03:52:34Z 5907529e17896a411a4a3189ba1258e6f86df88c
CHRNA1 #4611 46fb369be19bd1c2143fe00f4d2a02116ba08533 Approved 2026-10-11T04:30:24Z 74044c73dede57c71d69c52af72cb0e0fa7a538e
CHRNA4 #4630 773f99e05d03a6564bc922767d31b0097535c89d Approved 2026-10-11T04:37:31Z e597d4b125bc07507d5d636e76e2c631a062e89f
CISD2 #4673 8616575159a579b480a8cda060988c88fbd6a04d Approved 2026-10-11T05:36:17Z 6d2064d1ce862a8e2c601657c52eb2ba17369257
CLDN14 #4693 1b0fe59a6da31228619e53fc2a7eecc3a4862260 Approved 2026-10-11T06:08:52Z 0a6db3106b108a9001acebd41df887c750b41faf

All eleven approvals are attached to the stated heads, and both required checks
completed successfully before the corresponding merges. Final feedback remains
identical to the prior merge captures, with no unresolved review threads. Prior
completion-verification packets are reused at their stated scope; their eight
mutation-free verifiers pass again. CISD2 and CLDN14 have separate actual-merge
receipts and reviewed-file proofs. Remaining reviewer suggestions are nonblocking;
this tracker does not reopen their gene reviews or claim new primary-source reads.

Actual content and source checks

Gene Changed PR paths Complete gene-directory files Referenced cached-source pairs Gene-tree OID at head, merge and cutoff
CHEK2 20 6 56 d785335b2538644c97dc640e7b95009f97844f6b
CHAMP1 13 8 14 a283916c79c7cf5770f725290656311424afce56
CHN1 18 6 16 0b7bc02c021a8c029965176bdd104d971ba409ff
CIITA 24 6 20 b06a24540a9d6db2ad82717ae5b4464efee62601
CIB2 19 6 16 77a02aa95c4140225ca90f4ecf9c974e67bb702d
CHD3 35 6 47 a017b166fbe5fdec9f7a617dcfc280ea5caa76ed
CHD4 40 6 61 5115269721dffdc4ba099e0e52ed2c845b58041c
CHRNA1 36 6 16 28f1f6628ec5eb301ae7fc1f6adb86c8afeae190
CHRNA4 35 6 29 900c8dccabc8a3b9381ba2d33d6687562a67b6c3
CISD2 17 6 13 75250ac0a6e9bd038642ba802940797fbdc2bbbc
CLDN14 14 6 13 d810954830891988f3c5e8b48907657e82748722

All 271 changed PR paths match approved-head and merged
blobs. All 68 complete gene-directory files match at
approved head, individual merge, counted cutoff and authenticated source. The
301 referenced cached-source pairs are also exact
between each head, merge and current source; repeated publications across genes
are counted as pairs, not distinct files. Complete directory checks include
unchanged machine/provider inputs. Exact paths, byte counts, Git blob IDs and
SHA-256 hashes are recorded in queue update 58. There are no shared-path
exceptions in this eleven-gene batch; checkpoint 323's external CRLS1 exceptions
remain preserved in its historical record.

Baseline, cutoff and unchanged records

The baseline is the actually merged tracker323 #4688,
approved head 0558665cb9098522d9581177d3bbc4656b3438ee, merge 4e9ce09b86d9efc203871f8f7839b2645a7e3466,
API merge time 2026-10-11T06:07:21Z. Its seven changed files match
approved and merged content. This tracker merge is provenance, not a twelfth gene.
The gene cutoff and authenticated source are CLDN14 merge 0a6db3106b10,
API merge time 2026-10-11T06:08:52Z. Later application bases and open PRs are not counted.
API merge times and Git commit times are recorded separately.

The catalog keeps all 2,876 association texts and frontmatter. Exactly eleven
checkboxes change. All 235 queue objects, all 57 prior completion updates,
all unrelated queue metadata and the complete prior progress text remain exact;
update 58 is appended and both JSON mirrors are identical. All 151 existing
project histories and all eight existing parent-page history links are protected.
ROOT will append a new genuine history record at publication.

Checkpoint 323's phrase “prior 322-member verified set” means its published
315-member baseline plus the seven genes counted before CRLS1: CHD7, CHRNB1,
CHST6, CHSY1, CHRNG, CHST14 and CHRNB2. CRLS1 then made 323. CLPP and FH were in
neither group. This explicit derivation addresses review #4688's editorial
suggestion without rewriting the old checkpoint or append-only history. The
optional relocation of parent-page history links is deferred so existing links
remain intact.

CLPP and FH remain unchecked here. Their earlier external reviews were excluded
for evidence-specific campaign-policy follow-up; neither is among these eleven
qualifying merges. An unmerged corrective review cannot supply a completion.
This exclusion does not reverse a counted gene or change the preserved legacy
pending_followups counter. Counters are 334 for completed,
campaign_audited_merged and legacy original_merged, 0 for
pending_followups, and 2,542 remaining.

Validation and availability context

The ordinary frontmatter checks and both project renders use exact files from
the authenticated source. Parent availability warnings are 1,837,
identical for the fresh baseline and proposal; progress has zero. Compared with
checkpoint 323's preview (1,848), eleven availability warnings
resolve and none is new: ten newly counted genes plus RAD51D. CHAMP1 already had
a review file at the earlier source. Link availability is not audit completion;
RAD51D adds no count in this batch. The live queue is recorded for publication
applicability only and does not alter this frozen completion set.

Checkpoint 334 session history.

Completion checkpoint 323 — 2026-10-10 22:30:43 UTC

323 complete / 2,553 remaining in the frozen 2,876-gene catalog.
CHD7, CHRNB1, CHST6, CHSY1, CHRNG, CHST14, CHRNB2 and CRLS1 are the eight new
distinct completions beyond published checkpoint 315. Each counts once after its
first qualifying substantive audit, including audits of pre-existing reviews and
qualifying work in another project. Products, review rounds, annotation actions,
DRAFT status and justified uncertainty add neither counts nor completion holds.
The existing counter definitions and historical exceptions remain in force.

Gene PR Approved head Approval API merge time UTC Merge commit
CHD7 #4592 dd3f3c660230aef11063a848124a9c808b5e462a Approved 2026-10-10T21:11:56Z 0d8fed3b0f6a80edc6b776b818089929704101b8
CHRNB1 #4632 8607a3dfbf6f592233ea36a0fb2f33087712351d Approved 2026-10-10T21:13:31Z 93e292cb53ac066bf702090f2912ce2c0a22eb79
CHST6 #4650 6fca64372e56c4793852c15de4c3cf01b7e6c632 Approved 2026-10-10T21:14:38Z 35d102bc46bae9377ad6c60151bed1f07c62bf85
CHSY1 #4651 f6f28cf203783842e7124f2b34fa178bbf9284a4 Approved 2026-10-10T21:33:17Z 970f1d12e51dd7619a0c37b8d19c21abb34ed67a
CHRNG #4639 de8a670ac47a5907179bdaf9fd38fd59b22362a7 Approved 2026-10-10T21:35:04Z 7c548120f93ee47df41bc80084a48f655cf1a0e9
CHST14 #4643 e7b3c7df77fc5b7ddd849d9a4666701e5a522916 Approved 2026-10-10T21:42:16Z 6e2cfa65abae96aa195040053a5e22374eb11659
CHRNB2 #4637 1074fbc54ba5d27469230d2caf76dddb5862c0d9 Approved 2026-10-10T22:15:01Z 4a45273dbcf15330bbf4b9b0ea698104cbb1338f
CRLS1 #4476 870d8f5806dae5445751f1397a954ee8c718b53f Approved 2026-10-10T22:30:43Z a4b3afbbe831bdf07e4bea97064fd7a5fd814e71

Every approval and both required check completions match the final approved head
and precede its actual merge. Complete final formal reviews and detailed approval
comments were read; blocking findings were discharged and remaining suggestions
were explicitly nonblocking. All review-thread collections are complete with zero
unresolved threads. Reviews that could not run local validation do not substitute
for the separately authenticated successful required CI.

Changed PR paths, changed gene files and complete gene directories are distinct:

Gene Changed PR paths Changed gene files Complete gene-directory blobs Complete gene-tree OID
CHD7 30 6 6 2b4d8bdb67a42552926475d1a691117eacd4566c
CHRNB1 19 6 6 56b1f8bd83bd3bea7f57106d02bd76679bb54e16
CHST6 21 6 6 7510be5a4e91778c637728eaa311876c737b68e8
CHSY1 15 6 6 e8ddf7f66371437b826a346e8290a8ec0ef9fe94
CHRNG 17 6 6 a0f64b6cbef59a6d37d26d8ac2bdf6902cb4be7a
CHST14 17 6 6 a1a164dbce6b06ca767de59f2edebddbaf263807
CHRNB2 59 6 6 827e93c5245c7ae4c87dd635e248a74641b792d7
CRLS1 159 8 8 713e066f8c6ea2234b74baba4a3775694211b766

The first seven gene PRs have 178 changed paths, all exact between approved
heads and merges. The external MitoTOL PR has 159 changed paths, 156 exact:
cache/go/terms.csv, pages/projects/HOMOLOGY_PROPAGATION.html and
pages/projects/index.html incorporate unrelated shared context at merge.
The GO cache gains 129 rows without removal; the two project pages gain unrelated
links/cards. No whole-PR equality is claimed for #4476. Its complete CRLS1 directory,
relevant history and all 17 referenced source blobs match its approved head
and actual merge exactly. The 337 gene-PR paths plus seven tracker315 paths give
344 examined pairs, 341 exact and those three disclosed exceptions.

All 50 complete counted-gene directory blobs match at the approved head,
individual merge, counted cutoff and authenticated source. This includes unchanged
machine/provider sources. Exact paths, Git blobs, byte counts and SHA-256 hashes
are recorded in queue update 57.

External qualification and excluded merged reviews

CRLS1 (HGNC:16148) was unchecked and had no prior review at the pre-#4476 main.
The merged work reviews all 30 GOA assertions (27 ACCEPT, two REMOVE, one
UNDECIDED), preserves two products and 24 references, and supplies a specific
CDP-dependent cardiolipin-synthase core and curation history. Its 30 source tuples
match literally. ROOT accepted the independently audited qualification at
2026-10-10 23:01:03 UTC. The external approval and qualification audit are used
at their recorded scope; this checkpoint is not a new full primary-literature or
quotation audit of CRLS1. It adds one completion, not all genes in the MitoTOL PR.

CLPP and FH remain merged but incomplete for this campaign. Their #4476
reviews contain 22 and 13 generic protein-binding REMOVE decisions respectively,
justified by informativeness or unestablished native context while allowing the
reported interactions to be real. The project's retention instruction and its
existing BCKDHB/BCL10/BCS1L/BIN1/BLM precedent require evidence-specific follow-up.
Neither gene was in the prior 322-member verified set. CLPP's earlier #4426 review
and the existence of newly merged FH files do not bypass that rule. Keep both
checkboxes untouched; do not convert actions mechanically or declare the interactions
false. These excluded, not-yet-qualified audits are not reversals of counted
completions and do not alter the preserved legacy pending_followups counter.

Source, preserved history and editorial clarification

The frozen gene cutoff is CRLS1 merge a4b3afbbe831,
API merged_at 2026-10-10T22:30:43Z. The authenticated source is the later
tracker315 #4660 merge 147727e314dd,
API merged_at 2026-10-10T23:01:50Z. Tracker315 was approved on
c800bcdd95d5677cc6f4d93a74aebbead2baf50d; both required checks preceded its merge and all seven changed paths
match approved and merged blobs. API merge times and commit times are recorded
separately. Later source or publication-base dates cannot add uncounted genes.

All 150 existing project history files remain protected under tree
adf55b384cdda1e5d22295233b69b47b91af7267. All seven existing parent-page history links
and the complete prior progress text are preserved. Reviewer #4660's editorial
points are addressed in current prose: the rule is one count per gene, the
term is exact-head approval, and availability warnings are measured against
the actual source context. For checkpoint 315, the committed parent render changed
from 1,860 to 1,857 warnings because CHCHD10, CHD2 and CHD8 became available;
calling that historical preview delta unchanged was imprecise. An identical fresh
baseline/candidate warning set is a different comparison. This clarification does
not rewrite any prior append-only history. Current parent preview warnings are 1,848, equal to a fresh baseline using the
same source; progress has zero. Compared with checkpoint 315's preview, nine
availability warnings resolve (the eight counted genes plus FH), with no new
warnings. FH's newly available link does not grant campaign completion.

All 2,876 catalog association texts and frontmatter, the 235-object / 235-symbol
queue array, all 56 prior completion-update texts and unrelated queue metadata
remain exact. Eight checkboxes change and update 57 is appended with an identical
JSON mirror. The first unchecked literal entry remains ACBD5. Counters are 323 for
completed, campaign_audited_merged and legacy original_merged, zero for
pending_followups, and 2,553 remaining.

The saved 22:57 UTC queue audit includes 15 PRs, including CLCN4 #4681 and the
published CHST3/CIB2 follow-up heads. Tracker315 is now actually merged; the other
open PRs remain excluded. The new session provenance will be linked at publication.

Checkpoint 323 session history.

Completion checkpoint 315 — 2026-10-10 19:51:39 UTC

315 complete / 2,561 remaining in the frozen 2,876-gene catalog.
CHMP2B, CHCHD10, CHD8 and CHD2 are the four new distinct campaign completions
beyond published checkpoint 311. Each counts once after its first qualifying
substantive campaign audit, including audits of pre-existing reviews. Products,
review rounds, annotation actions, DRAFT status and justified uncertainty add
neither extra completions nor holds. Prior counting rules and exceptions stand.

Gene PR Approved head Approval API merge time UTC Merge commit
CHMP2B #4605 30be2a43fc2f Approved 2026-10-10T19:41:06Z 6e9b6acc8eb9
CHCHD10 #4574 7729ff7dad9e Approved 2026-10-10T19:42:32Z 3aedc52f8279
CHD8 #4595 10ab59bc71ac Approved 2026-10-10T19:43:14Z 0cb3cb1509e1
CHD2 #4583 3db922a437a0 Approved 2026-10-10T19:51:39Z e20dd96d4115

All approvals and required check completions match the final heads and precede
the corresponding merges; there are zero unresolved review threads. Complete
final formal approvals and detailed comments were read. The reviewers discharged
the important findings and identified only nonblocking suggestions. These are
completed campaign audits, not counts of newly created files or additional isoforms.

Changed paths and complete gene directories have different scopes:

Gene Changed PR paths Changed gene files All gene-directory blobs at cutoff Complete gene-tree OID
CHMP2B 13 6 8 16e1b37b20fcfd231e2b4e99b2e18b0a66307329
CHCHD10 18 6 6 95effecc352323b1531c537390b87a5c9804e75b
CHD8 24 5 5 eb0be3b2a37b700545e33eb8b1dd0eb1020a8358
CHD2 15 6 6 2f333a6dcc8c31e1ef06b4d596e53f92a048e703

All 70 changed gene-PR paths have equal blobs at the approved head and merge.
All 25 complete gene-directory artifacts match at the approved head, individual
merge, counted-gene cutoff and authenticated tracker source. Unchanged source and
provider artifacts are included in the complete directories. Exact paths, sizes,
Git blobs and SHA-256 hashes are recorded in queue update 56.

The frozen counted-gene cutoff is CHD2 merge e20dd96d4115,
API merged_at 2026-10-10T19:51:39Z. The later authenticated source is
tracker311 #4648 merge d1ce0f02e084,
API merged_at 2026-10-10T20:49:21Z. Tracker311 was approved on
8f74fe943668dfcdab99c2a50b20096babddb01d at 20:30:21 UTC;
both required checks succeeded before its merge, and all seven changed-path
blobs match its approved and merge trees. GitHub API merge times and commit times
are recorded separately. The source contains all four counted merges and the
published checkpoint 311; its later date does not count any additional gene.
A later publication base cannot advance the fixed count without reconciliation.
CHD7 and all other open or subsequent PR merges are outside this checkpoint.

All 149 existing session histories under history/projects/CLINGEN_MENDELIAN/
remain protected, authenticated by tree 877465c4fee26447284021757559a3ae195ef856.
The six existing history links remain unchanged. The prior checkpoint 311's
forward-looking history sentence is corrected to describe its already committed
record; no old session-history file is rewritten. All other prior progress is exact.

All 2,876 catalog associations and frontmatter, the 235-object / 235-symbol
serialized queue array, all 55 prior completion-update texts and unrelated
queue metadata remain unchanged. Only the four named checkboxes change; update
56 is appended with an identical JSON mirror. The first unchecked literal
entry remains ACBD5. Counter values are 315 for completed,
campaign_audited_merged and the legacy original_merged alias, zero for
pending_followups, and 2,561 remaining. Normal render previews use the complete
authenticated source-main inventory for link availability, independently of counts.

Session provenance accompanies this checkpoint at publication.

Checkpoint 315 session history.

Completion checkpoint 311 — 2026-10-10 19:26:28 UTC

311 complete / 2,565 remaining in the frozen 2,876-gene catalog.
CFTR is the sole new completion beyond checkpoint 310. This counts the first
qualifying campaign audit of an existing review, not a newly created gene file.
The prior counting rules and exceptions are unchanged: one completed campaign
audit per primary gene, with no additional count or hold for products, repeated
reviews, annotation actions or justified biological uncertainty.

Gene PR Approved head Approval API merge time UTC Merge commit
CFTR #4568 6d3565c7c9eb Approved 2026-10-10T19:26:28Z 4a9875aae93b

CFTR approval was submitted at 19:02:19 UTC;
test (3.12) succeeded at 19:18:13 UTC; claude-review succeeded at 19:02:31 UTC. All gates match the final head and precede the actual merge,
with zero unresolved threads. The full final formal approval and detailed comment
were read; remaining suggestions are explicitly nonblocking. The audit preserves
203 historical annotation objects while revising their scientific assessments and
three core functions; the review's expanded-source deferral remains explicit.

All 13 changed PR paths have equal blobs in the approved-head and merge
commit trees. Six changed gene-directory files are distinguished from the
12 total recursive gene-directory blobs at the cutoff: unchanged source and
provider artifacts remain part of the complete gene tree. The complete
CFTR tree at the cutoff
b42601a3ce347fec5156f10641d9cbcca0b00aca matches the approved, merge and authenticated source trees.
Exact paths, sizes, Git blobs and SHA-256 hashes are retained in queue update 55.

The authenticated source is commit 4a9875aae93b,
which is also the frozen CFTR completion cutoff. It contains the earlier
tracker310 #4631
merge bb51b3177deed88185627c2017483b18a4de0f94 at 19:25:37 UTC. That tracker was approved
at 19:08:32 UTC on a92f2976550ad7b7e9f37df24b2d85f5a04ea4e6;
both required checks succeeded before its merge, and all seven changed-path
blobs match the approved head and merge tree. Merge times use GitHub API
merged_at, with committedDate recorded separately; the values coincide for
both of these merges. A later publication base is distinct and cannot count any
subsequent gene merge without another reconciliation.

All 148 existing records in history/projects/CLINGEN_MENDELIAN/, authenticated
by tree c7db335f2efd5854a2d7e02d24c06c864facaf9a, are protected. The five session-history
links already present in the parent page remain unchanged:

The checkpoint 311 session history is committed and linked below.
No existing history or gene artifact is edited. Render previews use the complete
authenticated source-main gene-review inventory; later link availability can change
independently of this fixed count.

All 2,876 catalog associations and frontmatter, the 235-object / 235-symbol
serialized queue array, all 54 prior completion-update object texts, unrelated
queue metadata and prior progress are preserved. Only CFTR's checkbox changes;
update 55 is appended with an identical JSON mirror. The first unchecked
literal entry remains ACBD5. Counter values are 311 for completed,
campaign_audited_merged and the legacy original_merged alias, with zero
pending_followups and 2,565 remaining.

Checkpoint 311 session history.

Completion checkpoint 310 — 2026-10-10 17:19:03 UTC

310 complete / 2,566 remaining in the frozen 2,876-gene catalog.
CHAT is the sole new completion beyond checkpoint 309. The existing counting
rules and queue exceptions are unchanged: one qualifying campaign audit per
primary gene, with no additional count or hold for products, repeated reviews,
annotation actions or justified biological uncertainty.

Gene PR Approved head Approval API merge time UTC Merge commit
CHAT #4572 e589d7f1f8b2 Approved 2026-10-10T17:19:03Z d029f88f542f

CHAT approval was submitted at 17:12:28 UTC; test (3.12) succeeded at 14:36:38 UTC; claude-review succeeded at 17:13:28 UTC.
These gates all match the final head and precede the actual merge, with zero
unresolved review threads. The complete final approval and review comment were
read; remaining suggestions are explicitly nonblocking. This first campaign
review creates the CHAT review and counts once.

All 18 changed PR paths have equal blobs in the approved-head and merge
commit trees. The six changed gene-directory files are also the six total
recursive gene-directory blobs at the cutoff. The complete
CHAT tree at the cutoff
5cc5a36bb01904cd8ce8c39836dc47a6a6ff2a7a matches the approved, merge and authenticated source trees.
Exact path, size, Git-blob and SHA-256 evidence is retained in queue update 54.

The source snapshot is commit 8cd2c9286f44,
the actual tracker309 #4581
merge at 17:25:21 UTC, after the frozen CHAT cutoff at 17:19:03 UTC.
The source tracker was approved at 17:14:22 UTC on
ded21ac6da3d0cf79152a77d1ae65ad5aa5869f6 and both required checks succeeded before merge;
all seven tracker changed-path blobs match its approved head and merge tree.
The times in this checkpoint use GitHub API merged_at, not commit timestamps:
CHAT's merge commit has committedDate 17:19:02 UTC, while its API merge time
is 17:19:03 UTC. A later publication base is a third reference point and must
preserve the six project preimages without adding subsequent gene completions.

All 147 existing records in history/projects/CLINGEN_MENDELIAN/, authenticated
by tree f9251d3d41ff393dcc472a1a257b43acda7d81c3, are protected. In particular, the four
session-history links already present in the parent page remain unchanged:

The publisher will scaffold and validate the new session history normally.
No existing history or gene artifact is edited. The render preview uses the
complete authenticated source-main gene-review inventory; later link availability
can change independently of this fixed count.

All 2,876 catalog associations and frontmatter, the 235-object / 235-symbol
serialized queue array, all 53 prior completion-update object texts, unrelated
queue metadata and all prior progress are preserved. Only CHAT's checkbox changes;
update 54 is appended, with an identical JSON mirror. The first unchecked
literal catalog entry remains ACBD5. Counter values are 310 for completed,
campaign_audited_merged and the legacy original_merged alias, with zero
pending_followups and 2,566 remaining.

Checkpoint 310 session history.

Completion checkpoint 309 — 2026-10-10 13:12:56 UTC

309 complete / 2,567 remaining in the frozen 2,876-gene catalog. The first
qualifying campaign reviews for CFH, CFAP410, CFAP418, CFAP43, CFL2, CFI add 6 distinct completions
beyond published checkpoint 303. An older review's existence does not substitute
for its substantive campaign audit. Products, repeated reviews, annotation actions
and justified biological uncertainty add neither completions nor holds.

Gene PR Final head Approval Merged UTC Merge commit
CFH #4555 cebc1de09e28 Approved 2026-10-10T12:08:30Z 0cd7233f9167
CFAP410 #4550 e5d232ede4e4 Approved 2026-10-10T12:33:27Z 5173dba5df3f
CFAP418 #4553 2c646dedf1d1 Approved 2026-10-10T13:07:39Z 4b7aeee762b0
CFAP43 #4554 4c1d18eeca0c Approved 2026-10-10T13:09:11Z 7e2ad4dc8150
CFL2 #4562 33d284c3a2bc Approved 2026-10-10T13:11:24Z 76a745c581ad
CFI #4556 1cd882936145 Approved 2026-10-10T13:12:56Z 91bbc12a004a

CFH: approval at 11:40:56 UTC; test (3.12) succeeded at 12:02:41 UTC; claude-review succeeded at 11:41:52 UTC. All gates precede the actual merge at 12:08:30 UTC and refer to the same approved head, with zero unresolved threads. This is a newly added primary review, counted once. The 39 changed PR paths, 6 changed gene-directory files and 6 total recursive gene-directory blobs at the cutoff are separate measurements. All changed paths have equal blobs at the approved-head and merge-commit trees. The complete cutoff CFH tree 1dea1de4748d6e29411c4d1c020454ff033ff2c3 matches the approved and merge trees; exact artifacts and changed-path blobs are recorded in the queue update.

CFAP410: approval at 12:02:18 UTC; test (3.12) succeeded at 12:25:26 UTC; claude-review succeeded at 12:03:00 UTC. All gates precede the actual merge at 12:33:27 UTC and refer to the same approved head, with zero unresolved threads. This is a substantive campaign audit of a pre-existing review, counted once. The 6 changed PR paths, 4 changed gene-directory files and 11 total recursive gene-directory blobs at the cutoff are separate measurements. All changed paths have equal blobs at the approved-head and merge-commit trees. The complete cutoff CFAP410 tree deb34bbdd7a5bc9670fd0c0b1eab73022a7aa7c3 matches the approved and merge trees; exact artifacts and changed-path blobs are recorded in the queue update.

CFAP418: approval at 12:11:44 UTC; test (3.12) succeeded at 12:28:35 UTC; claude-review succeeded at 12:12:01 UTC. All gates precede the actual merge at 13:07:39 UTC and refer to the same approved head, with zero unresolved threads. This is a substantive campaign audit of a pre-existing review, counted once. The 15 changed PR paths, 9 changed gene-directory files and 33 total recursive gene-directory blobs at the cutoff are separate measurements. All changed paths have equal blobs at the approved-head and merge-commit trees. The complete cutoff CFAP418 tree 35e8ceff95da33f38db7b34a9099b8bc74b36bcb matches the approved and merge trees; exact artifacts and changed-path blobs are recorded in the queue update.

CFAP43: approval at 12:13:07 UTC; test (3.12) succeeded at 12:31:41 UTC; claude-review succeeded at 12:13:53 UTC. All gates precede the actual merge at 13:09:11 UTC and refer to the same approved head, with zero unresolved threads. This is a newly added primary review, counted once. The 16 changed PR paths, 6 changed gene-directory files and 6 total recursive gene-directory blobs at the cutoff are separate measurements. All changed paths have equal blobs at the approved-head and merge-commit trees. The complete cutoff CFAP43 tree 3cbd3238d7312e00ddcc773b5f08adec1aa49b6a matches the approved and merge trees; exact artifacts and changed-path blobs are recorded in the queue update.

CFL2: approval at 12:41:09 UTC; test (3.12) succeeded at 13:03:37 UTC; claude-review succeeded at 12:41:24 UTC. All gates precede the actual merge at 13:11:24 UTC and refer to the same approved head, with zero unresolved threads. This is a newly added primary review, counted once. The 16 changed PR paths, 6 changed gene-directory files and 6 total recursive gene-directory blobs at the cutoff are separate measurements. All changed paths have equal blobs at the approved-head and merge-commit trees. The complete cutoff CFL2 tree 376b6960951f160dd4451be2f224447bfe5d7635 matches the approved and merge trees; exact artifacts and changed-path blobs are recorded in the queue update.

CFI: approval at 12:50:10 UTC; test (3.12) succeeded at 13:09:26 UTC; claude-review succeeded at 12:50:21 UTC. All gates precede the actual merge at 13:12:56 UTC and refer to the same approved head, with zero unresolved threads. This is a newly added primary review, counted once. The 17 changed PR paths, 6 changed gene-directory files and 6 total recursive gene-directory blobs at the cutoff are separate measurements. All changed paths have equal blobs at the approved-head and merge-commit trees. The complete cutoff CFI tree 590581a3ed5d3312aaac972742382a57023d9c2f matches the approved and merge trees; exact artifacts and changed-path blobs are recorded in the queue update.

The authenticated source snapshot is
commit 91bbc12a004a.
It contains tracker303 PR #4551,
actually merged at 12:10:12 UTC in 39a7a8a8454f9a3efc2bee1ac1ff714afff70af5 from approved head
d5017584923ae614f2f6868737f9560bec24f573. Its exact-head approval, required checks and complete
changed-path blob equality were authenticated separately. The frozen gene-completion
cutoff is 13:12:56 UTC at 91bbc12a004a42b6c26f3f9c58a1bd5f33556398. Any later publication checkout is a third
reference point: ROOT must verify the six project preimages before import and must
not fold subsequent gene merges into this checkpoint. All four existing tracker
history records remain exact; new parent/progress history links will be scaffolded
normally by the publisher.

The render produced from main is authoritative for gene-link availability.
This preview uses the complete authenticated source-main gene-review inventory,
including the newly completed genes. Later link availability can change as genes
merge without changing this frozen completion count.

Counter meanings are unchanged: campaign_audited_merged, legacy original_merged
and completed are 309; pending_followups is zero. Literal $.genes remains
235 objects / 235 distinct symbols. All 2,876 catalog associations and
frontmatter, the serialized queue array, all 52 prior update object texts,
unrelated queue metadata and previous progress text remain exact. Only the listed
6 checkboxes change; update 53 is appended and the JSON mirror is
byte-identical. The first unchecked literal catalog gene remains ACBD5. No gene
science, source cache or old history record is edited.

Evidence inspected and checkpoint recorded at 2026-10-10 13:15:09 UTC.

Checkpoint 309 session history.

Completion checkpoint 303 — 2026-10-10 10:35:31 UTC

303 complete / 2,573 remaining in the frozen 2,876-gene catalog. Count only
CFAP300's first qualifying substantive campaign audit beyond checkpoint 302.
The primary YAML was modified, not newly created: its older review did not already
constitute this campaign's completion. Products, retained authored annotations and
unresolved molecular-function biology are not additional counts or completion holds.

Gene PR Final head Approval Merged UTC Merge commit
CFAP300 #4537 2ce993337db4 Approved 2026-10-10T10:35:31Z 2f68dd87cb96

Approval was submitted at 10:32:35 UTC; test (3.12) succeeded at 09:20:49 UTC; claude-review succeeded at 10:32:53 UTC.
All three gates refer to the same final head and precede the actual 10:35:31 UTC
merge. There are no unresolved review threads. All seven changed PR paths
have identical blobs at the approved-head and merge-commit trees. The four changed
gene-directory files are a different scope from all 19 recursive gene-directory
blobs at the cutoff, which include preserved sources and provider artifacts.
The complete CFAP300 tree
b7b7cdbf9c76ece61c8157b9a11517d6b7ef13cb is equal at head and merge/cutoff.
The appended queue record contains every changed-path blob and all 19 cutoff artifacts.

The exact tracker preimage is open PR #4551
head 13435e510e4f, preserving its
301/302 checkpoints, three existing history records and later review corrections.
It is not described as a merged tracker snapshot. The distinct biological cutoff
is actual main commit 2f68dd87cb96.
A later publisher base cannot advance that cutoff; ROOT must guard the same six
project preimages, preserve the PR ancestry and append genuine session history.
The prior correction distinguishing changed artifacts from whole-directory files
and the restored CERKL review link remain intact.

Counter definitions are unchanged: campaign_audited_merged, legacy
original_merged and completed are 303; pending_followups is zero. Literal
$.genes is still 235 objects / 235 distinct symbols, not the count of every
nested historical gene key. All 2,876 catalog associations and frontmatter, the
serialized queue array, all 51 prior update object texts, unrelated queue metadata
and all previous progress text are preserved. Only CFAP300's checkbox changes;
update 52 is appended and the JSON mirror is exact. The first unchecked literal
catalog gene remains ACBD5. No gene science or source cache is edited.

Evidence inspected and this follow-up recorded at 2026-10-10 10:51:57 UTC.

Checkpoint 303 session history.

Completion checkpoint 302 — 2026-10-10 09:06:56 UTC

302 complete / 2,574 remaining in the frozen 2,876-gene catalog. CERKL
adds one first counted primary campaign review beyond checkpoint 301. Its
primary review YAML was added by the qualifying PR. Its eight products and
COMPLETE artifact status are not additional campaign completions. No completion
holds remain, and no later gene merge is included.

Gene PR Final head Approval Merged UTC Merge commit
CERKL #4531 eea866be3895 Approved 2026-10-10T09:06:56Z 5928e194d4a4

The final head was approved at 08:42:54 UTC;
test (3.12) succeeded at 09:03:17 UTC on the same head; claude-review succeeded at 08:43:10 UTC on the same head. Both checks and approval precede the 09:06:56 UTC merge.
Authenticated review threads contain no unresolved entries. All
20 changed PR paths have equal blobs at the approved head and actual merge.
The six changed gene-directory files and all six gene-directory blobs at
the cutoff are separate counted scopes. For a case where the counts differ,
see the checkpoint 301 CEP290 example:
four changed gene files versus eight directory blobs. The complete CERKL tree
b0c153f1efc1
is identical at the approved head and merge/cutoff. The appended queue evidence
records every changed-path blob and every cutoff gene artifact, with hashes.

The tracker preimage is PR #4551
at head 7005ce6da531,
which already contains checkpoint 301 and its genuine session history. That PR
was open when this update was prepared; this is a follow-up on the same PR,
not a claim that checkpoint 301 had merged. The biological completion cutoff
is actual main commit 5928e194d4a4.
These are distinct source roles. The publisher must preserve the existing PR
ancestry, guard its exact project preimages, append genuine session history and
rerender. A later publication base does not move the cutoff.

The checkpoint 288 counter definitions continue unchanged:
campaign_audited_merged and its legacy compatibility alias original_merged
are 302; pending_followups is zero; completed is 302. The literal queue
array $.genes remains 235 objects / 235 distinct symbols, independently
parsed from baseline blob c3d049524fd0.
Historical nested observations are not queue-array entries. The checkpoint 301
cardinality and artifact-scope clarifications are preserved without rewriting.

All 2,876 catalog rows, association text and frontmatter, the complete serialized
235-object queue array, all 50 prior completion-update object texts, and all
previous progress text are preserved. Only the CERKL checkbox changes; update
51 is appended, and both queue mirrors remain identical. No gene science,
provider report or cached source is changed. DRAFT status or a justified
UNDECIDED annotation does not itself create a campaign hold. The first unchecked
gene in literal catalog order remains ACBD5.

Authenticated evidence was read and this follow-up recorded at 2026-10-10 09:20:21 UTC.

The committed project pages were regenerated using the six authenticated CERKL
artifacts at the frozen merge cutoff as temporary rendering context. CERKL now
links to its review; the parent page retains 1,865 missing-review warnings for
other genes. This rendering context does not add gene files to the tracker PR.

Tracker review follow-up history.

Checkpoint 302 session history.

Completion checkpoint 301 — 2026-10-10 07:58:54 UTC

301 complete / 2,575 remaining in the frozen 2,876-gene catalog. CEP57,
CEP85L and CFAP221 add three first counted primary campaign audits beyond
checkpoint 298. Each PR adds its primary review file and counts once as a
catalog gene, irrespective of product count. No required follow-up holds remain.
Supplementary products and repeated reviews of already counted genes add no
completion.

Gene PR Final head Approval Merged UTC Merge commit
CEP57 #4516 9b0f809ae8bf Approved 2026-10-10T07:45:32Z 074064fe4e3e
CEP85L #4525 056d7d9341c5 Approved 2026-10-10T07:46:04Z 2268291181e3
CFAP221 #4534 b3e0d12f0cb6 Approved 2026-10-10T07:58:54Z 8a69f3d2b551

CEP57's exact head was approved at 07:38:37 UTC; test (3.12) succeeded at 07:40:42 UTC; claude-review succeeded at 07:39:27 UTC, before its 07:45:32 UTC merge.

CEP85L's exact head was approved at 07:38:13 UTC; test (3.12) succeeded at 07:33:34 UTC; claude-review succeeded at 07:38:26 UTC, before its 07:46:04 UTC merge.

CFAP221's exact head was approved at 07:44:57 UTC; test (3.12) succeeded at 07:58:00 UTC; claude-review succeeded at 07:45:11 UTC, before its 07:58:54 UTC merge.

Authenticated records contain zero unresolved review threads. Every changed
PR path has the same blob at the approved head and actual merge. Each complete
gene-directory tree is also identical at the approved head, actual merge and
frozen CFAP221 cutoff. The baseline tracker298 final head, approval, required
checks, merge and all seven changed paths were independently verified.

Gene All changed PR paths Changed gene-directory files All gene-directory blobs at cutoff Cutoff tree
CEP57 19 6 6 cb01c0989f37
CEP85L 12 6 6 fcf3ce9f98fa
CFAP221 15 6 6 2fdda0119110

These are three separate scopes: the complete PR diff, changed files under the
gene directory, and every blob recursively present in that directory at the
cutoff. The new queue evidence names each scope explicitly and records the
path/blob lists. In the preserved checkpoint 298 records, the legacy
cutoff_gene_artifact_count field counted changed gene-directory files:
CEP290 had four changed files but eight total directory blobs; CEP41 had six
in both scopes. Those historical values are not rewritten.

The source snapshot is commit e49cb9becb5b,
the actual tracker298 #4533
merge at 2026-10-10T07:56:46Z. Four source files and two derived-page preimages
are authenticated there and unchanged at the later CFAP221 completion cutoff.
CEP57 and CEP85L merged before that tracker source snapshot, but its frozen
checkpoint 298 did not count them. The eventual publication branch base is
separate: if later, all six preimages must match and that base must be recorded.
No later completion is included.

The counter definitions established at checkpoint 288 remain in force:
campaign_audited_merged counts distinct frozen-catalog primary genes with a
merged campaign review; subtracting pending_followups gives completed.
original_merged remains the compatibility alias in this appended snapshot.
The three applicable values are 301, 0 and 301. Existing file presence,
supplementary products and repeated reviews do not independently add campaign
completions. Checkpoints 299 and 300 are not separately published; these three
verified merges are incorporated together without double counting.

The literal queue array $.genes has 235 objects and 235 distinct gene
values, independently parsed from the identical
queue blob 2a945cd59fc5
at tracker298's approved head, actual merge and this cutoff. The reviewer-reported
244 objects / 236 symbols is reproduced only by counting all six-space-indented
gene properties across the entire document. That includes nine historical
context fields outside $.genes: ATP1A1, ATP2B2, ATP6AP1 (three observations),
ATRX, BAP1, AKR1D1 and BRAF. BRAF is the additional distinct symbol. It is not
the array's cardinality; no queue object is added or removed to fit that count.
The appended machine evidence records the exact extra JSON paths and baseline
hash. This clarification preserves all prior records.

All 2,876 catalog rows and association text, all 235 historical queue objects,
all 49 prior completion updates and all previous progress text are preserved.
Only the CEP57, CEP85L and CFAP221 checkboxes change; update 50 is appended.
Both queue mirrors remain identical. Biological DRAFT status or justified
UNDECIDED annotations alone create no hold. Later work remains outside this
fixed completion cutoff. The first unchecked gene in literal catalog order
remains ACBD5.

Authenticated evidence was read and this proposal recorded at 2026-10-10 08:06:48 UTC.

Checkpoint 301 session history.

Completion checkpoint 298 — 2026-10-10 07:02:47 UTC

298 complete / 2,578 remaining in the frozen 2,876-gene catalog. CEP290 and
CEP41 add two first counted primary campaign audits beyond checkpoint 296.
CEP290 is a substantive audit of a pre-existing review; CEP41 adds a new review.
Both count once as primary genes, irrespective of products or prior file
presence. No required follow-up holds remain. Supplementary products and
repeated reviews of already counted genes add no completion.

Gene PR Final head Approval Merged UTC Merge commit
CEP290 #4512 25047b2caee9 Approved 2026-10-10T06:55:54Z 5b6c5bc6df4d
CEP41 #4513 08986810564b Approved 2026-10-10T07:02:47Z 3fbffb264074

CEP290's exact head was approved at 06:34:44 UTC; test (3.12) succeeded at 06:53:29 UTC; claude-review succeeded at 06:34:59 UTC, before its 06:55:54 UTC merge.
CEP41's exact head was approved at 06:43:40 UTC; test (3.12) succeeded at 07:01:34 UTC; claude-review succeeded at 06:44:21 UTC, before its 07:02:47 UTC merge.

Authenticated live records contain zero unresolved review threads. All eight
CEP290 and 15 CEP41 changed PR paths have identical approved-head and actual
merge-tree blobs. Their complete gene-directory trees also match their final
heads, actual merges and this frozen cutoff (8 CEP290 and 6 CEP41 entries).
The baseline tracker296 head, approval, required checks, merge and all changed
paths were independently verified.

The source snapshot is commit 156c3de28880,
the actual tracker296 #4515
merge at 2026-10-10T06:51:33Z. Four source files and two derived-page preimages
are authenticated at that snapshot and are unchanged at the later CEP41
completion cutoff. The eventual publication branch base is separate: if it is
later, all six preimages must match and that base must be recorded. No future
branch identity or subsequent completion is assumed.

The counter definitions established at checkpoint 288 remain in force:
campaign_audited_merged counts distinct frozen-catalog primary genes with a
merged campaign review; subtracting pending_followups gives completed.
original_merged remains the compatibility alias in this appended snapshot.
The three applicable values are 298, 0 and 298. Existing review-file presence,
supplementary products and repeated reviews do not independently add campaign
completions. No separate checkpoint297 is published; the two verified merges
are incorporated together without double counting.

All 2,876 catalog rows and association text, all 235 historical queue entries,
all 48 prior completion updates and all previous progress text are preserved.
Only the CEP290 and CEP41 checkboxes change; update 49 is appended. The queue
gene array remains unchanged. Biological DRAFT status or justified UNDECIDED
annotations alone create no hold. CEP57, CEP85L and later work remain outside
this fixed completion cutoff. The first unchecked gene in literal catalog
order remains ACBD5.

Authenticated evidence was read and this proposal recorded at 2026-10-10 07:07:28 UTC.

Checkpoint 298 session history.

Completion checkpoint 296 — 2026-10-10 06:07:16 UTC

296 complete / 2,580 remaining in the frozen 2,876-gene catalog. CEP164 and
CEP250 add two first counted primary campaign audits beyond checkpoint 294.
CEP164 is a substantive audit of a pre-existing review; CEP250 adds a new review
file. Both count once as primary genes, irrespective of products or prior file
presence. No required follow-up holds remain. Supplementary products and
repeated reviews of already counted genes add no completion.

Gene PR Final head Approval Merged UTC Merge commit
CEP164 #4508 f596d88e3b5c Approved 2026-10-10T05:43:15Z 88a6b9a1b7e9
CEP250 #4510 02a91a83f87b Approved 2026-10-10T06:07:16Z 88df55227943

CEP164's exact head was approved at 05:20:31 UTC, with successful claude-review
at 05:20:48 UTC and test (3.12) at 05:40:08 UTC, before its 05:43:15 UTC merge.
CEP250's exact head was approved at 05:43:02 UTC, with successful claude-review
at 05:43:33 UTC and test (3.12) at 06:06:00 UTC, before its 06:07:16 UTC merge.
Captured pre-merge and independent live records contain zero unresolved review
threads. All eight CEP164 and all 24 CEP250 changed PR paths have identical
approved-head blobs and blobs at their respective merge-commit trees. The
eight CEP164 and six CEP250 gene artifacts also match their approved heads,
the frozen cutoff and the authenticated source snapshot.

The source snapshot is commit f5d0abbae8a1,
the actual tracker294 #4514
merge at 2026-10-10T06:14:26Z. Its exact approved head and successful required
checks were independently verified. This later snapshot supplies the published
294 baseline without advancing the earlier CEP250 completion cutoff.
The eventual publication branch base is a separate fact. Four source-file and
two derived-page preimages are authenticated at this snapshot; if publication
uses a later base, all six must be checked identical and that base recorded in
the publication receipt. No future branch identity is assumed here.

The counter definitions established at checkpoint 288 remain in force:
campaign_audited_merged counts distinct frozen-catalog primary genes with a
merged campaign review; subtracting pending_followups gives completed.
original_merged remains the compatibility alias in this appended snapshot.
The three applicable values are 296, 0 and 296. Existing review-file presence,
supplementary products and repeated reviews do not independently add campaign
completions. A separate checkpoint295 was not published; its preliminary CEP164
evidence is incorporated into this two-gene checkpoint without double counting.

All 2,876 catalog rows and association text, all 235 historical queue entries,
all 47 prior completion updates and all previous progress text are preserved.
Only the CEP164 and CEP250 checkboxes change; update 48 is appended. The queue
gene array remains unchanged. Biological DRAFT status or justified UNDECIDED
annotations alone create no hold. CEP290, CEP41, CEP57 and later work remain
outside this fixed completion cutoff. The first unchecked gene in literal
catalog order remains ACBD5.

Authenticated evidence was read and this proposal recorded at 2026-10-10 06:17:06 UTC.

Checkpoint 296 session history.

Completion checkpoint 294 — 2026-10-10 05:23:30 UTC

294 complete / 2,582 remaining in the frozen 2,876-gene catalog. CEP152 adds
one first counted primary campaign audit beyond checkpoint 293. Its review file
already existed; this completion records the substantive current-rule audit,
not another count for that earlier file. No required follow-up holds remain.
Supplementary products and repeated reviews of already counted genes add no
completion.

Gene PR Final head Approval Merged UTC Merge commit
CEP152 #4507 0692518e68c0 Approved 2026-10-10T05:23:30Z 0762762ef0ee

The final head was approved at 04:55:42 UTC, with successful claude-review at
04:56:19 UTC and test (3.12) at 05:17:22 UTC, all before the 05:23:30 UTC merge.
The captured pre-merge and independent live records contain zero unresolved
review threads. All seven changed PR paths have identical approved-head blobs
and blobs at the merge-commit tree. All seven gene artifacts also match the
frozen cutoff and the source main.

The source main is commit b8e2b0a8753f,
which contains the gene merge and the later baseline tracker merge.
The published baseline tracker #4511
merged at 2026-10-10T05:38:06Z as b8e2b0a8753f.
The later source snapshot does not move the biological completion cutoff.

The counter definitions established at checkpoint 288 remain in force:
campaign_audited_merged counts distinct frozen-catalog primary genes with a
merged campaign review; subtracting pending_followups gives completed.
original_merged remains a compatibility alias in this new snapshot. The three
applicable values are 294, 0 and 294. Existing review-file presence, supplementary
products and repeated reviews do not independently add campaign completions.

All 2,876 catalog rows and association text, all 235 historical queue entries,
all 46 prior completion updates and all previous progress text are preserved.
Only the CEP152 checkbox changes; update 47 is appended. The queue gene array
remains unchanged; new completion evidence is appended to the update series.
Biological DRAFT status or justified UNDECIDED annotations alone create no hold.
CEP164 #4508, CEP250 #4510, CEP290 and later work are outside this fixed
cutoff. The primary CEP152 review file was modified by its PR. The first unchecked
gene in literal catalog order remains ACBD5.

Authenticated evidence was read and this proposal recorded at 2026-10-10 05:40:57 UTC.

Checkpoint 294 session history.

Completion checkpoint 293 — 2026-10-10 04:52:48 UTC

293 complete / 2,583 remaining in the frozen 2,876-gene catalog. CEP120 adds
one first primary campaign completion beyond checkpoint 292. No required
follow-up holds remain. Supplementary products and repeated reviews of already
counted genes add no completion.

Gene PR Final head Approval Merged UTC Merge commit
CEP120 #4505 cef801e8b875 Approved 2026-10-10T04:52:48Z 6ae4685964aa

The final head has successful test (3.12) and claude-review checks on that same
commit before merge. All 17 changed PR paths match their approved-head and merge
blobs; all six gene artifacts also match the frozen cutoff and source.
The source main is commit ea02a3dc102c,
which contains the gene merge and the later baseline tracker merge.
The published baseline tracker #4509
merged at 2026-10-10T05:09:12Z as ea02a3dc102c.
The later source snapshot does not move the biological completion cutoff.

The counter definitions established at checkpoint 288 remain in force:
campaign_audited_merged counts distinct frozen-catalog primary genes with a
merged campaign review; subtracting pending_followups gives completed.
original_merged remains a compatibility alias in this new snapshot. The three
applicable values are 293, 0 and 293. Existing review-file presence, supplementary
products and repeated reviews do not independently add campaign completions.

All 2,876 catalog rows and association text, all 235 historical queue entries,
all 45 prior completion updates and all previous progress text are preserved.
Only the CEP120 checkbox changes; update 46 is appended. The queue gene array
remains unchanged; new completion evidence is appended to the update series.
Biological DRAFT status or justified UNDECIDED annotations alone create no hold.
CEP152 #4507, CEP164 #4508, CEP250 #4510 and later work are outside this fixed
cutoff. The primary CEP120 review file was added by its PR. The first unchecked
gene in literal catalog order remains ACBD5.

Authenticated evidence was read and this proposal recorded at 2026-10-10 05:14:24 UTC.

Checkpoint 293 session history.

Completion checkpoint 292 — 2026-10-10 04:42:08 UTC

292 complete / 2,584 remaining in the frozen 2,876-gene catalog. CEBPA and
CEP104 add two first primary campaign completions beyond checkpoint 290. No
required follow-up holds remain. Supplementary products and repeated reviews of
already counted genes add no completion.

Gene PR Final head Approval Merged UTC Merge commit
CEBPA #4502 8dcb615dc28f Approved 2026-10-10T04:34:29Z 074caa8e219a
CEP104 #4503 cbd9e3d57ea9 Approved 2026-10-10T04:42:08Z 04685e86ca43

Both final heads have successful test (3.12) and claude-review checks on those
same commits before merge. All 50 changed PR paths match their approved-head and
merge blobs; all 16 gene artifacts also match the frozen cutoff and source.
The source main is commit 2b6a4561b112,
which contains both gene merges and the later baseline tracker merge.
The published baseline tracker #4506
merged at 2026-10-10T04:42:51Z as 2b6a4561b112.
The later source snapshot does not move the biological completion cutoff.

The counter definitions established at checkpoint 288 remain in force:
campaign_audited_merged counts distinct frozen-catalog primary genes with a
merged campaign review; subtracting pending_followups gives completed.
original_merged remains a compatibility alias in this new snapshot. The three
applicable values are 292, 0 and 292. Existing review-file presence, supplementary
products and repeated reviews do not independently add campaign completions.

All 2,876 catalog rows and association text, all 235 historical queue entries,
all 44 prior completion updates and all previous progress text are preserved.
Only the CEBPA and CEP104 checkboxes change; update 45 is appended. The queue gene
array remains unchanged; new completion evidence is appended to the update series.
Biological DRAFT status or justified UNDECIDED annotations alone create no hold.
CEP120 #4505, CEP152 #4507, CEP164 #4508 and later work are outside this fixed cutoff.
Both primary review files were added by their respective PRs. The first unchecked
gene in literal catalog order remains ACBD5.

For the previously counted CDKN2A gene, the separately rendered
ARF product review
and p16 product review
are both available. These two products still contribute one CDKN2A catalog completion.

Authenticated evidence was read and this proposal recorded at 2026-10-10T04:45:58.760797+00:00.

Checkpoint 292 session history.

Completion checkpoint 290 — 2026-10-10 04:04:04 UTC

290 complete / 2,586 remaining in the frozen 2,876-gene catalog. CDKN2A adds
one first primary campaign completion beyond checkpoint 289. No required
follow-up holds remain. Supplementary products and repeated reviews of already
counted genes add no completion.

Gene PR Final head Approval Merged UTC Merge commit
CDKN2A #4499 4841d73f6c01 Approved 2026-10-10T04:04:04Z ebb4123eeb1e

The final head has successful test (3.12) and claude-review checks on that same
commit before merge. All 66 changed PR paths match their approved-head and merge
blobs; all 19 gene artifacts also match the frozen source/cutoff. The source main
is commit 498c72e4bea4,
which contains both the CDKN2A merge at 2026-10-10T04:04:04Z and the later baseline tracker merge.
The published baseline tracker #4504
merged at 2026-10-10T04:06:05Z as 498c72e4bea4.
The later source snapshot does not move the biological completion cutoff.

The counter definitions established at checkpoint 288 remain in force:
campaign_audited_merged counts distinct frozen-catalog primary genes with a
merged campaign review; subtracting pending_followups gives completed.
original_merged remains a compatibility alias in this new snapshot. The three
applicable values are 290, 0 and 290. Existing review-file presence, supplementary
products and repeated reviews do not independently add campaign completions.

All 2,876 catalog rows and association text, all 235 actual historical queue
entries, all 43 prior completion updates and all previous progress text are
preserved. Only CDKN2A's checkbox changes; update 44 is appended. The queue gene
array remains unchanged; new completion evidence is appended to the update series.
Biological DRAFT status or justified UNDECIDED annotations alone create no hold.
CEBPA #4502, CEP104 #4503, CEP120 #4505, CEP152 and later work are outside this fixed cutoff.
The P42771 p16 and Q8N726 ARF reviews together count as one CDKN2A catalog completion, not two products.
The primary review file was added by #4499; this is its first counted campaign review. The first unchecked
gene in literal catalog order remains ACBD5.

Authenticated evidence was read and this proposal recorded at 2026-10-10T04:11:20.175487+00:00.

Checkpoint 290 session history.

Completion checkpoint 289 — 2026-10-10 03:28:19 UTC

289 complete / 2,587 remaining in the frozen 2,876-gene catalog. CDT1 adds
one first primary campaign completion beyond checkpoint 288. No required
follow-up holds remain. Supplementary products and repeated reviews of already
counted genes add no completion.

Gene PR Final head Approval Merged UTC Merge commit
CDT1 #4500 84bf468a05a4 Approved 2026-10-10T03:28:19Z 7a6b71b1a228

The final head has successful test (3.12) and claude-review checks on that same
commit before merge. All 27 changed PR paths match their approved-head and merge
blobs; all six gene artifacts also match the frozen source/cutoff. The source main
is commit 7a6b71b1a228,
the CDT1 merge at 2026-10-10T03:28:19Z. The published baseline tracker #4501
merged as 9dfaa0a45aed.

The counter definitions established at checkpoint 288 remain in force:
campaign_audited_merged counts distinct frozen-catalog primary genes with a
merged campaign review; subtracting pending_followups gives completed.
original_merged remains a compatibility alias in this new snapshot. The three
applicable values are 289, 0 and 289. Existing review-file presence, supplementary
products and repeated reviews do not independently add campaign completions.

All 2,876 catalog rows and association text, all 235 actual historical queue
entries, all 42 prior completion updates and all previous progress text are
preserved. Only CDT1's checkbox changes; update 43 is appended. The queue gene
array remains unchanged; new completion evidence is appended to the update series.
Biological DRAFT status or justified UNDECIDED annotations alone create no hold.
CDKN2A, CEBPA and later merges are outside this fixed cutoff. The first unchecked
gene in literal catalog order remains ACBD5.

Authenticated evidence was read and this proposal recorded at 2026-10-10T03:33:18.439324+00:00.

Checkpoint 289 session history.

Completion checkpoint 288 — 2026-10-10 02:29:14 UTC

288 complete / 2,588 remaining in the frozen 2,876-gene catalog. CDKL5 and
the substantive CDKN1C audit add two distinct primary campaign completions beyond
checkpoint 286. No required follow-up holds remain. Supplementary products and
repeat reviews of already counted genes add no completion.

Gene PR Final head Approval Merged UTC Merge commit
CDKL5 #4494 cbc605964281 Approved 2026-10-10T02:06:16Z e2c5e7f01a9f
CDKN1C #4497 79c234184757 Approved 2026-10-10T02:29:14Z e94991ceada8

Both final heads have successful test (3.12) and claude-review checks on the same
commit before the merge. All 35 changed PR paths match their approved-head and
merge blobs; all 10 gene artifacts additionally match the fixed source/cutoff.
The source main e94991ceada8
is the CDKN1C merge at 2026-10-10T02:29:14Z; the baseline tracker #4498
merged as eb43e5708cf3 at 2026-10-10T02:25:25Z.

The new campaign_audited_merged counter counts distinct frozen-catalog primary
genes with a merged campaign review, including any counted gene awaiting a
required follow-up; subtracting pending_followups gives completed. At this
cutoff all three applicable values are 288, 0 and 288. A substantive first
campaign audit of an existing review qualifies; creating a review file is not
the criterion. CDKN1C modifies an existing review, while CDKL5 adds one.

The legacy original_merged key and distinct_original_increment are retained
as compatibility fields in this new snapshot with that campaign scope. Their
names must not be read as a census of first-ever review-file merges. This is an
append-only clarification; it does not silently rewrite older records or assert
that every historical use of the old label was unambiguous.

The bounded audit of the published 41-update series found that every prior
original_merged equals completed + pending_followups. CDKN1B is unchecked
in the authenticated checkpoint-283 project and checked at checkpoint 286;
its first named completion entry is update 41, and it is absent from the 235
historical queue entries. An older CDKN1B review-file merge does not establish
that it was included in an earlier campaign count. No count is reduced on that
unsupported premise. This audit does not reconstruct every historical repository
review merge or change the authoritative checkbox count.

All 2,876 catalog rows and their association text, all 235 historical queue
entries, all 41 prior completion updates and all previous progress text remain
unchanged. Only CDKL5 and CDKN1C checkboxes change; update 42 is appended.
Biological DRAFT status or justified UNDECIDED annotations alone create no hold.
CDKN2A, CDT1 and later merges are outside this fixed cutoff. The first unchecked
gene in literal catalog order remains ACBD5.
Authenticated evidence was read and this proposal recorded at 2026-10-10T02:40:24.759913+00:00.

Checkpoint 288 session history.

Completion checkpoint 286 — 2026-10-10 01:50:04 UTC

286 complete / 2,590 remaining in the frozen 2,876-gene catalog. Three distinct
primary-gene campaign reviews add three originals and completions beyond checkpoint 283.
No follow-up holds remain. Supplementary genes and repeat reviews add no count.

Gene PR Final head Approval Merged UTC Merge commit
CDHR1 #4491 7d4210d5a86e Approved 2026-10-10T01:27:47Z 3eb71be1db01
CDK13 #4492 b26f957911df Approved 2026-10-10T01:49:55Z 407f9f331915
CDKN1B #4495 341379300d25 Approved 2026-10-10T01:50:04Z faaaf56614b1

Each approval belongs to its listed final head. Both test (3.12) and claude-review
succeeded on that same commit before merge, verified through check-suite commit IDs.
All 38 changed PR paths match approved heads and merge commits. All 17 gene artifacts
match both the fixed cutoff and later source main. CDKN1B receives its first campaign
completion after a substantive audit; its preexisting COMPLETE status did not close
the campaign task. Biological DRAFT status and justified UNDECIDED annotations do
not themselves create completion holds.

The completion cutoff is faaaf56614b1 at 2026-10-10T01:50:04Z.
The later source main snapshot 4d4eedf35ac6
contains these gene merges and tracker PR #4496,
which published checkpoint 283. Its later source-capture time does not add gene completions.
Authenticated evidence was read and this proposal recorded at 2026-10-10T01:53:45.247199+00:00.

All 2,876 catalog rows and association text, all 235 historical queue entries,
all 40 earlier completion updates and every prior dated progress section are preserved.
Only the three named primary checkboxes change, and a 41st completion update is appended.
Older dated observations remain historical. CDKL5, CDKN1C and CDKN2A are outside
this checkpoint regardless of later PR changes. The first unchecked gene in literal
catalog order remains ACBD5.

Checkpoint 286 session history.

Completion checkpoint 283 — 2026-10-10 01:04:37 UTC

283 complete / 2,593 remaining in the frozen 2,876-gene catalog. Five distinct
primary-gene campaign reviews add five originals and completions beyond checkpoint 278.
No follow-up holds remain. Supplementary genes and repeat reviews add no count.

Gene PR Final head Approval Merged UTC Merge commit
CDH11 #4486 36084b8f8c3b Approved 2026-10-10T00:52:07Z dccca414ec3a
CDH2 #4485 b94cb3bb39bd Approved 2026-10-10T00:52:57Z 936cc03bfaa4
CDH23 #4488 597e5068026d Approved 2026-10-10T00:55:59Z f7075527f6e4
CDH3 #4490 93e90cb9f65a Approved 2026-10-10T01:01:23Z 70c867e88cd2
CDH1 #4489 f09ac48d6dc1 Approved 2026-10-10T01:04:37Z 436d15327509

Each approval belongs to its listed final head. Both test (3.12) and claude-review
succeeded on that same commit before merge, verified through check-suite commit IDs.
All 85 changed PR paths match approved heads and merge commits. All 26 gene artifacts
match the fixed CDH1 cutoff commit. These checks preserve the accepted reviews
without reopening their scientific decisions. Biological DRAFT status and justified
UNDECIDED annotations do not themselves create completion holds.

The completion cutoff is 436d15327509 at 2026-10-10T01:04:37Z.
The later source main snapshot ffaf00ab93d4
contains these gene merges and tracker PR #4493,
which published checkpoint 278. Its later source-capture time does not add gene completions.
Authenticated evidence was read at 2026-10-10T01:21:45.219910+00:00.

All 2,876 catalog rows and association text, all 235 historical queue entries,
all 39 earlier completion updates and every prior dated progress section are preserved.
Only the five named primary checkboxes change, and a 40th completion update is appended.
Older dated observations remain historical; the cutoff excludes all later merges
and pending work. The first unchecked gene in literal catalog order remains ACBD5.

CDHR1, CDK13 and CDKL5 remain outside this checkpoint regardless of later PR changes.

Checkpoint 283 session history.

Completion checkpoint 278 — 2026-10-10 00:09:16 UTC

278 complete / 2,598 remaining in the frozen 2,876-gene catalog. This adds
CDC42 and CDC73 beyond published checkpoint 276.
The completion cutoff is the CDC73 merge, not the later source-capture time.

Gene PR Final head Approval Merged UTC Merge commit
CDC42 #4468 49587154183a Approved 2026-10-09T23:53:12Z 765c0cfb2adf
CDC73 #4474 9245b7b68999 Approved 2026-10-10T00:09:16Z c488afbe915c

Each approval belongs to the listed final head. The test (3.12) and claude-review
checks succeeded on that same commit before its actual merge time, verified
through check-suite commit IDs. All 102 changed PR paths match between approved
heads and merge commits. All 12 changed gene artifacts also match the cutoff
commit and the later fixed source-main snapshot. These checks preserve the
accepted scientific reviews; they do not reopen the genes or re-audit older completions.

Two new original reviews, no holds: both genes add one distinct primary
completion. The 276 prior originals and completions therefore become 278, with
zero pending completion holds. Only CDC42 and CDC73 primary checkboxes change.
Supplementary genes and repeat reviews add no completion. Biological DRAFT
status and justified UNDECIDED annotations do not themselves create a hold.

The completion cutoff is c488afbe915c at 2026-10-10T00:09:16Z.
The later source main snapshot 10eda3330253
contains both gene merges and the baseline tracker #4487, which merged at 2026-10-10T00:46:18Z.
That tracker publishes the earlier 276 checkpoint; its later merge time does
not shift this checkpoint's gene-completion cutoff. Any other later merges or
open PRs remain outside these totals.
Fresh source evidence was read at 2026-10-10T00:47:44.008147+00:00.

All 2,876 catalog entries and association text, 235 historical queue entries,
38 prior completion updates, the cleared current source-hold list and every
earlier dated progress section remain preserved. One 39th update is appended.
Older counts and states remain dated observations, superseded for current
totals by this checkpoint. The first unchecked gene in literal catalog order
remains ACBD5.

Checkpoint 278 session history.

Completion checkpoint 276 — 2026-10-09 23:33:32 UTC

276 complete / 2,600 remaining in the frozen 2,876-gene catalog. This adds
CDC45 and closes the AKR1D1 source hold beyond published checkpoint 274.
The fixed main snapshot 5c3a43a48ef7
contains both contributing merges and the preceding tracker merge. Completion
evidence stops at the AKR1D1 follow-up merge at the stated cutoff.

Gene PR Final head Approval Merged UTC Merge commit
CDC45 #4470 6026f164dc69 Approved 2026-10-09T19:39:58Z 64e6a5204644
AKR1D1 #4465 5239e0fca43d Approved 2026-10-09T23:33:32Z 5c3a43a48ef7

Each approval belongs to the listed final head. The test (3.12) and claude-review
checks completed successfully on that same commit before its actual merge time,
verified using their check-suite commit IDs. All 35 changed PR paths have the
same Git blob at the approved head and merge commit. All nine changed gene
artifacts also match the fixed cutoff snapshot. These checks preserve the
result of the accepted scientific reviews rather than reopening them.

The last hold closes without double-counting: AKR1D1 was already among
the 275 original reviewed genes at checkpoint 274. Its original review #3266
and prior follow-up #3941
had merged while the Reactome:R-HSA-193755 source gate remained open. The
accepted archived-source recovery and supporting-evidence corrections now
merged in #4465
close that gate. This adds one completion and no second original-gene merge.

CDC45 adds one new original reviewed gene to the prior 275, giving 276.
The AKR1D1 closure reduces the holds from one to zero, giving 276 complete.
Only the CDC45 and AKR1D1 primary checkboxes change. Supplementary genes and
repeat reviews add no further completion. Biological DRAFT status and justified
UNDECIDED annotations remain independent of campaign closure.

Fresh remote evidence was read at 2026-10-09T23:38:49.211263+00:00. Merge times determine inclusion,
not the later observation time. Tracker #4472 merged at 2026-10-09T23:31:07Z
and supplies the published 274 baseline; its own earlier evidence cutoff
excluded CDC45. Later merges and open work are outside this checkpoint. The
first unchecked gene in literal catalog order remains ACBD5.

The project status, queue status and latest completion timestamp use this
checkpoint. All 235 historical queue entries, 37 prior completion updates and
earlier dated progress sections are preserved. Their older states and counts
remain dated observations, superseded for current totals by this section.

Checkpoint 276 session history.

Completion checkpoint 274 — 2026-10-09 18:49:44 UTC

Session history.

274 complete / 2,602 remaining in the frozen 2,876-gene catalog. This adds
four completions beyond published checkpoint 270.
The fixed main snapshot db510ed9a7ef
contains all four gene/follow-up merges and the preceding tracker merge.
Completion evidence stops at the BCL10 follow-up merge at the stated cutoff.

Gene PR Final head Approval Merged UTC Merge commit
CDC14A #4463 38335fdf45db Approved 2026-10-09T18:26:46Z c93df3ff8545
BIN1 #4461 f2f8421ff73f Approved 2026-10-09T18:26:55Z 9e7ccfbd0ad4
BLM #4464 8bde66823a63 Approved 2026-10-09T18:27:02Z 70a01c34741c
BCL10 #4458 0b2a5d48eb48 Approved 2026-10-09T18:49:44Z db510ed9a7ef

Each approval belongs to the listed final head. The test (3.12) and claude-review
checks completed successfully on that same commit before its actual merge time,
verified using their check-suite commit IDs. All 43 changed PR paths have the
same Git blob at the approved head and merge commit. All 17 changed gene
artifacts also match the fixed cutoff snapshot. These checks do not substitute
for or re-open the already completed scientific reviews.

Three holds close without double-counting original reviews:

Gene Original review already counted Original merge Closing follow-up
BCL10 #3649 92de042a96a5 (2026-10-05T23:23:15Z) #4458
BIN1 #3689 8446f4d12098 (2026-10-05T23:24:18Z) #4461
BLM #3706 ed30b12d9918 (2026-10-05T23:24:31Z) #4464

CDC14A adds one distinct original reviewed gene to the prior 274, giving 275.
BIN1, BLM and BCL10 were already among those original reviews; their required
follow-ups supply three further completions and reduce the holds from four to
one. Thus 275 minus one hold gives 274 complete. Exactly these four primary
checkboxes change; supplementary genes and repeat reviews add no further
completion.

Merged original review but incomplete at this cutoff: AKR1D1 retains its
required Reactome:R-HSA-193755 source-follow-up gate. Its follow-up #4465
had not merged at the fixed cutoff, so proposed source recovery and evidence
corrections do not yet close the campaign hold. This does not claim that every
underlying source remains inaccessible. Biological DRAFT status and justified
UNDECIDED annotations remain independent of campaign closure.

Fresh remote evidence was read at 2026-10-09T18:54:37.586442+00:00. The recorded merge times,
rather than the later observation time, determine inclusion. Tracker #4467
merged at 2026-10-09T18:26:37Z and is the published baseline. Subsequent merges
and open work are outside this checkpoint. The first unchecked gene in literal
catalog order remains ACBD5.

The project status, queue status and latest completion timestamp use this
checkpoint. All 235 historical queue entries, 36 prior completion updates and
earlier dated progress sections are preserved. Their older PR states and counts
remain historical observations, superseded for current totals by this section.

Completion checkpoint 270 — 2026-10-09 17:36:48 UTC

270 complete / 2,606 remaining in the frozen 2,876-gene catalog. This adds
eight completions beyond published checkpoint 262.
The fixed main snapshot fd81ce72cba2
contains all eight gene merges and the preceding tracker merge. Completion
evidence stops at the BCS1L follow-up merge at the stated cutoff.

Gene PR Final head Approval Merged UTC Merge commit
BCAP31 #3605 d0650b3fbc6c Approved 2026-10-09T16:36:48Z f7911a500f1b
BCOR #3669 326a03a22810 Approved 2026-10-09T16:37:50Z 34a24b719bd0
CDAN1 #4456 316d1fe4894c Approved 2026-10-09T16:47:23Z fe9d0eec86d1
BCKDHB #4457 49370df72373 Approved 2026-10-09T16:55:25Z 8304d7366c63
CD70 #4446 36325439ce74 Approved 2026-10-09T17:34:07Z 3c072d130a74
CD79A #4453 ed8dff6d008e Approved 2026-10-09T17:34:17Z 956eca1abfa5
CD79B #4455 503f8b6beda9 Approved 2026-10-09T17:34:28Z a6fbc79b744d
BCS1L #4460 63120c89599a Approved 2026-10-09T17:36:48Z fd81ce72cba2

Each approval belongs to the listed final head. The test (3.12) and claude-review
checks completed successfully on that same commit before its actual merge time,
verified using their check-suite commit IDs. All 93 changed PR paths were checked
against their approved heads and merge commits. The 92 identical paths include
all 35 changed gene artifacts, which also match the fixed cutoff snapshot. The
sole shared-cache difference is BCOR: its merge retains the newer main GO cache
rows and adds only the approved GO:0140261 BCOR complex row. This cache is not
claimed to be byte-identical to its older PR head.

Two holds close without double-counting original reviews:

Gene Original review already counted Original merge Closing follow-up
BCKDHB #3616 c3f9ef9a3bdc (2026-10-05T23:23:02Z) #4457
BCS1L #3658 9da157e0d2bb (2026-10-05T23:23:38Z) #4460

BCAP31, BCOR, CDAN1, CD70, CD79A and CD79B add six distinct original reviewed
genes to the prior 268, giving 274. BCKDHB and BCS1L were already among
those original reviews; their follow-ups supply two further completions and
reduce the holds from six to four. Thus 274 minus four holds gives 270 complete.
Exactly these eight primary checkboxes change; supplementary genes and repeat
reviews add no further completion.

Merged but incomplete at this cutoff: AKR1D1 retains its recorded
Reactome:R-HSA-193755 source gate; BCL10, BIN1 and BLM retain their recorded
binding-policy follow-up requirement. Later proposed corrections do not close
these holds at this snapshot. Biological DRAFT status and justified UNDECIDED
annotations remain independent of campaign closure.

Fresh remote evidence was read at 2026-10-09T17:42:42.558201+00:00. The recorded merge times,
rather than the later observation time, determine inclusion. Tracker #4459
merged at 2026-10-09T17:34:40Z and is the published baseline. Subsequent merges
and open work are outside this checkpoint. The first unchecked gene in literal
catalog order remains ACBD5.

The project status, queue status and latest completion timestamp use this
checkpoint. All 235 historical queue entries, 35 prior completion updates and
earlier dated progress sections are preserved. Their older PR states and counts
remain historical observations, superseded for current totals by this section.

Checkpoint curation history records this update.

Completion checkpoint 262 — 2026-10-09 16:19:32 UTC

262 complete / 2,614 remaining in the frozen 2,876-gene catalog. This adds
five completions beyond published checkpoint 257.
The fixed main snapshot 1353583bdcc0
contains all five gene merges and the preceding tracker merge. Completion evidence
stops at the BBS5 merge at the stated cutoff.

Gene PR Final head Approval Merged UTC Merge commit
CD40LG #4442 95855ddee197 Approved 2026-10-09T15:32:28Z 4d0debe40f95
BBS7 #3596 10f97c076fce Approved 2026-10-09T15:34:07Z e1cf41205fa0
CD46 #4444 f58c5c03b1dd Approved 2026-10-09T16:02:20Z e92ea9b751fa
BBS9 #3604 94f9165fefd1 Approved 2026-10-09T16:09:49Z 7570bc0a5e0f
BBS5 #3592 0c231ad1487d Approved 2026-10-09T16:19:32Z 1353583bdcc0

Each approval belongs to the listed final head. The test (3.12) and claude-review
checks completed successfully on that same commit before merge, verified using
their check-suite commit IDs. Exactly these five primary checkboxes change.
Supplementary genes and repeat reviews add no completion.

Merged but incomplete: the six holds remain AKR1D1, BCKDHB, BCL10, BCS1L,
BIN1 and BLM. AKR1D1 retains its unresolved Reactome:R-HSA-193755 source gate;
the other five retain their recorded binding-policy follow-up requirement.
The fresh BCKDHB follow-up #4457
is open at the separate observation below and does not close its hold. Thus 268
distinct primary genes have merged original campaign reviews: 262 completions
and six holds. DRAFT review status and justified UNDECIDED annotations remain
independent of campaign closure.

Open campaign PRs, observed 2026-10-09T16:29:40.461702+00:00:
these dated observations add no completion at the fixed cutoff.

Gene PR Observed head Review test (3.12) Review workflow
BCAP31 #3605 d0650b3fbc6c APPROVED IN_PROGRESS SUCCESS
BCKDHB #4457 49370df72373 REVIEW_REQUIRED IN_PROGRESS IN_PROGRESS
BCOR #3669 326a03a22810 APPROVED IN_PROGRESS SUCCESS
CD70 #4446 936f131d4710 APPROVED IN_PROGRESS SUCCESS
CD79A #4453 752bbe2df6d3 CHANGES_REQUESTED SUCCESS SUCCESS
CD79B #4455 36973541616d CHANGES_REQUESTED IN_PROGRESS SUCCESS
CDAN1 #4456 316d1fe4894c REVIEW_REQUIRED IN_PROGRESS IN_PROGRESS

Continue these reviews and their actionable feedback. The first unchecked gene
in literal catalog order remains ACBD5; active work elsewhere does not mark
earlier catalog entries complete.

Checkpoint curation history records this update.

The project status, queue status and latest completion timestamp use this
checkpoint. All 235 historical queue entries, 34 prior completion updates and
earlier dated progress sections are preserved. Their older PR states and counts
remain historical observations, superseded for current totals by this section.

Completion checkpoint 257 — 2026-10-09 14:48:08 UTC

257 complete / 2,619 remaining in the frozen 2,876-gene catalog. This adds
six completions beyond published checkpoint 251.
The fixed main snapshot de56024a5a3e
includes the BBS4 merge at the stated cutoff. No pending approval or later merge
is included.

Gene PR Final approved head Merged UTC Merge commit
BBS1 #3586 0c25363c49ec 2026-10-09T13:57:01Z 67c4ec0a6e4a
BBS10 #3587 a751ae7465bf 2026-10-09T14:10:22Z 35f6d3a75628
CD3G #4431 9564eb79dd2e 2026-10-09T14:14:25Z fd0499e2fa48
BBS2 #3590 d2565cbf2cbc 2026-10-09T14:40:32Z 4f6e56c0f97e
CD40 #4437 0c3cb34ea333 2026-10-09T14:41:35Z c8681adfdbc0
BBS4 #3591 412f235a3d7a 2026-10-09T14:48:08Z de56024a5a3e

Each listed head has an APPROVED review and successful test (3.12) and
claude-review checks on that same commit. All six primary catalog checkboxes
change from unchecked to checked. No supplemental gene or repeated review adds
to the completion count.

Merged but incomplete: the same six required follow-ups remain unchecked:
AKR1D1 #3266/#3941
for the unresolved Reactome:R-HSA-193755 source gate;
BCKDHB #3616,
BCL10 #3649,
BCS1L #3658,
BIN1 #3689 and
BLM #3706 for the
previously documented, row-specific binding-policy follow-ups. Thus 263 primary
genes have merged campaign reviews, comprising 257 completions and six holds.
Justified UNDECIDED annotations and biological DRAFT status remain independent
of campaign closure.

Open campaign PRs, observed 2026-10-09T14:59:20.102408+00:00:
these are a separate current-work observation, not additional completions.

Gene PR Observed head Review test (3.12) Review workflow
BBS5 #3592 6963bc0c862a CHANGES_REQUESTED IN_PROGRESS SUCCESS
BBS7 #3596 32fbd403feac CHANGES_REQUESTED IN_PROGRESS QUEUED
BBS9 #3604 85458a897999 CHANGES_REQUESTED SUCCESS SUCCESS
BCAP31 #3605 e5edf4a90794 CHANGES_REQUESTED SUCCESS SUCCESS
BCOR #3669 2b44abc319a4 CHANGES_REQUESTED SUCCESS SUCCESS
CD40LG #4442 39cfbc94b731 CHANGES_REQUESTED SUCCESS SUCCESS
CD46 #4444 9022fd678447 CHANGES_REQUESTED IN_PROGRESS SUCCESS

BBS5 is the earliest open campaign PR. Continue the open reviews and their
feedback, with CD40LG and CD46 preceding the saved CD70 continuation. The first
unchecked gene in literal catalog order remains ACBD5; this work order does not
imply that earlier unchecked genes are complete.

The parent project status, queue status and latest completion timestamp all use
this checkpoint. The 235 historical queue entries and all earlier completion
updates are preserved. The prior reconciliation and dated tables below remain
historical observations at their original cutoffs, superseded for current totals
by this section.

Completion reconciliation — 2026-10-09

251 complete / 2,625 remaining in the frozen 2,876-gene catalog. The published
checkpoint 240 gains the following 11 completions. The first six were already
confirmed in the saved session checkpoint 246; the last five merged on October 6.

Gene PR Merged UTC Merge commit
CCM2 #4239 2026-10-05T01:59:05Z fa209203c572
CCNO #4253 2026-10-05T03:34:33Z 0c68977b2022
CCN6 #4240 2026-10-05T04:53:11Z 68355bad3b0b
CD19 #4256 2026-10-05T05:26:51Z 44c0cfeaa6a6
CD320 #4273 2026-10-05T06:00:49Z 7df8e72f6937
CD27 #4307 2026-10-05T06:48:46Z 866a9ea15d96
CD247 #4264 2026-10-06T11:39:16Z a834dfb54079
CD2AP #4287 2026-10-06T11:40:18Z 23bf11486ff1
CD3D #4293 2026-10-06T11:41:17Z 4987e0d39b1d
ASB10 #4308 2026-10-06T11:43:34Z 4fb7e051901a
CD3E #4313 2026-10-06T11:43:47Z 7c1ba7f73a84

All 11 PRs have approval on the final head and successful test (3.12) and
claude-review checks. For the five October 6 closures, current main retains
DRAFT review status and the recorded evidence uncertainties; campaign closure
does not turn these into resolved biological assertions. ASB10 is counted once
after its required binding-policy follow-up #4308.

Merged but incomplete: AKR1D1 #3266/#3941 retains its unresolved
Reactome:R-HSA-193755 source gate. Five other merged PRs require project-policy
follow-up; 29 generic-binding removals were identified for row-specific
assessment:

Gene Merged PR Generic GO:0005515 REMOVE rows requiring follow-up
BCKDHB #3616 5
BCL10 #3649 4
BCS1L #3658 1
BIN1 #3689 4
BLM #3706 15

Their approvals applied the repository-wide informational-exclusion policy,
whereas this project explicitly retains supported generic interactions as
KEEP_AS_NON_CORE unless a supported refinement exists. Review each row against
its evidence; do not replace removals mechanically. These five and AKR1D1 stay
unchecked. The 257 distinct primary genes with merged campaign PRs therefore
comprise 251 completed genes and six required follow-ups.

Open campaign PRs: all nine remain CHANGES_REQUESTED with required CI green.

Gene PR State
BBS1 #3586 CHANGES_REQUESTED; test (3.12) SUCCESS
BBS10 #3587 CHANGES_REQUESTED; test (3.12) SUCCESS
BBS2 #3590 CHANGES_REQUESTED; test (3.12) SUCCESS
BBS4 #3591 CHANGES_REQUESTED; test (3.12) SUCCESS
BBS5 #3592 CHANGES_REQUESTED; test (3.12) SUCCESS
BBS7 #3596 CHANGES_REQUESTED; test (3.12) SUCCESS
BBS9 #3604 CHANGES_REQUESTED; test (3.12) SUCCESS
BCAP31 #3605 CHANGES_REQUESTED; test (3.12) SUCCESS
BCOR #3669 CHANGES_REQUESTED; test (3.12) SUCCESS

Resume the saved in-progress review at CD3G, then CD40, CD40LG, CD46 and CD70;
keep the older open PRs and merged follow-ups visible in the queue. The literal
first unchecked Definitive inventory gene is ACBD5, so the saved continuation
cursor is not a claim that every earlier gene is complete.

The mixed 707-path MAPK_CASCADES PR #3381 is excluded from this count; its BRAF
changes still need a campaign assessment. Unrelated project reviews, repeated
reviews and supplemental work do not increment the primary denominator or
completion count. The mitochondrial, RNA, other-locus and undetermined-inheritance
lists are already included in the frozen 2,876.

The following historical status table and all earlier dated observations are
preserved at their original cutoff.

Campaign status — completion evidence through 2026-10-05 01:02:15 UTC

Gene Tier Starting review status Current state Branch PR
A4GALT Definitive INITIALIZED Merged; final validation and CI passed cmungall/clingen-a4galt #3127
AARS1 Definitive COMPLETE Post-merge source follow-up #3301 merged; exact-head approval and required CI passed; all 15 scoped merged blobs verified cmungall/clingen-aars1 #3129
AARS2 Definitive COMPLETE Merged; final validation and CI passed cmungall/clingen-aars2 #3128
AASS Definitive INITIALIZED Merged; final validation and CI passed cmungall/clingen-aass #3133
ABCA3 Definitive No review Post-merge source follow-up #3303 merged; current-head approval and required CI passed; all 15 scoped merged blobs verified cmungall/clingen-abca3 #3134
ABCA4 Definitive No review Post-merge source follow-up #3308 merged; current-head approval and required CI passed; all 16 scoped merged blobs verified cmungall/clingen-abca4 #3132
ABCB4 Definitive No review Merged; final approval and required CI passed cmungall/clingen-abcb4 #3135
ABCC6 Definitive No review Merged; final approval and required CI passed cmungall/clingen-abcc6 #3138
ABCC8 Definitive No review Post-merge source follow-up #3310 merged; current-head approval and required CI passed; all 19 scoped merged blobs verified cmungall/clingen-abcc8 #3136
ABCC9 Definitive No review Merged; final approval and required CI passed cmungall/clingen-abcc9 #3148
ABCD1 Definitive No review Post-merge source follow-up #3311 merged; current-head approval and required CI passed; all 20 scoped merged blobs verified cmungall/clingen-abcd1 #3150
ACAD8 Definitive INITIALIZED Merged; final approval and required CI passed cmungall/clingen-acad8 #3151
ACAD9 Definitive COMPLETE Merged; final approval and required CI passed cmungall/clingen-acad9 #3152
ACADM Definitive COMPLETE Merged; final-head approval and required CI passed; all required source caches published cmungall/clingen-acadm #3156
ACADS Definitive COMPLETE Merged; final approval and required CI passed cmungall/clingen-acads #3155
ACADSB Definitive INITIALIZED Merged; final approval and required CI passed cmungall/clingen-acadsb #3154
ACADVL Definitive COMPLETE Merged; final-head approval and required CI passed cmungall/clingen-acadvl #3157
ACAN Definitive COMPLETE Merged; final-head approval and required CI passed; all required source caches published cmungall/clingen-acan #3153
ACAT1 Definitive COMPLETE Original and follow-up merged; final-head approval and required CI passed; all 15 scoped merged blobs verified cmungall/clingen-acat1 #3158
ACOX1 Definitive INITIALIZED Merged; final-head approval and required CI passed; all required source caches published cmungall/clingen-acox1 #3159
ACOX2 Definitive INITIALIZED Post-merge source follow-up #3248 merged; exact-head approval and required CI passed; all 25 scoped merged blobs verified cmungall/clingen-acox2 #3161
ACSL4 Definitive COMPLETE Post-merge source follow-up #3247 merged; exact-head approval and required CI passed; all 50 scoped merged blobs verified cmungall/clingen-acsl4 #3160
ACTA1 Definitive COMPLETE Merged; final-head approval and required CI passed cmungall/clingen-acta1 #3163
ACTA2 Definitive COMPLETE Merged; final-head approval and required CI passed; all cited publication caches available cmungall/clingen-acta2 #3164
ACTB Definitive COMPLETE Post-merge source follow-up #3302 merged; current-head approval and required CI passed; all 24 scoped merged blobs verified cmungall/clingen-actb #3184
ADA Definitive INITIALIZED Merged; final-head approval and required CI passed; all required source follow-ups merged cmungall/clingen-ada #3179
ADGRV1 Definitive COMPLETE Post-merge source follow-up #3304 merged; current-head approval and required CI passed; all 21 scoped merged blobs verified cmungall/clingen-adgrv1 #3192
ADNP Definitive COMPLETE Review #3193 merged; exact-head approval and required CI passed; all 44 scoped merged blobs verified cmungall/clingen-adnp #3193
ADSL Definitive INITIALIZED Merged #3194; final-head approval and required CI passed; all 23 scoped merged blobs verified cmungall/clingen-adsl #3194
AFG3L2 Definitive COMPLETE Post-merge source follow-up #3312 merged; current-head approval and required CI passed; all 13 scoped merged blobs verified cmungall/clingen-afg3l2 #3196
AGK Definitive COMPLETE Post-merge source follow-up #3314 merged; current-head approval and required CI passed; all 46 scoped merged blobs verified cmungall/clingen-agk #3195
AGL Definitive INITIALIZED Merged; final-head approval and required CI passed; all required source follow-ups merged cmungall/clingen-agl #3197
AGO1 Definitive COMPLETE Post-merge source follow-up #3313 merged; current-head approval and required CI passed; all 13 scoped merged blobs verified cmungall/clingen-ago1 #3207
AGO2 Definitive COMPLETE Post-merge source follow-up #3288 merged; exact-head approval and required CI passed; all 21 scoped merged blobs verified cmungall/clingen-ago2 #3210
AGPAT2 Definitive INITIALIZED Merged; final-head approval and required CI passed; all required source caches published cmungall/clingen-agpat2 #3208
AGPS Definitive INITIALIZED Merged; final-head approval and required CI passed; all required source caches published cmungall/clingen-agps #3209
AGXT Definitive INITIALIZED Merged; final-head approval and required CI passed; all required source caches published cmungall/clingen-agxt #3212
AHDC1 Definitive COMPLETE Merged; final-head substantive approval and required CI passed; all required source follow-ups merged cmungall/clingen-ahdc1 #3213
AHI1 Definitive COMPLETE Review #3215 merged; exact-head approval and required CI passed; all 37 scoped merged blobs verified cmungall/clingen-ahi1 #3215
AKT1 Limited COMPLETE Review merged; final-head approval and required CI passed; all 69 scoped merged blobs verified cmungall/clingen-akt1 #3242
AGRN Definitive COMPLETE Review #3243 merged; current-head approval and required CI passed; all 55 scoped merged blobs verified cmungall/clingen-agrn #3243
AHCY Definitive COMPLETE Review merged; final-head approval and required CI passed; all 14 scoped merged blobs verified cmungall/clingen-ahcy #3244
AIMP1 Definitive COMPLETE Review merged; final-head approval and required CI passed; all 21 scoped merged blobs verified cmungall/clingen-aimp1 #3262
AIMP2 Definitive COMPLETE Post-merge source follow-up #3289 merged; exact-head approval and required CI passed; all 24 scoped merged blobs verified cmungall/clingen-aimp2 #3256
AIPL1 Definitive COMPLETE Merged #3257; final-head approval and required CI passed; all 24 scoped merged blobs verified cmungall/clingen-aipl1 #3257
AIRE Definitive COMPLETE Review merged; final-head approval and required CI passed; all 22 scoped merged blobs verified cmungall/clingen-aire #3265
AKR1D1 Definitive INITIALIZED Original #3266 externally observed merged; scoped reviewed/merged blobs verified; Required source R-HSA-193755 remains unresolved; merge does not grant completion. cmungall/clingen-akr1d1 #3266
ALAS2 Definitive INITIALIZED Merged #3267; final-head approval and required CI passed; all 21 scoped merged blobs verified cmungall/clingen-alas2 #3267
ALDH18A1 Definitive INITIALIZED Review merged; final-head approval and required CI passed; all 15 scoped merged blobs verified cmungall/clingen-aldh18a1 #3269
ALDH4A1 Definitive COMPLETE Review merged; final-head approval and required CI passed; all 9 scoped merged blobs verified cmungall/clingen-aldh4a1 #3271
ALDH5A1 Definitive INITIALIZED Review merged; final-head approval and required CI passed; all 11 scoped merged blobs verified cmungall/clingen-aldh5a1 #3268
ALDH7A1 Definitive IN_PROGRESS Review merged; final-head approval and required CI passed; all 18 scoped merged blobs verified cmungall/clingen-aldh7a1 #3277
ALDOB Definitive INITIALIZED Review #3279 merged; exact-head approval and required CI passed; all 16 scoped merged blobs verified cmungall/clingen-aldob #3279
ALG1 Definitive INITIALIZED Review merged; final-head approval and required CI passed; all 12 scoped merged blobs verified cmungall/clingen-alg1 #3280
ALG12 Definitive INITIALIZED Review #3281 merged; exact-head approval and required CI passed; all 10 scoped merged blobs verified cmungall/clingen-alg12 #3281
ALG13 Definitive INITIALIZED Review merged; final-head approval and required CI passed; all 9 scoped merged blobs verified cmungall/clingen-alg13 #3282
ALG3 Definitive INITIALIZED Review merged; final-head approval and required CI passed; all 12 scoped merged blobs verified cmungall/clingen-alg3 #3283
ABCG5 Definitive No review Review merged; final-head approval and required CI passed; all 28 scoped merged blobs verified cmungall/clingen-abcg5 #3285
ABCG8 Definitive No review Review #3284 merged; exact-head approval and required CI passed; all 24 scoped merged blobs verified cmungall/clingen-abcg8 #3284
ABHD12 Definitive No review Review #3286 merged; exact-head approval and required CI passed; all 24 scoped merged blobs verified cmungall/clingen-abhd12 #3286
ABHD5 Definitive No review Review merged; final-head approval and required CI passed; all 15 scoped merged blobs verified cmungall/clingen-abhd5 #3287
AICDA Definitive No review Review #3290 merged; exact-head approval and required CI passed; all 27 scoped merged blobs verified cmungall/clingen-aicda #3290
AGTPBP1 Definitive No review Review merged; final-head approval and required CI passed; all 19 scoped merged blobs verified cmungall/clingen-agtpbp1 #3292
AIFM1 Definitive No review Review #3295 merged; exact-head approval and required CI passed; all 25 scoped merged blobs verified cmungall/clingen-aifm1 #3295
AK2 Definitive No review Review #3297 merged; exact-head approval and required CI passed; all 19 scoped merged blobs verified cmungall/clingen-ak2 #3297
ALG6 Definitive INITIALIZED Review #3296 merged; exact-head approval and required CI passed; all 9 scoped merged blobs verified cmungall/clingen-alg6 #3296
ALG8 Definitive INITIALIZED Review #3298 merged; exact-head approval and required CI passed; all 10 scoped merged blobs verified cmungall/clingen-alg8 #3298
ALG9 Definitive INITIALIZED Review #3299 merged; exact-head approval and required CI passed; all 11 scoped merged blobs verified cmungall/clingen-alg9 #3299
ALB Definitive No review Review #3305 merged; current-head approval and required CI passed; all 41 scoped merged blobs verified cmungall/clingen-alb #3305
ALK Definitive INITIALIZED Review #3316 merged; current-head approval and required CI passed; all 70 scoped merged blobs verified cmungall/clingen-alk #3316
ALMS1 Definitive INITIALIZED Review #3318 merged; current-head approval and required CI passed; all 39 scoped merged blobs verified cmungall/clingen-alms1 #3318
ALPK1 Definitive INITIALIZED Review #3317 merged; current-head approval and required CI passed; all 29 scoped merged blobs verified cmungall/clingen-alpk1 #3317
AMT Definitive INITIALIZED Review #3315 merged; current-head approval and required CI passed; all 12 scoped merged blobs verified cmungall/clingen-amt #3315
ALPK3 Definitive INITIALIZED Review #3325 merged; current-head approval and required CI passed; all 18 scoped merged blobs verified cmungall/clingen-alpk3 #3325
ALPL Definitive COMPLETE Review #3320 merged; current-head approval and required CI passed; all 47 scoped merged blobs verified cmungall/clingen-alpl #3320
ALX3 Definitive INITIALIZED Review #3324 merged; current-head approval and required CI passed; all 13 scoped merged blobs verified cmungall/clingen-alx3 #3324
ALS2 Definitive INITIALIZED Review #3326 merged; current-head approval and required CI passed; all 23 scoped merged blobs verified cmungall/clingen-als2 #3326
ALX1 Definitive INITIALIZED Review #3327 merged; current-head approval and required CI passed; all 21 scoped merged blobs verified cmungall/clingen-alx1 #3327
ALX4 Definitive INITIALIZED Review #3328 merged; current-head approval and required CI passed; all 19 scoped merged blobs verified cmungall/clingen-alx4 #3328
AMER1 Definitive INITIALIZED Review #3329 merged; current-head approval and required CI passed; all 42 scoped merged blobs verified cmungall/clingen-amer1 #3329
ANK1 Definitive INITIALIZED Review #3332 merged; current-head approval and required CI passed; all 31 scoped merged blobs verified cmungall/clingen-ank1 #3332
ANGPTL3 Definitive INITIALIZED Review #3336 merged; current-head approval and required CI passed; all 18 scoped merged blobs verified cmungall/clingen-angptl3 #3336
ANK2 Definitive INITIALIZED Review #3338 merged; current-head approval and required CI passed; all 30 scoped merged blobs verified cmungall/clingen-ank2 #3338
ANKRD11 Definitive INITIALIZED Review #3337 merged; current-head approval and required CI passed; all 14 scoped merged blobs verified cmungall/clingen-ankrd11 #3337
ANKRD17 Definitive INITIALIZED Review #3340 merged; current-head approval and required CI passed; all 14 scoped merged blobs verified cmungall/clingen-ankrd17 #3340
ANKRD26 Definitive INITIALIZED Review #3339 merged; current-head approval and required CI passed; all 13 scoped merged blobs verified cmungall/clingen-ankrd26 #3339
ANKS6 Definitive COMPLETE Review #3343 merged; current-head approval and required CI passed; all 16 scoped merged blobs verified cmungall/clingen-anks6 #3343
ANO10 Definitive INITIALIZED Review #3347 merged; current-head approval and required CI passed; all 17 scoped merged blobs verified cmungall/clingen-ano10 #3347
ANO5 Definitive INITIALIZED Review #3349 merged; current-head approval and required CI passed; all 24 scoped merged blobs verified cmungall/clingen-ano5 #3349
ANOS1 Definitive INITIALIZED Review #3350 merged; current-head approval and required CI passed; all 15 scoped merged blobs verified cmungall/clingen-anos1 #3350
ANTXR1 Definitive INITIALIZED Review #3351 merged; current-head approval and required CI passed; all 22 scoped merged blobs verified cmungall/clingen-antxr1 #3351
ANTXR2 Definitive INITIALIZED Review #3352 merged; current-head approval and required CI passed; all 26 scoped merged blobs verified cmungall/clingen-antxr2 #3352
ANXA11 Definitive INITIALIZED Review #3353 merged; current-head approval and required CI passed; all 35 scoped merged blobs verified cmungall/clingen-anxa11 #3353
AP4E1 Definitive INITIALIZED Review #3354 merged; current-head approval and required CI passed; all 20 scoped merged blobs verified cmungall/clingen-ap4e1 #3354
AP5Z1 Definitive INITIALIZED Review #3355 merged; current-head approval and required CI passed; all 16 scoped merged blobs verified cmungall/clingen-ap5z1 #3355
AP1G1 Definitive INITIALIZED Review #3357 merged; current-head approval and required CI passed; all 47 scoped merged blobs verified cmungall/clingen-ap1g1 #3357
AP2M1 Definitive INITIALIZED Review #3358 merged; current-head approval and required CI passed; all 104 scoped merged blobs verified cmungall/clingen-ap2m1 #3358
APC2 Strong INITIALIZED Review #3359 merged; current-head approval and required CI passed; all 21 scoped merged blobs verified cmungall/clingen-apc2 #3359
APC Definitive INITIALIZED Review #3360 merged; current-head approval and required CI passed; all 122 scoped merged blobs verified cmungall/clingen-apc #3360
ARG1 Definitive COMPLETE Review #3361 merged; current-head approval and required CI passed; all 22 scoped merged blobs verified cmungall/clingen-arg1 #3361
APOL1 Definitive INITIALIZED Review #3363 merged; current-head approval and required CI passed; all 18 scoped merged blobs verified cmungall/clingen-apol1 #3363
ARHGAP29 Definitive INITIALIZED Review #3362 merged; current-head approval and required CI passed; all 17 scoped merged blobs verified cmungall/clingen-arhgap29 #3362
APOB Definitive INITIALIZED Review #3365 merged at 2026-10-03 02:24:02 UTC; final-head approval and required CI passed; 107 explicitly scoped files and 52 complete PR diff paths verified. Biological YAML remains COMPLETE, with 158 annotations and 33 UNDECIDED judgments. cmungall/clingen-apob #3365
AR Definitive INITIALIZED Review #3364 merged; current-head approval and required CI passed; all 114 scoped merged blobs verified cmungall/clingen-ar #3364
ARHGEF9 Definitive INITIALIZED Review #3366 merged; current-head approval and required CI passed; all 19 scoped merged blobs verified cmungall/clingen-arhgef9 #3366
ARID1A Definitive INITIALIZED Review #3367 merged; current-head approval and required CI passed; all 53 scoped merged blobs verified cmungall/clingen-arid1a #3367
ARID1B Definitive INITIALIZED Review #3370 merged; current-head approval and required CI passed; all 35 scoped merged blobs verified cmungall/clingen-arid1b #3370
ARID2 Definitive INITIALIZED Review #3372 merged at 2026-10-02 21:50:40 UTC; final-head approval and required CI passed; all 37 scoped merged blobs and 15 PR paths verified. Biological YAML remains COMPLETE independently of campaign completion. cmungall/clingen-arid2 #3372
ARMC2 Definitive INITIALIZED Review #3369 merged; current-head approval and required CI passed; all 11 scoped merged blobs verified cmungall/clingen-armc2 #3369
ARMC9 Definitive INITIALIZED Review #3371 merged at 2026-10-02 20:57:05 UTC; final-head approval and required CI passed; all 14 scoped merged blobs and 11 PR paths verified. Biological YAML remains COMPLETE independently of campaign completion. cmungall/clingen-armc9 #3371
ARL13B Definitive INITIALIZED Review #3374 merged at 2026-10-02 20:57:23 UTC; final-head approval and required CI passed; all 32 scoped merged blobs and 18 PR paths verified. Biological YAML remains COMPLETE independently of campaign completion. cmungall/clingen-arl13b #3374
ARL2BP Definitive INITIALIZED Review #3373 merged; current-head approval and required CI passed; all 33 scoped merged blobs verified cmungall/clingen-arl2bp #3373
ARPC1B Definitive INITIALIZED Review #3378 merged; current-head approval and required CI passed; all 27 scoped merged blobs verified cmungall/clingen-arpc1b #3378
ARSA Definitive PREEXISTING_REVIEW_AUGMENTED Review #3376 merged; current-head approval and required CI passed; all 31 scoped merged blobs verified cmungall/clingen-arsa #3376
ARSB Definitive PREEXISTING_REVIEW_AUGMENTED Review #3379 merged; current-head approval and required CI passed; all 30 scoped merged blobs verified cmungall/clingen-arsb #3379
ARSL Definitive NORMAL_PENDING_SEED_REVIEWED Review #3382 merged; current-head approval and required CI passed; all 13 scoped merged blobs verified cmungall/clingen-arsl #3382
ARX Definitive NORMAL_PENDING_SEED_REVIEWED Review #3384 merged; current-head approval and required CI passed; all 19 scoped merged blobs verified cmungall/clingen-arx #3384
ASAH1 Definitive PREEXISTING_REVIEW_AUGMENTED Review #3383 merged; current-head approval and required CI passed; all 32 scoped merged blobs verified cmungall/clingen-asah1 #3383
ASL Definitive PREEXISTING_REVIEW_AUGMENTED Review #3385 merged at 2026-10-02 20:57:44 UTC; final-head approval and required CI passed; all 25 scoped merged blobs and 8 PR paths verified. Biological YAML remains COMPLETE independently of campaign completion. cmungall/clingen-asl #3385
ASH1L Definitive NORMAL_PENDING_SEED_REVIEWED Review #3387 merged; current-head approval and required CI passed; all 17 scoped merged blobs verified cmungall/clingen-ash1l #3387
ASNS Definitive NORMAL_PENDING_SEED_REVIEWED Review #3438 merged at 2026-10-02 20:57:57 UTC; final-head approval and required CI passed; all 20 scoped merged blobs and 16 PR paths verified. Biological YAML remains COMPLETE independently of campaign completion. cmungall/clingen-asns #3438
ASPA Definitive NORMAL_PENDING_SEED_REVIEWED Review #3440 merged; current-head approval and required CI passed; all 25 scoped merged blobs verified cmungall/clingen-aspa #3440
ASS1 Definitive DRAFT (existing authored review) Review #3473 merged; current-head approval and required CI passed; all 35 scoped merged blobs verified; published YAML is COMPLETE; original merge receipt DRAFT metadata is a documented discrepancy cmungall/clingen-ass1 #3473
ASPM Definitive ABSENT Review #3501 merged; current-head approval and required CI passed; all 14 scoped merged blobs verified cmungall/clingen-aspm #3501
ASXL1 Definitive ABSENT Review #3526 merged; current-head approval and required CI passed; all 23 scoped merged blobs verified; biological YAML remains DRAFT with three documented generic-binding advisories cmungall/clingen-asxl1 #3526
ASXL2 Definitive ABSENT Review #3539 merged; current-head approval and required CI passed; all 16 scoped merged blobs verified; published YAML is COMPLETE; original merge receipt DRAFT metadata is a documented discrepancy cmungall/clingen-asxl2 #3539
ATF6 Definitive ABSENT Review #3536 merged; current-head approval and required CI passed; all 39 scoped merged blobs verified; published YAML is COMPLETE; original merge receipt DRAFT metadata is a documented discrepancy cmungall/clingen-atf6 #3536
ASXL3 Definitive ABSENT Review #3543 merged; current-head approval and required CI passed; all 12 scoped merged blobs verified cmungall/clingen-asxl3 #3543
ATL1 Definitive ABSENT Review #3545 merged; current-head approval and required CI passed; all 22 scoped merged blobs verified cmungall/clingen-atl1 #3545
ATM Definitive ABSENT Review #3547 merged; current-head approval and required CI passed; all 187 scoped merged blobs verified cmungall/clingen-atm #3547
ATP6AP2 Definitive Existing review audited Review #3548 merged; current-head approval and required CI passed; all 28 scoped merged blobs verified cmungall/clingen-atp6ap2 #3548
ATN1 Definitive Newly seeded Review #3549 merged; current-head approval and required CI passed; all 23 scoped merged blobs verified cmungall/clingen-atn1 #3549
ATP13A2 Definitive Newly seeded Review #3552 merged; current-head approval and required CI passed; all 38 scoped merged blobs verified cmungall/clingen-atp13a2 #3552
ATP1A1 Definitive Newly seeded Review #3553 merged at 2026-10-02 19:44:22 UTC; final-head approval and required CI passed; all 49 scoped merged blobs and 35 PR paths verified. Biological YAML remains DRAFT independently of campaign completion. cmungall/clingen-atp1a1 #3553
ATP6AP1 Definitive Existing review audited Review #3550 merged at 2026-10-02 20:58:10 UTC; final-head approval and required CI passed; all 30 scoped merged blobs and 8 PR paths verified. Biological YAML remains DRAFT independently of campaign completion. cmungall/clingen-atp6ap1 #3550
ATP6V0A2 Definitive Existing review audited Review #3551 merged at 2026-10-02 22:19:51 UTC; final-head approval and required CI passed; 27 explicitly scoped merged blobs and 12 complete PR diff paths verified. Biological YAML remains DRAFT, with 5 UNDECIDED judgments preserved. cmungall/clingen-atp6v0a2 #3551
ATP1A2 Definitive Newly seeded Review #3558 merged; current-head approval and required CI passed; all 26 scoped merged blobs verified cmungall/clingen-atp1a2 #3558
ATP1A3 Definitive Newly seeded Review #3555 merged; current-head approval and required CI passed; all 20 scoped merged blobs verified cmungall/clingen-atp1a3 #3555
ATP2B2 Definitive Newly seeded Review #3554 merged; current-head approval and required CI passed; all 24 scoped merged blobs verified cmungall/clingen-atp2b2 #3554
ATP6V1B1 Definitive Existing review audited Review #3556 merged; current-head approval and required CI passed; all 36 scoped merged blobs verified cmungall/clingen-atp6v1b1 #3556
ATP13A3 Definitive Newly seeded Review #3559 merged; current-head approval and required CI passed; all 12 scoped merged blobs verified cmungall/clingen-atp13a3 #3559
ATP7B Definitive Existing review audited Review #3560 merged at 2026-10-02 23:37:41 UTC; final-head approval and required CI passed; 35 explicitly scoped merged blobs and 9 complete PR diff paths verified. Biological YAML remains DRAFT, with 3 UNDECIDED judgments preserved. cmungall/clingen-atp7b #3560
ATP7A Definitive Newly seeded Review #3561 merged at 2026-10-02 22:18:02 UTC; final-head approval and required CI passed; 35 explicitly scoped merged blobs and 31 complete PR diff paths verified. Biological YAML remains DRAFT, with 8 UNDECIDED judgments preserved. cmungall/clingen-atp7a #3561
ATP8A2 Definitive Newly seeded Review #3562 merged; current-head approval and required CI passed; all 17 scoped merged blobs verified cmungall/clingen-atp8a2 #3562
B3GALNT2 Definitive Existing review Review #3563 merged at 2026-10-03 01:55:18 UTC; final-head approval and required CI passed; 16 explicitly scoped files and 6 complete PR diff paths verified. Biological YAML remains DRAFT, with 16 annotations and 1 UNDECIDED judgments. cmungall/clingen-b3galnt2 #3563
ATRX Definitive Not started Review #3564 merged; current-head approval and required CI passed; all 41 scoped merged blobs verified cmungall/clingen-atrx #3564
ATXN2 Definitive Not started Review #3566 merged at 2026-10-02 22:21:54 UTC; final-head approval and required CI passed; 34 explicitly scoped merged blobs and 21 complete PR diff paths verified. Biological YAML remains DRAFT, with 9 UNDECIDED judgments preserved. cmungall/clingen-atxn2 #3566
AUH Definitive Existing review Review #3565 merged; current-head approval and required CI passed; all 17 scoped merged blobs verified cmungall/clingen-auh #3565
AURKC Definitive Not started Review #3568 merged at 2026-10-02 21:31:27 UTC; final-head approval and required CI passed; all 24 scoped merged blobs and 19 PR paths verified. Biological YAML remains DRAFT independently of campaign completion. cmungall/clingen-aurkc #3568
AUTS2 Definitive Not started Review #3569 merged at 2026-10-02 21:35:42 UTC; final-head approval and required CI passed; all 17 scoped merged blobs and 12 PR paths verified. Biological YAML remains DRAFT independently of campaign completion. cmungall/clingen-auts2 #3569
AXIN2 Definitive Not started Review #3572 merged; current-head approval and required CI passed; all 48 scoped merged blobs verified cmungall/clingen-axin2 #3572
B3GALT6 Definitive Not started Review #3573 merged; current-head approval and required CI passed; all 16 scoped merged blobs verified cmungall/clingen-b3galt6 #3573
B3GLCT Definitive INITIALIZED seed Review #3575 merged; current-head approval and required CI passed; all 18 scoped merged blobs verified cmungall/clingen-b3glct #3575
B4GALNT1 Definitive Existing review Review #3574 merged; current-head approval and required CI passed; all 16 scoped merged blobs verified cmungall/clingen-b4galnt1 #3574
B4GALT1 Definitive Existing review Review #3576 merged at 2026-10-02 12:10:43 UTC; final-head approval and required CI passed; all 50 scoped merged blobs and 11 PR paths verified. cmungall/clingen-b4galt1 #3576
B4GALT7 Definitive INITIALIZED seed Review #3577 merged; current-head approval and required CI passed; all 20 scoped merged blobs verified cmungall/clingen-b4galt7 #3577
B9D1 Definitive INITIALIZED seed Review #3579 merged at 2026-10-02 21:39:02 UTC; final-head approval and required CI passed; all 21 scoped merged blobs and 10 PR paths verified. Biological YAML remains COMPLETE independently of campaign completion. cmungall/clingen-b9d1 #3579
BAG3 Definitive Existing review Review #3578 merged at 2026-10-02 21:37:39 UTC; final-head approval and required CI passed; all 44 scoped merged blobs and 8 PR paths verified. Biological YAML remains COMPLETE independently of campaign completion. cmungall/clingen-bag3 #3578
BAP1 Definitive INITIALIZED seed Review #3580 merged at 2026-09-30T14:22:32Z; exact-head approval and required CI passed; all 40 scoped merged blobs and 23 PR paths verified. cmungall/clingen-bap1 #3580
BARD1 Definitive INITIALIZED seed Review #3584 merged at 2026-09-30T15:49:23Z; exact-head approval and required CI passed; all 107 scoped merged blobs and 16 PR paths verified. cmungall/clingen-bard1 #3584
BBIP1 Definitive Existing review Review #3581 merged at 2026-09-30T15:58:42Z; exact-head approval and required CI passed; all 20 scoped merged blobs and 7 PR paths verified. cmungall/clingen-bbip1 #3581
BBS12 Definitive Existing review Review #3588 merged at 2026-09-30T16:54:55Z; exact-head approval and required CI passed; all 18 scoped merged blobs and 8 PR paths verified. cmungall/clingen-bbs12 #3588
BCAT2 Definitive Existing review Review #3606 merged at 2026-09-30T23:38:40Z; exact-head approval and required CI passed; all 24 scoped merged blobs and 9 PR paths verified. cmungall/clingen-bcat2 #3606
BCL11A Definitive INITIALIZED seed Review #3650 merged at 2026-10-01T03:07:23Z; final-head approval and required CI passed; all 22 scoped merged blobs and 19 PR paths verified. cmungall/clingen-bcl11a #3650
BCKDHA Definitive Existing review Review #3614 merged at 2026-10-01T03:11:14Z; final-head approval and required CI passed; all 35 scoped merged blobs and 17 PR paths verified. cmungall/clingen-bckdha #3614
BCKDK Definitive INITIALIZED seed Review #3646 merged at 2026-10-01T05:18:33Z; final-head approval and required CI passed; all 23 scoped merged blobs and 15 PR paths verified. cmungall/clingen-bckdk #3646
BCL11B Definitive INITIALIZED seed Review #3664 merged at 2026-10-01T06:16:11Z; final-head approval and required CI passed; all 16 scoped merged blobs and 10 PR paths verified. cmungall/clingen-bcl11b #3664
BEST1 Definitive INITIALIZED seed Review #3718 merged at 2026-10-01T12:20:24Z; final-head approval and required CI passed; all 32 scoped merged blobs and 19 PR paths verified. cmungall/clingen-best1 #3718
BLNK Definitive INITIALIZED seed Review #3741 merged at 2026-10-01T13:49:16Z; final-head approval and required CI passed; all 24 scoped merged blobs and 12 PR paths verified. cmungall/clingen-blnk #3741
BICRA Definitive INITIALIZED seed Review #3713 merged at 2026-10-01T17:30:00Z; final-head approval and required CI passed; all 16 scoped merged blobs and 11 PR paths verified. cmungall/clingen-bicra #3713
BLTP1 Definitive INITIALIZED seed Review #3796 merged at 2026-10-01T19:21:16Z; final-head approval and required CI passed; all 16 scoped merged blobs and 15 PR paths verified. cmungall/clingen-bltp1 #3796
BLVRA Moderate INITIALIZED seed Review #3775 merged at 2026-10-01T20:08:37Z; final-head approval and required CI passed; all 21 scoped merged blobs and 6 PR paths verified. cmungall/clingen-blvra #3775
BLOC1S5 Definitive INITIALIZED seed Review #3781 merged at 2026-10-01T20:37:09Z; final-head approval and required CI passed; all 20 scoped merged blobs and 10 PR paths verified. cmungall/clingen-bloc1s5 #3781
BLOC1S6 Definitive INITIALIZED seed Review #3770 merged at 2026-10-01T20:46:03Z; final-head approval and required CI passed; all 36 scoped merged blobs and 23 PR paths verified. cmungall/clingen-bloc1s6 #3770
BMPR1A Definitive INITIALIZED seed Review #3854 merged at 2026-10-02 16:24:25 UTC; final-head approval and required CI passed; all 47 scoped merged blobs and 45 PR paths verified. Biological YAML remains DRAFT independently of campaign completion. cmungall/clingen-bmpr1a #3854
BMP6 Limited INITIALIZED seed Review #3852 merged at 2026-10-02 17:42:12 UTC; final-head approval and required CI passed; all 37 scoped merged blobs and 34 PR paths verified. Biological YAML remains DRAFT independently of campaign completion. cmungall/clingen-bmp6 #3852
BOLA3 Definitive COMPLETE existing review Review #3860 merged at 2026-10-02 18:07:12 UTC; final-head approval and required CI passed; all 20 scoped merged blobs and 6 PR paths verified. Biological YAML remains COMPLETE independently of campaign completion. cmungall/clingen-bola3 #3860
BLOC1S1 Moderate INITIALIZED seed Review #3749 merged at 2026-10-02 19:42:37 UTC; final-head approval and required CI passed; all 24 scoped merged blobs and 10 PR paths verified. Biological YAML remains COMPLETE independently of campaign completion. cmungall/clingen-bloc1s1 #3749
BLOC1S3 Moderate INITIALIZED seed Review #3758 merged at 2026-10-02 21:40:19 UTC; final-head approval and required CI passed; all 16 scoped merged blobs and 9 PR paths verified. Biological YAML remains COMPLETE independently of campaign completion. cmungall/clingen-bloc1s3 #3758
BMP10 Limited INITIALIZED seed Review #3818 merged at 2026-10-02 21:41:37 UTC; final-head approval and required CI passed; all 22 scoped merged blobs and 21 PR paths verified. Biological YAML remains DRAFT independently of campaign completion. cmungall/clingen-bmp10 #3818
BMP4 Definitive INITIALIZED seed Review #3851 merged at 2026-10-02 21:43:03 UTC; final-head approval and required CI passed; all 62 scoped merged blobs and 44 PR paths verified. Biological YAML remains DRAFT independently of campaign completion. cmungall/clingen-bmp4 #3851
BMPR2 Definitive INITIALIZED seed Review #3878 merged at 2026-10-03 01:13:18 UTC; final-head approval and required CI passed; 43 explicitly scoped merged files and 15 complete PR diff paths verified. Biological YAML is COMPLETE, with 152 annotations and 38 UNDECIDED judgments preserved. cmungall/clingen-bmpr2 #3878
BPTF Definitive INITIALIZED seed Review #3880 merged at 2026-10-03 04:40:38 UTC; final-head approval and required CI passed; 28 explicitly scoped files and 24 complete PR diff paths verified. Biological YAML remains DRAFT: 45 source assertions plus one NEW H3K4me3-reader assertion, with three UNDECIDED judgments preserved. cmungall/clingen-bptf #3880
BRAT1 Definitive INITIALIZED seed Review #3884 merged at 2026-10-03 05:43:10 UTC after final-head approval and required CI success; 17 paths verified at that merge commit, 10 PR diff paths. Status-only #3892 merged at 07:20:29 UTC, correcting COMPLETE to DRAFT with 18 paths verified and four PR diff paths; zero additional gene completion. All 41 source assertions, three alternative_products and six UNDECIDED judgments remain; contextual mitochondrial-localization over-annotation is unchanged. cmungall/clingen-brat1 #3884, #3892
BRCA1 Definitive COMPLETE existing review Review #3888 merged at 2026-10-03 07:14:38 UTC after final-head approval and required CI success; 177 paths verified at that merge commit, five PR diff paths. Biological YAML is DRAFT with all 275 source assertions assessed, 26 UNDECIDED, no NEW and three cores. Eight named UniProt products are discussed in notes; the structured alternative_products slot remains absent. cmungall/clingen-brca1 #3888
BRCA2 Definitive Existing review audited PR #3893 merged at 2026-10-03 09:08:30 UTC after exact-head approval and required CI success. Six paths verified at the merge commit: three gene outputs and three histories. Biological DRAFT, 149 source assertions, 27 UNDECIDED, no NEW and two cores remain; campaign closure does not resolve evidence gaps. cmungall/clingen-brca2 #3893
BRIP1 Definitive Existing review audited PR #3895 merged at 2026-10-03 10:26:05 UTC after exact-head approval and required CI success. Six gene/history paths verified. Biological DRAFT, 92 source assertions, three UNDECIDED, three cores and two alternative products remain; campaign closure does not resolve the open crosslink-response step. cmungall/clingen-brip1 #3895
BRD4 Definitive INITIALIZED normal seed PR #3896 merged at 2026-10-03 10:42:33 UTC after exact-head approval and required CI success; 31 added paths verified. Biological DRAFT with 81 source assertions, 13 UNDECIDED, 40 references, three products, two cores and 21 warnings remains. Catalytic and individual-mark uncertainties are not resolved by campaign closure. cmungall/clingen-brd4 #3896
BRPF1 Definitive No review PR #3898 merged at 2026-10-03 10:55:34 UTC; 9 exact changed paths verified at the merge commit. Biological COMPLETE retains four UNDECIDED source assessments, 36 source assertions, four alternative products and two cores; no uncertainty is resolved merely by campaign closure. cmungall/clingen-brpf1 #3898
BRSK2 Definitive INITIALIZED normal seed PR #3899 merged at 2026-10-03 11:10:19 UTC; 14 exact changed paths verified at the merge commit. Biological DRAFT retains nine UNDECIDED assessments, 48 source assertions, six alternative products and one catalytic core. Combined SAD A/B experimental limits remain. cmungall/clingen-brsk2 #3899
BRWD3 Definitive No review PR #3901 merged at 2026-10-03 12:32:23 UTC; 13 exact changed paths verified at the merge commit. Biological COMPLETE retains the two supplied source assertions, five alternative products and one core. The documented UniProt/normal-GOA discrepancy and species limits remain explicit. cmungall/clingen-brwd3 #3901
BSCL2 Definitive No review PR #3902 merged at 2026-10-03 12:33:32 UTC; 17 exact changed paths verified at the merge commit. Biological DRAFT retains 30 original source assertions plus one NEW tether activity, seven UNDECIDED assessments, three alternative products and two cores. Thermogenesis and human and fly assay limits remain. cmungall/clingen-bscl2 #3902
BSND Definitive INITIALIZED normal seed PR #3903 merged at 2026-10-03 13:08:02 UTC; final-head approval and CI success verified; 16 exact changed paths verified at the merge commit. Biological DRAFT retains 52 source assertions and one channel-regulatory core; no structured products slot. Thirty-one screen-binding decisions retain explicit curator-deference and uninspected target-assay limits. Barttin is the auxiliary subunit, not the channel pore. cmungall/clingen-bsnd #3903
BTD Definitive Existing review audited (INITIALIZED) PR #3904 merged at 2026-10-03 13:08:19 UTC; final-head approval and CI success verified; 14 exact changed paths verified at the merge commit. Biological COMPLETE retains 20 source assertions, six UNDECIDED assessments, four products and one extracellular biotin-recycling core. Fine mitochondrial localization, screen-binding and CNS-development evidence remain unresolved. cmungall/clingen-btd #3904
BTK Definitive INITIALIZED normal seed PR #3905 merged at 2026-10-03 14:20:21 UTC; final-head approval and CI success verified; 35 exact changed paths verified at the merge commit. Biological DRAFT retains 149 source assertions, 31 UNDECIDED assessments, two products and two cores. PLC regulation is distinguished from covalent substrate phosphorylation; remaining interaction and source-access limits persist. cmungall/clingen-btk #3905
C19orf12 Definitive INITIALIZED normal seed PR #3906 merged at 2026-10-03 14:31:06 UTC; final-head approval and CI success verified; 12 exact changed paths verified at the merge commit. Biological COMPLETE retains 22 source assertions, four products and one process core. The molecular activity remains unresolved; positive autophagy regulation and contextual apoptosis over-annotation are preserved. cmungall/clingen-c19orf12 #3906
BUB1B Definitive COMPLETE existing review PR #3908 merged at 2026-10-03 14:49:33 UTC; final-head approval and CI success verified; 10 exact changed paths verified at the merge commit. Biological DRAFT retains 119 source assertions, 11 UNDECIDED assessments, three products and two cores. Seven catalytic assertions remain disputed; supported CDC20 inhibition and kinetochore adaptor functions do not settle the kinase controversy. cmungall/clingen-bub1b #3908
C1QA Definitive INITIALIZED normal seed PR #3909 merged at 2026-10-03 15:13:09 UTC; final-head approval and CI success verified; 34 exact changed paths verified at the merge commit. Biological DRAFT retains 83 source assertions, six UNDECIDED assessments and three cores; no structured products slot. Bibliography-only and fine synaptic/extracellular-matrix evidence limits remain. Whole-C1q contributions do not establish isolated A-chain sufficiency. cmungall/clingen-c1qa #3909
C1QB Definitive INITIALIZED normal seed PR #3916 merged at 2026-10-03 16:18:20 UTC; final-head approval and CI success verified; 8 exact changed paths verified at the merge commit. Biological DRAFT retains 62 source assertions, six UNDECIDED assessments and three cores; no structured products slot. Fine donor localization and other source limits remain; recognition, protease recruitment and signaling are scoped to contribution within C1q. cmungall/clingen-c1qb #3916
C1QTNF5 Definitive INITIALIZED normal seed PR #3911 merged at 2026-10-03 16:21:15 UTC; final-head approval and CI success verified; 13 exact changed paths verified at the merge commit. Biological DRAFT retains 23 source assertions, three UNDECIDED assessments and one core; no structured products slot. Collagen-stalk inference is distinguished from directly observed globular trimers, and receptor inhibition from chronic perturbation phenotypes. cmungall/clingen-c1qtnf5 #3911
C2CD3 Definitive INITIALIZED normal seed PR #3917 merged at 2026-10-03 16:41:31 UTC; final-head approval and CI success verified; 10 exact changed paths verified at the merge commit. Biological DRAFT retains 30 source assertions plus one NEW structural-function assertion, five products and one core. Human spatial/depletion evidence is separated from mouse cryo-ET context; direct microtubule affinity, ring-node composition and catalytic activity remain unestablished. cmungall/clingen-c2cd3 #3917
C1QBP Definitive Existing review audited PR #3914 merged at 2026-10-03 16:43:30 UTC; final-head approval and CI success verified; 9 exact changed paths verified at the merge commit. Biological DRAFT retains 125 source assertions, five UNDECIDED assessments and four cores; no structured products slot. Reconciled partner/donor distinctions and source-specific screen limits remain; precursor/mature localization is described without manufacturing product fields. cmungall/clingen-c1qbp #3914
C3 Definitive INITIALIZED normal seed PR #3925 merged at 2026-10-03 18:15:29 UTC; final-head approval and CI success verified; 72 exact changed paths verified at the merge commit. Biological DRAFT retains 142 source assertions, nine UNDECIDED assessments and three cores. Four authored processed-product classes are distinct from alternative splice products. C3a versus ASP/C5L2 context and exact source access limits remain; no new annotation is introduced. cmungall/clingen-c3 #3925
C9orf72 Definitive INITIALIZED normal seed PR #3927 merged at 2026-10-03 18:25:30 UTC; final-head approval and CI success verified; 18 exact changed paths verified at the merge commit. Biological DRAFT retains 110 source assertions, 23 UNDECIDED assessments, two alternative products and three cores. Reagent-specific localization and GEF/GAP context limits remain; campaign closure does not resolve those biological uncertainties. cmungall/clingen-c9orf72 #3927
CA5A Definitive INITIALIZED normal seed PR #3928 merged at 2026-10-03 20:22:13 UTC; final-head approval and CI success verified; 19 exact changed paths verified at the merge commit. Biological COMPLETE retains 20 source assertions, 0 UNDECIDED assessments and 1 core function. No new annotation is introduced. cmungall/clingen-ca5a #3928
CA8 Moderate Existing review PR #3929 merged at 2026-10-03 21:54:27 UTC; final-head approval and CI success verified; 7 exact changed paths verified at the merge commit. Biological DRAFT retains 26 source assertions plus 2 NEW assertions, 0 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-ca8 #3929
CABP2 Definitive INITIALIZED normal seed PR #3938 merged at 2026-10-04 04:18:38 UTC; final-head approval and CI success verified; 12 exact changed paths verified at the merge commit. Biological DRAFT retains 49 source assertions, 1 UNDECIDED assessment and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-cabp2 #3938
CACNA1B Moderate INITIALIZED normal seed PR #3947 merged at 2026-10-04 04:20:41 UTC; final-head approval and CI success verified; 15 exact changed paths verified at the merge commit. Biological DRAFT retains 29 source assertions, 1 UNDECIDED assessment and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-cacna1b #3947
CACNA1D Definitive INITIALIZED normal seed PR #3949 merged at 2026-10-04 04:21:48 UTC; final-head approval and CI success verified; 15 exact changed paths verified at the merge commit. Biological COMPLETE retains 78 source assertions, 6 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-cacna1d #3949
CAD Definitive Existing review PR #3980 merged at 2026-10-04 04:41:00 UTC; final-head approval and CI success verified; 15 exact changed paths verified at the merge commit. Biological DRAFT retains 84 source assertions, 16 UNDECIDED assessments and 3 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-cad #3980
CALM1 Definitive Existing review PR #3989 merged at 2026-10-04 04:42:55 UTC; final-head approval and CI success verified; 5 exact changed paths verified at the merge commit. Biological DRAFT retains 176 source assertions, 8 UNDECIDED assessments and 3 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-calm1 #3989
CACNA1E Definitive INITIALIZED normal seed PR #4020 merged at 2026-10-04 06:07:21 UTC; final-head approval and CI success verified; 11 exact changed paths verified at the merge commit. Biological DRAFT retains 23 source assertions, 1 UNDECIDED assessment and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-cacna1e #4020
CACNA1G Definitive INITIALIZED normal seed PR #4011 merged at 2026-10-04 06:16:13 UTC; final-head approval and CI success verified; 16 exact changed paths verified at the merge commit. Biological DRAFT retains 41 source assertions, 5 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-cacna1g #4011
CALM2 Definitive INITIALIZED normal seed PR #4018 merged at 2026-10-04 06:39:56 UTC; final-head approval and CI success verified; 7 exact changed paths verified at the merge commit. Biological DRAFT retains 105 source assertions, 3 UNDECIDED assessments and 3 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-calm2 #4018
CALM3 Definitive Existing review PR #4016 merged at 2026-10-04 07:07:22 UTC; final-head approval and CI success verified; 12 exact changed paths verified at the merge commit. Biological DRAFT retains 115 source assertions, 10 UNDECIDED assessments and 5 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-calm3 #4016
CACNA2D4 Definitive INITIALIZED normal seed PR #4022 merged at 2026-10-04 07:08:57 UTC; final-head approval and CI success verified; 11 exact changed paths verified at the merge commit. Biological COMPLETE retains 7 source assertions plus 1 NEW assertion, 1 UNDECIDED assessment and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-cacna2d4 #4022
CACNA1C Definitive INITIALIZED normal seed PR #3948 merged at 2026-10-04 07:13:11 UTC; final-head approval and CI success verified; 36 exact changed paths verified at the merge commit. Biological DRAFT retains 136 source assertions, 8 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-cacna1c #3948
CACNA1F Definitive INITIALIZED normal seed PR #4024 merged at 2026-10-04 07:22:48 UTC; final-head approval and CI success verified; 15 exact changed paths verified at the merge commit. Biological COMPLETE retains 24 source assertions, 4 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-cacna1f #4024
CAMK2A Definitive Existing review PR #4043 merged at 2026-10-04 08:21:48 UTC; final-head approval and CI success verified; 5 exact changed paths verified at the merge commit. Biological DRAFT retains 171 source assertions, 11 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-camk2a #4043
CA2 Definitive INITIALIZED normal seed PR #4042 merged at 2026-10-04 08:23:31 UTC; final-head approval and CI success verified; 68 exact changed paths verified at the merge commit. Biological DRAFT retains 89 source assertions, 4 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-ca2 #4042
CAMTA1 Definitive INITIALIZED normal seed PR #4049 merged at 2026-10-04 08:47:19 UTC; final-head approval and CI success verified; 12 exact changed paths verified at the merge commit. Biological COMPLETE retains 10 source assertions, 2 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-camta1 #4049
CANT1 Definitive INITIALIZED normal seed PR #4071 merged at 2026-10-04 10:34:22 UTC; final-head approval and CI success verified; 13 exact changed paths verified at the merge commit. Biological DRAFT retains 37 source assertions, 4 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-cant1 #4071
CAPN3 Definitive INITIALIZED normal seed PR #4093 merged at 2026-10-04 11:36:42 UTC; final-head approval and CI success verified; 25 exact changed paths verified at the merge commit. Biological DRAFT retains 96 source assertions, 16 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-capn3 #4093
CAPN5 Definitive INITIALIZED normal seed PR #4099 merged at 2026-10-04 12:13:23 UTC; final-head approval and CI success verified; 16 exact changed paths verified at the merge commit. Biological DRAFT retains 14 source assertions, 4 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-capn5 #4099
CARD11 Definitive INITIALIZED normal seed PR #4116 merged at 2026-10-04 12:47:21 UTC; final-head approval and CI success verified; 20 exact changed paths verified at the merge commit. Biological DRAFT retains 88 source assertions, 3 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-card11 #4116
CARMIL2 Definitive INITIALIZED normal seed PR #4121 merged at 2026-10-04 14:10:18 UTC; final-head approval and CI success verified; 16 exact changed paths verified at the merge commit. Biological DRAFT retains 45 source assertions plus 1 NEW molecular-function assertion, 3 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-carmil2 #4121
CASK Definitive INITIALIZED normal seed PR #4132 merged at 2026-10-04T14:29:51Z; final-head approval and CI success verified; 23 changed paths and 20 reused scoped paths verified. Biological DRAFT retains 118 source assertions, 31 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-cask #4132
CASP8 Definitive Existing review from PR #3672 PR #4139 merged at 2026-10-04T15:11:44Z; final-head approval and CI success verified; 6 changed paths and 128 reused scoped paths verified. Biological DRAFT retains 264 source assertions, 21 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. This is the first campaign completion of the existing review, not a second original review. cmungall/clingen-casp8-whole-review #4139
CASQ2 Definitive INITIALIZED normal seed PR #4142 merged at 2026-10-04T15:17:41Z; final-head approval and CI success verified; 22 changed paths and 1 reused scoped path verified. Biological DRAFT retains 57 source assertions, 12 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-casq2 #4142
CASR Definitive INITIALIZED normal seed PR #4147 merged at 2026-10-04T16:52:11Z; final-head approval and CI success verified; 42 changed paths and 6 reused scoped paths verified. Biological DRAFT retains 123 source assertions, 33 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-casr #4147
CAV1 Definitive INITIALIZED normal seed PR #4165 merged at 2026-10-04T18:27:15Z; final-head approval and CI success verified; 57 changed paths and 51 reused scoped paths verified. Biological DRAFT retains 273 source assertions, 37 UNDECIDED assessments and 3 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. cmungall/clingen-cav1 #4165
CAVIN1 Definitive INITIALIZED normal seed PR #4180 merged at 2026-10-04T19:58:03Z; final-head approval and CI success verified; 12 changed paths and 13 reused scoped paths verified. Biological DRAFT retains 77 source assertions plus 1 NEW assertion, 12 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. The one NEW assertion is GO:0070836 caveola assembly, not a molecular-function annotation. cmungall/clingen-cavin1 #4180
CAV3 Definitive INITIALIZED normal seed PR #4175 merged at 2026-10-04T20:37:20Z; final-head approval and required CI success verified; 27 changed and 9 reused scoped paths verified. Biological DRAFT retains 116 source assertions, 28 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged scientific evidence limits. cmungall/clingen-cav3 #4175
CBS Definitive Existing review PR #4191 merged at 2026-10-04T21:11:07Z; final-head approval and required CI success verified; 6 changed and 28 reused scoped paths verified. Biological DRAFT retains 101 source assertions, 12 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged scientific evidence limits. cmungall/clingen-cbs-whole-review #4191
CBFB Definitive INITIALIZED normal seed PR #4215 merged at 2026-10-04T22:33:17Z; final-head approval and required CI success verified; 86 changed and 33 reused scoped paths verified. Biological DRAFT retains 136 source assertions, 3 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged scientific evidence limits. cmungall/clingen-cbfb #4215
CBL Definitive Existing review PR #4210 merged at 2026-10-04T22:36:18Z; final-head approval and required CI success verified; 7 changed and 162 reused scoped paths verified. Biological DRAFT retains 305 source assertions plus 1 historical NEW proposal, 16 UNDECIDED assessments and 3 core functions. Campaign completion preserves the merged scientific evidence limits. The retained NEW-labelled FGFR-regulation row predates this campaign revision. cmungall/clingen-cbl-whole-review #4210
CCDC39 Definitive INITIALIZED normal seed PR #4228 merged at 2026-10-04T23:22:31Z; final-head approval and required CI success verified; 12 changed and 2 reused scoped paths verified. Biological COMPLETE retains 30 source assertions plus 1 NEW molecular-function assertion, 5 UNDECIDED assessments and 1 core function. COMPLETE is the normal validation status and does not resolve its five UNDECIDED assessments. cmungall/clingen-ccdc39 #4228
CC2D2A Definitive Existing review PR #4209 merged at 2026-10-04T23:39:16Z; final-head approval and required CI success verified; 6 changed and 10 reused scoped paths verified. Biological DRAFT retains 19 source assertions, 0 UNDECIDED assessments and 1 core function. Its DRAFT status reflects an unused-research advisory; no annotation remains UNDECIDED. cmungall/clingen-cc2d2a-whole-review #4209
CC2D1A Definitive INITIALIZED normal seed PR #4222 merged at 2026-10-04T23:54:43Z; final-head approval and required CI success verified; 13 changed and 8 reused scoped paths verified. Biological DRAFT retains 21 source assertions plus one NEW signaling-adaptor molecular-function assertion, 4 UNDECIDED assessments and 2 core functions. DRAFT is the validation-advisory status; campaign completion preserves the merged evidence limits. cmungall/clingen-cc2d1a #4222
CCDC40 Definitive INITIALIZED normal seed PR #4235 merged at 2026-10-05T00:59:13Z; final-head approval and required CI success verified; 7 changed and 7 reused scoped paths verified. Biological DRAFT retains 33 source assertions, 2 UNDECIDED assessments and 1 core function. DRAFT is the validation-advisory status; campaign completion preserves the merged evidence limits. cmungall/clingen-ccdc40 #4235
CCND2 Definitive INITIALIZED normal seed PR #4244 merged at 2026-10-05T01:02:15Z; final-head approval and required CI success verified; 7 changed and 29 reused scoped paths verified. Biological DRAFT retains 77 source assertions, 3 UNDECIDED assessments and 1 core function. DRAFT is the validation-advisory status; campaign completion preserves the merged evidence limits. cmungall/clingen-ccnd2 #4244

Branches for work without a PR may exist only in a local isolated checkout.
Published check and approval states are the last verified states from this session,
not a live dashboard. ABCC6 merged through protected auto-merge on September 26
at 21:22:34 UTC. A separate checkout inside the writable workspace supports local
Git commits while the original worktree's shared Git metadata remains read-only.
Publication uses GitHub's API with expected-head guards and exact tree verification.
Direct Git transport and normal publication-source downloads still encounter DNS
failures. No local or published draft is counted as merged or complete.

The publication queue retains immutable publication hashes,
signed publication/file checks and append-only receipt chains. 240 of 2,876 genes
are complete; 241 gene-level original reviews have merged, with 1 requiring a source
follow-up. The 161 dedicated full-audit PRs are the historical total at checkpoint 95;
this completion update does not refresh audit or import totals.

The table records independently verified publication and completion states. A published
source follow-up, imported normal cache, approval, successful CI and verified merge are
separate events. Earlier source-gate lists describe their historical publication time.
The original ALB PENDING seed and every prior publication/history receipt remain intact.

Checkpoint 95 uses the fixed 2026-09-30 13:59:34 UTC evidence cut. Seven publication revisions comprise B9D1’s first follow-up; BAP1’s initial audit, first follow-up and notes clarification; BBIP1’s initial audit and first follow-up; and BARD1’s initial audit. The three new audit PRs bring the total to 161. No new merge is counted: 139 complete / 140 original merges, with AKR1D1 the one pending source follow-up. BAP1 #3580 at cb70226f has exact-head approval, with required CI observed in progress. B9D1 #3579 remains on the documented generic-binding policy hold under the supplied ActionEnum. BBIP1 #3581 and BARD1 #3584 have exact-head changes requested; their subsequent scientific revisions are outside this cut. Six executed imports add 28 exact files: Seed43 primary3 and auxiliary14, Source83 one cache, Seed44 primary3 and auxiliary5, and Source84 two caches. The cumulative ledger reaches 71 import receipts / 435 creates; imports do not grant gene completion. Source85’s later observed/import lifecycle and any subsequent BAP1 merge are excluded. Earlier dated observations, the existing Seed42 zero-write disposition, seven older policy holds, six deferred import closures, and incomplete global validation remain preserved.

Completion reconciliation on 2026-10-01 UTC adds five verified merges after that cut: BAP1 #3580, BARD1 #3584, BBIP1 #3581, BBS12 #3588 and BCAT2 #3606. The saved final approvals, required CI, signed merge commits and complete scoped blob checks support 144 completed genes and 145 original merges; AKR1D1 remains the one required source follow-up. All 2,876 catalog genes and their ClinGen association text are retained. Checkpoint 95 and earlier observations remain historical records. Later open PRs, audit totals and import totals are outside this completion-only update; no fresh lifecycle polling or global validation is claimed.

Completion update at 2026-10-01 03:11:14 UTC adds BCL11A #3650 and BCKDHA #3614. Both have final-head approvals, passing required CI and signed merge commits with every scoped file verified. The count is now 146 completed genes and 147 original merges, with 2,730 genes remaining and AKR1D1 still requiring its source follow-up. Earlier completion and checkpoint observations remain historical; this update does not refresh other open PRs, audit totals or import totals.

Completion update at 2026-10-01 05:18:33 UTC adds BCKDK #3646. Its final-head approval, passing required CI and signed merge commit include verification of all 23 scoped files and 15 PR paths. The count is now 147 completed genes and 148 original merges, with 2,729 genes remaining and AKR1D1 still requiring its source follow-up. Earlier completion and checkpoint observations remain historical; this update does not refresh other open PRs, audit totals or import totals.

Completion update at 2026-10-01 06:16:11 UTC adds BCL11B #3664. Its final-head approval, passing required CI and signed merge commit include verification of all 16 scoped files and 10 PR paths. The count is now 148 completed genes and 149 original merges, with 2,728 genes remaining and AKR1D1 still requiring its source follow-up. Earlier completion and checkpoint observations remain historical; this update does not refresh other open PRs, audit totals or import totals.

Completion update at 2026-10-01 12:20:24 UTC adds BEST1 #3718. Its final-head approval, passing required CI and signed merge commit include verification of all 32 scoped files and 19 PR paths. The count is now 149 completed genes and 150 original merges, with 2,727 genes remaining and AKR1D1 still requiring its source follow-up. Earlier completion and checkpoint observations remain historical; this update does not refresh other open PRs, audit totals or import totals.

Completion update at 2026-10-01 13:49:16 UTC adds BLNK #3741. Its final-head approval, passing required CI and signed merge commit include verification of all 24 scoped files and 12 PR paths. The count is now 150 completed genes and 151 original merges, with 2,726 genes remaining and AKR1D1 still requiring its source follow-up. Earlier completion and checkpoint observations remain historical; this update does not refresh other open PRs, audit totals or import totals.

Completion update at 2026-10-01 17:30:00 UTC adds BICRA #3713. Its final-head approval, passing required CI and signed merge commit include verification of all 16 scoped files and 11 PR paths. The count is now 151 completed genes and 152 original merges, with 2,725 genes remaining and AKR1D1 still requiring its source follow-up. Earlier completion and checkpoint observations remain historical; this update does not refresh other open PRs, audit totals or import totals.

Completion update at 2026-10-01 19:21:16 UTC adds BLTP1 #3796. Its final-head approval, passing required CI and signed merge commit include verification of all 16 scoped files and 15 PR paths. The count is now 152 completed genes and 153 original merges, with 2,724 genes remaining and AKR1D1 still requiring its source follow-up. Earlier completion and checkpoint observations remain historical; this update does not refresh other open PRs, audit totals or import totals.

Completion update through 2026-10-01 20:46:03 UTC adds BLVRA #3775, BLOC1S5 #3781 and BLOC1S6 #3770. Their final-head approvals, passing required CI and signed merge commits include verification of all scoped files and complete PR path lists. The count is now 155 completed genes and 156 original merges, with 2,721 genes remaining and AKR1D1 still requiring its source follow-up. BLOC1S5 retains its biological YAML DRAFT status; its verified source-complete merge is counted separately from that field. Earlier completion and checkpoint observations remain historical; this update does not refresh other open PRs, audit totals or import totals.

Completion update through 2026-10-02 12:10:43 UTC adds B4GALT1 #3576. Its final-head approval, passing required CI and signed merge commit are confirmed with all 50 scoped files and the complete 11-path PR verified. The count is now 156 completed genes and 157 original merges, with 2,720 genes remaining and AKR1D1 still requiring its source follow-up. B4GALT1 retains its biological YAML DRAFT status independently of campaign completion. Checkpoint95 audit/import totals and prior completion observations remain historical.

Completion update through 2026-10-02 16:24:25 UTC adds BMPR1A #3854. Its final-head approval, passing required CI and signed merge commit are confirmed with all 47 scoped merged blobs and 45 PR paths verified. The count is now 157 completed genes and 158 original merges, with 2,719 genes remaining and AKR1D1 still requiring its source follow-up. BMPR1A retains its biological YAML DRAFT status independently of campaign completion. This supersedes its dated completion156 in-progress observation; all earlier checkpoint and source-import observations remain historical.

Completion update through 2026-10-02 18:07:12 UTC adds BMP6 #3852, BOLA3 #3860. Exact-head approvals, required CI success and signed merge receipts were independently confirmed by ROOT. The count is now 159 completed genes and 160 original gene PR merges, with 2,717 genes remaining and AKR1D1 still requiring its source follow-up. Biological YAML status is recorded separately from campaign completion. PANTHER family/index work is not a gene completion. Earlier completion, audit and import observations retain their dated checkpoint scope.

Completion update through 2026-10-02 19:44:22 UTC adds BLOC1S1 #3749, ATP1A1 #3553. Exact-head approvals, required CI success and signed merge receipts were independently confirmed by ROOT. The count is now 161 completed genes and 162 original gene PR merges, with 2,715 genes remaining and AKR1D1 still requiring its source follow-up. ATP1A1 retains biological YAML DRAFT status and its eight UNDECIDED source judgments; campaign completion does not assert that those evidence limits are resolved. BLOC1S1 retains biological YAML COMPLETE status. PANTHER family/index work is not a gene completion. Earlier completion, audit and import observations retain their dated checkpoint scope.

Completion update through 2026-10-02 21:50:40 UTC adds ARMC9 #3371, ARL13B #3374, ASL #3385, ASNS #3438, ATP6AP1 #3550, AURKC #3568, AUTS2 #3569, BAG3 #3578, B9D1 #3579, BLOC1S3 #3758, BMP10 #3818, BMP4 #3851, ARID2 #3372. Exact-head approvals, required CI success and signed merge receipts were independently confirmed by ROOT. The count is now 174 completed genes and 175 original gene PR merges, with 2,702 genes remaining and AKR1D1 still requiring its source follow-up. Biological YAML DRAFT status is preserved for ATP6AP1, AURKC, AUTS2, BMP10, BMP4. Campaign completion does not resolve remaining UNDECIDED evidence judgments. PANTHER family/index work is not a gene completion. Earlier completion, policy, audit and import observations retain their dated checkpoint scope.

Completion update through 2026-10-02 23:37:41 UTC adds ATP7A #3561, ATP6V0A2 #3551, ATXN2 #3566, ATP7B #3560. Exact-head approvals, required CI success and the enumerated merged blobs were independently confirmed by the coordinating ROOT agent. This internal verification is not external maintainer sign-off. The count is now 178 completed genes and 179 original gene PR merges, with 2,698 genes remaining and AKR1D1 still requiring its source follow-up. All four biological YAML records remain DRAFT; campaign completion does not resolve their UNDECIDED judgments. PANTHER and tracker infrastructure PRs contribute no gene completions. Earlier observations and checkpoint95 audit/import totals retain their dated scope.

Completion update through 2026-10-03 01:13:18 UTC adds BMPR2 #3878, independently confirmed by the coordinating ROOT agent after exact-head approval and required CI success. This internal verification is not external maintainer sign-off. The count is now 179 completed genes and 180 original gene PR merges, with 2,697 genes remaining and AKR1D1 still requiring its source follow-up. BMPR2 biological YAML is COMPLETE and preserves all 152 annotations, including 38 UNDECIDED judgments. The four earlier additions in checkpoint 178 retain their own DRAFT states and dated evidence. Campaign completion does not resolve annotation uncertainty; infrastructure PRs contribute no gene completions.

Completion update through 2026-10-03 04:40:38 UTC adds B3GALNT2 #3563, APOB #3365 and BPTF #3880. Exact-head approvals, required CI success and the enumerated merged blobs were independently confirmed by the coordinating ROOT agent; this internal verification is not external maintainer sign-off. The count is now 182 completed genes and 183 original gene PR merges, with 2,694 genes remaining and AKR1D1 still requiring its source follow-up. B3GALNT2 and BPTF retain biological YAML DRAFT status; APOB retains COMPLETE. Their 1, 3 and 33 UNDECIDED judgments, respectively, remain unchanged. BPTF has 45 source assertions plus one NEW H3K4me3-reader assertion and three alternative_products. BRAT1 remains unchecked pending a verified merge. Infrastructure PRs contribute no gene completions; earlier completion and checkpoint95 audit/import observations remain dated historical records.

Completion update through 2026-10-03 07:20:29 UTC adds BRAT1 #3884 and BRCA1 #3888, each from an approved, required-CI-passing, independently confirmed scoped merge. There are now 184 completed genes and 185 original gene PR merges, with 2,692 remaining and the AKR1D1 source follow-up still open. BRAT1 originally merged with COMPLETE; status-only #3892 subsequently corrected it to DRAFT without changing its biological assertions or adding a completion. BRCA1 also remains DRAFT. Their six and 26 UNDECIDED judgments remain unresolved. Campaign completion records merged curation work, not warning-free biological review or resolved evidence. ROOT means the internal coordinating agent, not external maintainer sign-off. Earlier dated checkpoint observations remain historical.

Completion update through 2026-10-03 09:08:30 UTC adds BRCA2 #3893 at signed merge cb7f1f3d8d7e9745fd1d498503c9ff4af71c67e4. The coordinating agent verified exact-head approval, required CI and six enumerated merged blobs; this is internal verification, not external maintainer sign-off. The campaign now has 185 completed genes, 186 original gene merges, one unresolved AKR1D1 source follow-up and 2,691 remaining. Biological DRAFT and all 27 UNDECIDED judgments are preserved. BRIP1 publication, BRD4 scientific peer and BRPF1 source retrieval contribute no completion increment. Earlier dated observations remain historical.

Source-limited UNDECIDED judgments remain valid. AKT1's completed Limited-tier audit
remains a scheduling exception. Project setup merged in
#3126.

Evidence scope and persistence for the completion update to 178

Local tmp/ receipt paths and SHA-256 values in the publication queue identify session-local verification records; those files are not promised as durable repository artifacts. Durable evidence is recorded separately in each updated gene’s durable_merge_evidence: the approved head, merge commit/tree and exact path-to-blob map. The links below resolve the published merge commits. The reported checked scope is only that explicit map, which can include unchanged source files; the complete PR diff count is a separate measure. A source category is covered only when its paths are present in the map.

Gene Published merge Explicitly checked paths Complete PR diff paths
ATP7A dc52f85f5976 35: 5 gene files, 3 history records, 25 publication caches, 2 Reactome caches 31
ATP6V0A2 7e750322d14f 27: 7 gene files, 4 history records, 12 publication caches, 4 Reactome caches 12
ATXN2 d84235c9c95f 34: 5 gene files, 3 history records, 26 publication caches 21
ATP7B 66ce2256a512 35: 6 gene files, 4 history records, 23 publication caches, 2 Reactome caches 9

ATXN2 has no Reactome paths in its checked map. ATP7B preserves its partner-specific COMMD1 and ATOX1 source assertions; independent corroboration does not imply that the original ATOX1 assay was read. No biological assertion or cached source is changed by this tracker update.

BMPR2 evidence scope for completion 179

The following durable merge evidence extends the preceding checkpoint; its session-local receipts and exact checked path/blob map are retained in the new BMPR2 queue entry. The 43 checked files are not 43 annotation objects: the unchanged review has 152 annotation objects.

Gene Published merge Explicitly checked paths Complete PR diff paths
BMPR2 ecd8e02fac9c 43: 5 gene files, 2 history records, 27 publication caches, 9 Reactome caches 15

No source, annotation, core function, product or negation was changed by this tracker update. The prior checkpoint 178 evidence, all 175 earlier queue entries and the existing checkpoint 178 history remain unchanged.

Evidence scope for completion 182

The exact checked path/blob maps and durable merge links are recorded in the three queue entries. Session-local TMP receipts are verification records, not promised repository artifacts. Checked file counts include only their enumerated paths, and differ from complete PR diff counts and annotation counts.

Gene Published merge Explicitly checked paths Complete PR diff paths
B3GALNT2 709497a019bd 16: 6 gene files, 3 history records, 5 publication caches, 2 Reactome caches 6
APOB e5820bd78bf5 107: 5 gene files, 4 history records, 31 publication caches, 67 Reactome caches 52
BPTF 2014c5cc32fa 28: 5 gene files, 3 history records, 20 publication caches 24

BPTF has no Reactome path in its checked map. No biological review, source, product or existing history changes in this tracker update. Earlier checkpoint records, including the unresolved AKR1D1 source follow-up, are preserved.

Evidence scope for completion 184

New queue entries contain durable merge, tree and path/blob records. Paths below were verified at the stated merge commit; the scope does not imply that every possible gene, publication or Reactome file was checked. Prior session-local TMP proof arrays remain historical and unchanged; this checkpoint adds none to the durable queue.

Gene or correction Published merge Paths verified at merge commit Complete PR diff paths
BRAT1 071161d1f8ec 17: 5 gene files, 2 history records, 10 publication caches 10
BRCA1 bd8838fb7cdc 177: 9 gene files, 2 history records, 111 publication caches, 55 Reactome caches 5
BRAT1 status correction ec5a323284fa 18: 5 gene files, 3 history records, 10 publication caches 4

No gene review, source, product or prior history is changed by this tracker update.

Evidence scope for completion 185

This checkpoint adds one completion queue entry, for BRCA2, plus three separate in-progress observations. The original queue snapshot_date_utc remains the 2026-09-27 initialization date; latest_completion_snapshot_utc identifies this 2026-10-03 completion evidence cut. Existing TMP proof arrays are preserved as historical records, and no new ones are added.

Gene Verified merge Paths verified at that merge commit Complete PR diff paths
BRCA2 cb7f1f3d8d7e Six: three gene outputs and three project-independent gene histories 6

Standard project history. The durable queue enumerates these six path/blob pairs. This scope does not assert that all BRCA2 publication or Reactome caches were newly checked.

Evidence scope for completion 240

Checkpoint 240 history.

The fixed 2026-10-05 01:02:15 UTC cutoff adds CC2D1A, CCDC40 and CCND2 to published checkpoint 237: 240 complete / 2,636 remaining, with 241 gene-level original review merges and one required source follow-up outstanding for AKR1D1. Tracker, source-workflow and validator PRs add no gene completions. CCM2, CCN6, CCNO and CD19 contribute none at this cutoff. External CD48 work is outside the verified campaign completion ledger.

Gene Verified merge Changed / reused scoped paths Biological assessment retained
CC2D1A 19c410fb456a, 2026-10-04T23:54:43Z 13 / 8; every path/blob pair is in the queue Biological DRAFT retains 21 source assertions plus one NEW signaling-adaptor molecular-function assertion, 4 UNDECIDED assessments and 2 core functions. DRAFT is the validation-advisory status; campaign completion preserves the merged evidence limits.
CCDC40 91bf7fd651da, 2026-10-05T00:59:13Z 7 / 7; every path/blob pair is in the queue Biological DRAFT retains 33 source assertions, 2 UNDECIDED assessments and 1 core function. DRAFT is the validation-advisory status; campaign completion preserves the merged evidence limits.
CCND2 450f063da90c, 2026-10-05T01:02:15Z 7 / 29; every path/blob pair is in the queue Biological DRAFT retains 77 source assertions, 3 UNDECIDED assessments and 1 core function. DRAFT is the validation-advisory status; campaign completion preserves the merged evidence limits.

The three final PR heads have verified approval and successful required checks. Their signed merges account for 27 changed path/blob pairs and 44 unchanged reused scope objects, totaling 71 verified scoped objects. These are per-review counts; shared sources can occur in several scopes. The queue enumerates both maps, identically in each new gene entry and the matching completion update.

The merged reviews retain 131 original source assertions and nine UNDECIDED assessments, with 132 total reviewed assertions. CC2D1A adds one reviewed GO:0035591 signaling-adaptor molecular-function assertion; CCDC40 and CCND2 add no annotations. All three retain DRAFT validation status because advisories remain, independently of their retained uncertainties. Alternative-product counts are 2, 5 and 2, and core counts are 2, 1 and 1, respectively.

The published checkpoint 237 merge 1c7db872ce45 remains the baseline. Its original post-merge guard stopped after an independent CD48 merge advanced main between readiness and merge. A separate signed proof verified the actual intervening parent edc890c57e8d, all seven unchanged tracker preimages, all seven tracker outputs and all five source trees preserved from that actual parent. The original readiness assessment and failed guard are retained; the supplemental proof adds no gene completion and does not certify CD48 campaign completion.

All 232 existing genes[] queue entries are preserved, followed by three entries. Queue-entry count is distinct from the completed-gene baseline. All 2,876 gene inventory entries and their frozen associations, the checkpoint 228 CASP8 correction, both corrected CARMIL2 reuse maps, earlier completion records and history, and the checkpoint 95 audit/import boundary remain exact.

Published checkpoint 237 history.

Evidence scope for completion 237

Checkpoint 237 history.

The fixed 2026-10-04 23:39:16 UTC cutoff adds CAV3, CBS, CBFB, CBL, CCDC39 and CC2D2A to published checkpoint 231: 237 complete / 2,639 remaining, with 238 gene-level original review merges and one required source follow-up outstanding for AKR1D1. Tracker, source-workflow and generated-page PRs add no gene completions. Reviews #4235, #4236, #4239 and #4222 contribute none at this cutoff.

Gene Verified merge Changed / reused scoped paths Biological assessment retained
CAV3 530eafda0322, 2026-10-04T20:37:20Z 27 / 9; every path/blob pair is in the queue Biological DRAFT retains 116 source assertions, 28 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged scientific evidence limits.
CBS 62791a27b3b4, 2026-10-04T21:11:07Z 6 / 28; every path/blob pair is in the queue Biological DRAFT retains 101 source assertions, 12 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged scientific evidence limits.
CBFB 673823f39a4f, 2026-10-04T22:33:17Z 86 / 33; every path/blob pair is in the queue Biological DRAFT retains 136 source assertions, 3 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged scientific evidence limits.
CBL e4cac0ee313f, 2026-10-04T22:36:18Z 7 / 162; every path/blob pair is in the queue Biological DRAFT retains 305 source assertions plus 1 historical NEW proposal, 16 UNDECIDED assessments and 3 core functions. Campaign completion preserves the merged scientific evidence limits. The retained NEW-labelled FGFR-regulation row predates this campaign revision.
CCDC39 8552bad4435e, 2026-10-04T23:22:31Z 12 / 2; every path/blob pair is in the queue Biological COMPLETE retains 30 source assertions plus 1 NEW molecular-function assertion, 5 UNDECIDED assessments and 1 core function. COMPLETE is the normal validation status and does not resolve its five UNDECIDED assessments.
CC2D2A ecc0fc3d9990, 2026-10-04T23:39:16Z 6 / 10; every path/blob pair is in the queue Biological DRAFT retains 19 source assertions, 0 UNDECIDED assessments and 1 core function. Its DRAFT status reflects an unused-research advisory; no annotation remains UNDECIDED.

The six final PR heads have verified approval and successful required checks. Their signed merges account for 144 changed path/blob pairs and 244 unchanged reused scope objects, totaling 388 verified scoped objects. These are per-review counts; shared sources can occur in several scopes. The queue enumerates both maps. CAV3 has 28 whole-PR paths but 27 merge changes after one exact shared-source reuse; the reused path remains within its nine-object reuse map.

The merged payloads retain 707 original source assertions and 64 UNDECIDED assessments, with 709 total reviewed assertions. Of the two NEW-labelled rows, CBL preserves its historical GO:0040037 FGFR-regulation proposal, whereas CCDC39 adds the reviewed GO:0005200 structural molecular function. No other gene in this tranche adds an annotation. Five reviews remain DRAFT and CCDC39 is COMPLETE. COMPLETE is a normal validation status, not a claim that its five UNDECIDED assessments are resolved; CC2D2A is DRAFT with no UNDECIDED rows because an unused-research advisory remains. The alternative-product counts are 0, 2, 2, 0, 2 and 4 in table order: CAV3 and CBL have no alternative-products slot, not an assertion of zero protein products. Core counts are 2, 1, 1, 3, 1 and 1.

All 226 existing genes[] queue entries are preserved, followed by six entries. Queue-entry count is distinct from the completed-gene baseline. All 2,876 gene inventory entries and their frozen associations, the checkpoint 228 CASP8 count correction, both corrected CARMIL2 reuse maps, earlier completion records and history, and the checkpoint 95 audit/import boundary remain exact.

Published checkpoint 231 history.

Evidence scope for completion 231

Checkpoint 231 history.

The fixed 2026-10-04 19:58:03 UTC cutoff adds CASR, CAV1 and CAVIN1 to published checkpoint 228: 231 complete / 2,645 remaining, with 232 gene-level original review merges and one required source follow-up outstanding for AKR1D1. Tracker, generated-page and source-workflow PRs add no gene completions. Open reviews #4209, #4210, #4191 and #4175 contribute none at this cutoff.

Gene Verified merge Changed / reused scoped paths Biological assessment retained
CASR 207bae9a4420, 2026-10-04T16:52:11Z 42 / 6; every path/blob pair is in the queue Biological DRAFT retains 123 source assertions, 33 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CAV1 acaa8bd532ef, 2026-10-04T18:27:15Z 57 / 51; every path/blob pair is in the queue Biological DRAFT retains 273 source assertions, 37 UNDECIDED assessments and 3 core functions. Campaign completion preserves the merged biological assessment and its evidence limits.
CAVIN1 e575922d0239, 2026-10-04T19:58:03Z 12 / 13; every path/blob pair is in the queue Biological DRAFT retains 77 source assertions plus 1 NEW assertion, 12 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. The one NEW assertion is GO:0070836 caveola assembly, not a molecular-function annotation.

The three final PR heads have verified approval and successful required checks. Their signed merges account for 111 changed path/blob pairs and 70 unchanged reused scope objects, totaling 181 verified scoped objects across the three reviews. These are per-review counts; a shared source may occur in more than one scope. The queue enumerates both maps. CAVIN1 has 15 whole-PR paths but only 12 merge changes: PMID:19525939, PMID:19726876 and PMID:24013648 had become exact main-branch source reuses before its merge and remain explicitly included in the 13-object reuse map.

All three biological reviews remain DRAFT, retaining 473 original source assertions and 82 UNDECIDED assessments. CAVIN1 adds one reviewed NEW biological-process assertion, GO:0070836 caveola assembly, for 474 total reviewed assertions across this tranche. CASR and CAV1 add none. CASR and CAV1 each retain two alternative products, CAVIN1 three; their core-function counts are one, three and two respectively. Campaign completion records finished review and publication while preserving these evidence limits.

All 223 existing genes[] queue entries are preserved, followed by three entries; queue-entry count is distinct from the completed-gene baseline. The checkpoint 228 CASP8 correction, both corrected CARMIL2 source reuse maps, all 2,876 gene inventory entries and their frozen associations, all earlier completion records and history, and the checkpoint 95 audit/import boundary remain exact.

Published checkpoint 228 history.

Evidence scope for completion 228

Checkpoint 228 history.

The fixed 2026-10-04 15:17:41 UTC cutoff adds CASK, CASP8 and CASQ2 to published checkpoint 225: 228 complete / 2,648 remaining, with 229 gene-level original review merges and one required source follow-up outstanding for AKR1D1. Tracker, generated-page and source-workflow PRs add no gene completions. Other pending reviews contribute none at this cutoff.

The planned total of 227 omitted CASP8 because its earlier repository review was mistaken for an already recorded campaign completion. The published checkpoint 225 inventory leaves CASP8 unchecked, and its queue and progress ledger contain no CASP8 entry. Original multi-gene apoptosis PR #3672 merged as 6202dafbf7a64866df30e2a500bf3c8a80427870 on 2026-10-03 at 21:22:04 UTC. The substantive campaign revision #4139 is now its first verified campaign completion. Thus 225 + 3 = 228; CASP8 original #3672 contributes one newly recognized gene-level original review, and #4139 is not counted as a second original. No prior published checkpoint count is rewritten.

Gene Verified merge Changed / reused scoped paths Biological assessment retained
CASK 72e64874c80b, 2026-10-04T14:29:51Z 23 / 20; every path/blob pair is in the queue Biological DRAFT retains 118 source assertions, 31 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged biological assessment and its evidence limits.
CASP8 91b5ea418917, 2026-10-04T15:11:44Z 6 / 128; every path/blob pair is in the queue Biological DRAFT retains 264 source assertions, 21 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged biological assessment and its evidence limits. This is the first campaign completion of the existing review, not a second original review.
CASQ2 b4fb9e72ca0a, 2026-10-04T15:17:41Z 22 / 1; every path/blob pair is in the queue Biological DRAFT retains 57 source assertions, 12 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged biological assessment and its evidence limits.

All three final PR heads have verified approval and successful required checks. Their signed merges account for 51 changed path/blob pairs and 149 unchanged reused scope objects, totaling 200 verified scoped objects across the three reviews. These are per-review counts; a shared source may occur in more than one scope. The durable queue enumerates both changed and reused blobs. All three biological reviews remain DRAFT, retaining 439 source assertions and 64 UNDECIDED assessments, with no NEW assertions. CASK retains six alternative products, CASP8 nine, and CASQ2 two; each has two core functions. Campaign completion records finished review and publication while preserving biological uncertainty.

All 220 existing genes[] queue entries are preserved, followed by three entries; this entry count is distinct from the 225 completed-gene baseline. The corrected CARMIL2 reuse maps for PMID:19946888 and PMID:23793062 remain exact in both durable locations. All 2,876 gene inventory entries and their frozen associations, all prior completion records and dated history, and the checkpoint 95 audit/import boundary remain unchanged.

Published checkpoint 225 correction history.

Evidence scope for completion 225

Checkpoint 225 history.

The fixed 2026-10-04 14:10:18 UTC cutoff adds CARMIL2 to published checkpoint 224: 225 complete / 2,651 remaining, with 226 original gene PR merges. AKR1D1 remains excluded pending its required source follow-up. Tracker, generated-page and source-workflow PRs add no gene completions. Other pending gene reviews contribute no completion in this checkpoint.

Gene Verified merge Exact changed paths verified at merge Biological assessment retained
CARMIL2 adee3d6ced9b, 2026-10-04 14:10:18 UTC 16; every path/blob pair is in the queue Biological DRAFT retains 45 source assertions plus 1 NEW molecular-function assertion, 3 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged biological assessment and its evidence limits.

The final PR head has verified approval and successful required checks. The signed merge record matches 16 changed path/blob pairs within an 18-path verified scope, including two reused sources: publications/PMID_19946888.md and publications/PMID_23793062.md. Their exact merge-commit blob hashes are enumerated in both matching durable-evidence entries in the queue; 16 changed paths plus two unchanged reused sources account for the 18-path scope. This is the checked merge scope, not a new audit of reused sources outside that scope. The merged biological review remains DRAFT, retaining 45 source assertions plus one NEW molecular-function assertion, for 46 total annotations: 33 ACCEPT, 8 KEEP_AS_NON_CORE, 3 UNDECIDED, 1 MODIFY and 1 NEW. The NEW annotation is GO:0035591 signaling adaptor activity; no new biological-process annotation is introduced. The review began with a normal initialized seed and retains two core functions. Campaign completion records the finished review and verified publication, without implying that every biological assertion is certain. All 219 existing genes[] queue entries are preserved, followed by this entry; that entry count is distinct from the 224 completed-gene baseline. All 2,876 inventory rows and association text, prior dated records, the fixed checkpoint 224 cutoff and history, and the checkpoint 95 audit/import boundary remain intact.

Published checkpoint 224 history.

Evidence scope for completion 224

Checkpoint 224 history.

The fixed 2026-10-04 12:47:21 UTC cutoff adds CAPN5 and CARD11 to published checkpoint 222: 224 complete / 2,652 remaining, with 225 original gene PR merges. AKR1D1 remains excluded pending its required source follow-up. Tracker, generated-page and source-workflow PRs add no gene completions. Other pending gene reviews contribute no completion in this checkpoint.

Gene Verified merge Exact changed paths verified at merge Biological assessment retained
CAPN5 33a9b5b4b20c, 2026-10-04 12:13:23 UTC 16; every path/blob pair is in the queue Biological DRAFT retains 14 source assertions, 4 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CARD11 47548efbbc18, 2026-10-04 12:47:21 UTC 20; every path/blob pair is in the queue Biological DRAFT retains 88 source assertions, 3 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.

Both final PR heads have verified approval and successful required checks. Signed merge records match 36 changed path/blob pairs. This is the checked merge scope, not a new audit of reused sources outside those diffs. Both merged biological states remain DRAFT, retaining 102 source assertions and 7 UNDECIDED assessments, with no NEW assertions. Both reviews began with normal initialized seeds. Campaign completion records the finished review and verified publication, without implying that every biological assertion is certain. All 217 existing genes[] queue entries are preserved, followed by these two entries; that entry count is distinct from the 222 completed-gene baseline. All 2,876 inventory rows and association text, prior dated records, the fixed checkpoint 222 cutoff and history, and the checkpoint 95 audit/import boundary remain intact.

Published checkpoint 222 history.

Evidence scope for completion 222

Checkpoint 222 history.

The fixed 2026-10-04 11:36:42 UTC cutoff adds CANT1 and CAPN3 to published checkpoint 220: 222 complete / 2,654 remaining, with 223 original gene PR merges. AKR1D1 remains excluded pending its required source follow-up. Tracker, generated-page and source-workflow PRs add no gene completions. Other pending gene reviews contribute no completion in this checkpoint.

Gene Verified merge Exact changed paths verified at merge Biological assessment retained
CANT1 c06607d5f36e, 2026-10-04 10:34:22 UTC 13; every path/blob pair is in the queue Biological DRAFT retains 37 source assertions, 4 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CAPN3 8b5e616456b0, 2026-10-04 11:36:42 UTC 25; every path/blob pair is in the queue Biological DRAFT retains 96 source assertions, 16 UNDECIDED assessments and 2 core functions. Campaign completion preserves the merged biological assessment and its evidence limits.

Both final PR heads have verified approval and successful required checks. Signed merge records match 38 changed path/blob pairs. This is the checked merge scope, not a new audit of reused sources outside those diffs. Both merged biological states remain DRAFT, retaining 133 source assertions and 20 UNDECIDED assessments, with no NEW assertions. Both reviews began with normal initialized seeds. Campaign completion records the finished review and verified publication, without implying that every biological assertion is certain. All 215 existing genes[] queue entries are preserved, followed by these two entries; that entry count is distinct from the 220 completed-gene baseline. All 2,876 inventory rows and association text, prior dated records, the fixed checkpoint 220 cutoff and history, and the checkpoint 95 audit/import boundary remain intact.

Published checkpoint 220 history.

Evidence scope for completion 220

Checkpoint 220 history.

The fixed 2026-10-04 08:47:19 UTC cutoff adds CACNA1F, CAMK2A, CA2 and CAMTA1 to published checkpoint 216: 220 complete / 2,656 remaining, with 221 original gene PR merges. AKR1D1 remains excluded pending its required source follow-up. Tracker, generated-page and source-workflow PRs add no gene completions. Other pending gene reviews contribute no completion in this checkpoint.

Gene Verified merge Exact changed paths verified at merge Biological assessment retained
CACNA1F 7f72807cfe3b, 2026-10-04 07:22:48 UTC 15; every path/blob pair is in the queue Biological COMPLETE retains 24 source assertions, 4 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CAMK2A ab4c372c9a04, 2026-10-04 08:21:48 UTC 5; every path/blob pair is in the queue Biological DRAFT retains 171 source assertions, 11 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CA2 798fb7343e8f, 2026-10-04 08:23:31 UTC 68; every path/blob pair is in the queue Biological DRAFT retains 89 source assertions, 4 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CAMTA1 938e8bc2b648, 2026-10-04 08:47:19 UTC 12; every path/blob pair is in the queue Biological COMPLETE retains 10 source assertions, 2 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.

All four final PR heads have verified approval and successful required checks. Signed merge records match 100 changed path/blob pairs. This is the checked merge scope, not a new audit of reused sources outside those diffs. The merged biological states remain two DRAFT and two COMPLETE, retaining 294 source assertions and 21 UNDECIDED assessments, with no NEW assertions. CAMK2A updates an existing review; the other three reviews began with normal initialized seeds. Campaign completion records the finished review and verified publication, without implying that every biological assertion is certain. All 211 existing genes[] queue entries are preserved, followed by these four entries; that entry count is distinct from the 216 completed-gene baseline. All 2,876 inventory rows and association text, prior dated records, the fixed checkpoint 216 cutoff and history, and the checkpoint 95 audit/import boundary remain intact.

Published checkpoint 216 history.

Evidence scope for completion 216

Checkpoint 216 history.

The fixed 2026-10-04 07:13:11 UTC cutoff adds CA5A, CA8, CABP2, CACNA1B, CACNA1D, CAD, CALM1, CACNA1E, CACNA1G, CALM2, CALM3, CACNA2D4 and CACNA1C to published checkpoint 203: 216 complete / 2,660 remaining, with 217 original gene PR merges. AKR1D1 remains excluded pending its required source follow-up. Tracker, generated-page and source-workflow PRs add no gene completions. Other pending gene reviews contribute no completion in this checkpoint.

Gene Verified merge Exact changed paths verified at merge Biological assessment retained
CA5A 201b20f8160a, 2026-10-03 20:22:13 UTC 19; every path/blob pair is in the queue Biological COMPLETE retains 20 source assertions, 0 UNDECIDED assessments and 1 core function. No new annotation is introduced.
CA8 bb9979ca5cdc, 2026-10-03 21:54:27 UTC 7; every path/blob pair is in the queue Biological DRAFT retains 26 source assertions plus 2 NEW assertions, 0 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CABP2 fd95b92c752b, 2026-10-04 04:18:38 UTC 12; every path/blob pair is in the queue Biological DRAFT retains 49 source assertions, 1 UNDECIDED assessment and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CACNA1B 3a94c2a1b96c, 2026-10-04 04:20:41 UTC 15; every path/blob pair is in the queue Biological DRAFT retains 29 source assertions, 1 UNDECIDED assessment and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CACNA1D a2df2d2932ce, 2026-10-04 04:21:48 UTC 15; every path/blob pair is in the queue Biological COMPLETE retains 78 source assertions, 6 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CAD 97c7c5ece722, 2026-10-04 04:41:00 UTC 15; every path/blob pair is in the queue Biological DRAFT retains 84 source assertions, 16 UNDECIDED assessments and 3 core functions. Campaign completion preserves the merged biological assessment and its evidence limits.
CALM1 96522b759322, 2026-10-04 04:42:55 UTC 5; every path/blob pair is in the queue Biological DRAFT retains 176 source assertions, 8 UNDECIDED assessments and 3 core functions. Campaign completion preserves the merged biological assessment and its evidence limits.
CACNA1E e519f0da8bd3, 2026-10-04 06:07:21 UTC 11; every path/blob pair is in the queue Biological DRAFT retains 23 source assertions, 1 UNDECIDED assessment and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CACNA1G b9ae52478bd7, 2026-10-04 06:16:13 UTC 16; every path/blob pair is in the queue Biological DRAFT retains 41 source assertions, 5 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CALM2 a96daa90cb60, 2026-10-04 06:39:56 UTC 7; every path/blob pair is in the queue Biological DRAFT retains 105 source assertions, 3 UNDECIDED assessments and 3 core functions. Campaign completion preserves the merged biological assessment and its evidence limits.
CALM3 ddb719a6b474, 2026-10-04 07:07:22 UTC 12; every path/blob pair is in the queue Biological DRAFT retains 115 source assertions, 10 UNDECIDED assessments and 5 core functions. Campaign completion preserves the merged biological assessment and its evidence limits.
CACNA2D4 93b454926db7, 2026-10-04 07:08:57 UTC 11; every path/blob pair is in the queue Biological COMPLETE retains 7 source assertions plus 1 NEW assertion, 1 UNDECIDED assessment and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.
CACNA1C fbf4cfae0dba, 2026-10-04 07:13:11 UTC 36; every path/blob pair is in the queue Biological DRAFT retains 136 source assertions, 8 UNDECIDED assessments and 1 core function. Campaign completion preserves the merged biological assessment and its evidence limits.

All thirteen final PR heads have verified approval and successful required checks. Signed merge records match 181 changed path/blob pairs. This is the checked merge scope, not a new audit of reused sources outside those diffs. CACNA1C’s PR diff contains 37 paths; its merge changes 36, because the identical PMID:12181424 cache was already on main after CACNA2D4. The merged biological states remain ten DRAFT and three COMPLETE, including 60 UNDECIDED assessments; CA8 retains two reviewed NEW assertions and CACNA2D4 retains one. Campaign completion records the finished review and verified publication, without implying that every biological assertion is certain. All 198 existing genes[] queue entries are preserved, followed by these thirteen entries; that entry count is distinct from the 203 completed-gene baseline. All 2,876 inventory rows and association text, prior dated records, and the checkpoint 95 audit/import boundary remain intact.

Published checkpoint 203 history.

Evidence scope for completion 203

Checkpoint 203 history.

The fixed 2026-10-03 18:25:30 UTC cutoff adds C3 and C9orf72 to published checkpoint 201: 203 complete / 2,673 remaining, with 204 original gene PR merges. AKR1D1 remains excluded pending its required source follow-up. Tracker, generated-page and source-workflow PRs add no gene completions. CA5A and CA8 remain unchecked in this checkpoint.

Gene Verified merge Exact changed paths verified at merge Biological assessment retained
C3 6b0ca24ae70c, 18:15:29 UTC 72; every path/blob pair is in the queue Biological DRAFT retains 142 source assertions, nine UNDECIDED assessments and three cores. Four authored processed-product classes are distinct from alternative splice products. C3a versus ASP/C5L2 context and exact source access limits remain; no new annotation is introduced.
C9orf72 46872d06c54e, 18:25:30 UTC 18; every path/blob pair is in the queue Biological DRAFT retains 110 source assertions, 23 UNDECIDED assessments, two alternative products and three cores. Reagent-specific localization and GEF/GAP context limits remain; campaign closure does not resolve those biological uncertainties.

Both final PR heads have verified approval and successful required checks. Signed merge records match 90 changed path/blob pairs. This is the checked merge scope, not a new audit of reused sources outside those diffs. Both biological reviews remain DRAFT with 32 UNDECIDED assessments in total. All 196 existing genes[] queue entries are preserved, followed by these two entries; that entry count is distinct from the 201 completed-gene baseline. All 2,876 inventory rows and association text, prior dated records, and the checkpoint 95 audit/import boundary remain intact.

Evidence scope for completion 201

Checkpoint 201 history.

The fixed 2026-10-03 16:43:30 UTC cutoff adds C1QA, C1QB, C1QTNF5, C2CD3 and C1QBP to the completion ledger published at checkpoint 196: 201 complete / 2,675 remaining, with 202 original gene PR merges. AKR1D1 remains excluded while its required source follow-up is outstanding. Tracker, generated-page and source-workflow PRs add no gene completions.

Gene Verified merge Exact changed paths verified at merge Biological assessment retained
C1QA b07074cf21fb, 15:13:09 UTC 34; every path/blob pair is in the queue Biological DRAFT retains 83 source assertions, six UNDECIDED assessments and three cores; no structured products slot. Bibliography-only and fine synaptic/extracellular-matrix evidence limits remain. Whole-C1q contributions do not establish isolated A-chain sufficiency.
C1QB f229b827c95c, 16:18:20 UTC 8; every path/blob pair is in the queue Biological DRAFT retains 62 source assertions, six UNDECIDED assessments and three cores; no structured products slot. Fine donor localization and other source limits remain; recognition, protease recruitment and signaling are scoped to contribution within C1q.
C1QTNF5 4086522913b0, 16:21:15 UTC 13; every path/blob pair is in the queue Biological DRAFT retains 23 source assertions, three UNDECIDED assessments and one core; no structured products slot. Collagen-stalk inference is distinguished from directly observed globular trimers, and receptor inhibition from chronic perturbation phenotypes.
C2CD3 311d3f706642, 16:41:31 UTC 10; every path/blob pair is in the queue Biological DRAFT retains 30 source assertions plus one NEW structural-function assertion, five products and one core. Human spatial/depletion evidence is separated from mouse cryo-ET context; direct microtubule affinity, ring-node composition and catalytic activity remain unestablished.
C1QBP 2bf7e325e50c, 16:43:30 UTC 9; every path/blob pair is in the queue Biological DRAFT retains 125 source assertions, five UNDECIDED assessments and four cores; no structured products slot. Reconciled partner/donor distinctions and source-specific screen limits remain; precursor/mature localization is described without manufacturing product fields.

All five final PR heads have verified approval and successful checks. Signed merge records and complete PR file lists match 74 changed path/blob pairs. This does not claim a new audit of reused sources outside those diffs. The five merged reviews remain DRAFT, including 20 UNDECIDED source assessments; C2CD3 separately retains one reviewed NEW structural-function assertion. All 191 earlier queue entries, all 2,876 gene rows and ClinGen association text, old dated checkpoints, the checkpoint 95 audit/import boundary and prior histories remain unchanged. Other pending gene work contributes no completion here.

Evidence scope for completion 196

Checkpoint 196 history.

The fixed 2026-10-03 14:49:33 UTC cutoff adds BSND, BTD, BTK, C19orf12 and BUB1B to the completion ledger published at checkpoint 191: 196 complete / 2,680 remaining, with 197 original gene PR merges. AKR1D1 remains excluded from completion while its required source follow-up is outstanding. Shared tracker, generated-page and source-workflow PRs add no gene completions.

Gene Verified merge Exact changed paths verified at merge Biological assessment retained
BSND 66aae0854d61, 13:08:02 UTC 16; every path/blob pair is in the queue Biological DRAFT retains 52 source assertions and one channel-regulatory core; no structured products slot. Thirty-one screen-binding decisions retain explicit curator-deference and uninspected target-assay limits. Barttin is the auxiliary subunit, not the channel pore.
BTD 56b1fad8f80c, 13:08:19 UTC 14; every path/blob pair is in the queue Biological COMPLETE retains 20 source assertions, six UNDECIDED assessments, four products and one extracellular biotin-recycling core. Fine mitochondrial localization, screen-binding and CNS-development evidence remain unresolved.
BTK a5d697b6e4af, 14:20:21 UTC 35; every path/blob pair is in the queue Biological DRAFT retains 149 source assertions, 31 UNDECIDED assessments, two products and two cores. PLC regulation is distinguished from covalent substrate phosphorylation; remaining interaction and source-access limits persist.
C19orf12 76ce56c2cfc3, 14:31:06 UTC 12; every path/blob pair is in the queue Biological COMPLETE retains 22 source assertions, four products and one process core. The molecular activity remains unresolved; positive autophagy regulation and contextual apoptosis over-annotation are preserved.
BUB1B 847ce08c9bc1, 14:49:33 UTC 10; every path/blob pair is in the queue Biological DRAFT retains 119 source assertions, 11 UNDECIDED assessments, three products and two cores. Seven catalytic assertions remain disputed; supported CDC20 inhibition and kinetochore adaptor functions do not settle the kinase controversy.

All five final PR heads have verified approval and successful checks. The signed merge records and complete PR file lists match 87 changed path/blob pairs; this does not claim a new audit of every reused publication or Reactome cache. All 186 earlier queue entries, all 2,876 gene rows and their ClinGen association text, old dated checkpoints, the checkpoint 95 audit/import boundary and earlier histories remain unchanged. Biological review statuses and unresolved source assessments remain as merged. C1QA, C1QB, C1QBP and other pending work contribute no completion here.

Evidence scope for completion 191

The fixed 2026-10-03 12:33:32 UTC cutoff adds BRPF1, BRSK2, BRWD3 and BSCL2 to published checkpoint 187: 191 complete / 2,685 remaining, with 192 original gene PR merges and AKR1D1’s one required source follow-up still outstanding. These are four gene completions; shared tracking and source-workflow changes contribute none.

Gene Verified merge Exact changed paths verified at merge Biological assessment retained
BRPF1 d221bee44a92, 10:55:34 UTC 9; the queue enumerates every path/blob pair Biological COMPLETE retains four UNDECIDED source assessments, 36 source assertions, four alternative products and two cores; no uncertainty is resolved merely by campaign closure.
BRSK2 a23171822631, 11:10:19 UTC 14; the queue enumerates every path/blob pair Biological DRAFT retains nine UNDECIDED assessments, 48 source assertions, six alternative products and one catalytic core. Combined SAD A/B experimental limits remain.
BRWD3 78cc3cc0e4d1, 12:32:23 UTC 13; the queue enumerates every path/blob pair Biological COMPLETE retains the two supplied source assertions, five alternative products and one core. The documented UniProt/normal-GOA discrepancy and species limits remain explicit.
BSCL2 20c0b77ea607, 12:33:32 UTC 17; the queue enumerates every path/blob pair Biological DRAFT retains 30 original source assertions plus one NEW tether activity, seven UNDECIDED assessments, three alternative products and two cores. Thermogenesis and human and fly assay limits remain.

The durable queue records 53 merge-specific path/blob pairs, not a universal gene/publication/Reactome inventory. All 182 earlier queue entries, all 2,876 ClinGen association rows, prior dated observations and the checkpoint 95 audit/import boundary remain intact. The four former pending table rows are updated; their earlier dated evidence sections remain historical. Other genes remain unchecked, and no pending approval, source import or local review is counted as a merge.

Standard project history.

Evidence scope for completion 187

This checkpoint uses the fixed 2026-10-03 10:42:33 UTC completion cutoff and adds BRIP1 and BRD4 to published checkpoint 185. It reaches 187 complete / 2,689 remaining, with 188 original gene PR merges including the unresolved AKR1D1 source follow-up. Both genes had exact-head approval and passing required CI before their signed merges.

Gene Verified merge Exact paths verified at merge Biological review retained
BRIP1 8156c9b7b58c, 10:26:05 UTC Six: three gene outputs and three histories DRAFT; 92 source assertions; 65 ACCEPT, 23 KEEP_AS_NON_CORE, three UNDECIDED, one REMOVE; three cores; two alternative products
BRD4 82005fc0057b, 10:42:33 UTC 31 added paths: five gene files, two histories, 22 normal publication caches, two Reactome caches DRAFT; 81 source assertions; 38 ACCEPT, 24 KEEP_AS_NON_CORE, six MODIFY, 13 UNDECIDED; 40 references; three products; two cores; 21 disclosed validation warnings

The durable queue enumerates all 37 merge-specific path/blob pairs. Campaign completion does not settle BRIP1's precise interstrand-crosslink-response step or BRD4's catalytic and individual-mark uncertainties. All 180 earlier queue entries, all 2,876 association rows and earlier dated observations are preserved. The unpublished intermediate 186 proposal is superseded by this combined checkpoint and contributes no extra completion or history.

As observed at fixed 2026-10-03 10:42:33 UTC, BRPF1's follow-up was published, with approval not yet verified in this checkpoint and required CI pending; BRSK2's core-coverage follow-up is applied and validated but unpublished; BRWD3's seed is imported and its six-paper fetch succeeded with artifact recovery pending; BSCL2's normal sources are imported and scientific review is underway. These four work observations add no completions. Later events are outside this fixed checkpoint. BRAF's previously observed mixed 725-path PR #3381 and AKR1D1's source follow-up remain excluded; no fresh BRAF ownership/lifecycle audit is claimed. PANTHER family/index work does not count as a gene completion. Historical checkpoint 95 audit/import totals remain unchanged.

Standard project history.

Verification log

AKT1 is in the Limited tier. Its already-started cached audit is an explicit scheduling exception while earlier gene initialization is unavailable; it does not change tier order or mark intervening genes complete.

Selected work in progress — 2026-10-02 receipt update

These dated observations add no completion and do not revise checkpoint95 totals.

Completion checkpoint 413 — 2026-10-14 01:31:47 UTC

413 complete; 2,463 remaining out of 2,876 primary catalogue genes.
The 19 distinct additions below extend merged checkpoint 394. The completion
cutoff is CTCF merge 5e2706cd8198.
The source tracker #4988
merged later as 488cf4ada7bb,
at 2026-10-14 02:23:05 UTC. These are deliberately different boundaries.

Rendering availability is separate from completion credit. The committed main-page render changed from 1,788 to 1,769 missing-review warnings (19 cleared; none added). Sixteen cleared warnings belong to the 19 counted genes; CPS1, CPT2 and CSF1R were already linked before this render. The other three cleared warnings are ADAM17, RIPK1 and RORB: their review links became available, but they remain unchecked and receive no completion credit. Under the same frozen 2,924-review inventory, a fresh baseline render also has 1,769 warnings, equal to the checkpoint render; that fresh-render comparison does not erase the committed 1,788-to-1,769 change. The progress page has zero rendering warnings.

Gene Review PR Approved head Actual merge Merged UTC Full PR paths / parent delta
CPS1 #4967 c758f4c5f7d5 350e9e3a9958 2026-10-13 16:55:45 45 / 45
CPT2 #4969 6885166bdbc8 7cb48b0a7894 2026-10-13 17:14:48 21 / 21
CR2 #4970 bd4986696bf5 444bd0a2197e 2026-10-13 17:41:25 23 / 23
CRADD #4971 44fd6c512ff6 c8be91268fbf 2026-10-13 18:03:33 27 / 27
CRB1 #4973 983cd30d33ac 2fb75d4c8ec7 2026-10-13 18:29:32 27 / 27
CRB2 #4974 7eef84585f12 38361ca08760 2026-10-13 18:57:05 24 / 20
CRPPA #4976 bd638a9dbaa8 d73f140b43a6 2026-10-13 19:23:15 12 / 12
CREBBP #4975 59a37cf72359 55b67a6a02e0 2026-10-13 19:50:48 99 / 99
CRX #4977 657584bac14a 314e2c866be9 2026-10-13 20:18:16 21 / 21
CSDE1 #4978 63cfd2557543 980669d44911 2026-10-13 20:40:02 15 / 14
CSF2RA #4980 228baf4cb705 967b016268fc 2026-10-13 21:06:27 26 / 26
CSF1R #4979 705af916d431 e2fdd68e95ed 2026-10-13 21:28:59 10 / 10
CSF2RB #4981 70a5ca76f485 ab45ccd17825 2026-10-13 21:49:55 35 / 27
CSNK2A1 #4982 4855783f0a0b 27eca918c9f0 2026-10-13 22:17:53 36 / 36
CSPP1 #4983 b27ea22b9780 1baaa9693348 2026-10-13 22:43:38 19 / 19
CSRP3 #4984 767e5bd09051 211f2c2993a0 2026-10-13 23:04:16 18 / 18
CSTB #4985 74f03ecb03b3 b0f4c5769323 2026-10-13 23:28:57 16 / 16
CTC1 #4986 3bdb911d96e3 aebcb27ec7bb 2026-10-13 23:55:58 28 / 28
CTCF #4987 12c2f7bbab59 5e2706cd8198 2026-10-14 01:31:47 31 / 31

Every listed gene has accepted final-head approval, required CI and an actual
merge. Complete PR-path modes, types and blobs match the approved head at the
merge; parent-relative deltas contain no unaccounted paths. The combined proof
covers 533 full PR-path occurrences,
520 changed-path occurrences and
13 paths already identical in their
respective parents. The queue JSON records complete
heads, merge IDs, approval/comment IDs and test-job locators.

This is an identity-based reconciliation. CPAMD8 was already corrected into
checkpoint 394 and remains counted once. CPS1 was still unchecked in that
merged tracker and is included here. Earlier local numerical receipts predate
the CPAMD8 correction; their original bytes and counters are preserved rather
than treated as new identities automatically.

The prior tracker passed its ordinary merge-queue test.
Its later main-push test
failed only the sorted/deduplicated GO-cache test: GO:0140632 precedes GO:0140619,
and GO:0006910 and GO:0097528 are duplicated. Exact committed parent 99d78b3 and
merge 488cf4a have identical cache bytes and reproduce those three findings;
the seven tracker paths did not introduce them. The reason the queue run passed
on the same merge commit is not established. This checkpoint preserves that
failed historical result and does not claim a successful post-main test.

All 235 historical queue records, all 73 prior completion updates, every earlier
progress paragraph and all 161 existing project history records remain
unchanged. The 2,876 HGNC identities and association texts are unchanged; only
the 19 unchecked entries above become checked. No queued or merely published
gene, including CTNNA1 or CTNNB1, receives completion credit. Existing review
status labels do not substitute for the accepted source-specific reviews and
merge evidence. No new gene annotation decision is made by this tracker update.

The complete 20-commit interval audit now resolves to these 19 accepted gene
reviews and the LRV tooling upgrade #4947.
CSF1R and CSF2RB were initially withheld from an unpublished 411-gene preparation.
Their full approved-head, ordinary-queue, later main-push and merged-path proofs
have since been accepted, so both are counted here once. That preparation remains
preserved separately; it was not a published tracker checkpoint. The completion
cutoff remains CTCF, and the later CTLA4 merge is outside this snapshot.

Curation session

Completion checkpoint 425 — 2026-10-14 07:48:59 UTC

425 complete; 2,451 remaining out of 2,876 primary catalogue genes.
The 12 distinct additions below extend merged checkpoint 413. The completion
cutoff is CUL3 699711b0e7d1;
this is a receipt-based snapshot, not an exhaustive claim about every repository
review merge. Source and rendering context are frozen at main 99a36bd05946bbd4d66a3a7e47b3260072c2e9c7.
ROOT, the coordinating AI agent, accepted each complete merge proof; this is
not a claim of human maintainer review.

Rendering availability is separate from completion credit. The committed main-page render has 1,769 missing-review warnings; the fresh baseline and checkpoint renders under the same frozen 2,946-review inventory have 1,751 (18 cleared; none added). Eight cleared warnings belong to these 12 counted genes. CTLA4, CTNNA1, CTNNB1, CUL3 were already linked. The other ten cleared warnings are CHM, CHST3, CIC, LDLR, LIPA, MSX1, PAX7, PCSK9, PNPLA2, TFAP2B: their review links became available, but they remain unchecked and receive no completion credit. This same-context comparison does not erase the committed-to-fresh change. The progress page has zero rendering warnings.

Gene PR Approved head Merge Merged UTC Full PR / parent delta paths
CTLA4 #4989 57752c15ea12 de285b1f26a4 2026-10-14 02:48:02 10 / 10
CTNNB1 #4991 6fcafcde4ce0 4ad9a0175d31 2026-10-14 03:16:44 12 / 12
CTNND1 #4992 f0d2744ed575 7d5c823e80e3 2026-10-14 03:44:07 36 / 36
CTPS1 #4993 cdc7baa1e1ab 22a69a66d01f 2026-10-14 04:11:24 22 / 22
CTNNA1 #4990 1bcc46b740d1 1a622391f31c 2026-10-14 04:30:33 18 / 18
CTSA #4994 036501714ac7 08e2a9d6fda7 2026-10-14 04:50:11 17 / 17
CTSF #4996 3eb0187853a4 9d1bdc6f9151 2026-10-14 05:17:16 19 / 19
CTSD #4995 8629b15c70da 4d4ed80803ac 2026-10-14 05:37:16 24 / 23
CTSK #4997 1ec38baa28f8 cb8992c9155e 2026-10-14 06:26:56 23 / 22
CUL4B #5000 b1ff3a07748d f4ad933c9bc4 2026-10-14 06:53:48 9 / 9
CWF19L1 #5002 fd2ac6bba817 6f3803683c26 2026-10-14 07:20:56 13 / 13
CUL3 #5001 757d855a65ce 699711b0e7d1 2026-10-14 07:48:59 12 / 12

Every listed gene has final approval on its exact head, a successful ordinary
merge-queue test and a separate successful post-merge main-push test. Queue
jobs passed the full test suite. Post-main scopes are recorded per gene in the
queue JSON; successful scoped-only runs are not
represented as full-suite runs. All 215 full PR-path occurrences match the
approved modes, types and blobs at merge. The exact parent deltas contain
213 changed-path occurrences; 2 PR paths were already identical in
their respective parents. No unaccounted parent changes were accepted.

The prior checkpoint 413 tracker #4999
merged at b9da9839c93ff74b6be6cf30102747f8973984f2 with its eight approved paths exact.
Its queue and separate main-push full suites succeeded after the independent
GO-cache repair. This later success does not rewrite the failed historical
checkpoint 394 post-main test recorded above.

All 235 historical queue records, all 74 prior completion updates, the complete
previous progress text, all 163 existing project history records and the frozen
catalogue source files remain unchanged. The 2,876 HGNC identities and their
association text are preserved; only these 12 unchecked identities become
checked. CYB5A, CWC27 and other published or available reviews receive no
completion credit in this snapshot. No gene annotation or source is changed.

Curation session

Completion checkpoint 426 — 2026-10-16 10:41:28 UTC

426 complete; 2,450 remaining out of 2,876 primary catalogue genes.
Only CWC27 is added to the 425 checked genes in tracker #5034,
whose exact approved head was 48efb320877bcbe219856ddcef8c5af42c8bbe5e and which subsequently
merged as 56a970dd16a3.
Tracker publication itself does not add gene credit. The completion cutoff is
the CWC27 merge below; this is not an exhaustive claim about every repository
review merge. ROOT, the coordinating AI agent, accepted this completion proof.

Gene PR Approved head Merge Merged UTC Full PR / parent delta paths
CWC27 #5003 c75d783131ad 8b87c39aea83 2026-10-16 10:41:28 9 / 9

The final formal approval
and complete detailed review
clear all prior scientific blockers on that exact head. Required
PR validation
passed. The ordinary merge-group run
passed all-gene schema validation, examples and the full test suite before merge.
The separate post-main push run
then materialized the exact merged commit and passed scoped CWC27 and history
validation. Its full test suite was skipped for the source-only push, not rerun.

All nine approved file modes, types and blobs equal the merged full PR paths,
and the actual parent delta contains exactly nine paths. Prior substantive
source review, the final Figure S1 locator correction, all 16 original source
objects, two official products and the explicit isoform-scoped new molecular
function are retained. Derived DRAFT reflects a nonblocking secondary-research
citation advisory, not an unresolved action or outstanding scientific blocker.
This completion follows validated final review, cleared actionable feedback and
merger; it does not infer completion from a status label alone.

All 2,876 catalogue identities and association texts, all 235 historical queue
records, all 75 prior completion updates and the entire previous progress text
remain unchanged. Only the previously unchecked CWC27 identity becomes checked.
Earlier statements excluding CWC27 remain historical checkpoint records.
Review-link availability and rendering warnings remain separate from completion;
no other gene is counted by this update. All earlier project history records
remain append-only and no gene annotation or source file changes.

Rendering availability remains separate from completion credit. The committed main-page render contains 1,751 missing-review warnings; the fresh baseline and checkpoint 426 render under the same frozen 2,966-human-review inventory contain 1,733 (18 cleared; none added). The cleared genes are CYB5A, DNAH17, DNAH8, FBXL4, MT-TC, MT-TH, MT-TK, MT-TL1, MT-TM, MT-TQ, MT-TS1, MT-TS2, MT-TV, MT-TW, MTFMT, SUCLA2, TARS2, TRMT10C. All remain unchecked and receive no completion credit here. CWC27 was already linked; its newly recorded completion follows the accepted merge evidence. The progress page has zero rendering warnings.

Curation session

Completion checkpoint 427 — 2026-10-16 11:40:12 UTC

427 complete; 2,449 remaining out of 2,876 primary catalogue genes.
Only CYB5A is added to the 426 checked genes in tracker #5053,
using its exact checkpoint-426 head 7173ebea8f29d62fb2f17eeb755e8f0c0f225d38 as the preimage.
This is a follow-up on that existing tracker PR. Tracker publication itself
adds no gene credit. ROOT, the coordinating AI agent, accepted the independent
completion proof; this is not a human maintainer sign-off.

Gene PR Approved head Merge Merged UTC Full PR / parent delta paths
CYB5A #5033 a0cbfb16972e 782b3b5a78c7 2026-10-16 11:40:12 21 / 21

The final formal approval
and complete detailed review
clear the four prior scientific blockers on that exact head. Three residual
presentation/exception suggestions are explicitly optional; there are no open
review threads. Required PR validation
passed. The merge-group run
passed scoped gene/history validation, all-gene schema validation, examples,
the full test suite and automation checks. The separate
actual-main push run
then materialized the same merged commit and passed scoped CYB5A and history
validation, completing at 11:45:27 UTC. Its full test suite was skipped by the
workflow; it is not represented as a full-suite rerun.

All 21 approved file modes, types and blobs equal the merged full PR paths,
and the actual parent delta contains exactly those 21 additions. All four final
review/notes/source-guide/render artifacts are exact, as are 24 protected
scientific paths. The accepted science preserves 21 original annotation source
objects, 23 reference identities, all three official product identities and
three exact quotations, with one explicitly homolog-inferred electron-transfer
assertion. The review's DRAFT status and three justified UNDECIDED annotations
remain biological/source-access statements, not outstanding required feedback.
The seven documented validation advisories are unchanged and nonblocking.

All 2,876 catalogue identities and association texts, all 235 historical queue
records, all 76 prior completion updates, the entire preceding progress text
(including checkpoint 426), and all existing project histories remain unchanged.
Only the previously unchecked CYB5A identity becomes checked. Earlier statements
excluding CYB5A retain their historical checkpoint scope. No gene annotations,
source caches or earlier histories change.

The rendering inventory remains frozen at main 782b3b5a78c788e9c88c99b98aae2baa0af3dba0:
7,824 total review YAMLs and 2,966 human review YAMLs. The checkpoint-426 baseline
has 1,733 main-page missing-review warnings and zero progress-page warnings.
No availability change is proposed here; ROOT will derive the two updated HTML
pages in this same inventory and record their actual results separately.

The final render passed all eight frontmatter checks and reproduced exactly the baseline warning lists: 1,733 for the main page and zero for the progress page. The completion counts are 427 checked and 2,449 unchecked catalogue genes.

Curation session

Completion checkpoint 428 — 2026-10-16 12:05:50 UTC

428 complete; 2,448 remaining out of 2,876 primary catalogue genes.
Only CXCR4 is added to checkpoint 427 in tracker #5053.
The exact prior tracker head is d69551859e986bbcb2e37d44ae14daebf7fd9851. ROOT, the coordinating
AI agent, accepted the independent completion audit; this is not a human
maintainer sign-off. The entire prior checkpoint 426 and 427 record is preserved.

Gene PR Approved head Merge Merged UTC Full PR / parent delta paths
CXCR4 #5035 f019a43cbb9c 9cff2a2e29e9 2026-10-16 12:05:50 54 / 54

The final formal approval
and complete detailed review
resolve the six prior review requests on that exact head. There are no open
review threads; the remaining presentation suggestions are optional.
Required PR validation
passed. The merge-group run
passed scoped gene/history validation, all-gene schema validation, examples,
3,889 tests and 251 automation tests. The separate
actual-main push run
validated the merged CXCR4 and history files, completing at 12:12:56 UTC.
The full suite was skipped on that push; its successful execution belongs to
the merge-group run.

All 54 approved file modes, types and blobs equal the merged full PR paths
and the complete actual parent delta. The accepted science preserves all 117
annotation source objects, both official products, 79 reference identities,
19 exact excerpts and one core. The original 118 GOA rows deterministically
seeded 117 objects through one duplicate collapse. All 84 protected scientific
paths remain exact. Five justified UNDECIDED decisions, DRAFT status and two
nonblocking validation advisories remain explicit; none is unresolved required
feedback. The review comment's count of eight new excerpts is an arithmetic
slip: the verified inventory is 12 prior plus seven new, totaling 19.

Current render inventory and correction of the prior freeze

The checkpoint-427 render was frozen at main 782b3b5a78c788e9c88c99b98aae2baa0af3dba0 even though its
branch had already incorporated the CXCR4 merge. Its 7,824 total / 2,966 human
inventory and 1,733 warnings describe that historical render only. They do not
describe the current branch. This appended disclosure corrects the current
state without rewriting either earlier checkpoint or history record.

The branch now has 7,825 review YAMLs, including 2,967 human reviews, exactly
matching main 9cff2a2e29e9221d04e45143abb00951b0277a49. CXCR4 is the sole added review since the
checkpoint-427 inventory and must become a link instead of a missing-review
warning. The complete tracker PR therefore has 19 cumulative availability
gains, reducing the prior-main warning list from 1,751 to 1,732, with no
new missing reviews. The 19 are CXCR4, CYB5A, DNAH17, DNAH8, FBXL4, MT-TC, MT-TH, MT-TK, MT-TL1, MT-TM, MT-TQ, MT-TS1, MT-TS2, MT-TV, MT-TW, MTFMT, SUCLA2, TARS2, TRMT10C.
The incremental change since checkpoint 427 is one link and one removed warning,
CXCR4. These are exact Git-inventory and frontmatter-path results; ROOT will
regenerate both HTML pages against the current branch and record the actual
1,732 / zero warning results before publication.

Availability and accepted completion are separate. CXCR4 is checked here only
because its independent audit and separate actual-main validation are now
accepted, not because its YAML is present. The earlier request to leave it
unchecked correctly described the pre-audit boundary. No other available review
receives credit. All 2,876 catalogue identities and association texts, all 235
historical queue objects, all 77 prior completion updates, the full preceding
progress text and all 166 prior project histories remain unchanged. Existing
cosmetic spacing in historical queue/history text remains preserved.

The final render passed all eight frontmatter checks and cleared exactly the stale CXCR4 availability warning: 1,732 warnings remain for the main page and zero for the progress page. The actual branch inventory contains 7,825 reviews, including 2,967 human reviews. The completion counts are 428 checked and 2,448 unchecked catalogue genes.

Curation session

Completion checkpoint 430 — 2026-10-17 05:42:20 UTC

430 complete; 2,446 remaining out of 2,876 primary catalogue genes.
CYFIP2 and CYB5R3 are the only additions to checkpoint 428 on tracker
#5053, whose prior head is
2409002e46c2034acd6d9fcabd7b7d76c3b3fae9. ROOT accepted both completion audits at 2026-10-17T05:52:50.199573+00:00.
ROOT is the coordinating AI agent; this records verified provenance and is not
a human maintainer sign-off. All earlier checkpoint text remains unchanged.

Gene PR Approved head Merge Merged UTC Full PR / parent delta paths Actual-main validation
CYFIP2 #5037 3184ce0f9edd 74290d411a6f 2026-10-17T00:11:09Z 19 / 19 run 38985181650
CYB5R3 #5036 2ce15d1c9773 04ba970bf897 2026-10-17T05:42:20Z 22 / 21 run 39007238786

The CYFIP2 approval
applies to the exact 19-file approved head, and all 19 merged files match it.
Its separate main push test job
completed successfully at 2026-10-17T00:16:42Z.
All 28 protected scientific source paths remained exact. Five documented
validation advisories remain; they are not unresolved required feedback.

The CYB5R3 approval
applies to all 22 final PR paths. The actual merge changes 21 paths because the
identical shared reactome/R-HSA-198824.md cache was already on parent main.
All 22 final modes, types and blobs still equal the approved files, and all 37
protected scientific source paths remained exact. The separate main push
test job completed
successfully at 2026-10-17T05:48:10Z.
Its 33 documented validation advisories remain explicit. The completion audits
check the scoped gene and history validation in these actual-main jobs; the job
name is not used to claim a full-suite run.

Current review availability

The tracker head contains 7,825 review YAMLs, including 2,967 human reviews.
Current main 04ba970bf8973abdda90bf8bbf3349870ee014ef contains 7,856 review YAMLs,
including 2,997 human reviews. The tracker branch has no gene changes since
its merge base, and main has not changed the selected tracker target files.
ROOT will incorporate current main and render the project against that actual
inventory. The exact frontmatter/path comparison predicts 1,716 missing-review
warnings, down from 1,732 at checkpoint 428, and zero progress-page warnings.
These are expected results from Git paths, not a claim that this owner ran the
renderer. ROOT records the actual render results before publication.

The 16 newly available catalogue reviews are AGA, CTNS, CYB5R3, CYFIP2, CYP27B1, FBP1, FUCA1, GALNT3, GNPTAB, HNF1A, HNF4A, KCNJ11, MT-ND1, MT-ND5, MT-ND6, NAGA.
No new missing review appears in the comparison. Only CYFIP2 and CYB5R3 earn
completion credit here; the other available reviews remain at their existing
checkbox states until separately accepted completion evidence is available.

Pending reviews remain uncredited

At the saved 2026-10-17 05:42:59 UTC queue observation, CYLD, CYP11B2, CYP27A1,
CYP1B1, CYP2U1, CYP4V2, CYP7B1, D2HGDH, DAG1 and DARS2 were approved and open in
the merge queue. The newer selected observation at 2026-10-17T05:56:13.253237+00:00 confirms
DCAF17 #5073 remains
approved and queued at 87bf8aa55fa996cd5b729b279b0e7870efec7228.
DBT #5074 has the revised
head 2a70bf366aca76c6eba7686b4d987df75ab7cfc4 and awaits fresh review; the
previous changes-requested decision remains visible. No pending PR receives
completion credit. These timestamped observations are not an exhaustive new
queue census or a guarantee of later queue positions.

All 2,876 catalogue identities and association texts, 235 historical queue
objects, 78 previous completion updates, the full preceding progress text and
167 prior project history records are preserved. This appends one completion
update containing two distinct genes. Products and follow-up commits are not
additional campaign genes.

ROOT incorporated main b17aa10c2915a7ed409475664718fbfff9e03dfe, including the newly merged CYLD review, before rendering. The final render passed all eight frontmatter checks: 1,715 missing-review warnings remain for the main page and zero for the progress page. Seventeen warnings cleared since checkpoint 428, including CYLD beyond the sixteen predicted above; no warnings were added. The actual branch inventory contains 7,857 reviews, including 2,998 human reviews. CYLD remains uncredited here pending its separate completion audit. The completion counts are 430 checked and 2,446 unchecked catalogue genes.

Curation session

Completion checkpoint 431 — 2026-10-17 06:04:48 UTC

431 complete; 2,445 remaining out of 2,876 primary catalogue genes.
CYLD is the only addition to checkpoint 430. Its approved head
5186f4184ce6e35e4e86343ef3829c0cadc641e3 in
#5045 merged as
b17aa10c2915.
All 28 approved file modes, types and blobs match the merge, all 28 paths form
the actual parent-to-merge delta, and all 56 protected scientific source paths
remain exact. The approval
applies to that exact head; all required review findings were resolved.

The separate actual-main push run 39008579742
and test job 117326023627
completed successfully at 2026-10-17T06:11:58Z. The scoped gene validation passed
with nine documented generic-binding advisories; 12,007 history records had no
issues, and all 42 history tests passed. This records scoped validation, not a
claim that the full repository test suite ran. ROOT is the coordinating AI
agent; its provenance acceptance is not a human maintainer sign-off.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 79 earlier completion updates, the complete
preceding progress text and 168 earlier project history records. The catalogue
changes only CYLD from unchecked to checked. The branch already contained the
CYLD review for checkpoint 430 rendering; its availability now gains completion
credit because the separate completion audit has passed.

DBT #5074 is approved
at 2a70bf366aca76c6eba7686b4d987df75ab7cfc4 and was confirmed in the normal
merge queue in the saved selected observation. DCC #5080
has passed checks at 63405caa5b9be2ccde240f170ea4149f40697717 and is undergoing
review follow-up. DCDC2 source review and DCLRE1C preparation are ongoing.
These selected status observations add no completion credit and are not a new
exhaustive queue census.

The actual branch inventory remains 7,857 reviews, including 2,998 human reviews. All eight frontmatter checks and both ordinary renders passed. The warning lists are unchanged from checkpoint 430: 1,715 missing-review warnings on the catalogue and zero on the progress page. Counts are 431 checked and 2,445 unchecked catalogue genes.

Curation session

Completion checkpoint 432 — 2026-10-17 06:35:24 UTC

432 complete; 2,444 remaining out of 2,876 primary catalogue genes.
CYP11B2 is the only addition to checkpoint 431. Its approved head
4b3aa8b4dafb59bafbc0c7c5d828ff0cb56d5037 in
#5046 merged as
a87ae568676c.
All nine approved file modes, types and blobs match the merge, all nine paths
form the actual parent-to-merge delta, and all 23 protected scientific source
paths remain exact. The approval
applies to that exact head; all required review findings were resolved.

The separate actual-main push run 39010474868
and test job 117331762104
completed successfully at 2026-10-17T06:43:28Z. Scoped gene validation passed
with two documented source-specific action advisories, including the distinction
between positive and negated cortisol claims. All 12,009 history records had
no issues, and all 42 history tests passed. The full test suite was skipped on
this push job; the completion check does not claim a full-suite run.
The coordinating AI agent's acceptance is not a human maintainer sign-off.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 80 earlier completion updates, the complete
preceding progress text and 169 earlier project history records. The catalogue
changes only CYP11B2 from unchecked to checked. JSON escaping is explicitly
kept at the preceding checkpoint's literal UTF-8 setting; earlier queue values
are unchanged. This update's queue prose uses ordinary spacing. The completion
cutoff is also stated directly on the main project page.

DCC #5080 is approved
at 08e1797356e01101c5de7091b61dd1b61c97e92b and entered the normal merge
queue. DCDC2 #5082
has passed validation and is undergoing review follow-up. DCLRE1C source
review continues. The existing DCX review requires a bounded interaction
follow-up before completion credit under the project's current instruction.
These selected status observations add no completion credit and are not a new
exhaustive queue census.

The actual branch inventory remains 7,857 reviews, including 2,998 human reviews. All eight frontmatter checks and both ordinary renders passed. The warning lists are unchanged from checkpoint 431: 1,715 missing-review warnings on the catalogue and zero on the progress page. Counts are 432 checked and 2,444 unchecked catalogue genes.

Curation session

Completion checkpoint 433 — 2026-10-17 07:07:09 UTC

433 complete; 2,443 remaining out of 2,876 primary catalogue genes.
CYP27A1 is the only addition to checkpoint 432. Its approved head
930aefe5b3b095210095b09bb33f425a815a3cb6 in
#5047 merged as
1f2d0f4c42bd.
All eleven approved file modes, types and blobs match the merge, all eleven paths
form the actual parent-to-merge delta, and all 38 protected scientific source
paths remain exact. The approval
applies to that exact head; all required review findings were resolved.

The separate actual-main push run 39012439782
and test job 117337633319
completed successfully at 2026-10-17T07:13:32Z. Scoped gene validation passed
without gene-validation warnings. All 12,011 history records had
no issues, and all 42 history tests passed. The full test suite was skipped on
this push job; the completion check does not claim a full-suite run.
The coordinating AI agent's acceptance is not a human maintainer sign-off.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 81 earlier completion updates, the complete
preceding progress text and 170 earlier project history records. The catalogue
changes only CYP27A1 from unchecked to checked. Earlier queue values and literal UTF-8 formatting are unchanged. The completion
cutoff is also stated directly on the main project page.

DCC #5080 is approved
at 08e1797356e01101c5de7091b61dd1b61c97e92b and entered the normal merge
queue. DCDC2 #5082
is approved at 6d095b754e8d53597421072c84270e86e1329603 and queued.
DCLRE1C #5083 and
DDB2 #5084 await review.
The DCX follow-up is undergoing validation; DDC and DDHD1 source assessment continues.
These selected status observations add no completion credit and are not a new
exhaustive queue census.

The actual branch inventory remains 7,857 reviews, including 2,998 human reviews. All eight frontmatter checks and both ordinary renders passed. The warning lists are unchanged from checkpoint 432: 1,715 missing-review warnings on the catalogue and zero on the progress page. Counts are 433 checked and 2,443 unchecked catalogue genes.

Curation session

Completion checkpoint 434 — 2026-10-17 07:38:48 UTC

434 complete; 2,442 remaining out of 2,876 primary catalogue genes.
CYP2U1 is the only addition to checkpoint 433. Its approved head
9e15617075a94611247854991769f782ba9a03d8 in
#5049 merged as
e32937e9a43d.
All 21 approved file modes, types and blobs match the merge, all 21 paths
form the actual parent-to-merge delta, and all 17 protected scientific source
paths remain exact. The approval
applies to that exact head.

The separate actual-main push run 39014407121
and test job 117343409663
completed successfully at 2026-10-17T07:45:38Z. Scoped gene validation passed
with one inherited mixed-action monooxygenase advisory. All 12,013 history
records were valid, all 42 history tests passed, and all 695 family files
validated. The full test suite was skipped on the main push; the separate
successful merge-group run 39012443172
provides the full-suite evidence for the merge candidate. These are distinct
validation events. The coordinating AI agent's acceptance is not a human
maintainer sign-off.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 82 earlier completion updates, the complete
preceding progress text and 172 earlier project history records. The catalogue
changes only CYP2U1 from unchecked to checked. Earlier queue values and literal
UTF-8 formatting are unchanged. The completion cutoff is also stated directly
on the main project page.

DDC #5086 and
DDHD1 #5087 have been
published for review. DDB2 #5084
has a provenance follow-up at ee8a2dd11241467cb1fe1c6666a0456275cd2689.
DCLRE1C #5083 is approved
at 5a2760761b431c0ba318236e86611fe3322c5be1 and entered the normal merge queue.
DCX documentation follow-up and DDR2/DDX11 source assessment continue. These
selected status observations add no completion credit and are not a new
exhaustive queue census.

The actual branch inventory remains 7,858 reviews, including 2,999 human reviews. All eight frontmatter checks and both ordinary renders passed. The catalogue has 1,714 missing-review warnings, one fewer than checkpoint 433 because CYP2U1 now has a review. The progress page has no warnings. Counts are 434 checked and 2,442 unchecked catalogue genes.

Curation session

Completion checkpoint 435 — 2026-10-17 08:10:20 UTC

435 complete; 2,441 remaining out of 2,876 primary catalogue genes.
CYP4V2 is the only addition to checkpoint 434. Its approved head
ab461cf6a1357c01b7e15f10219929d63f354a7b in
#5050 merged as
40c8c08b26b8.
All 14 approved file modes, types and blobs match the merge, all 14 paths
form the actual parent-to-merge delta, and all 15 protected source and prior
provenance paths remain exact. The approval
applies to that exact head.

The separate actual-main push run 39016360461
and test job 117349178779
completed successfully at 2026-10-17T08:17:21Z. Scoped CYP4V2 validation passed
with two generic-binding advisories retained under the explicit project policy.
All 12,015 history records were valid, all 42 history tests passed, and all
695 family files validated. The full test suite was skipped on the main push;
the separate successful merge-group run 39014408739
provides the full-suite evidence for the exact merge candidate. These are distinct
validation events. The coordinating AI agent's acceptance is not a human
maintainer sign-off.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 83 earlier completion updates, the complete
preceding progress text and 173 earlier project history records. The catalogue
changes only CYP4V2 from unchecked to checked. Earlier queue values and literal
UTF-8 formatting are unchanged. The completion cutoff is also stated directly
on the main project page. The rendered review links and availability counts are
qualified against incorporated main a3bfd308b643,
which also includes the newly available CYP1B1 review. CYP1B1 remains unchecked
pending completion verification; its availability adds no completion credit.

The actual branch inventory remains 7,860 reviews, including 3,001 human reviews. All eight frontmatter checks and both ordinary renders passed. The catalogue has 1,712 missing-review warnings, two fewer than checkpoint 434 because CYP4V2 and CYP1B1 now have reviews; CYP1B1 remains unchecked. The progress page has no warnings. Counts are 435 checked and 2,441 unchecked catalogue genes.

Curation session

Completion checkpoint 436 — 2026-10-17 08:31:18 UTC

436 complete; 2,440 remaining out of 2,876 primary catalogue genes.
CYP1B1 is the only addition to checkpoint 435. Its approved head
e46195e4fbeb664c4ef8cd6438662b34968a2142 in
#5048 merged as
a3bfd308b643.
All 49 approved file modes, types and blobs match the merge. The actual
parent-to-merge delta contains 46 paths; three shared Reactome files were already
identical on parent main. All 49 protected source and provenance positions remain
exact. These 49 protected paths comprise 42 machine sources, four prior history
records and three accepted authored review artifacts; this protection set is
distinct from the PR delta. The approval
applies to that exact head.

The separate actual-main push run 39017675880
and test job 117353019495
completed successfully at 2026-10-17T08:38:15Z. Scoped CYP1B1 validation passed
without annotation advisories. All 12,020 history records were valid, all 42
history tests passed, and all 695 family files validated. The full test suite
was skipped on the main push. The separate successful
merge-group run 39016362284
and job 117349183993
provide full-suite evidence for the exact merge candidate: 3,912 tests passed
with one skipped and 83 deselected, 252 passed with 37 skipped in the separate
suite, and 415 automation checks passed. These remain distinct validation events.
The coordinating AI agent's acceptance is not a human maintainer sign-off.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 84 earlier completion updates, the complete
preceding progress text and 174 earlier project history records. The catalogue
changes only CYP1B1 from unchecked to checked. Update 85 is appended; earlier
queue values and literal UTF-8 formatting are unchanged. Review availability at incorporated main
66f848da36501873b7f42e8edff5226bdff2702a is 7,860 review files, including 3,001 human
reviews. CYP7B1 was updated on main and remains unchecked pending completion
verification. CYP1B1 now
receives completion credit because its approval, merge and actual-main checks
have been verified; availability alone did not establish that credit.

The actual branch inventory contains 7,860 reviews, including 3,001 human reviews. All eight frontmatter checks and both ordinary renders passed. The catalogue has 1,712 missing-review warnings, unchanged from checkpoint 435; CYP7B1 remains unchecked. The progress page has no warnings. Counts are 436 checked and 2,440 unchecked catalogue genes.

Curation session

Completion checkpoint 437 — 2026-10-17 08:58:31 UTC

437 complete; 2,439 remaining out of 2,876 primary catalogue genes.
CYP7B1 is the only addition to checkpoint 436. Its approved head
75c32d63eb7a3594a4bed871c21b0b5e45324c01 in
#5051 merged as
66f848da3650.
All 19 approved file modes, types and blobs match the merge. The actual
parent-to-merge delta contains 18 paths; publication PMID 24275569 was already
identical on parent main. The separate protection set contains 62 positions:
32 machine source files, 29 other context files and one prior PR history record.
All remain exact. These counts describe distinct sets. The historical GOA
snapshot is preserved byte for byte, and both approved curation histories match
the merge. The approval
and final discussion
cover that exact head.

The separate actual-main push run 39019360739
and test job 117357894268
completed successfully at 2026-10-17T09:05:03Z. Scoped CYP7B1 validation passed
with the same two supported generic-binding KEEP_AS_NON_CORE advisories as the
approved-head and merge-group checks. All 12,022 history records were valid,
all 42 history tests passed, and all 695 family files validated. The full test
suite was skipped on the main push. The separate successful
merge-group run 39017677239
and job 117353023833
provide full-suite evidence for the exact same merge SHA: 3,912 tests passed
with one skipped and 83 deselected, 252 doctests passed with 37 skipped,
415 automation tests and 19 JavaScript tests passed. The all-gene schema,
12 valid/invalid examples, mypy and lint checks also passed. The standalone
changed-source-evidence step was skipped; it is not reported as passed.
These remain distinct validation events. DRAFT and two UNDECIDED annotations
are retained; project completion means the review was finished, approved and
merged, not that every scientific uncertainty was resolved. The coordinating
AI agent's acceptance is not a human maintainer sign-off.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 85 earlier completion updates, the complete
preceding progress text and 175 earlier project history records. The catalogue
changes only CYP7B1 from unchecked to checked. Update 86 is appended; earlier
queue values and literal UTF-8 formatting are unchanged. Review availability is
7,861 review files, including 3,002 human reviews, against incorporated main
9db646fd420946e2c8a9f325be9cd5b62b2c3d4c. D2HGDH is newly available but remains
unchecked pending verification; it receives no credit in this checkpoint. CYP7B1
already had a review; this accepted augmentation supplies completion credit
without adding an inventory item. Other available and pending reviews receive
no credit from this update.

The actual branch inventory contains 7,861 reviews, including 3,002 human reviews. All eight frontmatter checks and both ordinary renders passed. The catalogue has 1,711 missing-review warnings, one fewer than checkpoint 436 because D2HGDH is newly available but remains unchecked; CYP7B1 is now checked. The progress page has no warnings. Counts are 437 checked and 2,439 unchecked catalogue genes.

Curation session

Completion checkpoint 438 — 2026-10-17 09:29:48 UTC

438 complete; 2,438 remaining out of 2,876 primary catalogue genes.
D2HGDH is the only addition to checkpoint 437. Its approved head
50483db1f01e0e791d3a08ef907b39d287813714 in
#5052 merged as
9db646fd4209.
All 17 approved file modes, types and blobs match the merge, and all 17 paths
are actual parent-to-merge changes. The separate protection set contains 41
positions: 13 machine source files, 27 other context files and one prior PR
history record. All remain exact. These counts describe distinct sets. The
historical GOA snapshot is preserved byte for byte, and both approved curation
histories match the merge. The approval
and final discussion
cover that exact head.

The separate actual-main push run 39021341700
and test job 117363611688
completed successfully at 2026-10-17T09:36:40Z. Scoped D2HGDH validation passed
with zero gene advisories. All 12,024 history records were valid, all 42 history
tests passed, and all 695 family files validated. The full test suite was skipped
on the main push. The separate successful
merge-group run 39019362379
and job 117357899592
provide full-suite evidence for the exact same merge SHA: 3,912 tests passed
with one skipped and 83 deselected, 252 doctests passed with 37 skipped,
415 automation tests and 19 JavaScript tests passed. The all-gene schema,
12 valid/invalid examples, mypy and lint checks also passed. The standalone
changed-source-evidence step was skipped; it is not reported as passed.
These remain distinct validation events. The review retains COMPLETE status
and two UNDECIDED negated source assertions; project completion means the review
was finished, approved and merged, not that every scientific uncertainty was
resolved. The coordinating AI agent's acceptance is not a human maintainer sign-off.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 86 earlier completion updates, the complete
preceding progress text and 176 earlier project history records. The catalogue
changes only D2HGDH from unchecked to checked. Update 87 is appended; earlier
queue values and literal UTF-8 formatting are unchanged. Review availability is
unchanged from checkpoint 437: 7,861 review files, including 3,002 human reviews,
against incorporated main 9db646fd420946e2c8a9f325be9cd5b62b2c3d4c. D2HGDH
added one review at that merge; checkpoint 437 already recorded its availability
without credit. This update supplies the verified completion credit without
counting that inventory addition again. Other available and pending reviews
receive no credit from this update.

All eight frontmatter checks and both ordinary renders passed against the actual branch inventory of 7,861 reviews, including 3,002 human reviews. The catalogue has 1,711 missing-review warnings and the progress page has no warnings, unchanged from checkpoint 437. Counts are 438 checked and 2,438 unchecked catalogue genes.

Curation session

Completion checkpoint 439 — 2026-10-17 10:01:42 UTC

439 complete; 2,437 remaining out of 2,876 primary catalogue genes.
DAG1 is the only addition to checkpoint 438. Its approved head
3d949f3bd8f428c3e1d1710284b292e661a4954e in
#5054 merged as
f6be2985c3b5.
All 64 approved file modes, types and blobs match the merge, and all 64 paths
are actual parent-to-merge changes. The separate protection set contains 122
positions: 93 machine source files, 27 other context files and two prior PR
history records. All remain exact. These counts describe distinct sets. The
historical GOA snapshot is preserved byte for byte, and all three approved curation
histories match the merge. The approval
and final discussion
cover that exact head.

The separate actual-main push run 39023334577
and test job 117369341944
completed successfully at 2026-10-17T10:06:51Z. Scoped DAG1 validation passed
with five disclosed and accepted gene advisories: a stale GO-label warning,
three supported generic-binding policy warnings and one synthesized-core
coverage warning. All 12,027 history records were valid, all 42 history
tests passed, and all 695 family files validated. The full test suite was skipped
on the main push. The separate successful
merge-group run 39021343335
and job 117363615962
provide full-suite evidence for the exact same merge SHA: 3,912 tests passed
with one skipped and 83 deselected, 252 doctests passed with 37 skipped,
415 automation tests and 19 JavaScript tests passed. The all-gene schema,
12 valid/invalid examples, mypy and lint checks also passed. The standalone
changed-source-evidence step was skipped; it is not reported as passed.
These remain distinct validation events. The review retains DRAFT status
and ten UNDECIDED source assertions; project completion means the review
was finished, approved and merged, not that every scientific uncertainty was
resolved. The coordinating AI agent's acceptance is not a human maintainer sign-off.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 87 earlier completion updates, the complete
preceding progress text and 177 earlier project history records. The catalogue
changes only DAG1 from unchecked to checked. Update 88 is appended; earlier
queue values and literal UTF-8 formatting are unchanged. Review availability rises from checkpoint 438's 7,861 total / 3,002 human
reviews to 7,862 / 3,003 at main f6be2985c3b532458ebf9383357cc1e519d97c7e.
DAG1 adds one available review and receives the sole new verified credit.
Other available and pending reviews
receive no credit from this update.

All eight frontmatter checks and both ordinary renders passed against the actual branch inventory of 7,862 reviews, including 3,003 human reviews. The catalogue has 1,710 missing-review warnings and the progress page has no warnings, one fewer than checkpoint 438. Counts are 439 checked and 2,437 unchecked catalogue genes.

Curation session

Completion checkpoint 440 — 2026-10-17 10:32:17 UTC

440 complete; 2,436 remaining out of 2,876 primary catalogue genes.
DARS2 is the sole addition to checkpoint 439. Its approved head
722a2bd80bba55a3b3b34067d0a7d8ec6b0196bb in
#5060 merged as
6328c89e41e0.
All 11 approved PR file modes and blobs match the merge. The actual parent delta
contains 10 paths because PMID_24275569.md was already present with identical bytes.
The separate set of 59 protected positions comprises 28 machine-source/provider
files, 28 other context files and three earlier PR histories. All remain exact.
The 54 source annotation dictionaries, 35 inherited quotations, 3,446-byte notes
prefix and previously merged target history are preserved. The exact-head
approval
and final discussion
resolve the blockers and record the remaining nonblocking collagen-refinement judgment.

The actual-main push run 39025275210
and job 117374923665
passed at 2026-10-17T10:39:12Z. Scoped DARS2 validation passed with 11 accepted
advisories; all 12,030 histories validated, 42 history tests passed and 695 family
files validated. The full suite was skipped on this push. The separate successful
merge-group run 39023336329
and job 117369347335
tested the exact same merge SHA: 3,912 tests passed, one skipped, 83 deselected;
252 doctests passed, 37 skipped; 415 automation tests and 19 JavaScript tests passed.
All-gene schemas, 12 valid/invalid examples, mypy and lint also passed. The standalone
prediction/source-evidence step was skipped and is not claimed as executed.

DARS2 retains DRAFT status and three UNDECIDED source assertions. Completion means
the review was finished, approved and merged; it does not resolve all scientific
uncertainty or imply a human maintainer sign-off by the coordinating AI agent.
DARS2 was already available as a review: repository availability remains 7,862
reviews, including 3,003 human reviews. Of 1,166 catalogue genes with available
reviews, 440 are credited and 726 remain uncredited; 1,710 still lack review files.

This update preserves all 2,876 catalogue identities and association texts, 235
historical queue objects, all 88 earlier completion updates, the complete preceding
progress text and 178 prior project histories. Only the DARS2 checkbox changes;
completion update 89 is appended. Other available and pending reviews receive no
credit from this update.

All eight frontmatter checks and both ordinary renders passed against the actual branch inventory of 7,862 reviews, including 3,003 human reviews. The catalogue has 1,710 missing-review warnings and the progress page has no warnings, unchanged from checkpoint 439. Counts are 440 checked and 2,436 unchecked catalogue genes.

Curation session

Completion checkpoint 441 — 2026-10-17 10:58:01 UTC

441 complete; 2,435 remaining out of 2,876 primary catalogue genes.
DCAF17 is the sole addition to checkpoint 440. Its approved head
87bf8aa55fa996cd5b729b279b0e7870efec7228 in
#5073 merged as
1b47f6653c7f.
All 13 approved PR file modes and blobs match the merge. The actual parent delta
contains 12 paths; publications/PMID_15815621.md was already identical on the parent.
The exact-head approval
and separate actual-main validation establish this completion.

The actual-main push run 39026890723
and job 117379542492
succeeded at 2026-10-17T11:03:25Z. Scoped gene, history and family validation
passed; the full test suite was skipped on this push. The separate successful
merge-group run 39025277296
and job 117374929386
tested the same merge SHA and ran the full test suite, examples, all-gene schemas
and automation checks. The standalone prediction/source-evidence step was skipped
and is not claimed as executed. Completion records the finished, approved and
merged review; it is not a human maintainer sign-off by the coordinating AI agent.

The 46 inspected positions overlap the 13 approved PR paths: seven were added
among the 12 merge changes, one approved cache was already identical on the parent,
and 38 pre-existing context paths were unchanged. These are the selected
post-publication preservation inventory, not 46 files that all predated the merge.
Their explicit categories and paths are:

The runtime/build category records the exact historical DCAF17 execution inventory
listed above; it is not an exhaustive inventory of repository runtime. The merge
preserved the 38 pre-existing context paths and the already-identical cache, and
introduced the seven remaining listed paths. This checkpoint separately updates
the two tracker source records and their related project files; other positions
retain their accepted merge contents. DCAF17 had zero validation advisories.
No gene annotation is edited by this tracker update.

DCAF17 adds a review file. Repository availability is now 7,863 reviews,
including 3,004 human reviews. Of 1,167 catalogue genes with available
reviews, 441 are credited and 726 remain uncredited; 1,709 still lack
review files. Availability and completion remain different measures.

This update preserves all 2,876 catalogue identities and association texts, 235
historical queue objects, all 89 earlier completion updates, the complete preceding
progress text and 179 prior project histories. Only the DCAF17 checkbox changes;
completion update 90 is appended. Other available and pending reviews receive no
credit from this update.

All eight frontmatter checks and both ordinary renders passed against the actual branch inventory of 7,863 reviews, including 3,004 human reviews. The catalogue has 1,709 missing-review warnings and the progress page has no warnings, reflecting the new DCAF17 review. Counts are 441 checked and 2,435 unchecked catalogue genes.

Curation session

Completion checkpoint 442 — 2026-10-17 13:46:17 UTC

442 complete; 2,434 remaining out of 2,876 primary catalogue genes.
DNAH12 is the sole addition to checkpoint 441. Its approved head
d9a78ab63b0da51e49b3f80341668c68e2599efd in
#4877 merged as
298fede2212a.
The exact-head approval
resolves the required review changes. All 27 approved path modes and types are
preserved. Twenty-six blobs are identical; cache/go/terms.csv contains exactly
the approved GO:0036156 insertion applied to the newer parent. Removing that
single line reproduces the parent cache byte for byte. The actual merge delta
has 25 additions and two modifications. Its 17 machine-source/provider additions
and six history additions are exact approved blobs; all other tracked paths are
unchanged by this merge. These additions are not pre-existing protected files.

The separate actual-main push run 39037932465
and job 117411414646
completed successfully at 2026-10-17T14:07:58Z. Scoped DNAH12 validation passed
with zero gene curation advisories. All 12,200 history records validated, 42
history tests passed and 705 family files validated. The full suite actually ran
on this push: 3,912 tests passed, one skipped and 83 deselected; 252 doctests
passed and 37 skipped. All 12 valid/invalid examples, mypy and lint passed.

The distinct successful merge-group run 39035866797
and job 117405388809
tested the same merge SHA. They independently passed the full suite and doctests
with the same counts, plus all-gene schemas, modules, 415 automation tests and
19 JavaScript tests. All-gene schemas, modules and agentic automation were skipped
on the main push. Standalone changed prediction/source-evidence steps were
skipped in both events and are not claimed as executed.

Zero DNAH12 curation advisories does not mean every check was warning-free.
The passing suites reported nine test warnings and eight doctest warnings;
family checks retained unrelated unresolved membership/residue cases and skipped
snippet checks. The approving reviewer left three nonblocking notes: attribute
the mouse expression panel precisely, move a curation-framed phylogeny sentence
out of the description, and investigate a prior DuplicateKeyError as tooling.
The review remains COMPLETE with one UNDECIDED binding assertion. Completion
records finished, approved and merged curation; it does not resolve all scientific
uncertainty or imply a human maintainer sign-off by the coordinating AI agent.

Repository availability is now 7,965 reviews, including 3,005 human reviews.
DNAH12 accounts for the one new human review since checkpoint 441; other net
review-file additions receive no completion credit here. Of 1,168 catalogue
genes with available reviews, 442 are credited and 726 remain uncredited;
1,708 catalogue genes still lack reviews. The later publication source main
bff21ea8eb90bc3e07bb2fbedf14c25d37080161 has the same inventory; the completion
cutoff remains the DNAH12 merge at 13:46:17 UTC.

This update preserves all 2,876 catalogue identities and association texts, all
235 historical queue objects, all 90 earlier completion updates, the complete
preceding progress text and 181 prior project history records. Only the DNAH12
checkbox changes; completion update 91 is appended. No gene annotation, source
cache or earlier history record is edited by this tracker update.

All eight frontmatter checks and both ordinary renders passed against the actual branch inventory of 7,965 reviews, including 3,005 human reviews. The catalogue has 1,708 missing-review warnings and the progress page has no warnings, reflecting the new DNAH12 review. Counts are 442 checked and 2,434 unchecked catalogue genes.

Curation session

Completion checkpoint 443 — 2026-10-18 15:14:14 UTC

443 complete; 2,433 remaining out of 2,876 primary catalogue genes.
DCC is the sole addition to checkpoint 442. Its approved head
08e1797356e01101c5de7091b61dd1b61c97e92b in
#5080 merged as
7bbbe4f59c5b.
The exact-head approval
and detailed review
close the required changes. The reviewer explicitly retracts the earlier
generic-binding objection after verifying the project's binding instruction and
accepts the revised core representation. There are no inline comments or review
threads. The older changes-requested review belongs to an earlier revision.

All 18 approved files have identical blobs and modes in the merge. Its sole
parent is 23a506fc6b8bd5a2822d76bc2151276fa7bddac4; the complete delta contains
exactly those 18 additions, including two DCC history records and ten publication
caches. All 158,727 paths outside the delta are unchanged.
Complete saved tree listings were reconstructed and authenticated against the
Git commit tree hashes, and the 18 captured file contents were checked against
their Git blob identifiers.

The actual-main push run 39139563867
and test job 117710997259
completed successfully at 2026-10-18T15:21:25Z. The complete raw job log is retained
in the merge audit. Its operative sections identify this main revision and its
parent, detect the exact 18-file delta, and execute strict changed-gene validation
on DCC. That validation passed with six generic-binding policy warnings, whose
scientific dispositions were accepted in the approving review. All 12,956 history
records validated, 42 history tests passed, and 708 family files validated. Family
checks reported no failures while retaining unrelated unresolved membership and
residue cases and skipped snippet checks.

This was a scoped main-push workflow: the general test suite, example validation,
agentic checks and standalone source-evidence validation were skipped. No fresh
full-suite run is claimed. All test-job steps and its three annotations were
read; the annotations concern Node.js migration, scoped validation and the future
runner image, not DCC scientific failures. The separate main-push documentation
run 39139563863 also succeeded. The distinct merge-group run 39137566672
completed successfully at the same merge SHA; its run metadata is preserved, but
its full job log was not re-audited and is not substituted for actual-main proof.

The review file remains DRAFT, with three UNDECIDED annotations and the six
acknowledged policy warnings. The approving reviewer left only nonblocking
suggestions about provenance wording, comparator interpretation and a structured
knowledge gap. Completion records approved and merged curation, not resolution
of every biological uncertainty or a human maintainer sign-off by the
coordinating AI agent.

Repository availability at this actual-main cutoff is 7,981 reviews,
including 3,006 human reviews. Of 1,169 catalogue genes with
available reviews, 443 are credited and 726 remain uncredited;
1,707 catalogue genes still lack reviews. These counts were recomputed
from the complete main tree and the unchanged catalogue, not copied from the
preceding checkpoint. DCC alone receives new completion credit.

This update preserves all 2,876 catalogue identities and association texts,
all 235 historical queue objects, all 91 earlier completion updates, the complete
preceding progress text and 182 prior project history records. Only the DCC
checkbox changes; completion update 92 is appended. No gene review, source cache,
runtime file or earlier history record is edited by this tracker update.

All eight frontmatter checks and both ordinary renders passed against the actual branch inventory of 7,981 reviews, including 3,006 human reviews. The catalogue has 1,707 missing-review warnings and the progress page has no warnings, reflecting the new DCC review. Counts are 443 checked and 2,433 unchecked catalogue genes.

Curation session

Completion checkpoint 444 — 2026-10-18 15:47:45 UTC

444 complete; 2,432 remaining out of 2,876 primary catalogue genes.
DCDC2 is the sole addition to checkpoint 443. Its approved head
6d095b754e8d53597421072c84270e86e1329603 in
#5082 merged as
28ce6af8efa0.
The exact-head approval
and detailed review
resolve the two required changes. The reviewer accepts the microtubule-binding
support and withdraws the blocking partner-class objection after checking the
project instruction and explicit assay limits. Remaining suggestions are advisory;
there are no inline comments or unresolved review threads.

All 17 approved files have identical blobs and modes in the merge. Its sole
parent is 7bbbe4f59c5b14d9b053d691deba3a8c5726d9bf; the complete delta contains
exactly those 17 additions, including two DCDC2 history records and ten publication
caches. All 158,745 paths outside the delta are unchanged.
Complete saved trees were authenticated against the Git commit tree hashes, and
all 17 captured file contents were checked against their Git blob identifiers.

The actual-main push run 39142088672
and test job 117718406876
completed successfully at 2026-10-18T15:53:59Z. Its full raw log is preserved in the
merge audit. The operative log identifies main and its parent, detects the exact
17-file delta and passes strict changed-gene validation on DCDC2 with 19 documented
generic-binding policy advisories. The approving reviewer accepts the retained
association/class distinctions under the project instruction. All 12,958 history
records validated, 42 history tests passed and 708 family reviews validated.
Residue-site checks recorded 10,417 passes, no failures and 23 unresolved cases;
gene residue checks recorded 617 passes, no failures and two unresolved cases.
Other unrelated family/member uncertainties remain disclosed by those checks.

This main-push workflow was scoped: general tests, examples, merge-queue schema,
agentic checks and standalone source-evidence validation were skipped. No fresh
full-suite execution is claimed. ROOT read all test/docs steps and annotations;
the owner independently read all test steps and operative gene/history/family
results. There are no failure annotations. The separate documentation push
run 39142088680 also succeeded. The distinct merge-group run 39139566172
succeeded at the same SHA; only its run metadata is used here, not a repeated
full job-log audit or a substitute for actual-main evidence.

The review file remains DRAFT with the 19 accepted policy advisories. Advisory
review suggestions about wording, product representation and knowledge gaps do
not become required changes. Completion records approved, merged curation; ROOT
is the coordinating AI agent, not a human maintainer sign-off.

Availability was recomputed from the complete actual-main tree: 7,982
reviews, including 3,007 human reviews. Of 1,170 catalogue
genes with reviews, 444 are credited and 726 remain uncredited;
1,706 catalogue genes still lack a review. DCDC2 alone supplies the
one added review and completion since the preceding checkpoint.

This update preserves all 2,876 catalogue identities and association texts,
all 235 historical queue objects, all 92 earlier completion updates, the complete
preceding progress text and 183 prior project history records. Only the
DCDC2 checkbox changes; completion update 93 is appended. No gene review, source
cache, runtime file or earlier history record is edited by this tracker update.

Completion checkpoint 445 — 2026-10-18 16:14:34 UTC

445 complete; 2,431 remaining out of 2,876 primary catalogue genes.
DCLRE1C is the sole addition to checkpoint 444. Its approved head
5a2760761b431c0ba318236e86611fe3322c5be1 in
#5083 merged as
e734e32bef52.
The exact-head formal approval
and detailed review
accept the three requested changes and qualifier correction. Remaining observations
are nonblocking; no inline comments or unresolved review threads remain at the audit.

All 45 approved files have identical blobs and modes in the merge. The immediate
parent is 28ce6af8efa0c260e8bae7b6b0783376deef99cf. The delta consists of six gene
files, two append-only history records, 30 publication caches and seven Reactome
caches. All 158,762 paths outside that delta are unchanged. Complete saved trees
were authenticated against their Git commit hashes, and every changed file was
checked against its Git blob identifier. The commit's older authored timestamp
does not replace the verified PR merge event time.

The actual-main push run 39144107165
and test job 117724327377
completed successfully at 2026-10-18T16:21:02Z. Its saved log shows strict validation
of the changed DCLRE1C review, 12,960 history records, 42 history tests and 708 family
files passing. General tests, examples, all-gene schema validation and automation
were skipped on this scoped push; those are not represented as post-merge runs.

The distinct merge-group run 39142091286
at the same exact SHA completed successfully before merge. Its actual log shows
all-gene schema validation with no issues, 12 valid/invalid examples passing,
3,940 main tests passing with one skipped and 84 deselected, 252 doctests passing
with 37 skipped, and 415 automation tests passing. Typing and lint checks passed.
All 82 selected job steps and eight annotations were inspected across the merge
group, main push and documentation run 39144107160.
No failure annotation was present. Unrelated module/family ontology warnings,
documentation-link warnings and action deprecations remain disclosed. The docs
workflow pushed gh-pages; no independent served-page inspection is asserted.
Eight incidental issue-comment workflows were skipped. Earlier PR test/review
success is retained as metadata, distinct from the inspected merge/main logs.

The merged review is COMPLETE and retains one explicit UNDECIDED annotation.
Completion records accepted and merged curation, not a claim that every scientific
uncertainty is resolved. ROOT independently accepted the merge proof after replay
and complete review/CI inspection; ROOT is the coordinating AI agent, not a human
maintainer sign-off.

The complete actual-main tree contains 7,983 reviews, including 3,008
human reviews. Of 1,171 catalogue genes with reviews, 445 are
credited and 726 remain uncredited; 1,705 catalogue
genes still lack a review file. DCLRE1C alone supplies the additional available
review and completion since checkpoint 444.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 93 prior completion updates, the complete preceding
progress text and 183 prior project history records. Only the DCLRE1C checkbox
changes relative to checkpoint 444, and update 94 is appended. No gene review,
source cache, runtime file or earlier history is edited by this tracker update.

Completion checkpoint 446 — 2026-10-18 16:48:20 UTC

446 complete; 2,430 remaining out of 2,876 primary catalogue genes.
DDB2 is the sole addition to checkpoint 445. Its approved head
ee8a2dd11241467cb1fe1c6666a0456275cd2689 in
#5084 merged as
95963b9be78a.
The exact-head formal approval
and detailed review
accept the clarified original-source provenance and the complex-contribution core
correction. Remaining suggestions are nonblocking. No inline comments or
unresolved review threads were present in the audit.

All five approved file blobs and modes are identical in the merge. The immediate
parent is e734e32bef526741f14422b1489a0a6cf03f1e50. The delta modifies the review
YAML and HTML and adds notes plus two history records. All 158,805 paths outside
that delta are unchanged. Complete saved head, merge and parent trees were
authenticated against their commit objects, and each changed file against its Git
blob identifier. The PR merge event time above is distinct from authored dates.

The actual-main push run 39146677012
and test job 117731814617
completed successfully at 2026-10-18T16:54:49Z. Strict DDB2 validation passed with
18 retained generic-binding advisories under the standing ClinGen instruction.
The log separately shows 12,962 history records, 42 history tests and 708 family
files passing. History coverage, all-gene schemas, general tests, examples,
modules and automation were skipped on this scoped push; no pass is claimed for
those skipped steps.

The separate exact-SHA merge-group run 39144109780
completed successfully before merge. Its actual log shows all-gene schemas with
no issues, 12 examples passing, 3,940 main tests passing with one skipped and 84
deselected, 252 doctests passing with 37 skipped, and 415 automation tests passing.
Typing and lint passed. The earlier exact-head PR test also passed scoped review
validation with the same 18 advisories; its history-coverage step passed. The
reviewer could not run the ordinary suite itself, so its approval is not used as
a substitute for these actual CI results.

All 130 job steps and 14 annotations were inspected across the PR test/review,
merge group and main push test/docs. No failure annotation was present. Unrelated
family/module ontology notices, test dependency and infrastructure deprecations,
and documentation-link warnings remain disclosed. The docs push 39146676998
completed and pushed gh-pages, without an independent served-page inspection.
Incidental issue-comment workflows are outside this DDB2 gate and were inspected
only as metadata; one was still active at capture.

The sole YAML semantic change moves the second core's GO:0004842 from
molecular_function to contributes_to_molecular_function. All 81 source and
review objects, 60 references, five products and other YAML content remain exact.
The merged file retains its inherited COMPLETE status, while the accepted
histories disclose the pre-existing computed DRAFT discrepancy. No new status
calculation or warning-driven rewrite is implied. ROOT independently accepted the
merge proof after replay and full review/CI inspection; this is coordinating AI
agent acceptance, not a human maintainer sign-off.

There are still 7,983 review files, including 3,008 human reviews.
Of 1,171 catalogue genes with reviews, 446 are credited and
725 remain uncredited; 1,705 catalogue genes lack a review
file. DDB2 already had a review, so availability is unchanged. This is its first
accepted campaign completion, not an extra credit for a product or follow-up.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 94 prior completion updates, the full preceding
progress text and 183 prior project history records. Only DDB2's checkbox changes
relative to checkpoint 445, and update 95 is appended. No gene review, source
cache, runtime file or earlier history is edited by this tracker update.

Completion checkpoint 447 — 2026-10-18 17:10:05 UTC

447 complete; 2,429 remaining out of 2,876 primary catalogue genes.
DCX is the sole addition to checkpoint 446. Approved head
2204701c7274a7aa9228e34739139db55cac3751 in
#5085 merged as
22f429edcf1a,
with immediate parent 95963b9be78a614c8db78e75759e02b15ed645b5.
The exact-head formal approval
and detailed review
resolve the blocking evidence objections. The reviewer withdrew the ancestor and
stoichiometry objections, accepted the assay versus native-context limits, and
recorded the axoneme-action disagreement as nonblocking. No inline comments or
review threads were present. Remaining evidence-navigation and historical-prose
suggestions are nonblocking and do not authorize rewriting earlier histories.

All eight approved file blobs and modes match the merge. Three DCX files are
modified (review YAML, rendered HTML and notes); the source-evidence guide, two
history records and two publication caches are added. All 158,807 paths outside
this delta are unchanged. Complete saved head, parent and merge trees were
authenticated against their commits, and each changed blob against its Git
identifier. The merge event time above is distinct from authored dates.

The actual-main push run 39148316947
and test job 117736623696
completed successfully at 2026-10-18T17:17:27Z. Its full log and operative command,
validation and warning windows were inspected: strict DCX validation passed with
seven retained generic-binding advisories under the explicit ClinGen project
instruction; 12,964 history records, 42 history tests and 708 family files passed.
All-gene schemas, modules, general tests, examples and automation were skipped on
this scoped push. The current-main snapshot equals the audited merge.

The separate exact-SHA merge-group run 39146679553
passed before merge. Its operative log shows all-gene schemas with no issues,
12 examples passing, 3,940 tests passing with one skipped and 84 deselected,
252 doctests passing with 37 skipped, and 415 automation tests passing; typing
and lint passed. The exact-head PR test also succeeded with the same seven
advisories, satisfying the review's conditional approval. The reviewer did not
run the ordinary suite itself; that approval is not substituted for actual CI.
The docs push 39148316995
completed and pushed gh-pages; no served-page inspection is claimed.

The first merge audit captured the push while running; a separately sealed
terminal addendum completed the proof without replacing that earlier snapshot.
All 35 terminal push steps and all three current annotations were read, with no
failed step or failure annotation. The two other merge-SHA jobs contributed
47 inspected steps and five annotations; the earlier pending push annotation
snapshot was empty and is not treated as the final annotation count. Family
validation retains unrelated unresolved records and infrastructure notices.
The complete logs remain available, with actual read windows and scope stated;
no source-paper body reading or new gene validation was performed for this audit.

All 39 imported annotation dictionaries and the inherited NEW dictionary are
preserved. The merged 40 entries comprise 11 ACCEPT, 13 MODIFY,
12 KEEP_AS_NON_CORE, 3 UNDECIDED and one inherited NEW. Description, both products
and core functions are unchanged from the immediate parent. The merged DRAFT
status and seven accepted policy advisories are explicit; completion here means
an accepted, verified campaign review, not disappearance of unresolved evidence.
ROOT accepted both saved proofs and the complete operative review/CI evidence.
That is coordinating AI-agent acceptance, not a human maintainer sign-off.

There remain 7,983 review files, including 3,008 human reviews.
Of 1,171 catalogue genes with reviews, 447 are credited and
724 remain uncredited; 1,705 catalogue genes lack a review
file. DCX already had a review, so availability is unchanged. Only its first
accepted campaign completion is counted.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 95 prior completion updates, the complete preceding
progress text and 183 prior project history records. Only DCX's checkbox changes
relative to checkpoint 446, and update 96 is appended. No gene review, source
cache, runtime file or prior history is edited by this tracker update.

Completion checkpoint 448 — 2026-10-18 17:32:58 UTC

448 complete; 2,428 remaining out of 2,876 primary catalogue genes.
DDC is the sole addition to checkpoint 447. Approved head
b276d279c68e23af68285f74a3b4a94433c87862 in
#5086 merged as
c4be76827e7a,
with immediate parent 22f429edcf1adff6285ecc152aa2a898d56646e5.
The exact-head formal approval
and detailed review
accept the previous blockers as resolved or adequately answered. The amino-acid
process was refined to GO:0009072; the AR-term objection was withdrawn after
consideration of the dated official ontology response. The remaining external
source-note reproducibility limitation was explicitly nonblocking because the
load-bearing claims had independent validator-checked support. Residual core-scope,
ontology-cache and wording suggestions are optional. No inline comments or review
threads were present; this tracker does not implement optional scientific edits.

All ten approved file blobs and modes match the merge. Three DDC files are modified
(review YAML, rendered HTML and notes); two evidence/source guides, two history
records and three publication caches are added. All 158,812 paths outside this
delta are unchanged. Complete saved head, parent and merge trees, commit identities
and changed blobs were authenticated. This proves the approved payload at the
merge, not equality between the entire PR tree and main. The merge event time above
is distinct from authored dates.

The actual-main push run 39150099881
test job 117741791093
completed successfully at 2026-10-18T17:40:19Z. All 35 terminal step records and three
annotations were read. Its full log is saved, with operative command/result windows
inspected: strict DDC validation passed with one retained generic-binding NC
advisory, 12,966 history records had no issues, 42 history tests passed, and 708
family files had no blocking issues. All-gene schemas, modules, history coverage,
examples, general tests, agentic automation and full upstream PAINT were skipped on
this scoped push. They are not claimed to have run on actual main.

The separate exact-SHA merge-group run 39148319713
passed before merge. Its operative log shows all-gene schemas, scoped modules,
12 examples, 3,940 tests with one skipped and 84 deselected, 252 doctests with 37
skipped, and 415 automation tests passing; typing passed for 268 files. It also
passed the history and family checks. History-coverage and full upstream-PAINT
steps were skipped. The exact-approved-head test and reviewer jobs succeeded.
The reviewer's eight permission denials and is_error: false are reported
separately from its independently present exact-head approval; they are not CI
failures. The docs push 39150099911
completed and pushed the site; no served-page inspection is claimed.

The original merge snapshot captured actual-main CI while running. A separately
sealed terminal addendum completed that proof without replacing the prior snapshot.
The four previously terminal jobs supplied 95 recorded steps and 11 annotations;
the later push supplied its own 35 steps and three annotations. All annotations
were notices/warnings, with no failure-level annotation. Unrelated family
adjudication categories and infrastructure notices remain explicitly distinct
from blocking failures. Complete logs are archived, but only stated operative
windows are claimed read. No source-paper body or new local gene suite was read or
run for this completion update.

The merged review retains 27 annotations: 17 ACCEPT, five TOO_GENERAL,
three KEEP_AS_NON_CORE and two MODIFY, with no UNDECIDED. It contains four products
and two core functions and remains DRAFT. The accepted generic-binding advisory
and DRAFT status do not prevent completion of an accepted and verified campaign
review. ROOT accepted both saved merge proofs and their review/CI evidence; this
is coordinating AI-agent acceptance, not a human maintainer sign-off.

There remain 7,983 review files, including 3,008 human reviews.
Of 1,171 catalogue genes with reviews, 448 are credited and
723 remain uncredited; 1,705 catalogue genes lack a review
file. DDC already had a review, so availability is unchanged. Only its first
accepted campaign completion is counted.

This update preserves all 2,876 catalogue identities and association texts,
235 historical queue objects, 96 prior completion updates, the complete preceding
progress text and 183 prior project history records. Only DDC's checkbox changes
relative to checkpoint 447, and update 97 is appended. No gene review, source
cache, runtime file or prior history is edited. The publication preimage remains
queued checkpoint 443; this private successor is held until ROOT separately
requalifies and authorizes publication.

Completion checkpoint 449 — 2026-10-18 18:05:01 UTC

449 complete; 2,427 remaining out of 2,876 primary catalogue genes.
DDHD1 is the sole addition to checkpoint 448. Approved head
bbe34f00d09d848d64d3e3ebb3cea1fda256b6e6 in
#5087 merged as
66220febb3d8,
with immediate parent c4be76827e7a4cb01fb9c77ed9d3f4b98933b1fb.
The exact-head formal approval
and detailed review
accept the prior blockers as resolved. The reviewer explicitly withdraws its
generic-binding objection under the standing ClinGen instruction. Tissue and
SPG28 context, product scope, oligomerization notes, source locators and append-only
history are accepted. Experiments, a possible later HuRI refinement, policy-warning
wording and optional short quotations remain suggestions, not blocking requests.
There are no inline comments or review threads.

All 20 approved PR file blobs and modes match the merge. The actual immediate-parent
delta contains 19 additions: six gene files, two histories, two PANTHER lookup
files, eight publication caches and one Reactome cache. The twentieth PR path,
publications/PMID_23186163.md, was already identical in the parent. All 158,822
paths outside the 19-path delta are unchanged. Complete saved head, parent and
merge trees and their commit objects were authenticated, together with all 20
saved blobs. This establishes approved-path equality, not equality of the entire
PR branch and main. The cutoff is the merge event time, not an authored date.

The actual-main push test run 39152524224
and job 117748902797
passed strict changed-DDHD1 validation with one expected generic-binding non-core
advisory, 12,968 history records without issues, 42 history tests, and 708 family
files. Its all-gene schemas, modules, history coverage, examples, general tests,
automation and full upstream PAINT steps were skipped. Those scopes are not
claimed as actual-main executions.

The exact-SHA merge-group run 39150102446
passed the scoped checks and broad schemas/modules, 12 examples, 3,940 tests with
one skipped and 84 deselected, 252 doctests with 37 skipped, typing for 268 files,
Ruff, 415 Python automation tests and 19 JavaScript tests with zero failures.
History coverage and full upstream PAINT were skipped there. An ignored SQL
destructor exception appears after the successful general-test summary; subsequent
checks and the job succeeded. The event is retained in the evidence rather than
silently omitted or characterized as a failed suite.

The approved-head test run 39017424539
passed scoped DDHD1 validation, 12,017 histories, 42 history tests, 695 family files
and history coverage identifying both DDHD1 session records. Its broad test scopes
were skipped. The review run 39017424544
succeeded and recorded the exact-head approval; three permission denials with
is_error: false did not prevent that output. Independent test jobs provide the
validation evidence. The actual-main documentation run 39152524403
successfully built and pushed gh-pages despite nonblocking documentation warnings;
no served-page inspection is claimed.

All five operative jobs were terminal success. All 130 step records and 14
annotations were read; annotations were notices/warnings, with no failure level.
Full logs are archived and exact operative windows were inspected; whole
installation logs are not claimed read. Incidental comment/mention workflows
were inventoried separately as skipped, not counted as DDHD1 validation.

The merged review deliberately remains DRAFT: 12 source assertions comprise three
ACCEPT, four MODIFY, two REMOVE, two KEEP_AS_NON_CORE and one UNDECIDED, with no NEW.
It retains four products, one core function and 15 references. The one undecided
source and accepted policy advisory remain visible; neither changes the fact that
the campaign review was approved, merged and verified. ROOT accepted the saved
merge proof and complete review/CI audit as completion 449. This is coordinating
AI-agent acceptance, not a human maintainer sign-off. No primary source body or
ordinary local suite was reread or run for this tracker update.

The authenticated main tree now contains 7,984 review files, including
3,009 human reviews. Of 1,172 catalogue genes with reviews,
449 are credited and 723 remain uncredited; 1,704 lack a review
file. DDHD1 adds one available review and one completion; no other gene receives
credit. Availability was re-inventoried from this exact tree.

All 2,876 catalogue identities and association texts, 235 historical queue objects,
97 prior completion updates, the entire preceding progress text and 183 project
history records remain preserved. Only DDHD1's checkbox changes relative to
checkpoint 448; update 98 is appended. No gene, source cache, runtime or prior
history is edited. The publication preimage remains queued checkpoint 443; this
private successor is held until ROOT separately requalifies publication.

Completion checkpoint 450 — 2026-10-18 18:27:44 UTC

450 complete; 2, 426 remaining out of 2,876 primary catalogue genes.
DDR2 is the sole addition to checkpoint 449. Approved head
a43188ff51c0ddbaa3e409cbcd119b943bf4eaf5 in
#5089 merged as
ac35012f4993,
with immediate parent 66220febb3d8e4c2c16095885a79ceaac6d3b937.
The exact-head formal approval
and detailed review
accept the two expression-response annotations as UNDECIDED, rather than the
reviewer's earlier over-annotation suggestion. The reviewer acknowledges the
limits of abstract-only evidence. All seven earlier suggestions were implemented
or explicitly declined; the remaining cache-versus-original-access wording
suggestion is expressly nonblocking. Both earlier inline threads are resolved
and outdated.

All 25 approved PR blobs and modes match the merge. All 25 paths are additions
relative to the immediate parent: seven gene files, including historical rendered
HTML, two history records and 16 publication caches. All 158,841 paths outside
that delta are unchanged. Complete saved head, parent and merge trees authenticate
against their commit objects. This proves equality of the approved paths, not
identity of the whole PR branch and main. The cutoff is the merge event time.

The actual-main push test run 39154253413
and job 117754074534
passed strict changed-DDR2 validation with two expected generic-binding non-core
advisories, 12,970 history records, 42 history-schema tests and 708 family files.
Broad schemas, modules, examples, general tests and automation were skipped in
this job; they are not represented as actual-main executions.

The exact-SHA merge-group run 39152527229
passed those scoped checks plus broad schemas/modules, 12 examples, 3,940 tests
with one skipped and 84 deselected, 252 doctests with 37 skipped, typing/lint,
415 Python automation tests and 19 JavaScript tests. An ignored SQL destructor
exception followed the passing pytest summary; later checks and the whole job
succeeded. History coverage and full upstream PAINT were skipped in this job.

The approved-head test run 39021892379
passed scoped DDR2 validation, 12,026 histories, 42 history tests, 695 families and
history coverage. Its broad suites were skipped. The successful second attempt
of review run 39021892380
produced the exact-head approval. Its nine permission denials did not prevent
artifact review; the reviewer explicitly deferred unavailable local validation
to independent CI. The first attempt failed on a logged session limit, with 13
steps and 7 annotations, four at failure level. That historical service failure
is preserved separately and was superseded on the same head; it is not fresh
scientific changes requested.

The actual-main documentation run 39154253423
built and pushed gh-pages despite nonfatal link/deprecation warnings. No browser
inspection of every deployed page is claimed. All five operative jobs were
terminal success. The accepted merge audit read all 130 operative steps and 14
annotations, none at failure level, plus the full current reviews and resolved
threads. Full logs are archived with exact operative windows; whole installation
logs are not claimed read. Incidental comment/mention workflows were inventoried
as skipped and are not counted as DDR2 validation.

The merged review remains DRAFT with 74 source rows: 17 ACCEPT, 38 KEEP_AS_NON_CORE,
14 MODIFY, 4 UNDECIDED and 1 TOO_GENERAL. One core and 31 references are retained.
There is no alternative_products or gene_products block; the committed history
records one 855-residue precursor. This tracker update makes no new product
judgment or status recomputation. The four unresolved sources and two policy
advisories remain visible. ROOT accepted the full merge/CI evidence as completion
450; ROOT is the coordinating AI agent, not a human maintainer sign-off.

The authenticated main tree now contains 7,985 reviews, including
3,010 human reviews. Of 1,173 catalogue genes with reviews,
450 are credited and 723 remain uncredited; 1,703 lack a review
file. DDR2 adds one available review and one completion. No other gene gains credit.

All 2,876 catalogue identities and association texts, 235 historical queue objects,
98 prior completion updates, the complete prior progress text and 183 project
history records remain preserved. Only DDR2's checkbox changes relative to 449;
update 99 is appended. No gene, source cache, runtime or prior history is edited.
The publication preimage remains queued checkpoint 443. This private successor
is held until ROOT separately requalifies publication; no remote action occurs.

Completion checkpoint 451 — 2026-10-18 19:00:24 UTC

451 complete; 2,425 remaining out of 2,876 primary catalogue genes.
DDX11 is the sole addition to checkpoint 450. Approved head
38c2dcfcb8bca92ce14b2492f50375025ad35d74 in
#5088 merged as
d00415e9a6d8,
with immediate parent ac35012f4993a7d06938bf7b7069c6e7d921dcc0.
The exact-head formal approval
and detailed review
resolve all three blockers: seven action/reason mismatches, source-specific
helicase refinements, and replication/cohesion core process coverage. Remaining
suggestions are optional. There are no inline comments or review threads.

All 18 approved PR blobs and modes match the merge. All are additions relative
to the immediate parent: six gene files (including historical rendered HTML),
two history records, nine publication caches and one Reactome cache. All 158,866
outside paths remain unchanged. Complete saved trees authenticate against their
commit objects. This verifies approved paths without asserting whole-branch
identity. The cutoff is the merge event time.

The actual-main push test run 39156749671
(job 117761445338)
passed strict changed-DDX11 validation, 12,972 histories, 42 history tests and
708 family files. Eight generic-binding non-core warnings and one chromatin-binding
consistency advisory remain acknowledged. Broad schemas, modules, examples,
general tests and automation were skipped in this actual-main job.

The exact-SHA merge-group run 39154256066
passed those scoped checks plus all-gene schemas, 673 modules, 12 examples,
3,940 tests (one skipped, 84 deselected), 252 doctests (37 skipped), typing/lint,
415 Python automation tests and 19 JavaScript tests. An ignored SQL destructor
exception followed the passing pytest summary; subsequent checks and the job
passed. History coverage and full upstream PAINT checks were skipped here.

The approved-head test run 39021231928
passed strict DDX11 validation, 12,024 histories, 42 history tests, 695 family
files and history coverage. Its broad suites were skipped. Attempt 2 of
review run 39021231914
produced the approval. Its seven permission denials and unavailable local
validation are recorded; independent CI passed. Attempt 1 failed on an explicit
session limit (13 steps, seven annotations, four at failure level) and was
superseded on the same head. That service failure is retained separately.

The actual-main documentation run 39156749659
built and pushed gh-pages despite nonfatal link/deprecation warnings. No visual
inspection of every deployed page is claimed. All five operative jobs passed;
the accepted audit accounts for all 130 operative steps and 14 annotations,
none at failure level. Full logs and operative windows are archived. Incidental
skipped comment workflows are not counted as validation.

The merged review remains DRAFT with 87 sources: 34 ACCEPT, 31 KEEP_AS_NON_CORE,
19 MODIFY and three UNDECIDED. It retains five official alternative products,
one core, 22 references and its NOT flag. No new product judgment or status
recomputation is made here. ROOT, the coordinating AI agent, accepted the
merge evidence as completion 451; this is not a human maintainer sign-off.

The authenticated tree contains 7,986 reviews, including 3,011 human reviews.
Of 1,174 catalogue genes with reviews, 451 are credited and
723 remain uncredited; 1,702 lack a review file.
All 2,876 catalogue identities and association texts, 235 historical queue
objects, 99 prior completion updates, prior progress text and 183 project
histories remain preserved. Only DDX11's checkbox changes relative to 450;
update 100 is appended. Gene, source, runtime and historical files are unchanged.
The publication preimage remains queued checkpoint 443. This private successor
is held pending separate publication qualification; no remote action occurs.

Completion checkpoint 452 — 2026-10-18 20:02:38 UTC

452 complete; 2,424 remaining out of 2,876 primary catalogue genes.
DEPDC5 is the sole addition to checkpoint 451. Approved head
1df572006295104a82e18622efe4e94f20f24144 in
#5091 merged as
790ca0a86e3a,
with immediate parent a82ae1968bd472f368fe7c141c5938229db1168c.
The exact-head formal approval
and detailed review
resolved the core-coverage and evidence-support requests. Minor spacing and
duplication suggestions are nonblocking. There are no inline comments or review threads.

All 26 approved PR blobs and modes match the merge, and all are additions relative
to its immediate parent. The other 158,912 paths are unchanged. Complete saved
trees authenticate against their commit objects. The two append-only histories,
machine sources, rendered artifact and accepted candidate files match the final
published evidence. This verifies the approved paths without asserting whole-branch identity.

The approved-head test run 39027766145,
review run 39027766126,
exact-SHA merge-group run 39158973668,
actual-main push test 39161493056,
and actual-main documentation run 39161492882
all succeeded. The actual-main test completed at 20:10:15 UTC; documentation built
and pushed gh-pages. No visual inspection of the deployed site is claimed.

All three test jobs passed strict DEPDC5 validation with five expected generic-binding
non-core advisories under the standing project instruction. Actual-main and
merge-group history validation covered 12,996 records and 42 tests; family validation
covered 708 families. Broad schema, examples, tests and automation ran in the merge
group, including 3,940 passing tests, 252 doctests, 415 automation tests and 19 JavaScript
tests. Those broad suites were skipped on the PR and actual-main jobs. An ignored SQL
destructor exception followed the passing test summary; later checks and the job passed.
The reviewer could not run local validation; the successful independent CI is separate
evidence. Nonfatal dependency and documentation-link warnings remain recorded.

The audit captured ten runs, twelve jobs, 130 steps and fourteen annotations, with no
failure annotation. Five jobs executed; seven incidental comment/review jobs were skipped.
Full logs and operative windows are archived. The merged review remains DRAFT with
44 sources (25 ACCEPT, seven MODIFY, twelve KEEP_AS_NON_CORE), eight official products,
one integrated core and 28 references. No new product judgment or status recomputation
is made here. ROOT, the coordinating AI agent, accepted the merge evidence as completion
452; this is not a human maintainer sign-off.

The authenticated tree contains 7,987 reviews, including 3,012 human reviews.
Of 1,175 catalogue genes with reviews, 452 are credited and
723 remain uncredited; 1,701 lack a review file.
All 2,876 catalogue identities and association texts, 235 historical queue objects,
100 prior completion updates and prior progress text remain preserved. Only DEPDC5's
checkbox changes relative to 451; update 101 is appended. Gene, source, runtime and
historical files are unchanged. The publication preimage remains queued checkpoint 443;
this private successor is held pending separate publication qualification.

Completion checkpoint 473 — 2026-10-21 00:21:17 UTC

473 complete; 2,403 remaining out of 2,876 primary catalogue genes.
This update preserves checkpoint 452 and adds exactly 21 distinct genes: DDX41
(452→453), the first ten-gene audit batch (453→463), and the second ten-gene batch
(463→473). Later batches are excluded. The coordinating agent accepted the three
sealed audit records; this is not a human maintainer sign-off or a new biological
re-review. Accepted source decisions, unresolved annotations and product limits
remain unchanged.

Gene / PR Approved head / merge Approval / detail Exact PR paths Immediate main test / docs Exact merge-group test
DDX41 #5090 babb88ce2f40 / 653a15c8309e approval / detail 29 39164000966 success / 39164000992 success 39161495647 success
DGKE #5094 f94d4f7d86c9 / 51f9e16d8801 approval / detail 22 39166466485 success / 39166466508 success 39164003526 success
DEGS1 #5092 277db2c325e2 / 4a05f894ee6d approval / detail 9 39168514887 success / 39168515160 success 39166468593 success
DDX3X #5093 465ce8334e2d / f4a4941aefd6 approval / detail 55 39180447214 success / 39180447185 success 39179010406 success
DES #5095 00ffdd5fac63 / 94ac62eafce3 approval / detail 31 39181828974 success / 39181828957 success 39180449829 success
DGUOK #5096 49076e9e3e15 / f8a49c1b5036 approval / detail 12 39183168173 cancelled / 39183168066 success 39181831026 success
DHCR24 #5097 587ac7bda814 / a76e2eefb45e approval / detail 16 39183672110 cancelled / 39183672116 success 39182172955 success
DHDDS #5098 8c035e287392 / 3fe42af909db approval / detail 14 39183673052 cancelled / 39183673049 cancelled 39182174939 success
DHCR7 #5099 95e4139036f8 / 3df2def4d26b approval / detail 9 39183674278 cancelled / 39183674220 cancelled 39182177176 success
DHODH #5100 244b6c627a7f / 02ba969a6693 approval / detail 12 39183674954 success / 39183674944 success 39182178020 success
DHTKD1 #5101 dbc5c226176e / 41c0e159f6cb approval / detail 20 39187058970 cancelled / 39187058954 cancelled 39182180976 success
DHX30 #5104 acb5a15c1f0e / 6e2c9512f547 approval / detail 15 39187061624 cancelled / 39187061641 cancelled 39183560931 success
DIAPH3 #5107 624277d51efb / 093159b74f94 approval / detail 29 39187083163 cancelled / 39187083168 cancelled 39183628155 success
DIS3L2 #5112 e589819b9cdb / 3b05624a9f1e approval / detail 16 39187084244 cancelled / 39187084239 cancelled 39183629782 success
DICER1 #5111 398a29f56c91 / 9b42a011248d approval / detail 39 39187085727 cancelled / 39187085740 cancelled 39183677788 success
DISP1 #5113 2560fb0489f4 / bd4061b01e12 approval / detail 18 39187106249 cancelled / 39187106248 cancelled 39184686456 success
DIAPH1 #5106 b2cc6c0f777a / 6155bb365387 approval / detail 31 39187107447 cancelled / 39187107461 cancelled 39184893342 success
DIABLO #5105 54140f8251fe / 894e016ddd0f approval / detail 10 39187108123 cancelled / 39187108065 cancelled 39185053319 success
DKC1 #5116 e3607a505307 / 57fb4720a939 approval / detail 31 39187610495 cancelled / 39187610587 success 39186097967 success
DLG3 #5115 c2c50812909a / 1ed4061082c2 approval / detail 28 39187653317 cancelled / 39187653845 success 39186302052 success
DLD #5126 4033131ca553 / bf0db45a4fe2 approval / detail 19 39187910583 cancelled / 39187910613 cancelled 39186483421 success

All 465 approved PR path occurrences match their merge blobs and modes. The
saved audits also verify that paths outside each PR delta are unchanged relative
to its immediate parent. All selected paths still match main 0ad352a6266763efcd3daaaa2a32a0755d5b54cd;
a captured chain of commit objects proves containment of every merge. Shared
publication paths may occur in more than one audit, so this sum is not a count of
unique files. Optional review suggestions are preserved in the audits; no current
mandatory request or unresolved review thread was accepted as completed.

DDX41 and five genes in the first batch have successful immediate main test runs.
For DGUOK, DHCR24, DHDDS, DHCR7 and DHTKD1, and all ten genes in the second batch,
the immediate main test was cancelled. DHX30 and DLG3 also have failed aggregate
gates caused by cancellation. These outcomes remain recorded as cancellations or
failures, not successful main gene validation. Each exact merge commit separately
passed its merge-group checks. Successful descendants support the finite bridge:
DGUOK, DHCR24, DHDDS and DHCR7 retain their approved payloads and executable runtime
at 02ba969a6693,
with test 39183674954 and
docs 39183674944. DHTKD1 and the second batch retain
their payloads at bb50821d7123,
with test 39200674021 and
docs 39200673967. Its only relevant runtime differences
are documented additive GO-cache rows, affecting no reviewed term of those genes.
A descendant job's scoped gene validation covers its own changed paths; it is not
claimed to rerun validation for every earlier gene. The original approved-head and
exact merge-group validations provide that earlier gene-specific evidence.

Documentation success means the recorded MkDocs/schema build and deployment;
it does not establish regeneration or visual inspection of every gene HTML page.
The original audits retain event-specific skipped steps, warning annotations,
review-service limitations and optional suggestions. No ordinary suite, source
research or workflow rerun was performed to prepare this tracker update.

The current main snapshot contains 8,467 review files, including 3,102 human
reviews; 1,248 catalogue genes have reviews, 1,628 lack them, and
775 available catalogue reviews remain uncredited. This inventory includes
other existing reviews without awarding them completion credit. All 2,876 catalogue
identities and association texts, 235 historical queue objects, 101 earlier
completion updates and prior progress bytes are preserved. Update 102 appends the
three accepted audit stages and exact per-gene evidence. No gene, publication,
runtime or history file is modified.

The publication preimage is checkpoint 443, merged through
#5053 at
7873440186c6
on 2026-10-19 at 04:13:34 UTC. Its six tracker files still match this captured main.
Accepted private checkpoints 444–452 are retained in full before this addition.
The current runtime includes dependency update #4972;
publication uses the publisher's current-runtime checks, two ordinary project
renders and a new append-only history record. The publication checkout at
a17627810d4a13efede28a3c07a481aa0b44131b contains 8,472 review files, including
3,102 human reviews. All eight frontmatter checks and both renders passed;
the catalogue reports 1,628 missing-review warnings and the progress page reports none.
The inventory above remains the explicitly pinned audit snapshot.

Curation session

Completion checkpoint 541 — 2026-10-21 00:53:59 UTC

541 complete; 2,335 remaining out of 2,876 primary catalogue genes.
This appends exactly 68 accepted distinct genes from batches 03–09 to the published
473 checkpoint. The coordinating agent accepted the sealed merge audits; this is
not a human maintainer sign-off or a new biological review. EGR2, EHMT1 and EGFR
remain excluded. Existing source decisions, unresolved annotations and product
limits are unchanged.

Gene / PR Approved head / merge Approval / detail Exact PR paths Immediate main test / docs Exact merge-group test
DMD #5143 4aefd77b3080 / d87957d33b6b approval / detail 93 39187911774 cancelled / 39187911820 cancelled 39186523486 success
DMRT1 #5137 039a1748dfd9 / bfd1a7762bd2 approval / detail 23 39187961366 cancelled / 39187961360 cancelled 39186566983 success
DNAJB6 #5159 a6b6af6fe047 / b39a1cb3f4e3 approval / detail 9 39187962574 cancelled / 39187962550 success 39186610942 success
DNAJC21 #5160 8bfb849689de / c8ec8c24406e approval / detail 10 39188517354 cancelled / 39188517394 success 39187131353 success
DNAAF1 #5142 48e448043ff3 / 91b8d9960ee6 approval / detail 9 39188517758 cancelled / 39188517713 success 39187168564 success
DLG4 #5141 cfaa650ed3a9 / 3aedf3afbe24 approval / detail 65 39188940630 cancelled / 39188940588 cancelled 39187507583 success
DNAAF19 #5145 144f1e87eb82 / d0d98a87fe34 approval / detail 14 39189048360 cancelled / 39189048306 cancelled 39187612323 success
DNAAF5 #5150 4356434a016b / ef281598e742 approval / detail 14 39189049668 cancelled / 39189049667 success 39187655939 success
DNAJC30 #5161 2152e7a87a89 / 69b742f2ee16 approval / detail 9 39189233128 cancelled / 39189233126 cancelled 39187768552 success
DNAAF11 #5146 4117de879ccf / aa1885d8bb10 approval / detail 18 39189234291 cancelled / 39189234305 success 39187914173 success
DNAL1 #5162 db557d9516b0 / 002583730642 approval / detail 10 39189632983 cancelled / 39189633015 success 39187965245 success
DNAJB2 #5158 4274e9cc4f6f / cf96752efc52 approval / detail 13 39189743504 cancelled / 39189743506 success 39188201729 success
DNAJC19 #5157 628c6d0a23fd / af2d3d44164a approval / detail 11 39190257375 cancelled / 39190257374 success 39188519926 success
DNAH8 #5152 2eca53bbcb0a / 8035864699cb approval / detail 5 39190404930 cancelled / 39190405014 cancelled 39188894055 success
DNAI1 #5155 c823aef039b3 / 310c7ae87d11 approval / detail 17 39190405751 cancelled / 39190405824 cancelled 39188942834 success
DNAI2 #5156 fc0c50b25008 / 7bd7d235ed1a approval / detail 27 39190449220 cancelled / 39190449173 cancelled 39189051611 success
DNAAF3 #5148 57422dc7a00d / 2e5ae6740fe6 approval / detail 15 39190449878 cancelled / 39190449905 success 39189052844 success
DNAAF4 #5149 6d980bcdaf60 / ed8061507edb approval / detail 18 39190699924 cancelled / 39190700045 success 39189236702 success
DNAAF2 #5147 d0374e4a65f6 / c4d984a59437 approval / detail 20 39191111520 cancelled / 39191111317 success 39189634754 success
DNAAF6 #5151 441ccd42b8d9 / 2a58063332e6 approval / detail 24 39191112043 cancelled / 39191112553 success 39189745266 success
DOCK11 #5171 c015258574f8 / e7adbec2048f approval / detail 27 39191657344 cancelled / 39191657475 success 39190260091 success
DNMT3A #5170 bfb486a5fc25 / 29efd5e1e346 approval / detail 28 39191833685 cancelled / 39191833696 cancelled 39190309258 success
DNMT1 #5167 822362e01633 / 9a1b5a39a111 approval / detail 20 39191835649 cancelled / 39191835674 success 39190409062 success
DNMT3B #5169 09e528221f4b / 26236c3c82d6 approval / detail 22 39191834266 cancelled / 39191834319 cancelled 39190407682 success
DNM1L #5166 ad720c8913ed / e902e7ed5bfb approval / detail 13 39191971333 cancelled / 39191971311 cancelled 39190451175 success
DOCK6 #5174 eaa59b3d397d / afdc59380483 approval / detail 14 39192127336 cancelled / 39192127466 success 39190701958 success
DNM2 #5168 09e9a65cdec6 / c9dd834fefc5 approval / detail 41 39192497984 cancelled / 39192498061 success 39191114254 success
DOCK2 #5175 e0ef2857f3a3 / 0372a9c59eb2 approval / detail 24 39192499221 cancelled / 39192499143 success 39191115546 success
DOCK7 #5176 75d22cf922bc / 1ddc38b26cc3 approval / detail 38 39193043623 cancelled / 39193043621 success 39191658870 success
DOK7 #5177 b6399867d721 / d1c971ac8733 approval / detail 18 39193157984 cancelled / 39193158011 cancelled 39191660369 success
DOCK8 #5178 beb3d6d0d283 / a066dcf2b38d approval / detail 31 39193158990 cancelled / 39193158943 cancelled 39191837788 success
DOLK #5179 b702277e430e / ee9a871cc585 approval / detail 39 39193160109 cancelled / 39193159955 success 39191838572 success
DPAGT1 #5180 594f32073592 / a7a19e059c4b approval / detail 10 39193322914 cancelled / 39193322917 success 39191973501 success
DPF2 #5181 caff9ddfe06c / 21c22151b39e approval / detail 26 39193640339 cancelled / 39193640407 cancelled 39192128880 success
DPY19L2 #5184 34272ec51bcd / 40ac2eaa80d5 approval / detail 18 39193778825 cancelled / 39193778832 success 39192366441 success
DPH1 #5182 4330af836f24 / a44f07ba473d approval / detail 15 39194050778 cancelled / 39194050729 success 39192501158 success
DPM1 #5183 92402e4181d4 / 4b38a493196d approval / detail 23 39194608242 cancelled / 39194608284 cancelled 39193070200 success
DRC1 #5186 623841bd26d1 / 9b5c8c67d999 approval / detail 12 39194653608 cancelled / 39194653597 cancelled 39193111849 success
DRC2 #5187 ef2c0153f4a6 / 023c6f73c5e9 approval / detail 12 39194654994 cancelled / 39194655058 success 39193162028 success
DRC4 #5188 7ab4969cb43f / d05e9f2348ac approval / detail 27 39194863186 cancelled / 39194863196 success 39193325269 success
DSE #5190 ab6b0fdca25f / 21eda734da77 approval / detail 15 39195171996 cancelled / 39195171953 success 39193642108 success
DSC2 #5189 e636319d505f / 2556e031729c approval / detail 25 39195350971 cancelled / 39195350913 cancelled 39193780479 success
DSPP #5191 d94ee03e2a0d / 5b34aefb94ae approval / detail 24 39195398487 cancelled / 39195398424 success 39194052484 success
DSP #5192 95a97d3c58fc / a532a7e2a80a approval / detail 42 39195900296 cancelled / 39195900287 success 39194505866 success
DSG2 #5193 cc1b22a58fcf / 75aa3e00937b approval / detail 35 39195901249 cancelled / 39195901445 cancelled 39194610015 success
DST #5194 572573c3c88d / fc7905919eba approval / detail 27 39196041995 cancelled / 39196041953 success 39194656802 success
DYNC2H1 #5195 589cc2bcfa69 / cf4e305fd676 approval / detail 16 39196191841 cancelled / 39196191806 success 39194657870 success
DTNBP1 #5196 03d41d65b557 / fb63079d569c approval / detail 38 39196449647 cancelled / 39196449636 cancelled 39194865002 success
DYNC1H1 #5197 6e18c9fee11d / 80e71bc89765 approval / detail 16 39196612953 cancelled / 39196612959 success 39195173513 success
DYNC2I1 #5198 1e03c1c23080 / fb4523358525 approval / detail 13 39196818398 cancelled / 39196818396 cancelled 39195352469 success
DYNC2I2 #5199 b62674f50cce / d27e12acf159 approval / detail 15 39196864128 cancelled / 39196864086 success 39195400174 success
DZIP1L #5200 6f162afe0af2 / 226af0294fc8 approval / detail 24 39197258526 cancelled / 39197258604 cancelled 39195902343 success
DYSF #5201 49b5a265f90e / 1068c61a9bc4 approval / detail 64 39197257972 cancelled / 39197257858 success 39195858820 success
DYRK1A #5202 6597d1785ec4 / 406f5938e971 approval / detail 40 39197545128 cancelled / 39197545204 success 39196042828 success
EARS2 #5203 47586cd9ec28 / 112b5bcc30f5 approval / detail 19 39197634082 cancelled / 39197633986 success 39196193202 success
EBF3 #5204 c40488eaa2a4 / 6ed8e2a7f55e approval / detail 17 39197924600 cancelled / 39197924606 cancelled 39196451008 success
EBP #5206 68f7809eaf59 / b54117406d6e approval / detail 18 39198396486 cancelled / 39198396497 cancelled 39196820332 success
ECHS1 #5207 59891106a316 / 398bc75deb14 approval / detail 18 39198538846 cancelled / 39198538917 success 39197217052 success
EDAR #5209 ee11a9c9ed0b / 71b6c5799dfc approval / detail 26 39198820516 cancelled / 39198820467 success 39197259771 success
EEF1A2 #5210 4c9c7d3ac8f4 / d564c0d6318a approval / detail 27 39199086385 cancelled / 39199086378 cancelled 39197546581 success
EFL1 #5212 ed0f1b2d871f / 6a7cc1874c90 approval / detail 20 39199088053 cancelled / 39199087994 success 39197635176 success
EFEMP1 #5211 eebf417e370c / 8e7fec328553 approval / detail 22 39199472305 cancelled / 39199472302 cancelled 39197926121 success
EFNB1 #5216 c25a84d61d9f / aedd27b9cba6 approval / detail 32 39199555560 cancelled / 39199555516 success 39198104288 success
EFEMP2 #5214 c8945f77bb2a / 1032e54fff10 approval / detail 38 39200006193 cancelled / 39200006150 success 39198398570 success
EFTUD2 #5217 dc7af6e90ee4 / f83a00550e18 approval / detail 31 39200007097 cancelled / 39200007094 cancelled 39198400037 success
EGLN1 #5218 f0b9710c5988 / 58b90b0b579a approval / detail 39 39200135501 cancelled / 39200135508 cancelled 39198540735 success
DNAH17 #5154 ba791f830b16 / 0b6ca0183624 approval / detail 7 39297514802 cancelled / 39297514592 cancelled 39293010123 success
DNASE1L3 #5164 95c9f6a6bb26 / 87ce1e9437b5 approval / detail 20 39297517088 success / 39297516955 success 39293061047 success

All 1,610 approved PR path occurrences match their merge blobs and modes and
remain identical at captured main a17627810d4a13efede28a3c07a481aa0b44131b. Saved commit objects prove
containment of all 68 merges. Each accepted audit also establishes unchanged
paths outside its complete PR delta relative to its immediate parent. Shared
source paths may occur in multiple audits; this total counts path occurrences.
No accepted current mandatory review request or unresolved thread remains.

The immediate main builds comprise 67 cancellations and one success
(DNASE1L3); 40 immediate documentation runs succeeded. These outcomes are
preserved individually above. Exact approved-head and actual-merge merge-group
checks supply gene-specific evidence. Successful descendants corroborate preserved
payload and runtime; they are not claimed to revalidate every earlier gene.
The accepted batch limits are retained explicitly:

Batch 03 (473→483): All ten immediate main builds cancelled; six aggregate gates failed due to cancellation. DNAJB6 and DNAAF1 completed actual-main gene validation before later cancellation, without a successful whole main build. Each exact merge commit passed merge-group checks. Descendant bridge preserves all payloads and executable runtime; only eleven unrelated GO-cache terms added. Its scoped validation does not revalidate these ten. Docs deployments do not imply fresh individual gene HTML. No new science/quotes or ordinary local suite in this audit.

Batch 04 (483→493): All ten immediate main builds cancelled; six cancellation-dependent gates failed. DNAJB2, DNAAF4 and DNAAF6 passed actual-main gene/history checks before later family-step cancellation. No whole main build is relabeled successful. Exact actual merge commits all passed merge-group checks. The successful descendant preserves all 160 payload paths and executable runtime; eleven unrelated GO-cache additions only. Its scoped validation does not revalidate these ten. Seven immediate docs successes describe schema/MkDocs deployment, not individual gene HTML regeneration. Two failed log-retrieval attempts and v1 prose-total correction remain recorded. Effective recovered log and 160-path proof passed. No ordinary local suite or scientific quotations added.

Batch 05 (493→503): All ten immediate main builds cancelled. Exact approved-head and actual-merge merge-group checks passed; cancelled aggregate outcomes remain cancelled or failed. Successful descendant bb50821d71232c86e36c9dee6ed1d0604f6b5505 preserves selected payloads and executable runtime, with eleven unrelated additive GO-cache rows. Its scoped validation does not revalidate these earlier genes. Six immediate docs successes are schema/MkDocs deployment, not individual gene HTML regeneration. No ordinary local suite or scientific quotation added during audit. DOCK6/DOCK2 passed gene/history checks before later family cancellation; six aggregate gates failed due to cancellation. DNM2 and DOCK2 retain explicitly disclosed stale committed HTML.

Batch 06 (503→513): All ten immediate main builds cancelled. Exact approved-head and actual-merge merge-group checks passed; cancelled aggregate outcomes remain cancelled or failed. Successful descendant bb50821d71232c86e36c9dee6ed1d0604f6b5505 preserves selected payloads and executable runtime, with eleven unrelated additive GO-cache rows. Its scoped validation does not revalidate these earlier genes. Six immediate docs successes are schema/MkDocs deployment, not individual gene HTML regeneration. No ordinary local suite or scientific quotation added during audit. DPAGT1 gene validation passed but history pytest was interrupted. DPH1 displayed validations passed but job/API conclusion remains cancelled and gate failed. Eight aggregate gates failed due to cancellation. DOLK eight resolved inline threads were read by delegated auditor.

Batch 07 (513→523): All ten immediate-main builds cancelled; eight aggregate gates failed due to cancellation. DSPP gene/history passed before family cancellation; DYNC2H1 gene passed but history interrupted. No cancelled or skipped test is relabeled successful. Exact approved-head and actual-merge merge-group checks passed. Successful bb508 descendant preserves 251 selected paths and executable runtime, with eleven unrelated additive GO-cache rows; it does not revalidate these ten earlier genes. Six immediate docs successes mean schema/MkDocs deployment, not individual gene HTML regeneration. No local ordinary suite or scientific quote added by this audit.

Batch 08 (523→533): All ten immediate-main builds cancelled; seven aggregate gates failed due to cancellation. DYNC2I2 gene/history passed before family cancellation; DZIP1L/EARS2/ECHS1 gene passed but history completion not established. Main broad tests were skipped. Exact approved-head and actual-merge merge-group checks passed. Successful bb508 descendant preserves all 268 paths and executable runtime, with eleven or ten unrelated additive GO-cache rows. Its scoped validation does not revalidate these ten earlier genes. Six immediate docs successes mean schema/MkDocs deployment, not individual gene HTML regeneration. No ordinary local suite or scientific quotation added during audit.

Batch 09 (533→541): Seven immediate-main builds cancelled; three aggregate gates failed due to cancellation. EFL1/EFNB1 gene/history passed before family cancellation. DNASE1L3 actual main gene/history/family passed; broad suite and history coverage were skipped. Exact approved-head and actual-merge merge-group checks passed for all eight. First six preserve selected paths/runtime to bb508 except ten unrelated additive GO-cache rows. DNAH17 instead preserves all payload and 298 runtime blobs to later successful DNASE1L3 merge 87ce1e9437b5. DNASE1L3 uses its own actual-main pass; neither successor is claimed to revalidate prior genes. Four immediate docs successes mean schema/MkDocs deployment, not individual gene HTML regeneration. Incorrect old-successor attempt retained as failure and replaced by versioned correct proof. No ordinary local suite or scientific quotation added during audit.

The shared successful descendant bb50821d7123
has build 39200674021 and
docs 39200673967.
DNAH17 uses the later DNASE1L3 merge 87ce1e9437b5,
with build 39297517088 and
docs 39297516955; DNASE1L3 uses its own main pass.
Documentation success denotes schema/MkDocs generation and deployment, not fresh
rendering or visual inspection of every gene HTML page. DNM2 and DOCK2 retain the
explicitly disclosed stale committed HTML. Accepted generic-binding advisories
and source uncertainties are not silently removed by this completion update.

The current main inventory contains 8,472 review files, including 3,102 human
reviews. 1,248 catalogue genes have reviews and 1,628 lack them;
707 available catalogue reviews remain uncredited. All 2,876 catalogue
identities and association texts and 235 historical queue objects remain exact.
The 102 updates already published on this PR branch remain exact; 92 of those
pre-existed on main. This follow-up appends update 103. Previous progress text,
including checkpoint 473's original inventory, is preserved byte-for-byte.

The publication preimage is open PR #5253 at
a6b08818d82e62d653bd9f330df66697ecb082cb, containing checkpoint 473 and its existing history.
Relative to main checkpoint 443, the combined PR has 98 checkbox changes
(30 already published plus these 68) and 103 updates rather than main's 92.
The publisher ran all eight project frontmatter checks, rendered both project
pages and validated a new append-only history record. The catalogue render
reports 1,628 missing-review warnings; the progress render reports none. The
combined PR has eight paths, retaining the earlier checkpoint 473 history.
Gene reviews, source caches and runtime files remain unchanged by this update.

Curation session

Terminal publication preflight observed EGR2 merging after that evidence cut,
advancing main to a1dc7cee46ff.
A complete 26-path tree comparison confirms no tracker, project-history or runtime
change and no change to the 1,610 accepted path occurrences. The inventory counts
remain 8,472 total reviews, 3,102 human, 1,248 available catalogue reviews and
1,628 missing. The open-head gate changed only by removing merged PR #5249 and
then stabilized at 163 heads. This bridge adds no EGR2 completion credit; the
frozen checkpoint remains 541.

Completion checkpoint 544 — 2026-10-21 02:35:41 UTC

544 complete; 2,332 remaining out of 2,876 primary catalogue genes.
This checkpoint adds exactly EGR2, EHMT1 and EGFR to the merged 541 checkpoint.
The coordinating AI agent accepted each complete merge audit; this is not a
human maintainer sign-off or a new biological review. Products, follow-up PRs
and the tracker publication receive no additional gene credit.

Gene / PR Approved head / merge Approval / detail Exact PR paths Immediate main build / docs Exact merge-group build
EGR2 #5249 53560956d08a / a1dc7cee46ff approval / detail 26 39524461723 success / 39524461748 success 39522566057 success
EHMT1 #5251 a455c87f9263 / f1f1f9b20ec6 approval / detail 34 39526942091 success / 39526942097 success 39525021979 success
EGFR #5252 0638a3b2722e / 8eeb6f927b0f approval / detail 35 39531434283 cancelled / 39531434228 success 39529711313 success

All 95 approved PR path occurrences match their merged blobs and modes and
remain identical at main 81298ef287dae81220ae068a10a524f17628bf7d. Authenticated commit objects establish
the EGR2 → EHMT1 → EGFR → tracker sequence. Each accepted merge audit also
checks the complete immediate-parent delta and unchanged paths outside it.
The final approved heads have no unresolved review threads or blocking requests.

EGR2 passed scoped gene validation and 42 history tests on its PR and main
builds; broad suites, all-schema and module checks ran on the merge-group.
History coverage ran on the PR only. Its DRAFT status and inherited uncited
research-report advisory remain recorded. EHMT1 passed scoped gene, history
and family checks on main, with broad suites, schemas and modules on the
merge-group; unresolved scientific contexts and optional suggestions remain.

EGFR's immediate main build 39531434283
was cancelled during checkout by a higher-priority main request. Its aggregate
failed because dependencies were cancelled; this is not a successful run.
The immediate tracker successor 81298ef287da
changed only eight project, render and history paths, preserving all 35 EGFR
payload paths and 18 runtime/workflow roots. Its successful
build 39531567708 ran broad tests and
history checks but explicitly skipped scoped gene validation. EGFR's exact
approved-head and actual-merge merge-group checks supply the gene checks;
successor success is not presented as fresh EGFR validation. The earlier failed
merge-group 39526448256, caused by a
stale source-report assertion, remains part of the record; the corrected final
head and merge-group passed.

EGFR remains DRAFT with 1,008 reviewed rows, 41 UNDECIDED annotations, four
products and one core function. Its 177 advisories comprise 169 generic-binding
and eight source-context warnings. Completion denotes accepted review delivery,
not certainty about every annotation. The documentation runs succeeded,
including the tracker successor docs;
the EGFR/successor docs retained 21 warnings. Documentation success covers
schema/MkDocs generation and deployment, not fresh individual gene HTML
rendering or visual inspection.

Tracker PR #5253 landed checkpoint 541 at
81298ef287dae81220ae068a10a524f17628bf7d from approved head e556803f9ba33e51eac8d98e197940424083881f. Its eight
paths were verified exactly; that publication adds no gene credit. This update
starts from that merged main snapshot rather than modifying the closed PR.
All 235 historical queue objects and 103 previous completion updates remain
exact; this is update 104. Prior progress text, including older inventories and
then-pending gene statements, is preserved as historical evidence.

Current main has 8,473 review files, including 3,103 human reviews.
1,249 catalogue genes have reviews and 1,627 lack them; 705
available catalogue reviews remain uncredited. All 2,876 catalogue identities
and association texts are unchanged; only the three accepted checkboxes change.
No gene review, cache, runtime file or existing history is modified by this
checkpoint. The publisher passed eight project frontmatter checks, rendered both project
pages and validated one new append-only history record. The catalogue render
reports 1,627 missing-review warnings; the progress render reports none. These
four source changes, two HTML renders and new history form seven publication paths.

Curation session

Completion checkpoint 545 — 2026-10-21 16:59:33 UTC

545 complete; 2,331 remaining out of 2,876 primary catalogue genes.
This checkpoint adds only EIF2B2 #5283
to the merged 544 checkpoint. The coordinating AI agent accepted the complete
merge audit; this is not a human maintainer sign-off. Products, follow-up PRs
and the tracker publication receive no additional gene credit.

Approved head 184a3beedb18
merged at 078fd7636b0a
on 2026-10-21 at 06:27:56 UTC. All 25 approved paths, blobs and modes equal
the complete merge delta and this later pinned main snapshot; no extra path was
introduced. The current approval
and detailed review
have no unresolved threads or blocking requests.

The actual merge-group build
passed strict EIF2B2 validation, all gene-schema and module checks, 14,749
history records, 42 history tests and family checks. It actually ran the full
suite: 4,168 tests passed, 268 doctests passed, 12 examples passed, typing and
lint passed, and 432 agentic plus 19 JavaScript tests passed. Skips and
dependency warnings remain in the audit.

The actual main build
passed strict EIF2B2, history and family checks. Change filtering skipped
the general suite and all-gene/module scopes; the final test job only checked
upstream conclusions. The documentation run
successfully built and deployed MkDocs, retaining navigation/dependency
warnings. This is not a claim of fresh gene HTML visual inspection.

EIF2B2 remains DRAFT with 42 reviewed source rows: 18 ACCEPT, 9 MODIFY,
8 KEEP_AS_NON_CORE, 4 UNDECIDED and 3 MARK_AS_OVER_ANNOTATED; one core function,
33 references and no publication quotations. The four accepted validation
advisories concern generic binding and source-specific action differences.
Completion means accepted review delivery, not certainty about every annotation.
Renderer PR #5285
is the immediate merge parent; its three approved files remain exact and it
receives no gene credit.

Main advanced through 1,212 unrelated paths after the merge audit. A bounded
comparison preserves all 25 EIF2B2 and three renderer paths exactly; it supplies
no additional gene credit or new CI claims. The inventory below is freshly
recounted from that successor.

This update starts from main 613523bf19bba276b9ea72840a06c56e606897f2, with the seven
checkpoint-544 publication paths inherited from merged tracker #5271.
All 235 historical queue objects and 104 previous completion updates remain
exact; this is update 105. Previous progress text remains byte-for-byte intact.
All 2,876 catalogue identities and association texts are unchanged; only the
EIF2B2 checkbox changes.

The pinned inventory has 8,550 review files, including 3,109 human reviews.
1,252 catalogue genes have reviews and 1,624 lack them; 707
available catalogue reviews remain uncredited. Four source changes, two
generated project pages and one new append-only history record form the
publication scope. No gene, source cache, runtime or prior history is edited.

The publisher passed eight project frontmatter checks, rendered both project
pages and validated the appended history record. The catalogue render reports
1,624 missing-review warnings; the progress render reports none.

Curation session

Completion checkpoint 546 — 2026-10-21 17:57:11 UTC

546 complete; 2,330 remaining out of 2,876 primary catalogue genes.
This checkpoint adds only EIF2B3 #5284
to merged checkpoint 545. The coordinating AI agent accepted the complete
merge audit and terminal main addendum; this is not a human maintainer sign-off.
Products, follow-up PRs and tracker publications receive no additional credit.

Approved head 39624d66898c
merged at 06bb22ebd22c
on 2026-10-21 at 17:24:29 UTC. All 20 approved paths, blobs and modes equal
the complete merge delta and remain exact on the pinned main snapshot. The
current approval
and detailed review
have no unresolved threads or blocking requests. Advisory suggestions remain
recorded with their original scope.

The actual merge-group build
passed strict EIF2B3 validation, all gene-schema and module checks, 14,895 history
records, 42 history tests and family checks. It actually ran the full suite:
4,176 tests passed, 268 doctests passed, 12 examples passed, typing and lint
passed, and 432 agentic plus 19 JavaScript tests passed. Skips, dependency
warnings and unresolved corpus diagnostics remain in the audit.

The actual main build
passed strict EIF2B3, history and family checks. Change filtering skipped
the general suite and all-gene/module scopes; the final test job only checked
upstream conclusions. The documentation run
successfully built and deployed MkDocs, retaining navigation/dependency warnings.
This is not a claim of fresh gene HTML visual inspection.

EIF2B3 has computed status COMPLETE with 34 reviewed source rows: 21 ACCEPT,
5 MODIFY, 4 KEEP_AS_NON_CORE, 3 UNDECIDED and 1 MARK_AS_OVER_ANNOTATED;
three natural products, one core function and no publication quotations.
Completion records accepted review delivery; the three unresolved source
judgments remain visible. The strict gene validation returned no annotation
warnings. The tracker publication adds no scientific decision or gene credit.

This update starts from main 31717524f1710d19c5f8b22c5418f37b9e08b6eb, whose seven checkpoint-545
publication paths equal the approved payload of merged tracker #5313.
All 235 historical queue objects and 105 previous completion updates remain
exact; this is update 106. Previous progress text remains byte-for-byte intact.
All 2,876 catalogue identities and association texts are unchanged; only the
EIF2B3 checkbox changes.

The pinned inventory has 8,551 review files, including 3,110 human reviews.
1,253 catalogue genes have reviews and 1,623 lack them; 707
available catalogue reviews remain uncredited. Four source changes, two generated
project pages and one new append-only history record form the publication scope.
No gene, source cache, runtime or prior history is edited.

The publisher passed eight project frontmatter checks, rendered both project
pages and validated the appended history record. The catalogue render reports
1,623 missing-review warnings; the progress render reports none.

Curation session

Completion checkpoint 547 — 2026-10-21 18:55:39 UTC

547 complete; 2,329 remaining out of 2,876 primary catalogue genes.
This checkpoint adds only EIF2B4 #5301
to merged checkpoint 546. The coordinating AI agent accepted the complete
merge audit and terminal main addendum; this is not a human maintainer sign-off.
Products, follow-up PRs and tracker publications receive no additional credit.

Approved head 566979dc1095
merged at 538ebfa38cf7
on 2026-10-21 at 18:28:09 UTC, with actual parent 31717524f1710d19c5f8b22c5418f37b9e08b6eb.
All 19 approved paths, blobs and modes equal the complete merge delta and
remain exact on the pinned main snapshot. The current
approval
and detailed review
have no unresolved threads or blocking requests.

The actual merge-group build
passed strict EIF2B4 validation, all gene-schema checks, 699 module checks,
14,900 history records, 42 history tests and 715 family checks. It actually ran
the full suite: 4,176 tests, 268 doctests, 12 examples, typing, lint, 432 automation
Python tests and 19 JavaScript tests passed. Skips, dependency warnings and an
ignored destructor error remain disclosed in the audit; the jobs succeeded.

The actual main build
passed strict gene, history and family validation. Change filtering skipped the
general suite; the final test job checked upstream conclusions. Strict gene
validation retains 10 advisories: nine supported generic-binding policy warnings
and one inherited Falcon quotation mismatch. The existing quoted text was
preserved. The documentation run
successfully built and deployed MkDocs, with navigation/dependency warnings.
This is not a claim of fresh gene HTML visual inspection.

The accepted review preserves 53 source objects: 49 active and four retired
contexts. Its actions are 21 ACCEPT, 13 MODIFY, 14 KEEP_AS_NON_CORE,
2 UNDECIDED and 3 MARK_AS_OVER_ANNOTATED. It records three natural products,
one core function and 57 inherited quotations; no new quotation was added.
Completion records accepted review delivery, with unresolved judgments visible.

This update starts from main d2587858a920bf0ebb731c6c8e9cb74036c4d5db. Its seven checkpoint-546
publication paths equal the approved payload of merged
tracker #5316, merge d2587858a920bf0ebb731c6c8e9cb74036c4d5db.
All 235 historical queue objects and 106 previous completion updates remain
exact; this is update 107. Previous progress text remains byte-for-byte intact.
All 2,876 catalogue identities and association texts are unchanged; only the
EIF2B4 checkbox changes. The project instructions also document the standing
campaign convention of adding no new publication quotations, while preserving
inherited quotations and requiring verifiable sources and access limits.

The pinned inventory has 8,551 review files, including 3,110 human reviews.
1,253 catalogue genes have reviews and 1,623 lack them;
706 available catalogue reviews remain uncredited. Four source changes,
two generated project pages and one new append-only history record form the
publication scope. No gene, source cache, runtime or prior history is edited.

The publisher passed eight project frontmatter checks, rendered both project
pages and validated the appended history record. The catalogue render reports
1,623 missing-review warnings; the progress render reports none.

Curation session

Completion checkpoint 549 — 2026-10-21 19:46:21 UTC

549 complete; 2,327 remaining out of 2,876 primary catalogue genes.
This checkpoint adds EIF2S3 #5314
and EIF3F #5315 to merged checkpoint 547.
The coordinating AI agent accepted their merge audits; this is not a human
maintainer sign-off. Products, follow-ups and trackers receive no extra credit.

EIF2S3 approved head d7140993c185a1dea61187562e05358af517377a merged at 4d4b0ea1e8ede4bd5ce45128123c83b6d529ff39
with actual parent c5d0b8f3d69bb45714a85a7734651e317b93ece0. All 31 approved paths, blobs and modes
match the actual merge delta and pinned main. The current formal approval and
detailed review remain unchanged with no unresolved threads. Its
merge-group build ran
4,176 tests, 268 doctests, 12 examples, typing, lint and 432 Python/19 JavaScript
automation tests successfully. Its actual main build
passed strict EIF2S3 validation, 14,905 history records, 42 history tests and 715
family checks. Main change filtering skipped the general suite. The 33 strict
advisories comprise 32 supported generic-binding warnings and one optional
propagation-metadata warning. Its documentation run
built and deployed successfully. The review retains 81 sources from 82 raw
records, two cores, one 472-residue product and zero new quotations.

EIF3F approved head 18c2b74730af07e228e4f60ac58903e4075956e2 merged at c5d0b8f3d69bb45714a85a7734651e317b93ece0
with actual parent d2587858a920bf0ebb731c6c8e9cb74036c4d5db. All 29 approved paths, blobs and modes
match the actual merge delta and pinned main. Its formal approval and detailed
review remain unchanged with no unresolved threads. Its
merge-group build passed
the same full test suite, strict EIF3F validation, 14,903 history records,
42 history tests and 715 family checks. Its documentation run
built and deployed successfully.

EIF3F's actual main run
was cancelled because a higher-priority main build was waiting. Strict EIF3F
validation passed with 49 supported generic-binding advisories and 14,903 history
records were checked, but the history pytest step was interrupted and the
aggregate failed. The general suite was filtered out. None of those incomplete
or skipped checks is reported as executed success.

The successful immediate EIF2S3 descendant preserves all 29 EIF3F payloads,
388 protected positions, 316 runtime pins and 14 complete validation-runtime
roots. This is the campaign's documented cancelled-main bridge convention;
it does not reclassify the cancelled run or claim that EIF2S3's strict step
revalidated EIF3F. EIF3F retains 119 sources: 30 ACCEPT, 36 MODIFY,
52 KEEP_AS_NON_CORE and one UNDECIDED; two cores, one 357-residue product and
zero new quotations. Review completion leaves that uncertainty visible.

This update starts from main bf2af2d12324277c67537afb3e8f55cb96a21c57. All seven predecessor tracker paths
match approved tracker #5318, merge bf2af2d12324277c67537afb3e8f55cb96a21c57.
All 235 queue objects and 107 previous completion updates remain exact; this is
update 108. Previous progress text remains byte-for-byte intact. All 2,876
catalogue identities and association texts remain unchanged; only EIF2S3 and
EIF3F checkboxes change. The existing quotation convention now explicitly
attributes its authority to the user's standing instruction.

The pinned inventory has 8,553 reviews, including 3,112 human reviews.
1,255 catalogue genes have reviews; 1,621 lack them, and
706 available catalogue reviews remain uncredited. Three source files,
three generated files and one append-only history record form the publication
scope. No gene, source cache, runtime or previous history is edited.

The publisher passed eight project frontmatter checks, rendered both project
pages and validated the appended history record. The catalogue render reports
1,621 missing-review warnings; the progress render reports none.

Curation session

Completion checkpoint 552 — 2026-10-21 22:15:21 UTC

552 complete; 2,324 remaining out of 2,876 primary catalogue genes.
This checkpoint adds ELAC2, ELF4 and ELANE to merged checkpoint 549.
The coordinating AI agent accepted their exact-head reviews and merge audits;
this is not a human maintainer sign-off. Products, follow-ups and tracker
publications receive no extra credit. ELN and ELOVL4 receive no credit here.

Gene / PR Approved head Actual merge Actual parent Exact approved paths at merge
ELAC2 #5317 75b47d953f5e 1abe4bf2c030 0d5a010702a4 32/32
ELF4 #5321 e1de9ec5ca9e 44cdc2dbe050 1abe4bf2c030 25/26
ELANE #5320 db127beeec42 cd7e12584376 44cdc2dbe050 51/52

ELAC2 preserves all 32 approved path modes/OIDs, including its 29 science
payloads. ELF4 preserves 25 of 26 paths exactly; its aggregate report contains
all 18 parent rows plus two exact ELF4 rows, for 20. Relative to its approved
18-row report, the two ELAC2 parent rows are retained. ELANE preserves 51 of
52 paths exactly; its aggregate contains all 20 parent rows plus its exact
query row, for 21. Relative to its approved 17-row report, four ELAC2/ELF4
parent rows are retained. These are explicit report-union exceptions, not
claims that every aggregate blob equals its approved head. All three merges'
other payloads remain exact at the pinned main, and all report records are preserved.

The accepted CI evidence is linked separately for each event:

All three merge groups passed the full suite: 4,176 Python tests (one skipped,
84 deselected), 268 doctests (37 skipped), 12 examples, typing, lint, 432
Python automation tests and 19 JavaScript tests. Their actual-main builds
passed scoped strict validation, history validation/tests and family checks;
the broad main suites were skipped by path filters. Aggregate jobs checked
job conclusions and did not execute these tests. ELAC2 retains one accepted
advisory; ELANE retains 11, including ten generic-binding policy warnings and
one source-specific exosome warning. The actual log governs that count even
though reviewer prose omitted the latter. Docs workflows built and pushed
gh-pages successfully; no independent live-page or pixel inspection is claimed.

The merged reviews retain ELAC2's 36 sources/four products/one core, ELF4's
42 sources/one product/one core and ELANE's 102 sources/one product/one core.
All add zero publication quotations. ELAC2 and ELANE keep computed DRAFT
status; ELF4 is COMPLETE. ELAC2 retains one UNDECIDED annotation, ELF4 four,
and ELANE five. Campaign completion records accepted merged
review work and does not relabel those uncertainties as resolved.

The baseline is main cd7e12584376e4fff47f4e9b13d8bd20c967a7b6. All seven predecessor tracker paths match approved
tracker #5319, head 6749bce965d6f56e161bb620a9b5986d57495b42
and actual merge 0d5a010702a4fcbf92209dc76eda9f22a8e1a81b. All 235 queue objects and 108 prior completion
updates remain exact; this is update 109. Previous progress bytes and all
2,876 catalogue identities/association texts are preserved. Only ELAC2,
ELF4 and ELANE checkboxes change; the existing quotation convention is unchanged.

The pinned inventory contains 8,556 reviews, including 3,115 human reviews.
1,258 catalogue genes have files; 1,618 lack files and
706 available reviews remain uncredited. Three source files, the queue
mirror, two rendered pages and an append-only history record form the
publication scope. No gene, source cache, runtime or prior history is
changed by this tracker.
The publication passed eight project frontmatter checks, rendered both project
pages and validated the appended history record. The catalogue render reports
1,618 missing-review warnings; the progress render reports none.

Curation session

Completion checkpoint 553 — 2026-10-21 23:25:39 UTC

553 complete; 2,323 remaining out of 2,876 primary catalogue genes.
This checkpoint adds only ELN #5322
to merged checkpoint 552. The coordinating AI agent accepted the exact-head
review and merge audit; this is not a human maintainer sign-off. Products,
follow-ups, private drafts and tracker publications add no credit.

Gene / PR Approved head Actual merge Actual parent Exact approved paths at merge
ELN #5322 2fd23fe02242 c4275075822f cd7e12584376 31/31

All 31 approved path modes and blobs match the actual ELN merge. Its aggregate
source-defect report preserves 21 parent records and adds one exact conditional
ELN/MGI query, for 22 records. The tracker successor changes no ELN payload.
The review preserves 48 source annotations and 13 natural products, with two
core functions and zero new publication quotations. Decisions are 9 ACCEPT,
17 MODIFY and 22 KEEP_AS_NON_CORE. Its computed status remains DRAFT with five
accepted advisories; completion does not suppress these qualifications.

The merge-group build
executed the full suite: 4,176 Python tests (one skipped, 84 deselected),
268 doctests (37 skipped), 12 examples, typing, lint, 432 Python automation
tests and 19 JavaScript tests. The actual-main build
passed strict gene validation, 14,915 history records, 42 history tests and
715 family checks. Its broad suite was filtered, not executed again.
Aggregate jobs checked conclusions rather than running these tests.
The documentation workflow
built and pushed gh-pages successfully; no independent live-page inspection is claimed.

The pinned inventory at main 7f1f8f7147f165a688c45300b0da8052adfdadf1 contains 8,557 reviews, including 3,116
human reviews. Of the 2,876 catalogue genes, 1,259 have review files and 1,617
lack them; 706 available reviews remain uncredited. All seven predecessor
tracker #5324 paths
match its approved head 797605851a52befe7c870379624d1a16b1ab0714 at the merge.
All 235 queue objects, 109 earlier completion updates and earlier progress
bytes remain exact. This is update 110; only the ELN checkbox changes, and all
2,876 catalogue identities and association texts are preserved.

Publication scope is three project sources, their queue mirror, two rendered
pages and a scaffolded append-only history record. It changes no gene review,
source cache, runtime or earlier history. ELOVL4 and ELP2 remain uncredited.
The publication passed eight project frontmatter checks, rendered both project
pages and validated the appended history record. The catalogue render reports
1,617 missing-review warnings; the progress render reports none.

Curation session

Completion checkpoint 557 — 2026-10-24 06:14:02 UTC

557 complete; 2,319 remaining out of 2,876 primary catalogue genes.
This checkpoint adds four accepted merges to checkpoint 553, tracker #5326.
The coordinating AI agent accepted the exact-head reviews and merge audits;
this is not a human maintainer sign-off. Products, follow-ups, private drafts
and tracker publications add no credit.

Gene / PR Approved head Actual merge Actual parent Exact approved paths
ELP2 #5325 21343d5f60e3 1a193ad5a9a8 eb83fa701eb9 20/20
ELOVL4 #5323 9ed941653b45 f96d2abc07b1 1a193ad5a9a8 20/20
EML1 #5327 b28e213dbe95 02a780ad3cef f96d2abc07b1 19/19
EMILIN1 #5329 3e2b4f91315b 83dcbe1d939d 02a780ad3cef 29/29

All 88 approved path modes and Git objects match at the actual merges and
pinned main, including source caches, supporting material and histories.
The full gene directories also match. The reviews retain their imported
annotations and natural products; no new publication quotations were added.
ELOVL4's 32 inherited quotations remain preserved.

Gene Sources Products Cores Decisions Computed status
ELP2 20 7 1 7 ACCEPT, 7 KEEP_AS_NON_CORE, 6 MODIFY COMPLETE
ELOVL4 37 1 1 19 ACCEPT, 5 KEEP_AS_NON_CORE, 7 MODIFY, 2 REMOVE, 4 UNDECIDED DRAFT
EML1 39 2 1 11 ACCEPT, 23 KEEP_AS_NON_CORE, 4 MODIFY, 1 UNDECIDED DRAFT
EMILIN1 99 2 2 29 ACCEPT, 48 KEEP_AS_NON_CORE, 17 MODIFY, 1 REMOVE, 4 UNDECIDED DRAFT

Product counts include the displayed canonical protein when no alternative-product
list is present; ELOVL4 has one source-described 314-aa product.

ELOVL4 retains four unresolved annotations and two binding advisories; EML1
retains one unresolved annotation and eight binding advisories. EMILIN1 retains
four unresolved annotations and 24 advisories (22 binding, two propagation).
ELP2 has no gene-validation warnings. Accepted campaign completion does not
convert DRAFT files to COMPLETE or remove uncertainty.

Each accepted merge-group build executed 4,214 Python tests (one skipped,
84 deselected, nine warnings), 270 doctests (37 skipped, eight warnings),
12 examples, typing across 284 files, lint, 438 additional Python automation
tests and 19 JavaScript tests. The additional automation tests overlap the
broad suite and are not additive unique coverage. Validation executed 42 history
tests, scoped gene validation, all-gene schema checks, modules and families.
The all-gene check is schema-only; aggregate jobs report job conclusions.

Builds: ELP2, ELOVL4, EML1, EMILIN1.

The inventory at main 83dcbe1d939d3a29daecb0e16145bdd29c339d3a contains 8,868 reviews,
including 3,196 human reviews. Of the 2,876 catalogue genes, 1,277
have review files and 1,599 lack them; 720 available reviews remain
uncredited. All 235 queue objects, 110 earlier completion updates and earlier
progress bytes are preserved. This is update 111; only four checkboxes change,
and all 2,876 catalogue identities and association texts remain exact.

Publication scope is three project sources, their queue mirror, two rendered
pages and a scaffolded append-only history record. ENG, ENPP1, ENTPD1 and EOGT
remain uncredited by this checkpoint. This checkpoint does not claim an
independent documentation build or live-page inspection for the four merges.

Curation session

Completion checkpoint 559 — 2026-10-24 07:08:59 UTC

559 complete; 2,317 remaining out of 2,876 primary catalogue genes.
This checkpoint adds ENG and ENPP1 to merged checkpoint 557, tracker #5379.
The coordinating AI agent accepted the exact-head reviews and actual-merge audits;
this is not a human maintainer sign-off. Products, follow-ups, private drafts
and tracker publications add no credit.

Gene / PR Approved head Actual merge Actual parent Exact approved paths
ENG #5374 ca7bef2fb4fe eeb6b2ea3fe4 83dcbe1d939d 41/41
ENPP1 #5377 a3d10688e084 ec0663817767 eeb6b2ea3fe4 32/32

All 73 approved file objects and modes, including normal caches and histories,
match the actual merges and pinned main. Complete gene directories also match.
Imported annotation contexts and source-described natural products are preserved;
no new publication quotations were added. ENPP1 has one displayed canonical
product because the source does not enumerate alternative products; this is not
a claim that no other transcript exists.

Gene Sources Products Cores Decisions Computed status Advisories
ENG 104 2 2 29 ACCEPT, 59 KEEP_AS_NON_CORE, 2 MARK_AS_OVER_ANNOTATED, 4 MODIFY, 10 UNDECIDED DRAFT 13
ENPP1 97 1 2 39 ACCEPT, 20 KEEP_AS_NON_CORE, 6 MARK_AS_OVER_ANNOTATED, 11 MODIFY, 21 UNDECIDED DRAFT 6

ENG retains ten unresolved annotations and 13 advisories: eleven generic binding,
one source-action split and one CI ontology-label lag. ENPP1 retains 21 unresolved
annotations and six advisories: one generic binding, three propagation-metadata
and two source-action splits. Accepted campaign completion does not convert
DRAFT files to COMPLETE or remove uncertainty.

Each actual merge-group suite ran 4,214 Python tests (one skipped, 84 deselected,
nine warnings), 270 doctests (37 skipped, eight warnings), 12 examples, mypy on 284
files, Ruff, 438 overlapping Python automation tests and 19 JavaScript tests.
Validation included scoped gene checks, all-gene schema checks, 703 modules,
718 families and 42 history tests. History-record totals were 15,627 for ENG and
15,629 for ENPP1. Global advisories and skipped steps remain documented; the
ignored post-pytest SQLAlchemy destructor diagnostic did not fail either job.
The all-gene check is schema-only; aggregate jobs report job conclusions.

Builds: ENG, ENPP1.

At main 04f1f31db8f36ff1bed22c0e5ff8220567c219ce, the inventory contains 8,870 reviews,
including 3,198 human reviews. Of 2,876 catalogue genes, 1,279 have
review files and 1,597 lack them; 720 available reviews remain uncredited.
All 235 queue objects, 111 earlier completion updates and earlier progress bytes
are preserved. This is update 112; only the ENG and ENPP1 checkboxes change,
and all 2,876 catalogue identities and association texts remain exact.

Publication scope is three project sources, their queue mirror, two rendered
pages and a scaffolded append-only history record. EOGT, ENTPD1 and EP300 remain
uncredited by this checkpoint. No independent documentation build or live-page
inspection for these gene merges is claimed.

Curation session

Completion checkpoint 561 — 2026-10-24 07:51:14 UTC

561 complete; 2,315 remaining out of 2,876 primary catalogue genes.
This checkpoint adds EOGT and ENTPD1 to merged checkpoint 559, tracker #5382.
The coordinating AI agent accepted the exact-head reviews and actual-merge audits;
this is not a human maintainer sign-off. Products, follow-ups, private drafts
and tracker publications add no credit.

Gene / PR Approved head Actual merge Actual parent Exact approved paths
EOGT #5381 70677246ec7e bc777faa7a96 04f1f31db8f3 22/22
ENTPD1 #5380 536ec2d369d3 9ba348f4516c bc777faa7a96 33/33

All 55 approved file objects and modes, including normal caches and histories,
match the actual merges and pinned main. Complete gene directories also match.
Imported annotation contexts and source-described natural products are preserved;
no new publication quotations were added.

Gene Annotation rows Products Cores Decisions Computed status Advisories
EOGT 8 3 1 7 ACCEPT, 1 MODIFY COMPLETE 0
ENTPD1 70 6 1 53 ACCEPT, 3 KEEP_AS_NON_CORE, 8 MODIFY, 1 REMOVE, 5 UNDECIDED DRAFT 4

EOGT retains eight reviewed annotation rows, three source-described products and
one core function, with COMPLETE status and no validation warnings. ENTPD1 retains
70 reviewed annotation rows, six products, one core function and five unresolved
annotations. Its four actual CI advisories comprise one generic-binding warning,
one UDP-annotation action split and two stale-exception warnings. The latter reflect
the validator's exception matching; they were not erased by the approving review.
Accepted campaign completion does not convert ENTPD1 from DRAFT to COMPLETE.

Each actual merge-group suite ran 4,214 Python tests (one skipped, 84 deselected,
nine warnings), 270 doctests (37 skipped, eight warnings), 12 examples, mypy on 284
files, Ruff, 438 overlapping Python automation tests and 19 JavaScript tests.
Validation included scoped gene checks, all-gene schema checks, 703 modules,
718 families and 42 history tests. History-record totals were 15,632 for EOGT and
15,634 for ENTPD1. Global advisories and skipped steps remain documented; the
ignored post-pytest SQLAlchemy destructor diagnostic did not fail either job.
The all-gene check is schema-only; aggregate jobs report job conclusions.

Builds: EOGT, ENTPD1.

At main 273712aad3cb515aa95f60294a37dff884258011, the inventory contains 8,872 reviews,
including 3,200 human reviews. Of 2,876 catalogue genes, 1,281 have
review files and 1,595 lack them; 720 available reviews remain uncredited.
All 235 queue objects, 112 earlier completion updates and earlier progress bytes
are preserved. This is update 113; only the EOGT and ENTPD1 checkboxes change,
and all 2,876 catalogue identities and association texts remain exact.

Publication scope is three project sources, their queue mirror, two rendered
pages and a scaffolded append-only history record. EP300 and EPCAM remain
uncredited by this checkpoint. No independent documentation build or live-page
inspection for these gene merges is claimed.

Curation session

Completion checkpoint 563 — 2026-10-24 09:38:44 UTC

563 complete; 2,313 remaining out of 2,876 primary catalogue genes.
This checkpoint adds only EP300 and EPCAM to merged checkpoint 561, tracker #5383.
The coordinating AI agent accepted both exact-head reviews and independent actual-merge
audits; this is not a human maintainer sign-off. Products, follow-ups, private drafts
and tracker publications add no credit. EP300 was accepted as gene 562 and EPCAM
as gene 563; both are recorded together in this publication update.

Gene / PR Approved head Actual merge Actual parent Exact approved paths
EP300 #5384 7b5643c079a0 cb6bb5ec57f8 7293c5a1c39e 90/90
EPCAM #5385 fe9ed9ed05ca 5cc22e30227e cb6bb5ec57f8 24/24

All approved paths match in mode, object type and blob ID at their approved heads,
actual merges and pinned main. Each complete five-file gene directory also matches.
Imported annotation contexts, normal source caches and displayed protein products
are preserved. No new publication quotations were added.

EP300 retains 471 reviewed annotations: 218 ACCEPT, 115 MODIFY,
115 KEEP_AS_NON_CORE and 23 UNDECIDED. Its two core functions are distinct from
its one displayed canonical protein product, Q09472 (2,414 residues). EPCAM retains
40 reviewed annotations: 15 ACCEPT, 16 KEEP_AS_NON_CORE, four MODIFY and five
UNDECIDED. It has one core function and one displayed canonical product, P16422
(314 residues). Neither committed review or UniProt record lists alternative
products. EPCAM's released EpEX/EpICD fragments are not counted as splice products.
Accepted completion preserves both DRAFT statuses and unresolved questions.

EP300 merge-group Build and test run 40079507159
and EPCAM run 40081006893
each completed all three jobs successfully before their respective merges at
2026-10-24T09:09:21Z and 2026-10-24T09:31:30Z. Each suite executed 4,239 Python
tests (one skipped, 84 deselected, nine warnings), 275 doctests (37 skipped, eight
warnings), 12 examples, mypy on 285 files, Ruff, 438 overlapping Python automation
tests and 19 JavaScript tests. Aggregate dependency gates did not execute additional
suites. Counts overlap and are not summed as unique tests.

Changed-gene validation actually ran in each run. EP300 passed with 48 advisories:
42 generic-binding policy warnings and six source-specific action-consistency
warnings. EPCAM passed with four generic-binding policy advisories. The separate
all-gene batches were schema-only. Both runs also checked 703 modules and 718
families; EP300 checked 15,640 history records and EPCAM checked 15,643, each followed
by 42 history tests. Ignored post-pytest oaklib/SQLAlchemy destructor diagnostics
did not fail the jobs. Prediction-review, BioReason/GO-GPT, prediction-upload,
curation-history-coverage, sequence-save and full-run upstream PAINT checks were
skipped; the captured job steps distinguish these from executed checks. No
independent actual-main scientific validation or documentation build is claimed.

At fixed main 5cc22e30227e8948cc5f800b9e91213750e533ea, there are 8,874 reviews,
including 3,202 human reviews. Of 2,876 catalogue genes, 1,283 have review
files and 1,593 lack them; 720 available reviews remain uncredited.
All 235 queue objects, 113 earlier completion updates and earlier progress bytes
are preserved. This is update 114; only EP300 and EPCAM checkboxes change, and all
2,876 catalogue identities and association texts remain exact.

This checkpoint updates three project sources, their queue mirror and two rendered
pages. The append-only curation history is linked below.

Curation session

Completion checkpoint 566 — 2026-10-24 10:52:05 UTC

566 complete; 2,310 remaining out of 2,876 primary catalogue genes.
This checkpoint adds only EPHB4, EPG5 and EPM2A to merged checkpoint 563, tracker #5389.
The coordinating AI agent accepted all three exact-head reviews and independent
actual-merge audits; this is not a human maintainer sign-off. EPHB4 was accepted
as gene 564, EPG5 as gene 565 and EPM2A as gene 566. Products, follow-ups, private
drafts, queued work and tracker publications add no credit. ERCC2 is not included.

Gene / PR Approved head Actual merge Actual parent Exact approved paths
EPHB4 #5387 8545c5a11968 cbc176846687 5cc22e30227e 19/19
EPG5 #5386 f7a58aaa3629 775e51508889 cbc176846687 9/9
EPM2A #5388 cf1b24450a65 671b48213218 775e51508889 46/46

All approved paths match in mode, object type and blob ID at their approved heads,
actual merges and pinned main. Complete gene directories also match: five EPHB4,
six EPG5 and five EPM2A files. The accepted audits verify 53, eight and 46 published
normal-source dependencies, respectively. Imported annotation contexts, historical
records, normal caches and distinct source-described products are preserved.
No new publication quotations were added.

EPHB4 retains 76 imported annotation records: 46 ACCEPT, 22 MODIFY and eight
UNDECIDED. It has one core function and COMPLETE status with no CI advisories;
COMPLETE does not erase its eight unresolved records. Its four source-described
products remain distinct: P54760-1 (987 residues), P54760-2 (516), P54760-3 (306)
and P54760-4 (414). Their shared activity is not assumed.

EPG5 retains 16 total records, comprising 12 imported contexts, three historical
proposal contexts and one newly proposed record. Fifteen are active and one
historical UNDECIDED record remains retired. Total actions are three ACCEPT,
four MODIFY, four KEEP_AS_NON_CORE, two UNDECIDED and three NEW; active actions
exclude the one retired UNDECIDED. All 33 inherited publication quotation values
and their paths remain exact. The two distinct products, Q9HCE0-1 (2,579 residues)
and Q9HCE0-2 (2,481), and two core functions remain explicit. The review is DRAFT
with one generic-binding CI advisory.

EPM2A retains 81 imported O95278 annotation contexts: 31 ACCEPT,
17 KEEP_AS_NON_CORE, 19 MODIFY, 11 UNDECIDED, two MARK_AS_OVER_ANNOTATED and one
REMOVE. It has 48 references, two core functions and DRAFT status. Three CI
advisories concern action consistency for nucleus, endoplasmic-reticulum membrane
and protein dephosphorylation. Seven O95278 products retain lengths 331, 317,
152, 224, 88, 177 and 193 residues (products 1, 2, 4, 5, 6, 7 and 8). The eighth,
external B3EWF7-1, is independently sourced at 344 residues; its four GO assertions
remain separate from the 81 O95278 contexts. No activity equivalence is inferred.
The accepted audit also preserves all 50 private normal-publication cache
preimages; only the 33 cited publication caches are public dependencies. There
are no new annotations or publication quotations in this EPM2A review.

EPHB4 merge-group Build and test run 40082869200,
EPG5 run 40084288443
and EPM2A run 40084842231
each completed all three jobs successfully before their respective actual merges
at 2026-10-24T10:02:23Z, 2026-10-24T10:21:55Z and 2026-10-24T10:37:48Z.
Each suite executed 4,239 Python tests (one skipped, 84 deselected, nine warnings),
275 doctests (37 skipped, eight warnings), 12 examples, mypy on 285 files, Ruff,
438 overlapping Python automation tests and 19 JavaScript tests. Aggregate
dependency gates did not execute additional suites. Counts overlap and are not
summed as unique tests.

Changed-gene validation actually ran in all three runs. EPHB4 passed with no
advisories, EPG5 with one and EPM2A with three. The separate all-gene batches were
schema-only. Each run also checked 703 modules, 718 families and 42 history tests;
the history-record counts were 15,645, 15,648 and 15,650, respectively. Ignored
post-pytest oaklib/SQLAlchemy destructor diagnostics did not fail the jobs.
Prediction-review, BioReason/GO-GPT, prediction-upload, curation-history-coverage,
sequence-save and full-run upstream PAINT checks were skipped; captured job steps
distinguish these from executed checks. No independent actual-main scientific
validation or documentation build is claimed.

At fixed main fcbef68494c3bd156a9c3625ae37de0a9f5df27c, there are 8,876 reviews,
including 3,204 human reviews. Of 2,876 catalogue genes, 1,285 have review
files and 1,591 lack them; 719 available reviews remain uncredited.
All 235 queue objects, 114 earlier completion updates and earlier progress bytes
are preserved. This is update 115; only EPHB4, EPG5 and EPM2A checkboxes change,
and all 2,876 catalogue identities and association texts remain exact.

Curation session

Completion checkpoint 570 — 2026-10-24 14:30:02 UTC

570 complete; 2,306 remaining out of 2,876 primary catalogue genes.
This adds only ERCC2, ERCC3, ERCC4 and ERCC5 to the
merged 566 tracker, PR #5391.
Each has an exact-head approval and an independently accepted actual-merge audit.
Acceptance by the coordinating AI agent is not a human maintainer sign-off.
Products, follow-ups and tracker publications do not add gene credit. ERCC6 and
ERCC6L2 remain uncredited here.

Gene / PR Approved head Actual merge Merged at (UTC) Approved paths
ERCC2 #5390 965e844b78cb 41adae91d2e7 2026-10-24T11:04:03Z 24
ERCC3 #5392 6b2d97d944ad b60f053738c4 2026-10-24T12:17:42Z 23
ERCC4 #5393 451ee1dc76a7 d6debbce31dd 2026-10-24T13:38:28Z 10
ERCC5 #5396 a038096b703e e7236877cf14 2026-10-24T14:00:39Z 25

All 82 approved paths match in mode, type and blob at approved head, actual merge
and pinned main e7236877cf14aa3343182f032eb225f15ed4efe4. The complete ERCC2/3/4/5 gene
directories also match (six, six, seven and six files), with 102, 112, 48 and 35
normal-source dependencies verified in the accepted audits. ERCC4 has ten PR paths
but nine net merge changes because PMID:22323595 was already present on its parent.
Actual merge times come from GitHub merge metadata, not queue-commit timestamps.

ERCC2 retains 151 contexts, 109 references, two products (760 and 405 residues)
and two cores. Its actions are 97 ACCEPT, 22 MODIFY, 21 KEEP_AS_NON_CORE,
ten UNDECIDED and one MARK_AS_OVER_ANNOTATED. Measured ATP hydrolysis remains
separate from directional helicase activity; the scaffold role does not imply
an additional catalytic activity.

ERCC3 retains 162 contexts, 118 references, one displayed 782-residue product and
two cores. Actions are 93 ACCEPT, 14 MODIFY, 45 KEEP_AS_NON_CORE, eight UNDECIDED
and two MARK_AS_OVER_ANNOTATED. The principal DNA-translocation role and measured
ATP hydrolysis remain explicit; historical unwinding assays retain their bounded
non-core interpretation.

ERCC4 retains 97 records: 96 active imported contexts plus one retired historical
proposal. Its 100 genuine refreshed GOA rows reconcile to those 96 imported
contexts; the legacy UniProt and provider files remain unchanged. Actions are
45 ACCEPT, 32 KEEP_AS_NON_CORE, 12 MODIFY, six UNDECIDED, one REMOVE and one retired
TOO_GENERAL. The 55 references, two products (916 and 372 residues), two contextual
nuclease core units, negated source assertion and all 52 inherited quotation paths
remain preserved. The two core units describe contexts of the same enzyme.

ERCC5 retains 77 contexts, 41 references, three products (1,186, 419 and 232
residues) and one core. Actions are 35 ACCEPT, 20 MODIFY, 13 KEEP_AS_NON_CORE,
eight UNDECIDED and one TOO_GENERAL. No shared activity is assumed among the
natural products. None of these four publications adds a new annotation or a new
publication quotation.

All four reviews remain DRAFT. Their successful changed-gene validations retain
18, 34, 22 and five advisories: respectively 17, 33, 21 and four supported
generic-binding warnings, plus one research/provider-citation advisory per gene.
These warnings and unresolved annotations are not erased by completion credit.

Actual merge-group run Broad Python tests passed Doctests passed Gene advisories History records
ERCC2 run 40087008874 4,239 275 18 15,653
ERCC3 run 40092038098 4,239 275 34 15,656
ERCC4 run 40097532447 4,245 276 22 15,667
ERCC5 run 40099095412 4,245 276 5 15,669

All three jobs in each merge-group run completed successfully. Each run also
executed 12 examples, 438 overlapping automation tests, 19 JavaScript tests,
mypy on 285 source files and two Ruff commands. Broad pytest had one skipped,
84 deselected and nine warnings; doctests had 37 skipped and eight warnings.
Counts overlap and are not summed. Changed-gene validation ran; the separate
all-gene batch was schema-only. Each run checked 703 module schemas, 718 family
schemas and 42 history tests. The aggregate dependency gate added no suite.
An ignored destructor diagnostic did not fail the runs.

The PR broad suites were skipped by path filtering; their success labels alone
are not broad-test evidence. Prediction/BioReason checks, prediction evidence
upload, curation-history coverage, sequence-save and full-run upstream PAINT
steps were skipped in the captured merge workflows. No independent actual-main
scientific validation or documentation build is claimed by this update.

All 2,876 catalogue identities and association text, 235 queue objects, 115 earlier
completion updates and preceding progress bytes remain exact. This is update 116;
only the four named checkboxes change. Source inventories and dated availability
snapshots are preserved without a fresh availability recount. The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session

Completion checkpoint 574 — 2026-10-24 17:14:26 UTC

574 complete; 2,302 remaining out of 2,876 primary catalogue genes.
This adds only ERCC6, ERCC6L2, ERCC8 and ERF to the
merged 570 tracker, PR #5409.
Each has an exact-head approval and an independently accepted actual-merge audit.
Acceptance by the coordinating AI agent is not a human maintainer sign-off.
Products, fusion siblings, follow-ups and tracker publications do not add gene
credit. ERLIN1 and ERLIN2 remain uncredited here.

Gene / PR Approved head Actual merge Merged at (UTC) Approved path entries
ERCC6 #5401 698d023e16e8 8dd02fff434c 2026-10-24T15:16:17Z 51
ERCC6L2 #5405 97d48ec2383b b28805f7842b 2026-10-24T16:48:20Z 14
ERCC8 #5408 0d421ad2bf24 e5a60e057d21 2026-10-24T16:51:32Z 17
ERF #5411 243b49524eda a98198438715 2026-10-24T16:59:30Z 13

Approved-head and actual-merge payloads match for all 95 path entries across the
four PRs. Complete gene directories (11 ERCC6/cognate fusion files, five ERCC6L2,
five ERCC8 and six ERF) retain exact mode/type/blob parity at fixed main
a9819843871530062eb4b2878778b5bdd778e6b9. Normal-dependency comparisons cover 70, ten,
39 and nine external paths respectively. These counts overlap across genes.
ERCC6 has 51 PR paths but 50 net merge changes because PMID:16246722 was already
present on its parent; ERCC6L2 has 14 PR paths but 12 net changes because the two
PTHR45629 files already matched its parent. ERCC8 has 17 net changes, including
one accepted publication refresh; ERF has 13 additions.

One historical source blob is deliberately superseded on this fixed main:
ERCC6's abstract-only PMID:26620705 was replaced by the accepted ERCC8 genuine
full-text record. The original body remains an exact prefix, with only the
availability/extraction metadata changed and the original text appended.
The current blob exactly matches the ERCC8 approved head and actual merge;
every other selected gene/dependency blob retains its prior accepted content.
The later remote-main observation a5be4091f08c69c7238275dd2200e4aaf474e1a8 is recorded as an
observation, not as a second payload-parity cut.

ERCC6 retains 139 primary contexts (53 ACCEPT, 21 MODIFY, 61 KEEP_AS_NON_CORE,
four UNDECIDED), 62 references and four core activity units. The 1,493-residue
CSB and external 1,061-residue CSB-PGBD3 product remain distinct. The validated
ERCC6__P0DP91 sibling separately retains all 11 fusion contexts, including literal
extension groups/partner identifiers, four references and no core. Its three
ACCEPT, five KEEP_AS_NON_CORE and three UNDECIDED assessments do not imply that
the fusion inherits the CSB motor. Its three product records include external
cross-references to CSB and PGBD3, not three extra ERCC6 gene credits. Both reviews
remain DRAFT, with 44 and three advisories respectively.

ERCC6L2 retains 24 imported contexts plus one accepted NEW DNA-helicase activity
annotation specifically on the experimentally tested Q5T890-1 product. Its 25
assessments are nine ACCEPT, two MODIFY, eight KEEP_AS_NON_CORE, five UNDECIDED
and one NEW, with 13 references and one core. The source-described 1,561-, 1,550-
and 712-residue products remain distinct. The ATP-dependent unwinding component
is bounded to the tested short-overhang/substrate and SSB conditions; residual
melting and the unresolved link to repair contexts remain explicit. DRAFT retains
four binding advisories; the NEW assertion was justified by the measured activity,
not by warning removal.

ERCC8 retains 77 source contexts, 43 references, distinct 396- and 205-residue
products and one substrate-adaptor core. Actions are 45 ACCEPT, 12 MODIFY,
17 KEEP_AS_NON_CORE and three UNDECIDED. Ligase substrate recruitment is separated
from RBX1 catalytic machinery and the CSB motor, with species and experimental
assembly boundaries retained. It remains DRAFT with five generic-binding
advisories.

ERF retains 24 source contexts, 15 references, distinct 548- and 473-residue
products and one chromatin-localized transcriptional-repression core. Actions
are eight ACCEPT, 11 MODIFY and five KEEP_AS_NON_CORE. Promoter-specific DNA
recognition remains distinct from the HT-SELEX naked-DNA motif assay; bounded
TLE5/AES-2 binding does not imply an assayed recruitment mechanism. DRAFT retains
five advisories: three generic-binding, one deliberate source-specific action
split, and one unused manual-research-reference warning.

None of these publications adds a supporting-text quotation. Source contexts,
natural product boundaries and unresolved judgments remain part of the accepted
records; completion credit does not imply every annotation is resolved.

Actual merge-group run Broad Python tests passed Doctests passed Gene advisories History records
ERCC6 run 40104791174 4,245 276 44 + 3 fusion 15,675
ERCC6L2 run 40110584409 4,245 276 4 15,683
ERCC8 run 40110626350 4,245 276 5 15,688
ERF run 40112161497 4,245 276 5 15,691

All three jobs in each actual merge-group run completed successfully. Each run
executed 12 examples, 438 overlapping automation tests, 19 JavaScript tests,
mypy on 285 source files and two Ruff commands. Broad pytest had one skipped,
84 deselected and nine warnings; doctests had 37 skipped and eight warnings.
Counts overlap and are not summed. Changed-gene validation ran (two reviews for
ERCC6); the separate all-gene batch was schema-only. Each run checked 703 module
schemas, 718 family schemas and 42 history tests. The aggregate gate added no
suite. The PR broad suites were skipped by path filtering, so their successful
labels alone are not broad-test evidence. Prediction and upstream PAINT checks
were skipped in these captured merge workflows.

ERF's saved API response reports completed/SUCCESS jobs while five nested suite
steps still have pending/in-progress states and the gate has no step array.
A bounded direct-job recheck resolved the validation steps but retained these
metadata limits. Full terminal logs establish the successful commands and counts;
no terminal nested-step metadata was invented. No independent all-main biological
validation or documentation build is claimed by this update.

All 2,876 catalogue identities and association text, 235 queue objects, 116 earlier
completion updates and preceding progress bytes remain exact. This is update 117;
only the four named checkboxes change. Source inventories and dated availability
snapshots are preserved without a fresh availability recount. The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session

Completion checkpoint 579 — 2026-10-24 20:10:52 UTC

579 complete; 2,297 remaining out of 2,876 primary catalogue genes.
This adds only the five accepted actual merges below to
tracker 574, PR #5438.
Each exact-head approval and actual-merge audit was checked independently;
acceptance by the coordinating AI agent is not a human maintainer sign-off.
ESRRB, ETFB and ETFDH remain uncredited.

Gene / PR Approved head Actual merge Active + retired contexts References / cores DRAFT advisories
ERLIN1 #5429 38e73810a2a8 46463aea153a 53 + 5 33 / 2 25
ERLIN2 #5441 8aa9bf645000 7d2955f3f04f 59 + 5 49 / 3 16
ESCO2 #5443 884b57b4e82f 625ad38e3a3b 29 + 0 15 / 1 4
ESPN #5446 1519f7b56246 f93a466f6e7a 18 + 0 12 / 1 1
ETFA #5452 d2e21e55a62e 0974627b3c89 36 + 1 26 / 4 2

All 82 approved PR path entries, 36 complete gene-directory files and 178
external dependency entries match their approved head, actual merge and fixed
main 0974627b3c895ff1e5701f6c6013c4b98de29d5c in mode, type and blob. Dependency counts overlap across genes.
ERLIN2 has 18 PR paths but 17 net changes because PMID:19751772 already matched
its merge parent; the other PR path sets equal their net changes. The read-only
remote-main observation was 0974627b3c895ff1e5701f6c6013c4b98de29d5c; it is recorded
separately from the fixed parity cut. The five records preserve 132 inherited
quotation anchors in total and introduce no new quotation or NEW annotation.

ERLIN1 and ERLIN2 retain distinct protein and substrate scopes. Their structural
units contribute to the erlin complex's scaffold activity; neither is assigned
ubiquitin-transfer chemistry. ERLIN1 cholesterol binding is distinguished from
unresolved ERLIN2-specific native-cholesterol binding. Activated receptor turnover
and misfolded-protein quality control remain separate experimental contexts.
ERLIN1's 348-residue product and ERLIN2's 339-, 152- and 206-residue products are
not treated as functionally equivalent.

ESCO2 retains acetyl-CoA-dependent protein-lysine acetylation coupled to cohesion
and replication-fork regulation. Human ESCO2-fragment, combined ESCO1/2-depletion
and mouse-loss evidence remain distinct; no purified full-length human
ESCO2–SMC3 assay is implied. ESPN retains direct actin cross-linking and
microvillar assembly, with human espin 3A assays distinguished from rodent
localization and the two source products.

ETFA retains direct alpha-subunit FAD contacts alongside its contribution to the
assembled ETFA–ETFB carrier. MCAD/GCDH-to-DCIP assays do not establish isolated
alpha activity, ETFDH's separate ubiquinone reaction or complete metabolic flux.
The 333-residue precursor, its processed mature chain and the alternative
284-residue product remain distinct. Five ETFA judgments are UNDECIDED; retired
historical contexts in ETFA and the erlins remain visible. Completion is not a
claim that every annotation or product mechanism is resolved.

All three jobs in each actual merge-group run succeeded: ERLIN1, ERLIN2, ESCO2, ESPN, ETFA.
Each broad suite ran 4,245 Python tests (one skipped, 84 deselected), 276 doctests
(37 skipped), 12 examples, 438 overlapping automation tests and 19 JavaScript
tests, plus mypy and Ruff. Counts overlap and are not summed. Changed-gene
validation ran with the advisories above; the separate all-gene batch was
schema-only. The corresponding PR broad suites were path-filtered and skipped.
Prediction and upstream PAINT checks were skipped in the recorded merge jobs;
the aggregate gates added no tests. Recorded warnings and an ignored SQL
finalizer diagnostic are not hidden by the successful terminal conclusions.

All 2,876 catalogue identities and association text, 235 queue objects, 117
earlier completion updates and preceding progress bytes are preserved. This is
update 118; only the five named checkboxes change. Dated source inventories
remain historical and are not refreshed by this completion update.

The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session

Completion checkpoint 582 — 2026-10-24 22:42:53 UTC

582 complete; 2,294 remaining out of 2,876 primary catalogue genes.
This adds only the three accepted actual merges below to
tracker 579, PR #5467.
Independent audit acceptance is by the coordinating AI agent, not a human
maintainer sign-off. Other pending genes receive no credit.

Gene / PR Approved head Actual merge Contexts References / cores Status / advisories
ESRRB #5461 2dc84ba6ac5b 2cb3afa8a856 53 31 / 1 COMPLETE / 0
ETFDH #5468 246dc94621f1 9cb3fe3a3e21 37 19 / 5 DRAFT / 7
ETHE1 #5470 8cf5cbe3040e 5cffa2f757b5 27 16 / 1 DRAFT / 5

All 46 approved PR paths, 16 complete gene-directory files and 49 external
dependency entries match approved head, actual merge and fixed main
5cffa2f757b5ae147f0f128177b0ffd0dbe0d096 in mode, type and blob. Dependency counts can overlap.
The separate remote-main observation was 5cffa2f757b5ae147f0f128177b0ffd0dbe0d096.
All 42 inherited quotation anchors belong to ETFDH and remain exact; ESRRB and
ETHE1 have none. No new quotation or NEW annotation is introduced.

ESRRB retains human DNA-binding and transcription-activation evidence, with
long and short constructs corresponding to current 508- and 433-residue
accession sequences, without verifying historical plasmid sequences or the
untested 500-residue product. Mouse developmental contexts remain separate. Its computed COMPLETE
status leaves six UNDECIDED judgments visible.

ETFDH retains the ETF-to-ubiquinone reaction with FAD and a 4Fe–4S cluster,
separate from the soluble ETFA–ETFB carrier. Human enzyme assays and the native
porcine structure remain distinct; neither establishes full respiratory flux or
functional equivalence of the 617- and 570-residue products. Two stress-process
judgments remain UNDECIDED.

ETHE1 retains iron-dependent glutathione-persulfide oxidation to sulfite and
glutathione in the matrix. Historical cytoplasmic observations remain non-core;
independent matrix evidence and the unresolved two-zinc source-model query are
preserved. Engineered truncations, native processing and separate shorter
RefSeq products are not treated as functionally equivalent.

All three jobs succeeded in each actual merge-group run: ESRRB, ETFDH, ETHE1.
Each broad suite executed 4,268 Python tests (one skipped, 84 deselected),
277 doctests (37 skipped), 12 examples, 438 overlapping automation tests and
19 JavaScript tests, plus mypy over 285 source files and Ruff. Counts overlap
and are not summed. Changed-gene validation retained the advisories above;
the separate all-gene batch was schema-only. The PR broad suites, prediction
checks and upstream PAINT checks were skipped in their recorded scopes.
Global warnings and unresolved residue claims remain; aggregate gates add no tests.

This is update 119. All 2,876 identities and association text, 235 queue objects,
118 earlier updates and preceding progress bytes remain exact; only the three
named checkboxes change. Dated availability inventories are unchanged.

The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session

Completion checkpoint 585 — 2026-10-24 23:50:50 UTC

585 complete; 2,291 remaining out of 2,876 primary catalogue genes.
This adds only the three accepted actual merges below to
tracker 582, PR #5479.
Independent audit acceptance is by the coordinating AI agent, not a human
maintainer sign-off. Other pending genes receive no credit.

Gene / PR Approved head Actual merge Contexts References / cores Status / advisories
ETFB #5466 4ac38fb32d36 d0388f87fd10 28 22 / 2 DRAFT / 4
ETV6 #5472 75ee95de50ee e4ed1ee4b2ab 43 32 / 1 DRAFT / 7
EVC #5476 61dc504b83df 1ca4af83c61f 19 15 / 1 COMPLETE / 0

All 36 approved PR paths, 16 complete gene-directory files and 54 external
dependency entries match approved head, actual merge and fixed main
5e62db5cf9887be68578d786c36f0e647a90cf7b in mode, type and blob. Dependency counts can overlap.
The separate remote-main observation was 5e62db5cf9887be68578d786c36f0e647a90cf7b.
All 41 inherited quotation anchors belong to ETFB and remain exact; ETV6 and
EVC have none. No new quotation or NEW annotation is introduced.

ETFB contributes to the assembled mitochondrial ETFA–ETFB electron carrier,
with a distinct AMP-binding facet. Its fatty-acid and amino-acid oxidation roles
are kept separate from ETFDH-mediated quinone reduction. Human heterodimer
assays do not establish isolated beta-subunit turnover or equivalence of the
255- and 346-residue products; the S1P-stabilized assembly remains model-bounded.

ETV6 retains native ETS-site recognition and transcriptional repression with
functional corepressor associations, alongside contextual activation evidence.
Ten pathological fusion-protein projections are removed from native ETV6
annotations. M1/M43 experimental constructs and separately documented natural
transcripts remain distinct; no universal product equivalence or native kinase
activity is asserted.

EVC retains ciliary Smoothened-pathway participation and positive regulation,
with basal-body and ciliary-membrane localization bounds. Mouse mechanistic
experiments remain distinct from human imaging and gene-level inference. Its
individual molecular function remains unspecified, and one judgment is
UNDECIDED despite computed COMPLETE status and zero advisories.

All three jobs succeeded in each actual merge-group run: ETFB, ETV6, EVC.
Each broad suite executed 4,293 Python tests (one skipped, 84 deselected),
278 doctests (37 skipped), 12 examples, 438 overlapping automation tests and
19 JavaScript tests, plus mypy over 287 source files and Ruff. Counts overlap
and are not summed. Changed-gene validation retained the advisories above;
the separate all-gene batch was schema-only. The PR broad suites, prediction
checks and upstream PAINT checks were skipped in their recorded scopes.
Global warnings and unresolved residue claims remain; aggregate gates add no tests.

This is update 120. All 2,876 identities and association text, 235 queue objects,
119 earlier updates and preceding progress bytes remain exact; only the three
named checkboxes change. Dated availability inventories are unchanged.

The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session

Completion checkpoint 587 — 2026-10-25 02:14:40 UTC

587 complete; 2,289 remaining out of 2,876 primary catalogue genes.
This adds only EVC2 and EXOC6B to
tracker 585, PR #5489.
Independent audit acceptance is by the coordinating AI agent, not a human
maintainer sign-off. Other pending genes receive no credit.

Gene / PR Approved head Actual merge Contexts References / cores Status / advisories
EVC2 #5477 9909a981c35d 60c2825da3e3 14 10 / 1 DRAFT / 1
EXOC6B #5480 3acaf58e2071 0fcfcd6ce63d 11 17 / 1 DRAFT / 4

All 28 approved PR path entries, 10 complete gene-directory files and 24
external dependency entries match approved head, actual merge and fixed main
0fcfcd6ce63d58c6f9ee4830337d5cce9454eb43 in mode, type and blob. There are 26 net merge paths:
two EVC2 publication caches already existed identically on its merge parent.
Dependency counts can overlap. The separate remote-main observation was
0fcfcd6ce63d58c6f9ee4830337d5cce9454eb43. Both reviews contain zero quotations and zero
NEW assertions. Three EVC2 products and two EXOC6B products remain distinct.

EVC2 retains seven ACCEPT, four MODIFY and three KEEP_AS_NON_CORE decisions.
EXOC6B retains five ACCEPT, four KEEP_AS_NON_CORE and two UNDECIDED decisions.
Both remain DRAFT, with one core-coverage advisory and four generic-binding
advisories respectively. No biological uncertainty is silently resolved by
recording the merges.

All three jobs succeeded in each actual merge-group run: EVC2, EXOC6B.
Each broad suite executed 4,293 Python tests (one skipped, 84 deselected),
278 doctests (37 skipped), 12 examples, 438 overlapping automation tests and
19 JavaScript tests, plus mypy over 287 source files and Ruff. Counts overlap
and are not summed. Strict target validation retained the advisories above;
the separate all-gene batch was schema-only. History validation covered
16,471 and 16,474 records respectively, with 42 history tests in each run.
The earlier PR broad suites and conditional prediction/upstream PAINT checks
were skipped in their recorded scopes. Global warnings, unresolved residue
claims and the nonfatal SQL cleanup exception remain recorded; aggregate
gates add no tests.

The accepted gene histories use immutable merge-commit links:

This is update 121. All 2,876 identities and association text, 235 queue objects,
120 earlier updates and preceding progress bytes remain exact; only the two
named checkboxes change. Dated availability inventories are unchanged.

The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session: history/projects/CLINGEN_MENDELIAN/2026-10-25T021558Z-codex-69f821.yaml.

Completion checkpoint 591 — 2026-10-25 03:26:01 UTC

591 complete; 2,285 remaining out of 2,876 primary catalogue genes.
This adds only EXT2, EXT1, EYA1 and EYS to
tracker 587, PR #5494.
Independent actual-merge acceptance is by the coordinating AI agent, not a
human maintainer sign-off. Other pending genes receive no credit.

Gene / PR Approved head Actual merge Contexts References / cores Status / advisories
EXT2 #5490 f3299defabac 212f56f04101 60 33 / 1 DRAFT / 6
EXT1 #5488 0621827756fb ab72d4752747 61 30 / 2 DRAFT / 1
EYA1 #5491 62fe39ec04f1 980ac0e0a2f1 33 28 / 2 COMPLETE / 0
EYS #5493 3367c5a7fbbe 501b51748c62 21 15 / 1 COMPLETE / 0

All 56 approved PR path entries, 21 complete gene-directory files and 89
external dependency entries match approved heads, actual merges and fixed main
b2b10f56fdd7e6996d24885376d9ff6b10f19377 in mode, type and blob. The 51 net merge paths
exclude five EXT1 publication paths already present identically on its parent.
The dependency ledger distinguishes 25 entries introduced by their gene merge
from 64 reused entries; shared dependencies can appear more than once.
EYA1 retains all 60 inherited quotation anchors and its two inherited NEW
annotations. No quotations, source bytes or gene decisions change here.

EXT2. EXT2 supplies the principal GlcNAc-transfer step of the Golgi EXT1–EXT2 heparan-sulfate elongation complex. Its assembled contribution to GlcA transfer is distinct from low activity in older separately expressed preparations.

EXT1. EXT1 supplies the principal GlcA-transfer step and has measured secondary GlcNAc-transfer capacity. Its quantitative GlcNAc contribution in the native complex remains unresolved; the review retains preparation and protein-stability limits.

EYA1. EYA1 combines conserved SIX-associated transcriptional coactivation with protein-tyrosine dephosphorylation, including H2AX-dependent regulation of the DNA-damage response. It is not assigned DNA strand-restoration chemistry, and intrinsic Ser/Thr catalysis remains unresolved.

EYS. EYS provides conserved extracellular structural support associated with photoreceptor maintenance. The precise human interphotoreceptor topology and the functions of the four natural products remain unresolved; observed intracellular pools are not assumed to perform the same structural role.

EXT2 and EXT1 retain one and two UNDECIDED judgments, respectively; EYA1 and
EYS retain three and four despite their computed COMPLETE status. Source and
product limits remain part of the accepted reviews.

All three jobs passed in each actual merge-group run: EXT2, EXT1, EYA1, EYS.
Each broad suite ran 4,293 Python tests (one skipped, 84 deselected),
278 doctests (37 skipped), 12 examples, 438 overlapping automation tests,
19 JavaScript tests, mypy over 287 files and Ruff. Counts overlap and are not
summed. Target strict checks retained the advisories shown above; the separate
all-gene batch was schema-only. Conditional prediction and upstream PAINT
checks were skipped. Global warnings, unresolved checks and the nonfatal SQL
cleanup exception remain recorded in the accepted audits; aggregate gates
add no tests. The queue update preserves the per-run evidence and skip lists.

Update 122 preserves all 2,876 identities and association text, 235 queue
objects, 121 earlier updates and preceding progress bytes. Only the four named
checkboxes change. The separate remote-main observation at 2026-10-25T03:26:01.626618+00:00
was b2b10f56fdd7e6996d24885376d9ff6b10f19377; source inventories remain historical.

The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session: history record.

Completion checkpoint 595 — 2026-10-25 04:57:30 UTC

595 complete; 2,281 remaining out of 2,876 primary catalogue genes.
This adds only EYA4, EZH2, F10 and F11 to
tracker 591, PR #5498.
Actual-merge acceptance is by the coordinating AI agent, not a human
maintainer sign-off. Other pending genes receive no credit.

Gene / PR Approved head Actual merge Contexts References / cores Status / advisories
EYA4 #5492 bdadf273c590 a47ce8ba01b1 19 14 / 2 COMPLETE / 0
EZH2 #5496 cc0254df56f8 f477bb7bd7f4 186 108 / 2 DRAFT / 54
F10 #5497 4486ba7bcb42 df37cff6f3ba 58 42 / 1 DRAFT / 4
F11 #5500 d5255b7e6464 db8135f603bf 38 28 / 1 DRAFT / 1

All 140 approved PR paths are also the 140 net merge paths. The 20 complete
gene-directory files and 177 external dependency entries match approved heads,
actual merges and fixed main db8135f603bf131e28c36950b3162c2610e55b64 in mode,
type and blob. Of those dependency entries, 108 were introduced by the
corresponding gene merge and 69 reused from its parent; there are 177 unique
external paths in this four-gene closure. These counts describe overlapping
payload and dependency sets and are not added together. EYA4 retains its three
explicitly authorized NEW rows. No gene decisions, source bytes or quotations
change in this tracker update.

EYA4. EYA4 combines protein-tyrosine phosphatase activity with SIX-associated transcriptional coactivation. Human PLK1 regulation and peptide chemistry remain distinct from conserved DNA-repair inference; historical construct and five-product boundaries remain explicit.

EZH2. EZH2 supplies the H3K27 methyltransferase site in PRC2 and binds tested long noncoding RNAs. EED reader activity and accessory targeting are kept separate from EZH2 catalysis; RNA binding does not impose a universal recruitment or regulatory outcome.

F10. Activated factor Xa converts prothrombin to thrombin and acts on additional coagulation substrates. The same protease activity also cleaves PAR2 with barrier protection in a defined endothelial-cell model; that result is not generalized to all signaling contexts or mTOR regulation.

F11. Activated factor XIa performs sequential factor IX cleavage in the intrinsic coagulation pathway. Its A3 recognition region and platelet-surface association support this catalytic unit; untested shorter-product equivalence and contextual fibrinolysis evidence remain bounded.

Local status computation and validation recorded EYA4 as COMPLETE with zero
advisories, while one UNDECIDED judgment remains. EZH2, F10 and F11 remain DRAFT
with 54, four and one advisories, and 16, three and one UNDECIDED judgments,
respectively. The advisories concern supported generic-binding contexts;
completion does not erase these source and biological limits.

All three jobs passed in each actual merge-group run: EYA4, EZH2, F10, F11.
The accepted operative CI reads record 4,293 Python test passes (one skipped,
84 deselected), 278 doctest passes (37 skipped), 12 examples, 438 overlapping
automation tests, 19 JavaScript tests, mypy over 287 files and Ruff. Counts
overlap and are not summed. Target strict checks retained the advisories above;
the separate all-gene batch was schema-only. Module, history and family checks
ran, while conditional prediction checks, history-coverage checks and full-run
upstream PAINT verification were skipped. Global snippet skips, unresolved
identifiers and the nonfatal SQL cleanup exception remain in the accepted
receipts. Aggregate gates add no tests. The queue update retains per-run job
links and exact skipped-step lists. No new workflow or validator ran for this
private tracker proposal.

Update 123 preserves all 2,876 identities and association text, 235 queue
objects, 122 earlier updates and preceding progress bytes. Only the four named
checkboxes change. The separate remote-main observation at 2026-10-25T04:57:30.932556+00:00
was db8135f603bf131e28c36950b3162c2610e55b64; source inventories remain historical.

The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session: history record.

Completion checkpoint 597 — 2026-10-25 06:51:14 UTC

597 complete; 2,279 remaining out of 2,876 primary catalogue genes.
Only F12 and F13A1 are added to tracker 595, PR #5504.
Acceptance is by the coordinating AI agent, not a human maintainer sign-off.

Gene / PR Approved head Actual merge Contexts References / cores Status / advisories
F12 #5501 abe1ca5de2c0 cb90c6f3df01 63 38 / 1 DRAFT / 10
F13A1 #5502 3b34fd96c0f4 5e597e6e08e8 48 26 / 1 DRAFT / 22

The accepted F12 and F13A1 closures contain 45 and 31 files, respectively,
including their complete gene directories, histories and selected sources.
Every file matches the accepted head and actual merge evidence and fixed main
5e597e6e08e8006c81764e88155a19a826b63dee. These overlapping sets are not summed.
F12 has 31 approved PR paths and 30 net merge paths: the identical
R-HSA-9936430 cache was already present on its actual merge parent. F13A1 has
23 approved PR paths and 23 net merge paths. No gene decision or source byte
changes in this tracker update. The accepted F13A1 review retains its one NEW
calcium-binding annotation, and neither review adds publication quotations.

F12. Activated factor XII supplies serine endopeptidase activity in contact-system and coagulation reactions. Source-specific signaling, surface and product boundaries remain explicit; two contexts remain undecided.

F13A1. Activated factor XIII A catalyzes protein cross-linking that stabilizes fibrin. The added calcium-binding annotation is supported by a human A-subunit structure and corroborating evidence, while precursor versus active-complex and inaccessible-original limits remain explicit.

F12 remains DRAFT with 10 advisories (eight supported non-core binding and two
context-consistency advisories) and two UNDECIDED contexts. F13A1 remains DRAFT
with 22 supported non-core binding advisories and one UNDECIDED context.
Original-access and assay limits remain visible in the gene reviews.

The three Build and test jobs passed on each actual merge in
F12 run 40165165689
and F13A1 run 40168349716.
Accepted operative log reads cover the executed test, strict-target, schema,
history and family checks. Global skipped snippets, unresolved family/gene
claims and the nonfatal post-test SQL cleanup exception remain disclosed in
the accepted evidence. Aggregate gates add no tests. This tracker proposal
does not rerun gene validators or claim those global uncertainties are resolved.

Update 124 preserves all 2,876 catalogue identities and association text,
235 queue objects, 123 earlier updates and all preceding progress bytes.
Only the F12 and F13A1 checkboxes change. Dated source inventories remain historical.

The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session: history record.

Completion checkpoint 599 — 2026-10-25 07:46:49 UTC

599 complete; 2,277 remaining out of 2,876 primary catalogue genes.
Only F13B and F5 are added to tracker 597, PR #5507.
Acceptance is by the coordinating AI agent, not a human maintainer sign-off.

Gene / PR Approved head Actual merge Contexts References / cores Status / advisories
F13B #5503 82a9b4b2d9f8 f877133cb49b 12 11 / 1 COMPLETE / 0
F5 #5505 e19cdce4c81b 98a7416f5cc6 55 54 / 2 DRAFT / 2

The accepted F13B and F5 closures contain 18 and 57 files, respectively,
including their complete gene directories, histories and selected sources.
Every file matches the accepted head and actual merge evidence and fixed main
82d5cc827a695fa875ab377fe3262865cbe5f413. These overlapping sets are not summed.
F13B has 15 approved PR paths and 10 net merge paths: five identical shared
source files were already present on its actual merge parent. F5 has 27
approved PR paths and 27 net merge paths. The queue records the exact shared
paths and hashes. No gene decision or source byte changes in this tracker update.
F13B retains one NEW structural-molecule annotation and F5 retains two NEW
cofactor annotations. Neither review adds publication quotations.

F13B. The factor XIII B subunit organizes and stabilizes the circulating A2B2 zymogen. It is released during activation, before A-subunit cross-linking; the accepted structural-molecule annotation does not assign A-subunit catalysis or a clearance mechanism to B.

F5. Activated Va enhances Xa-mediated prothrombin activation. In a distinct state, FV-short and protein S support TFPIalpha inhibition of Xa, with TFPIalpha providing the direct inhibitory contact. Two accepted NEW annotations capture demonstrated cofactor work; five source-specific contexts remain undecided.

F13B is COMPLETE with no validation advisories. F5 remains DRAFT with two
supported non-core binding advisories and five UNDECIDED contexts.
Original-access and assay limits remain visible in the gene reviews.

The three Build and test jobs passed on each actual merge in
F13B run 40170451404
and F5 run 40172434424.
Accepted operative log reads cover the executed test, strict-target, schema,
history and family checks. Global skipped snippets, unresolved family/gene
claims and the nonfatal post-test SQL cleanup exception remain disclosed in
the accepted evidence. Aggregate gates add no tests. This tracker proposal
does not rerun gene validators or claim those global uncertainties are resolved.

Update 125 preserves all 2,876 catalogue identities and association text,
235 queue objects, 124 earlier updates and all preceding progress bytes.
Only the F13B and F5 checkboxes change. Dated source inventories remain historical.

The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session: history record.

Completion checkpoint 600 — 2026-10-25 09:12:43 UTC

600 complete; 2,276 remaining out of 2,876 primary catalogue genes.
Only F7 is added to tracker 599, PR #5510.
Acceptance is by the coordinating AI agent, not a human maintainer sign-off.

Gene / PR Approved head Actual merge Contexts References / cores Status / advisories
F7 #5506 6daec8360043 305207f43d2d 76 56 / 1 COMPLETE / 0

The accepted F7 closure contains 61 files: its five-file gene directory,
three curation histories and 53 external normal dependencies. Its 47 approved
PR paths and 47 net merge paths, including the relevant source additions,
match the accepted head, actual merge and fixed main 305207f43d2d8c1add6219c550d1dc651ca1fdc4.
Of those external dependencies, 39 were introduced by the F7 merge and 14
were reused byte-for-byte from its parent; the queue distinguishes both sets.
The queue records the exact paths and source hashes. This update changes no
gene decision, product, quotation or source byte. F7 has no publication quotation
anchors and receives no new annotations here.

F7. Activated FVIIa cleaves factors IX and X in the tissue-factor-dependent extrinsic coagulation pathway. Tissue factor binding and calcium-supported membrane assembly support this same catalytic unit. This performed cleavage is distinct from activation of FVII itself. The two literal precursor products, A (466 residues) and B (444 residues), remain separate; their processing and functional equivalence are not assumed.

F7 is COMPLETE with zero validation advisories while retaining 20 UNDECIDED
source contexts. Its original-access, preparation and organism limits remain
explicit in the gene review and source guide.

All three Build and test jobs succeeded on the actual merge in
run 40177853365.
Accepted operative reads cover strict F7 validation, all-gene schema checks,
704 module schemas, 16,546 histories and 42 history tests, and 718 family checks.
The suite actually ran 12 examples, 4,293 tests, 278 doctests, mypy on 287 files,
Ruff, 438 workflow tests and 19 JavaScript tests. The saved logs retain skipped
tests and snippets, unresolved family/gene records, module advisories and a
nonfatal SQL cleanup exception after successful tests. Aggregate gating adds
no tests. This proposal neither reruns those validators nor resolves their
unrelated scientific uncertainties.

F7 accepted curation history.

Update 126 preserves all 2,876 catalogue identities and association text,
235 queue objects, 125 earlier updates and all preceding progress bytes.
Only the F7 checkbox changes. Dated source inventories remain historical.
The campaign instructions now also identify authored source guides as evidence
and locator records, distinct from generated provider deep-research outputs.

The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session: history record.

Completion checkpoint 602 — 2026-10-25 10:35:39 UTC

602 complete; 2,274 remaining out of 2,876 primary catalogue genes.
Only F8 and F9 are added to tracker 600, PR #5512.
Acceptance is by the coordinating AI agent, not a human maintainer sign-off.

Gene / PR Approved head Actual merge Contexts References / cores Status / advisories
F8 #5508 54dd62a301f9 84279f79ce1c 53 51 / 1 DRAFT / 3
F9 #5509 1fa8926a132a a2300ffcb10c 64 46 / 1 DRAFT / 1

F8's accepted closure has 58 files: five gene files, four histories and 49
external normal dependencies (21 introduced by its merge, 28 reused from its
parent). F9's closure has 50 files: five gene files, three histories and 42
external normal dependencies (21 introduced, 21 reused). These are 108 closure
entries across the two genes, representing 101 unique paths, including 84
unique external dependencies. The complete closures match approved heads,
actual merges and fixed main a2300ffcb10cba1966804d3cb56813eabb60ba59. The preceding tracker600 closure of
682 paths and its 209 project histories also remain unchanged at this cut.

The F8 PR has 30 paths and 30 net merge changes. The F9 PR has 35 paths and
29 net merge changes: six approved PR paths were already identical, including
mode, on its actual merge parent. In the queue, already_present_on_parent
names those no-op PR paths; it does not count all reused closure dependencies.
Reuse of an uncited or cited dependency from a parent is not itself a PR no-op.
The two PRs have 65 path entries (63 unique paths), while their net changes
cover 59 unique paths. The queue records every path, hash and classification.

F8. Activated FVIIIa is a nonenzymatic cofactor that enhances FIXa cleavage of factor X in intrinsic tenase on extracellular phospholipid surfaces. FIXa supplies the catalysis. VWF carrier binding and the separate unactivated-FVIII/ADAMTS13 assays remain distinguished; copper coordination is a supporting structural facet. The natural 216-residue F8B product remains distinct from activated FVIIIa and engineered B-domain deletions.

F9. Activated FIXa performs the serine-endopeptidase step that converts factor X to Xa in intrinsic tenase; FVIIIa enhances that reaction as a cofactor. Calcium binding and membrane association support the same catalytic unit. The natural 461- and 423-residue precursor products remain separate from activation-generated light and heavy chains, without assuming equivalent secretion, processing or activity.

F8 retains two UNDECIDED contexts and three supported generic-binding
advisories; F9 retains one supported generic-binding advisory. Both remain
DRAFT. Their accepted source and product limits remain explicit. The F8 review
contains 52 imported contexts and one previously accepted NEW cofactor row;
F9 contains 64 imported contexts and no NEW rows. This tracker update adds no
annotation, gene edit or publication quotation. Both reviews have zero
publication quotation anchors.

For clarity about the unchanged preceding F7 checkpoint: A (466 residues)
and B (444 residues) are natural splice isoforms, both represented as precursor
products. They are not the proteolytic activation products of one another.
Their processing and functional equivalence are not assumed. This clarification
is appended here; the earlier F7 progress record remains byte-for-byte intact.

All three Build and test jobs succeeded on each actual merge:
F8 run 40180125540
and F9 run 40183249079.
Accepted operative reads cover strict changed-gene validation and all-gene
schema validation, which are distinct checks. Both suites actually ran 12
examples, 4,293 tests (one skipped and 84 deselected), 278 doctests (37 skipped),
mypy on 287 files, Ruff, 438 workflow tests and 19 JavaScript tests. Saved logs
retain existing module advisories, unresolved family/gene cases and the
nonfatal SQL cleanup exception after passing tests. Aggregate gating adds no
tests. This proposal reuses those accepted reads; it runs no validators and
claims no new original-source reading.

F8 final curation history and
F9 final curation history.

Update 127 preserves all 2,876 catalogue identities and association text,
235 queue objects, 126 earlier updates and all preceding progress bytes.
Only the F8 and F9 checkboxes change. Existing source-guide instructions and
dated source inventories remain exact.

The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session: history record.

Completion checkpoint 605 — 2026-10-25 12:14:40 UTC

605 complete; 2,271 remaining out of 2,876 primary catalogue genes.
Only FAM111A, FA2H and FAM111B are added to
tracker 602, PR #5515.
Acceptance is by the coordinating AI agent, not a human maintainer sign-off.

Gene / PR Approved head → actual merge PR / net paths Closure / external (introduced + reused) Contexts; refs / cores; status / advisories Merge-group Build
FAM111A #5513 f8cce69f8514 → 188ffae23080 10 / 10 16 / 9 (3 + 6) 25; 8 / 2; DRAFT 2 40185677456
FA2H #5511 b3f037d162d3 → 5570083290e2 28 / 28 34 / 19 (13 + 6) 60; 24 / 1; DRAFT 28 40186388342
FAM111B #5514 40503049cf7c → 30b2d8c689e0 10 / 9 19 / 12 (2 + 10) 19; 10 / 1; DRAFT 7 40188806293

The three closures contain 69 entries across 61 unique paths, including
40 external dependency entries across 32 unique paths. Complete gene directories,
all seven gene histories and selected dependencies match the approved heads, actual
merges and fixed main 30b2d8c689e0b0984bd9c707bb30a8ae0ade7349. The preceding tracker602 closure of 761 paths and
all 210 project histories also remain unchanged at this cut. The three PRs contain
48 path entries and 47 net changes. FAM111B's publications/PMID_32776417.md was
already identical, including mode, on its actual merge parent; that PR entry is a
no-op. The queue separately records all dependency reuse from each merge parent.

For precision about the unchanged preceding checkpoint, the shared F8/F9 PR paths
reactome/R-HSA-158278.md and reactome/R-HSA-9669959.md are both F9
already_present_on_parent entries. Both were byte- and mode-identical on F9's
actual merge parent, so neither is an F9 net change. This term counts no-op PR
entries, not every reused dependency in a gene's closure. This clarification is
appended here; all earlier progress and queue records remain exact.

FAM111A. FAM111A combines serine endopeptidase activity and single-stranded DNA binding in replication-associated nuclear work. Controlled autocleavage is directly measured; repair of TOP1–DNA complexes and fork progression do not establish TOP1 or PARP1 as purified cleavage substrates. Its context-dependent antiviral role remains distinct from direct cleavage of viral I3. No natural alternative-product field is asserted.

FA2H. FA2H hydroxylates free fatty acids at carbon 2 in the ER membrane, supplying hydroxylated acyl precursors for sphingolipids. Rodent lipid and myelin experiments support downstream pathway participation; human disease evidence is complementary and is not a direct human myelin-maintenance assay. Direct hydroxylation of ceramide-bound acyl chains and activity of the natural 159-residue product remain unresolved.

FAM111B. FAM111B is a predominantly nuclear serine endopeptidase with directly measured self-cleavage. Its physiological trans-substrates and the reactions connecting proteolysis to nuclear architecture and telomere phenotypes remain unresolved. Nuclear-peripheral localization does not establish lamin-complex membership. The natural 734- and 704-residue products are not assumed functionally equivalent.

FAM111A, FA2H and FAM111B retain two, 28 and seven supported-binding advisories,
respectively, and remain DRAFT. FA2H retains one UNDECIDED context; FAM111B retains
three. FAM111B's 19 contexts comprise 18 imported annotations and one previously
accepted NEW autoprocessing annotation. The other two genes contain only imported
contexts. All three have zero publication quotation anchors. This tracker update
adds no annotation, gene edit or publication quotation.

All three Build jobs succeeded on each actual merge. Accepted ROOT operative
reads distinguish strict changed-gene validation from all-gene schema validation.
All three broad suites executed 12 examples, 4,293 tests (one skipped and 84
deselected), 278 doctests (37 skipped), mypy on 287 files, Ruff, 438 workflow tests
and 19 JavaScript tests. Their history checks covered 16,556, 16,559 and 16,562
records, respectively, with 42 history tests each. Existing module advisories,
unresolved family/gene cases and the nonfatal SQL cleanup exception after passing
tests remain documented. Aggregate gating adds no tests. This proposal reuses
the accepted operative reads; it runs no validators and claims no new original
source reading.

Update 128 preserves all 2,876 catalogue identities and association text, 235
queue objects, 127 earlier updates and every preceding progress byte. Only the
FAM111A, FA2H and FAM111B checkboxes change. Existing curation instructions and
dated source inventories remain exact.

The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session: history record.

Completion checkpoint 608 — 2026-10-25 14:29:02 UTC

608 complete; 2,268 remaining out of 2,876 primary catalogue genes.
Only FAM149B1, FAM20C and FAN1 are added to tracker 605, PR #5517.
Acceptance is by the coordinating AI agent, not a human maintainer sign-off.

Gene / PR Approved head → actual merge PR / net paths Closure paths Contexts; refs / cores Merge-group Build
FAM149B1 #5516 bb4891f80b94 → e66137d23a68 14 / 14 14 6; 4 / 1 40196661463
FAM20C #5518 6e6e5f210468 → fe796a54bcf2 11 / 11 24 62; 22 / 1 40199680527
FAN1 #5519 a9d14408071f → 6987a3bd0ad7 10 / 10 21 51; 16 / 2 40199887007

The 59 closure entries comprise 16 gene-directory files, eight gene histories and 35 external source entries.
The approved revisions, actual merges and fixed main 6987a3bd0ad703b71e385a800f02f05875107597 match in paths,
blob contents and modes across each complete gene/history tree and selected source
dependency. All 35 PR paths contribute net changes; none is a parent-relative no-op.
The queue records introduced sources separately from unchanged dependencies reused
from each merge parent. The preceding checkpoint 605 content and all earlier progress
remain intact. No gene annotation or publication quotation is changed by this update.

FAM149B1 retains its source-bounded ciliary function assessment and one supported
generic-binding advisory. FAM20C is a secretory-pathway serine/threonine kinase;
its core keeps supported biomineral tissue breadth and distinguishes calcium binding
from kinase activation. FAN1 combines structure-selective endonuclease and exonuclease
activities in cross-link repair and repeat maintenance; its substrate and fork-response
claims remain bounded to the measured experiments. FAM149B1 retains one UNDECIDED
context, FAM20C two and FAN1 four. The reviews remain DRAFT with one, 19 and 13 advisories, respectively;
accepted completion does not erase those limitations.

All three Build jobs passed on each actual merge. The exact merge SHAs equal the
inspected merge-group SHAs, permitting reuse of those actual operative log reads.
Strict changed-gene validation and all-gene schema validation both ran. Each broad
suite executed 12 examples, 4,293 tests (one skipped, 84 deselected), 278 doctests
(37 skipped), mypy on 287 files, Ruff, 438 workflow tests and 19 JavaScript tests.
History validation covered 16,568, 16,570 and 16,572 records, with 42 history tests
each. Existing module advisories, unresolved family/gene cases and the nonfatal SQL
cleanup exception after passing tests remain explicit. Aggregate gating adds no tests.

Update 129 preserves all 2,876 catalogue identities and association text, 235 queue
objects, 128 earlier updates and every preceding progress byte. Only the three
completed genes' checkboxes change. Dated availability inventories are unchanged.

The append-only history was scaffolded and validated through the normal repository commands; both project pages were regenerated.

Curation session: history record.

Completion checkpoint 610 — 2026-10-25 17:19:58 UTC

610 complete; 2,266 remaining out of 2,876 primary catalogue genes.
Only FANCA, FANCB are added to tracker 608, PR #5522.
Acceptance is by the coordinating AI agent, not a human maintainer sign-off.

Gene / PR Approved head → actual merge PR / net paths Closure paths Contexts; refs / cores Merge-group Build
FANCA #5521 6d8229275c4b → 2de34762844b 8 / 8 53 52; 42 / 2 40207731845
FANCB #5523 0ef38f207cf5 → 571674a8fdce 6 / 6 36 23; 27 / 1 40209792239

The complete gene/history trees and selected source dependencies match the approved
heads, actual merges and fixed main 571674a8fdcef44aa071005ab30c36f786808ea0 in contents and modes.
The queue retains the complete path/blob evidence and distinguishes introduced
sources from dependencies reused unchanged from each merge parent. All three Build
jobs passed on each actual merge; the recorded operative reads retain the limits,
skips, advisories and unresolved cases of those runs. No post-merge deployment is
claimed. The biological reviews remain DRAFT, and their unresolved assessments
remain intact. This update changes no gene annotation or publication quotation.

All 235 queue objects, 129 earlier completion updates, catalogue identities, association
text and preceding progress bytes remain preserved. Only the listed genes'
checkboxes change; pending reviews remain unchecked. Dated source inventories are
unchanged. The project pages are regenerated and the session history is validated.

Curation session: history record.

Completion checkpoint 613 — 2026-10-25 18:05:07 UTC

613 complete; 2,263 remaining out of 2,876 primary catalogue genes.
Only FANCC, FANCD2 and FANCE are added to tracker 610, PR #5530.
Acceptance is by the coordinating AI agent, not a human maintainer sign-off.

Gene / PR Approved head → actual merge PR / net paths Closure: gene+history / dependencies Contexts; refs / cores DRAFT warnings / active UNDECIDED Merge-group Build
FANCC #5526 ddd5b943ebcb → c61100c42961 11 / 11 11 / 39 (50 total) 40; 40 / 1 4 / 5 40215803538
FANCD2 #5529 2a2d408bcc59 → 85f750e7c513 14 / 14 8 / 43 (51 total) 51; 50 / 1 6 / 1 40217084225
FANCE #5528 96be4d204154 → 6b6a7f038abc 7 / 7 9 / 29 (38 total) 27; 31 / 1 3 / 0 40217424810

The complete gene/history trees and selected source dependencies match the approved
heads, actual merges and fixed main 4589b35c1162dd5956356ff482dfdfaf7a044639 in contents and modes.
The queue retains the complete path/blob evidence and distinguishes introduced
sources from dependencies reused unchanged from each merge parent. The validation, suite and aggregate test jobs passed on each actual merge; the recorded operative reads retain the limits,
skips, advisories and unresolved cases of those runs. No post-merge deployment is
claimed. The biological reviews remain DRAFT, and their unresolved assessments
remain intact. This update changes no gene annotation or publication quotation.

All 235 queue objects, 130 earlier completion updates, catalogue identities, association
text and preceding progress bytes remain preserved. Only the listed genes'
checkboxes change; pending reviews remain unchecked. Dated source inventories are
unchanged. The project pages are regenerated and the session history is validated.

Curation session: history record.

Completion checkpoint 614 — 2026-10-26 01:50:51 UTC

614 complete; 2,262 remaining out of 2,876 primary catalogue genes.
Only FANCF is added to tracker 613, PR #5533.
Acceptance is by the coordinating AI agent, not a human maintainer sign-off.

Gene / PR Approved head → actual merge PR / net paths Closure: gene+history / dependencies Contexts; refs / cores DRAFT warnings / active UNDECIDED Merge-group Build
FANCF #5531 4d6d2dd1b2c5 → 23a88e84c365 8 / 8 11 / 24 (35 total) 27; 26 / 1 3 / 0 40220975572

The complete gene/history tree and selected source dependencies match the approved
head, actual merge and fixed main dd6e9ba2bd94ac4f513cb106bca7c984339f1985 in contents and modes.
The queue retains all 35 path/blob/hash records; all 24 external source dependencies
were reused unchanged from the merge parent. The validation, suite and aggregate
test jobs passed on the actual merge; the coordinating agent's accepted operative
reads retain the limits, skips, advisories and unresolved cases of that run.
No post-merge deployment is claimed. The biological review remains DRAFT with three
validation advisories. This update changes no gene annotation or publication quotation.

All 235 queue objects, 131 earlier completion updates, catalogue identities,
association text and preceding progress bytes remain preserved. Only FANCF's
checkbox changes; pending reviews, including FANCG and FANCI, remain unchecked.
Dated source inventories are unchanged. Both project pages are regenerated and the append-only session history is validated.

Curation session: history record.

Completion checkpoint 617 — 2026-10-26 03:52:08 UTC

617 complete; 2,259 remaining out of 2,876 catalogue genes.
This update adds FANCI, FANCG and FANCL to tracker 614.

Review Active / stored annotations Review limits Merge and validation
FANCI #5548 32 / 32 DRAFT; 1 UNDECIDED; 4 advisories Accepted merge · Checks
FANCG #5549 74 / 76 DRAFT; 1 UNDECIDED; 27 advisories Accepted merge · Checks
FANCL #5553 92 / 92 DRAFT; 3 UNDECIDED; 46 advisories Accepted merge · Checks

The approved gene files, complete histories and source dependencies match their
actual merges and the recorded main snapshot. Merge-group validation and tests
passed; the coordinating AI agent accepted the operative results. The reviews
retain their documented biological uncertainty and DRAFT status.

Earlier progress, catalogue associations, queue records and dated source inventories
remain preserved. Acceptance records the campaign review and is not a human
maintainer sign-off.

Curation session: history record.

Completion checkpoint 619 — 2026-10-26 08:38:26 UTC

619 complete; 2,257 remaining out of 2,876 catalogue genes.
This update adds FANCM and FARS2 to tracker 617.

Review Active / stored annotations Review limits Merge and validation
FANCM #5556 53 / 55 DRAFT; 1 active UNDECIDED; 9 advisories Accepted merge · Checks
FARS2 #5559 107 / 107 DRAFT; 0 active UNDECIDED; 81 advisories Accepted merge · Checks

Active counts exclude retired records retained for provenance. FANCM has one active
UNDECIDED among 53 active annotations; its 55 stored records include two UNDECIDED.
FANCG was already credited at checkpoint 617: its current review has 74 active
annotations and one active UNDECIDED, versus 76 stored records and two stored
UNDECIDED. This clarification adds no completion and changes no gene review.

The accepted gene files, complete histories and source dependencies match their
actual merges and the recorded main snapshot. The coordinating AI agent accepted the actual merge-group
validation, full suite and gate results. The reviews retain DRAFT status and their
documented biological uncertainty.

All prior progress, catalogue associations, dated queue objects and source inventories
remain preserved. Acceptance records the coordinating AI agent’s campaign audit;
it is not a human maintainer sign-off.

Curation session: history record.

Completion checkpoint 622 — 2026-10-26 11:57:37 UTC

622 complete; 2,254 remaining out of 2,876 catalogue genes.
This update adds FAT4, FAS and FASTKD2 to tracker 619.

Review Active / stored annotations Review limits Merge and validation
FAT4 #5573 21 / 21 DRAFT; 1 active UNDECIDED; 1 binding advisory Accepted merge · Checks
FAS #5567 111 / 117 DRAFT; 6 active UNDECIDED; 37 binding advisories Accepted merge · Checks
FASTKD2 #5570 31 / 31 DRAFT; 1 active UNDECIDED; 4 binding advisories Accepted merge · Checks

FAT4 retains 20 inherited source contexts and one proposed molecular-function
annotation. FAS retains all 117 stored contexts, including six retired historical
contexts; its active projection is 111. FASTKD2 retains all 31 source contexts.
The reviews retain three, seven and two natural product objects respectively.
DRAFT status and source-specific uncertainty remain explicit; completion records
accepted campaign reviews rather than certainty in every biological claim.

Their accepted source closures contain 30, 94 and 32 paths respectively
(156 distinct paths in the union), including all 9, 21 and 11 gene/history
paths. These objects match each actual merge and the captured main snapshot.
The coordinating AI agent accepted the complete actual merge-group validation,
suite and gate logs. This tracker proposal reuses those acceptances and does not
claim another complete log reading.

All 235 dated queue objects, 134 preceding completion updates, catalogue associations,
source inventories and earlier progress remain preserved. Only FAT4, FAS and FASTKD2
receive new completion credit. Acceptance is the coordinating AI agent's campaign
audit, not a human maintainer sign-off or a site-deployment claim.

Curation session: history record.

Completion checkpoint 624 — 2026-10-26 17:13:06 UTC

624 complete; 2,252 remaining out of 2,876 catalogue genes.
This update adds the original FBN1 review and FBN2 directly to
tracker 622.

Review Active / stored annotations Review limits Merge and validation
FBN1 #5577 154 / 154 DRAFT; 18 active UNDECIDED; 34 advisories Accepted merge · Checks
FBN2 #5583 60 / 60 DRAFT; 1 active UNDECIDED; 9 advisories Accepted merge · Checks

The original FBN1 review retains all 154 source contexts, 81 references, two
cleavage-product objects and five core functions. It has no splice-product
objects or quotations. It remains DRAFT with 18 UNDECIDED decisions; its other
actions are 59 ACCEPT, 46 KEEP_AS_NON_CORE, 14 MARK_AS_OVER_ANNOTATED, 11 MODIFY
and six TOO_GENERAL. Its 34 merge-validation advisories comprise 28 conditional
generic-binding and six source/product/claim consistency advisories.

FBN2 retains all 60 source contexts, 32 references, two splice products and two
curated cleavage products, three core functions and no quotations. It remains
DRAFT with 22 ACCEPT, 29 KEEP_AS_NON_CORE, seven MODIFY, one TOO_GENERAL and one
UNDECIDED decision. Its nine merge-validation advisories comprise eight permitted
generic-binding cases and one source-specific extracellular-matrix consistency
warning. Completion records accepted campaign reviews rather than certainty in
every biological claim.

The accepted FBN1 and FBN2 source closures contain 93 and 43 paths, including
all 16 and 15 gene/history paths respectively. Their union has 112 distinct
paths; each matches its actual merge and the captured main snapshot. The
coordinating AI agent accepted all three operative merge-group logs for each
review. This tracker proposal reuses those acceptances without claiming another
independent full log reading.

All 235 dated queue objects, 135 preceding completion updates, catalogue associations,
source inventories and earlier progress remain preserved. FBN1 and FBN2 are the
only newly credited distinct genes. FBN1 follow-up PR #5589 receives no additional
completion credit. Acceptance is the coordinating AI agent's campaign audit, not
a human maintainer sign-off or a site-deployment claim.

Curation session: history record.

Completion checkpoint 627 — 2026-10-26 19:04:30 UTC

627 complete; 2,249 remaining out of 2,876 catalogue genes.
This update adds FBXL4, FCHO1 and FDXR to the accepted public checkpoint 624.

Review Active / stored annotations Review limits Merge and validation
FBXL4 #5585 29 / 29 DRAFT; 1 active UNDECIDED; 1 advisory Accepted merge · Checks
FCHO1 #5587 38 / 38 DRAFT; 1 active UNDECIDED; 4 advisories Accepted merge · Checks
FDXR #5590 27 / 27 COMPLETE; 0 active UNDECIDED; 0 advisories Accepted merge · Checks

FBXL4 retains 29 source contexts, 29 references, one core function and all 60
inherited quotation associations (54 annotation and six core). No product objects
were added. Its DRAFT actions are eight ACCEPT, five TOO_GENERAL, four MODIFY,
ten MARK_AS_OVER_ANNOTATED, one KEEP_AS_NON_CORE and one UNDECIDED. One inherited
provider-citation advisory remains; the historical submitochondrial localization
conflict remains explicit.

FCHO1 contains 37 imported source contexts and one separately proposed NEW
annotation, 25 references, three natural splice products, one core and no
quotations. Its DRAFT actions are 24 ACCEPT, eight KEEP_AS_NON_CORE, three MODIFY,
one TOO_GENERAL, one UNDECIDED and one NEW. Four permitted generic-binding
advisories and the source-specific uncertainty remain explicit. Completion does
not mean all biological uncertainty is resolved.

FDXR retains 27 source contexts, 23 references, seven natural splice products,
one activity-centered core and no quotations. Its computed status is COMPLETE,
with 25 ACCEPT, one KEEP_AS_NON_CORE and one TOO_GENERAL decision, and zero target
validation advisories. The splice-product identities and context-specific
localization distinctions remain part of the accepted review.

The accepted source closures contain 55 FBXL4, 48 FCHO1 and 47 FDXR paths, including
all 22, 18 and 16 gene/history paths respectively. Their union contains
144 distinct paths, with no conflicting shared bytes or modes. Each
matches the actual merge and the captured main snapshot. ROOT accepted all three
operative merge-group logs for each review; this tracker proposal reuses those
acceptances without claiming another independent full-log reading.

FBN1 follow-up #5589
merged as fcc63846.
It receives no additional gene credit. Its six accepted file successors and
three appended history records are preserved in the actual public624 baseline;
earlier expected hashes and the reconciliation record remain unchanged.

For clarity, FBN2's two natural splice products P35556-1 and P35556-2 are in
alternative_products in FBN2-ai-review.yaml.
Product evidence records the
sequence/provenance detail. Those splice products are separate from the two
curated cleavage products. This is an appended clarification, not another completion.

All 235 dated queue objects, 136 preceding completion updates, 220 project
histories, catalogue identities/associations, source inventories and earlier
progress remain exact. Only FBXL4, FCHO1 and FDXR are newly credited. The unpublished tracker626 draft
is preserved separately; this update goes directly from public checkpoint 624 to 627.
Acceptance denotes the coordinating AI agent's campaign audit, not a human
maintainer sign-off or a site-deployment claim.

Curation session: history record.

Completion checkpoint 630 — 2026-10-26 22:45:32 UTC

630 complete; 2,246 remaining out of 2,876 catalogue genes.
This update adds FERMT1, FERMT3 and FGA to public checkpoint 627.

Review Active / stored annotations Review limits Merge and validation
FERMT1 #5594 31 / 31 COMPLETE; 2 UNDECIDED; 0 advisories Accepted merge · Checks
FERMT3 #5596 31 / 31 COMPLETE; 3 UNDECIDED; 0 advisories Accepted merge · Checks
FGA #5598 131 / 131 DRAFT; 10 UNDECIDED; 7 advisories Accepted merge · Checks

FERMT1 retains 31 source contexts, 13 references, four natural splice products,
one integrin-binding core and no quotations. Its computed status is COMPLETE,
with nine ACCEPT, 16 KEEP_AS_NON_CORE, three MODIFY, one TOO_GENERAL and two
UNDECIDED decisions. The nuclear-import and actin-binding questions remain
source-specific uncertainties; zero target validation advisories do not resolve them.

FERMT3 retains 31 source contexts, 20 references, two natural splice products,
one core and no quotations. Its computed status is COMPLETE, with ten ACCEPT,
16 KEEP_AS_NON_CORE, two MODIFY and three UNDECIDED decisions. Two functional
splice-product records map to those same two natural products, rather than adding
two more products. Platelet-granule and exosome source uncertainties remain explicit.
No target validation advisories remain.

FGA retains 131 source contexts, 90 references, two natural splice products and
two distinct cleavage-product records, with 2 cores and no quotations.
Its computed status is DRAFT, with 76 ACCEPT, 36 KEEP_AS_NON_CORE, three MODIFY,
six TOO_GENERAL and ten UNDECIDED decisions. Seven previously adjudicated target
advisories remain. The source map preserves processed-product contexts omitted
from the seed; free fibrinopeptide A is not assigned the mature fibrin chain's
functions. Completion records an accepted evidence review, not resolution of every
source-specific uncertainty.

The accepted source closures contain 37 FERMT1, 44 FERMT3 and 105 FGA paths,
including 16, 15 and 18 complete gene/history paths respectively. Their union
contains 175 distinct paths, all matching the actual merges and this
captured main snapshot. FERMT3's 29 published payload paths yield 27 actual merge
deltas because two shared sources were already byte-identical in the parent;
those two files remain in its full closure. ROOT accepted all three operative
merge-group jobs for each review. This proposal reuses those acceptances and
makes no independent full-log or global zero-warning claim.

All 235 dated queue objects, 137 preceding completion updates, 221 project
histories, catalogue identities, source inventories and earlier progress remain
unchanged. Only these three distinct genes are newly credited, taking the public
checkpoint directly from 627 to 630. No further review or private proposal receives
credit. Acceptance denotes the coordinating AI agent's campaign audit, not a human
maintainer sign-off or a site-deployment claim.

Curation session: history record.

Completion checkpoint 631 — 2026-10-27 01:52:57 UTC

631 complete; 2,245 remaining out of 2,876 catalogue genes.
The preceding checkpoint records FERMT1, FERMT3 and FGA; this adds only
FGD1 #5600, merged at
2026-10-27 01:40:27 UTC as
51dbf45991.
Together these four accepted merges reconcile the public count from 627 to 631.

FGD1 preserves 34 imported annotation contexts and 15 references, with one core
function. Its computed status is COMPLETE: 11 ACCEPT, 14 KEEP_AS_NON_CORE, six
TOO_GENERAL, two MODIFY and one UNDECIDED. Completion does not resolve that
source-specific uncertainty. All 27 source-closure objects matched the accepted
commit, including the complete 17-file gene/history namespace and 23-file merge
delta.

Merge-group validation and tests
passed. The suite actually executed: 4,400 pytest tests, 282 doctests, 444 agent
tests and 19 JavaScript tests passed. Changed-gene validation, all-gene schema
checks and 17,990 history records passed. This records the accepted actual merge
and its checks, not a new independent full-log audit or a site-deployment claim.

All earlier progress, 138 preceding completion updates, 235 dated queue objects,
catalogue identities and availability inventories are preserved. Pending PRs and
private work receive no completion credit.

Curation session: history record.

Completion checkpoint 637 — 2026-10-27 03:13:47 UTC

637 complete; 2,239 remaining out of 2,876 catalogue genes.

This checkpoint adds six distinct genes to the accepted public checkpoint 631. Each has an accepted actual merge and successful merge-group validation and tests.

Gene / accepted PR Actual merge Merge-group run Stored / active rows References Splice / functional products Core / inherited quotations Status / UNDECIDED
DNM1 #5165 003959e40f 40435442289 79 / 79 53 4 / 0 1 / 6 DRAFT / 2
EIF2B1 #5263 55e14dbbbd 40435444970 53 / 53 36 2 / 0 1 / 0 DRAFT / 3
FGB #5602 c007674672 40437006493 113 / 113 82 0 / 2 1 / 0 DRAFT / 14
EIF2B5 #5302 53b5f5de89 40438681445 58 / 58 46 0 / 0 1 / 0 DRAFT / 3
FGD4 #5604 58dd1e3474 40439675014 25 / 25 18 3 / 0 1 / 0 DRAFT / 3
EIF2AK4 #5259 35e316d166 40440792703 52 / 52 24 3 / 0 2 / 0 COMPLETE / 2

Five reviews remain DRAFT; EIF2AK4 is COMPLETE. Completion records accepted merged reviews, not resolution of every annotation. DNM1 retains two source-specific uncertainties; EIF2B1 retains three and its source-defect assessments. FGB retains 14 unresolved contexts, including beta-chain attribution and inaccessible target identifications; its two functional records describe cleavage products, not splice isoforms. EIF2B5 retains three uncertainties and a PROBABLE/CHECK ovarian-source query, without asserting a corrected citation. FGD4 retains three source-specific uncertainties. EIF2AK4 retains two unresolved contexts, cold response and transfer of fungal checkpoint participation to human, despite its computed COMPLETE status. The six inherited DNM1 quotations remain unchanged; no new publication quotations are added.

Actual merge-group suites executed for all six merges: each passed 4,400 pytest tests, 282 doctests, 444 agent tests and 19 JavaScript tests. ROOT accepted the full operative logs, including the nonfatal ignored SQLAlchemy destructor diagnostic; this tracker reuses that acceptance and makes no global zero-warning or independent full-log-audit claim.

The accepted PR payloads contain 41, 16, 23, 35, 17 and 30 paths respectively. Their complete gene/history namespaces contain 17, 13, 17, 17, 14 and 18 paths. DNM1 has three and EIF2B5 five parent-byte-identical source no-ops, yielding actual deltas of 38 and 30 paths; the other deltas equal their payload counts. The new machine-readable completion entry records exact Git blobs, modes and SHA-256 values for these accepted payloads. This is not a new audit of all normal source dependencies.

All 235 dated queue objects, 139 preceding completion updates, catalogue identities, prior histories, dated source inventories and the exact earlier progress prefix are preserved. Only these six accepted merges receive credit; pending work remains unchecked. Acceptance is the coordinating AI agent’s campaign audit, not human maintainer sign-off or a site-deployment claim.

Curation session: history record.

Completion checkpoint 638 — 2026-10-27 04:24:18 UTC

638 complete; 2,238 remaining out of 2,876 catalogue genes.

This checkpoint adds FGF12 after verification of its actual merge from PR #5606.

The merged review remains DRAFT, with 49 stored/active annotation contexts, 19 references, two natural splice products, no functional-product records, one core function and no quotations.

FGF12 retains 7 ACCEPT, 25 KEEP_AS_NON_CORE, 1 MODIFY, 3 MARK_AS_OVER_ANNOTATED and 13 UNDECIDED decisions. Its two natural splice products, 15 isoform-bearing contexts and two historical NOT contexts remain distinct; no NEW annotation or publication quotation is added. The core describes sodium-channel regulation. Unresolved contexts preserve inaccessible-source limits, construct- and assay-dependent receptor/release findings, and uncertainty about productive ribosome-biogenesis participation. PAINT loss judgments are retained without counting their unidentified underlying publications as independent experiments. Completion does not resolve every annotation or change its DRAFT status.

The actual merge-group run passed validation, suite and aggregate checks. The suite executed 4,400 pytest tests, 282 doctests, 444 agent tests and 19 JavaScript tests successfully. Changed-gene validation, all-gene schema checks and 18,009 history records passed. The accepted log review retained the nonfatal ignored SQLAlchemy destructor diagnostic; this records that verification without a global zero-warning or site-deployment claim.

All 28 accepted payload files match the actual merge, including the complete 19-file FGF12 gene/history namespace and its two history records. The parent comparison also contains 28 changed paths; no accepted payload files were already identical in the parent commit. Exact Git blobs, modes and SHA-256 values are recorded in the completion entry. This is not a new audit of all normal source dependencies.

All 235 dated queue objects, 140 preceding completion updates, catalogue identities, prior histories, dated source inventories and the exact earlier progress prefix are preserved. Only FGF12 receives additional credit. Acceptance is the coordinating AI agent's campaign audit, not human maintainer sign-off.

Curation session: history record.

Completion checkpoint 640 — 2026-10-27 09:14:21 UTC

640 complete; 2,236 remaining out of 2,876 catalogue genes.

This checkpoint adds FGF3 from PR #5610 and FGF9 from PR #5611 after verification of their actual merges.

The FGF3 merge retains 99 stored/active annotation contexts, 86 references, no natural or functional product records, one core function and no quotations. Its computed status remains DRAFT, with six UNDECIDED contexts. Its actual merge-group run supplies the CI evidence below.

The FGF9 merge retains 179 stored/active contexts, 180 references, no natural or functional product records, one core function and no quotations. Its computed status is COMPLETE, with two explicitly UNDECIDED contexts. Its actual merge-group run supplies the separate CI evidence below.

FGF3 retains 85 ACCEPT, 8 KEEP_AS_NON_CORE and 6 UNDECIDED decisions. FGF9 retains 166 ACCEPT, 10 KEEP_AS_NON_CORE, 1 MARK_AS_OVER_ANNOTATED and 2 UNDECIDED decisions. Each has one FGF receptor ligand core; neither review adds a NEW annotation or publication quotation. Missing original evidence remains explicit: FGF3 retains five PMID2470007 contexts and an RPS2 interaction context as unresolved, while FGF9 retains the two PMID8575785 contexts as unresolved. Cytoplasm annotations remain bounded positive ancestral inferences; neither review claims an independently demonstrated endogenous human soluble-cytoplasmic mechanism. Completion does not resolve every annotation or require every review to have the same status.

Both actual merge-group runs passed validation, suite and aggregate checks. Each executed 4,400 pytest tests, 282 doctests, 444 agent tests and 19 JavaScript tests successfully; 86 pytest cases were deselected and 37 doctests skipped. The runs retained 9 pytest warnings and 8 doctest warnings each. FGF3 validation passed with three documented source-specific advisories and 18,020 history records; FGF9 validation passed and checked 18,022 history records. Both logs retained a nonfatal ignored SQLAlchemy cleanup exception after successful pytest; subsequent checks and aggregate jobs succeeded. Existing repository advisories and explicitly skipped checks remain recorded in the accepted evidence; this is not a claim of warning-free validation or site deployment.

The accepted heads contain 15 FGF3 and 24 FGF9 payload files, with complete gene/history namespaces of 8 and 9 files, respectively. Their retained source closures contain 93 and 186 files. FGF3 added all 15 payload files. FGF9 added 23 files; its accepted publications/PMID_20094046.md was already byte-identical in the actual parent from the FGF3 merge. Exact payload objects, modes and actual parent comparisons are recorded in the completion entry; shared source files already identical in the parent commit are counted separately from changed paths.

All 235 dated queue objects, 141 preceding completion updates, catalogue identities, prior histories, dated source inventories and the exact earlier progress prefix are preserved. Only FGF3 and FGF9 receive additional credit. Acceptance is the coordinating AI agent's campaign audit, not human maintainer sign-off or a site-deployment claim.

Curation session: history record.

Completion checkpoint 642 — 2026-10-27 12:07:41 UTC

642 complete; 2,234 remaining out of 2,876 catalogue genes.

This checkpoint adds FGG from PR #5614 and FGFR2 from PR #5613 after verification of their actual merges.

The FGG merge retains 121 active annotation contexts: 68 ACCEPT, 33 KEEP_AS_NON_CORE, 16 UNDECIDED, 2 MODIFY and 2 TOO_GENERAL. It has 83 references, two natural products, one structural-molecule core function and no publication quotations. Five genuine source extensions retain their specimen-specific uncertainty. Its two adhesion-related binding refinements do not assign the partner's activity to FGG. Its computed status remains DRAFT.

The FGFR2 merge retains all 229 source contexts: 147 ACCEPT, 68 KEEP_AS_NON_CORE, 7 MODIFY and 7 UNDECIDED. It has 95 references, 17 natural products, one receptor core function and all 65 inherited quotation associations. Seven ligand-binding refinements retain tested ligand and fragment limits; current cell/tissue alternatives are documented without flattening them into a conjunction or presenting current records as identical to the historical seed. Its computed status remains DRAFT. Neither review adds a NEW annotation or a new publication quotation.

Both actual merge-group runs passed their executed validation, suite and aggregate jobs: FGG run 40494967182 and FGFR2 run 40497991566. Each executed 12 example checks, 4,400 pytest tests, 282 doctests, 444 agent tests and 19 JavaScript tests successfully. Each retained 86 deselected pytest cases, 37 skipped doctests, nine pytest warnings and eight doctest warnings. An ignored oaklib/SQLAlchemy destructor exception appeared after successful pytest; subsequent checks succeeded. FGG retained four target advisories and validated 18,025 histories; FGFR2 retained three target binding advisories and validated 18,028 histories. Prediction/BioReason and upstream PAINT checks were skipped by scope. This is not a claim of warning-free validation or site deployment.

The accepted payloads contain 64 FGG and seven FGFR2 files. All are changes relative to their actual parents, with no parent-identical payload files. Complete gene/history namespaces contain eight and eleven files; qualified source closures contain 143 and 103 files, respectively. The completion entry records exact payload objects, modes, sizes and hashes; ROOT independently compared both complete closures against the accepted heads and actual merges. FGFR2's three histories preserve both earlier branch sessions, and all qualified normal source bytes remain intact.

All 235 dated queue objects, 142 preceding completion updates, catalogue identities and association text, prior histories, dated source inventories and the exact earlier progress prefix are preserved. Only FGG and FGFR2 receive additional credit. Completion records accepted merged work while retaining evidence uncertainty; it does not require changing either computed DRAFT status. Acceptance is the coordinating AI agent's campaign audit, not human maintainer sign-off.

Curation session: history record.

Completion checkpoint 644 — 2026-10-28 13:53:07 UTC

644 complete; 2,232 remaining out of 2,876 catalogue genes.

This checkpoint adds FH from PR #5658 and FHOD3 from PR #5661 after ROOT independently accepted both actual merges.

The FH merge stores 61 annotation rows: 60 active contexts and one retired authored duplicate. Its active decisions are 34 ACCEPT, 15 KEEP_AS_NON_CORE, 5 MODIFY, 2 TOO_GENERAL, 2 MARK_AS_OVER_ANNOTATED, 1 UNDECIDED and 1 NEW. The retired NEW row remains visible for provenance and is excluded from this active histogram. The review retains 35 references, two natural products, three core functions and all 78 inherited quotation associations. No new publication quotation was added. Its computed status remains DRAFT.

The FHOD3 merge retains all ten source contexts: 5 ACCEPT, 3 KEEP_AS_NON_CORE, 1 MODIFY and 1 UNDECIDED. It has ten references, four natural products, one core function, no NEW annotations and no publication quotations. Its computed status remains DRAFT. Neither review asserts a functional-isoform block or an isoform-specific or negated annotation context.

Both actual merge-group runs passed their executed validation, suite and aggregate jobs: FH run 40637089658 and FHOD3 run 40641064222. Each executed 12 example checks, 4,408 pytest tests, 282 doctests, 444 agent tests and 19 JavaScript tests successfully, with mypy covering 292 source files and Ruff passing. Each retained 86 deselected pytest cases, 37 skipped doctests, nine pytest warnings and eight doctest warnings. An ignored oaklib/SQLAlchemy destructor exception appeared after successful pytest; subsequent checks succeeded. FH retained 13 target advisories and validated 18,182 histories; FHOD3 retained two target advisories and validated 18,184 histories. Each passed 42 history tests and validation of 717 modules and 734 families. Prediction/BioReason and upstream PAINT checks were skipped by scope. These results do not imply warning-free validation or site deployment.

The accepted payloads contain eight FH and thirteen FHOD3 files, all different from their actual parents, with no parent-identical payload files. Complete gene/history namespaces contain thirteen and seven files; qualified source closures contain 43 and 22 files, including 30 and 15 normal source files, respectively. The completion entry records all 21 payload objects with exact modes, sizes and hashes. ROOT independently compared both complete closures against the approved heads and actual merges; the tracker writer also verified their objects against the current tracker base. Earlier gene histories and normal source bytes remain preserved.

All 235 dated queue objects, 143 preceding completion updates, catalogue identities and association text, prior histories, dated source inventories and the exact earlier progress prefix are preserved. Only FH and FHOD3 receive additional tracker credit. The existing open project-page audit PR #4518 owns generated pages, slide assets and an older project history; this checkpoint does not modify those paths. Completion records accepted merged work while retaining evidence uncertainty and both computed DRAFT statuses. Acceptance is the coordinating AI agent's campaign audit, not human maintainer sign-off.

Curation session: history record.

Completion checkpoint 646 — 2026-10-28 17:05:03 UTC

646 complete; 2,230 remaining out of 2,876 catalogue genes.

This checkpoint adds FIG4 from PR #5689 and FITM2 from PR #5692 after ROOT independently accepted both actual merges.

The FIG4 merge retains all 45 source contexts: 20 ACCEPT, 16 KEEP_AS_NON_CORE, 4 MODIFY, 3 MARK_AS_OVER_ANNOTATED and 2 TOO_GENERAL. It has 38 references and two core functions. The FITM2 merge retains all 35 source contexts: 26 ACCEPT, 6 KEEP_AS_NON_CORE, 2 MARK_AS_OVER_ANNOTATED and 1 UNDECIDED. It has 24 references and two core functions. Both computed statuses remain DRAFT. Neither review contains NEW annotations, publication quotations, recorded natural alternative products, functional-isoform blocks, isoform-specific contexts or negated contexts. FITM2's unresolved context remains visible.

Both actual merge-group runs passed their executed validation, suite and aggregate jobs: FIG4 run 40722595580 and FITM2 run 40726403726. Each executed 12 example checks, 4,431 pytest tests, 283 doctests, 444 agent tests and 19 JavaScript tests successfully, with mypy covering 295 source files and Ruff passing. Each retained 86 deselected pytest cases, 37 skipped doctests, nine pytest warnings and eight doctest warnings. An ignored oaklib/SQLAlchemy destructor exception appeared after successful pytest; subsequent checks succeeded.

FIG4 retained five target generic-binding advisories and validated 18,222 histories; FITM2 retained four target generic-binding advisories and validated 18,224 histories. Each passed 42 history tests and validation of 717 modules and 734 families. Module validation reported 2,187 advisories for FIG4 and 2,217 for FITM2. The 30 additional FITM2-run warnings occurred in ten unchanged modules and included unavailable CHEBI ontology-label checks; the successful run does not establish that every ontology label resolved. Each family run checked 2,163 snippets and skipped 4,255, with no reference issues; residue checks reported 12,955 validated, zero errors and 24 skipped. Family cross-checks retained zero conflicts, nine requiring adjudication, 177 with missing information and 339 consistent. Gene residue checks reported 668 validated, zero errors and two skipped; finding residue checks reported eight validated with no errors or skips. Prediction/BioReason, history-coverage, downloaded-sequence-save and upstream PAINT verification steps were skipped by scope. The full merge-group suites and global schema validation executed. These results do not imply warning-free validation or site deployment.

The accepted payloads contain 22 FIG4 and 18 FITM2 files, all different from their actual parents, with no parent-identical payload files. Complete gene/history namespaces contain eight and seven files; qualified closures contain 39 and 26 files, including 31 and 19 normal source files, respectively. The completion entry records all 40 payload objects with exact modes, sizes and hashes. ROOT independently compared both complete closures against the approved heads and actual merges. The tracker writer also verified all 65 per-gene closure objects, representing 61 distinct paths, against the qualified tracker base. Earlier gene histories and normal source bytes remain preserved.

All 235 dated queue objects, 144 preceding completion updates, catalogue identities and association text, 227 earlier project histories, dated source inventories and the exact earlier progress prefix are preserved. Only FIG4 and FITM2 receive additional tracker credit. Fresh ownership checks covered complete current and former open-PR paths; PR #4518 still owns generated project pages, slide assets and an older project history, with no overlap with this checkpoint's five-file delta. Completion records accepted merged work while retaining evidence uncertainty and both computed DRAFT statuses. Acceptance is the coordinating AI agent's campaign audit, not human maintainer sign-off.

Curation session: history record.

Completion checkpoint 648 — 2026-10-28 19:23:02 UTC

648 complete; 2,228 remaining out of 2,876 catalogue genes.

This checkpoint adds FKRP from PR #5694 and FLAD1 from PR #5697 after ROOT independently accepted both actual merges.

The FKRP merge preserves 36 original source contexts in 35 stored annotation rows: 25 ACCEPT, 8 KEEP_AS_NON_CORE and 2 TOO_GENERAL. One shared source key combines UniProt and ComplexPortal assignment contexts, so the original-context counts are 26 ACCEPT, 8 KEEP_AS_NON_CORE and 2 TOO_GENERAL. It has 21 references, one core function, no recorded natural alternative products and no publication quotations. The two broad cytoplasm rows retain the ontology-supported TOO_GENERAL correction. Source-specific organism, construct, localization and sequential-enzyme limits remain documented.

The FLAD1 merge preserves 43 current contexts plus two retired contexts, for 45 stored rows. Current actions are 26 ACCEPT, 15 KEEP_AS_NON_CORE and 2 MODIFY. It retains 34 references, two catalytic core functions, five natural products and all 38 inherited quote/reference occurrences across 24 distinct pairs. Two inherited NADH excerpts were relocated unchanged into their truthful source findings; no new quotation was authored. Product-specific localization and catalytic scope remain explicit, and experimental transcript or construct names are not equated with unverified natural products. Both reviews retain computed DRAFT status, no NEW annotations, no functional-isoform block and no isoform-specific or negated annotation contexts.

Both actual merge-group runs passed their executed validation, suite and aggregate jobs: FKRP run 40742629833 and FLAD1 run 40748200991. Each executed 12 example checks, 4,431 pytest tests, 283 doctests, 444 agent tests and 19 JavaScript tests successfully; mypy covered 295 source files and Ruff passed. Each retained 86 deselected pytest cases, 37 skipped doctests, nine pytest warnings and eight doctest warnings. An ignored oaklib/SQLAlchemy destructor exception followed successful pytest; subsequent checks succeeded. FLAD1's earlier speculative run is not credited.

FKRP retained two target generic-binding advisories and validated 18,227 histories; FLAD1 retained six target generic-binding advisories and validated 18,229 histories. Each passed 42 history tests and validation of 717 modules and 734 families. Repository-wide module diagnostics remain disclosed; FLAD1's run reported 2,187 module advisories, while no separate aggregate was captured for FKRP. Each family run checked 2,163 snippets and skipped 4,255, with no reference issues; residue checks reported 12,955 passing, zero errors and 24 unresolved. Family cross-checks retained zero conflicts, nine requiring adjudication, 177 with missing information and 339 consistent. Gene residue checks reported 668 passing, zero errors and two unresolved; finding residue checks reported eight passing with no errors or unresolved cases. Prediction/BioReason, history-coverage, downloaded-sequence-save and full upstream PAINT verification steps were skipped by scope. The full merge-group suites and global schema validation executed. The Markdown citation helper matched no pathway files and does not establish validation of all notes or evidence prose. These results do not imply warning-free validation or site deployment.

The accepted payloads contain 17 FKRP and 12 FLAD1 files, all different from their actual parents, with no parent-identical payload files. Each complete gene/history namespace contains eight files; qualified closures contain 27 and 42 files, including 19 and 34 normal source files, respectively. The completion entry records all 29 payload objects with exact modes, sizes and hashes. ROOT independently accepted both complete closures, actual parent deltas and executed checks. The tracker writer verified all 69 distinct closure objects at the approved heads, actual merges and qualified tracker base, without rerunning accepted gene tests. Existing gene histories and normal source bytes remain preserved.

All 235 dated queue objects, 145 preceding completion updates, catalogue identities and association text, 228 earlier project histories, dated source inventories and the exact earlier progress prefix are preserved. Only FKRP and FLAD1 receive additional tracker credit. Fresh ownership checks covered complete current and former open-PR paths; PR #4518 still owns generated project pages, slide assets and an older project history, with no overlap with this checkpoint's five-file delta. Completion records accepted merged work while retaining evidence limitations and both DRAFT statuses. Acceptance is the coordinating AI agent's campaign audit, not human maintainer sign-off.

Curation session: history record.

Completion checkpoint 650 — 2026-10-28 20:59:41 UTC

650 complete; 2,226 remaining out of 2,876 catalogue genes.

This checkpoint adds FKTN from PR #5705 and FLCN from PR #5707 after ROOT independently accepted both actual merges.

The FKTN merge preserves 44 original source contexts in 43 stored annotation rows: 26 ACCEPT, 13 KEEP_AS_NON_CORE, 2 TOO_GENERAL, 1 UNDECIDED and 1 MARK_AS_OVER_ANNOTATED. The genuine seed combines one shared source key, so the original-context action counts contain 27 ACCEPT with the other counts unchanged. The review retains 24 references, one core function, two natural products and no publication quotations. The endoplasmic-reticulum uncertainty, source-specific cell-type effects, JNK over-annotation decision and limits on transferring assays between products remain explicit.

The FLCN merge preserves all 121 inherited review rows: 36 ACCEPT, 63 KEEP_AS_NON_CORE, 19 MODIFY and 3 TOO_GENERAL. Its separately preserved GOA TSV contains 124 data rows; these action totals describe the inherited review rows, without asserting an unverified 124-row action projection. It retains 38 references, two core functions, three natural products and all 244 inherited quotation/reference occurrences across 46 distinct pairs. Twenty-six inherited occurrences were relocated without changing their text, including six negative-TOR excerpts moved to source findings during review follow-up; four Finding groups were consolidated without quotation loss. Contextual biological-process rationales retain organism, construct, partner and pathway-output limits. Both reviews remain DRAFT, with no NEW annotations, newly authored quotations, functional-isoform block, isoform-specific annotation contexts or negated contexts.

The actual merge-group runs for FKTN, 40756560414 and FLCN, 40763660683 each passed their executed validation, full-suite and aggregate jobs. Each ran 12 example checks, 4,431 pytest tests, 283 doctests, 444 agent tests and 19 JavaScript tests successfully; mypy covered 295 source files and Ruff passed. Each retained 86 deselected pytest cases, 37 skipped doctests, nine pytest warnings and eight doctest warnings. An ignored oaklib/SQLAlchemy destructor exception followed passing pytest; subsequent checks and the aggregate gate succeeded.

FKTN retained six target generic-binding advisories and validated 18,289 histories; FLCN retained twenty target advisories and validated 18,292 histories. Each passed 42 history tests, global gene schema validation, and validation of 717 modules and 734 families. Each run reported 2,192 module advisories, an aggregate of per-module summaries rather than a count of every job warning. Repository-wide family/reference diagnostics and unresolved checks remain disclosed in the durable records. Prediction/BioReason validation, history-coverage, downloaded-sequence-save and full upstream PAINT verification steps were skipped by scope; the full merge-group suites executed. The Markdown citation helper found no pathway files and does not establish validation of all notes or evidence prose. These results do not imply warning-free validation or site deployment.

The accepted payloads contain 12 FKTN and 6 FLCN files, all changed from their actual parents, with no parent-identical payload files. Each complete gene/history namespace contains eight files. Their qualified closures contain 29 and 40 files, including 21 and 32 normal source files, respectively. The completion entry records all 18 payload objects with exact modes, sizes and hashes. ROOT independently accepted both complete closures, actual parent deltas and executed checks; tracker preparation verified all 69 distinct closure objects at the approved heads, actual merges and qualified tracker base without rerunning accepted gene tests. Earlier histories and unchanged normal sources remain preserved.

All 235 dated queue objects, 146 prior completion updates, 2,876 catalogue identities and association text, 229 earlier project histories, dated source inventories and the exact earlier progress prefix are preserved. Only FKTN and FLCN receive additional tracker credit. Fresh ownership checks covered complete current and former paths of all 268 open PRs. PR #4518 still owns generated project pages, slide assets and an older project history, without overlap with this checkpoint's five-file delta. Completion records accepted merged work while retaining evidence limitations and DRAFT statuses. Acceptance is the coordinating AI agent's campaign audit, not human maintainer sign-off.

Curation session: history record.

Completion checkpoint 652 — 2026-10-28 22:27:18 UTC

652 complete; 2,224 remaining out of 2,876 catalogue genes.

This checkpoint adds FLNA from PR #5708 and FLT4 from PR #5711 after ROOT independently accepted both actual merges.

The FLNA merge preserves 152 original QuickGO contexts through 151 unchanged TSV data rows and 150 genuine seeded review rows. The stored decisions are 25 ACCEPT, 102 KEEP_AS_NON_CORE, 9 MODIFY, 7 UNDECIDED, 2 MARK_AS_OVER_ANNOTATED and 5 TOO_GENERAL. The separately replayed original-context counts contain 26 ACCEPT and 103 KEEP_AS_NON_CORE, with the other counts unchanged. The review retains 78 references, two core functions and three natural products. Nine binding refinements use supported partner classes; source-specific uncertainty, contextual transcription and deacetylation evidence, and limits on transferring assays between species, constructs and products remain explicit. The additional core describes the supported actin-network/integrin-tail adaptor role without adding a NEW annotation.

The FLT4 merge preserves all 89 original contexts one-to-one: 43 ACCEPT, 21 KEEP_AS_NON_CORE, 13 TOO_GENERAL, 10 MODIFY and 2 UNDECIDED. It retains 39 references, one receptor-signaling core and three natural products. Supported specific binding refinements, contextual process and cytoplasm decisions, ten source-traced IBA assertions and the unchanged 159-row PTHR24416 source slice remain recorded. Both nuclear assertions remain UNDECIDED; original primary access, ligand, chimera, species and natural-product limits are preserved. Both reviews remain DRAFT, with no NEW annotations, publication quotations, functional-isoform blocks, isoform-specific annotation contexts or negated contexts.

The actual merge-group runs for FLNA, 40774238869 and FLT4, 40776951319 each passed their executed validation, full-suite and aggregate jobs. Each ran 12 example checks, 4,431 pytest tests, 283 doctests, 444 agent tests and 19 JavaScript tests successfully; mypy covered 295 source files and Ruff passed. Each retained 86 deselected pytest cases, 37 skipped doctests, nine pytest warnings and eight doctest warnings. An ignored oaklib/SQLAlchemy destructor exception followed passing pytest; subsequent checks and the aggregate gate succeeded.

FLNA retained 40 target advisories, including 39 generic-binding advisories and the disclosed unmirrored-adaptor-core advisory; FLT4 retained two generic-binding advisories. Their runs validated 9,387 and 9,388 gene-review schemas, respectively, and 18,296 and 18,300 histories. Each passed 42 history tests and validation of 717 modules and 734 families. Each run reported 2,192 module advisories, an aggregate of per-module summaries rather than a count of every job warning. Repository-wide family/reference diagnostics and unresolved checks remain disclosed in the accepted source evidence. Prediction/BioReason validation, history-coverage, downloaded-sequence-save and full upstream PAINT verification steps were skipped by scope; the full merge-group suites executed. These results do not imply warning-free validation or site deployment.

The accepted payloads contain 44 FLNA and 32 FLT4 files, all changed from their actual parents, with no parent-identical payload files. Each complete gene/history namespace contains nine files. Their qualified closures contain 82 and 41 files, including 73 and 32 normal source files, respectively. The completion entry records all 76 payload objects with exact modes, sizes and hashes. ROOT independently accepted both complete closures, actual parent deltas and executed checks; tracker preparation verified all 123 distinct closure objects at the approved heads, actual merges and qualified tracker base without rerunning accepted gene tests. Earlier histories and unchanged normal sources remain preserved.

All 235 dated queue objects, 147 prior completion updates, 2,876 catalogue identities and association text, 230 earlier project histories, dated source inventories and the exact earlier progress prefix are preserved. Only FLNA and FLT4 receive additional tracker credit; pending FLNC work is not counted. Fresh ownership checks covered complete current and former paths of all 269 open PRs, including FLNC #5712. PR #4518 still owns generated project pages, slide assets and an older project history, without overlap with this checkpoint's five-file delta. Completion records accepted merged work while retaining evidence limitations and DRAFT statuses. Acceptance is the coordinating AI agent's campaign audit, not human maintainer sign-off.

Curation session: history record.

Completion checkpoint 654 — 2026-10-28 23:52:45 UTC

654 complete; 2,222 remaining out of 2,876 catalogue genes.

This checkpoint adds FLNC from PR #5712 and FLNB from PR #5714 after ROOT independently accepted both actual merges.

The FLNC merge preserves all 32 original contexts one-to-one: 10 ACCEPT, 8 KEEP_AS_NON_CORE, 10 MODIFY and 4 TOO_GENERAL. It retains 20 references, one integrated actin-filament/sarcomere structural core and two natural products. Specific binding refinements retain the original partners and assay context. Muscle structural contacts are described without transferring an untested FLNA adaptor mechanism or assuming that every interaction supplies a separate core. Two original singleton extensions are explicitly restored without changing their meaning.

The FLNB merge preserves all 37 original contexts one-to-one: 13 ACCEPT, 6 KEEP_AS_NON_CORE, 8 MODIFY, 3 TOO_GENERAL and 7 UNDECIDED. It retains 27 references, one integrated actin-cytoskeleton structural core and nine natural products. The core describes supported dimerization and receptor-tail contacts with construct and assay limits; it does not assign every variant to focal contacts. The original ISG15 binding assertion remains unresolved because documented covalent conjugation does not independently establish noncovalent binding. The source-specific GRB2 SH2-bait complex is distinguished from separately tested SH3 interfaces. Confirmed wrong-reference and suspected partner-identifier defects remain recorded without guessing a correction or claiming they have been reported upstream. Three original singleton extensions are explicitly restored. Both reviews remain DRAFT, with no NEW annotations, publication quotations, functional-isoform blocks, isoform-specific annotation contexts or negated contexts.

The actual merge-group runs for FLNC, 40784576746 and FLNB, 40787294351 each passed their executed validation, full-suite and aggregate jobs. Each ran 12 example checks, 4,431 pytest tests, 283 doctests, 444 agent tests and 19 JavaScript tests successfully; mypy covered 295 source files and Ruff passed. Each retained 86 deselected pytest cases, 37 skipped doctests, nine pytest warnings and eight doctest warnings. An ignored oaklib/SQLAlchemy destructor exception followed passing pytest; subsequent checks and the aggregate gate succeeded.

FLNC retained two target advisories and FLNB retained one generic-binding advisory under the explicit campaign policy. Their runs validated 9,389 and 9,390 gene-review schemas, respectively, and 18,303 and 18,306 histories. Each passed 42 history tests and validation of 717 modules and 734 families. Each run reported 2,192 module advisories, with unresolved repository-wide family/reference checks retained in the source evidence. Prediction/BioReason validation, history-coverage, downloaded-sequence-save and full upstream PAINT verification steps were skipped by scope; the full merge-group suites executed. These results do not imply warning-free validation or site deployment.

The accepted payloads contain 14 FLNC and 12 FLNB files, all changed from their actual parents, with no parent-identical payload files. Each complete gene/history namespace contains eight files. Their qualified closures contain 25 and 31 files, including 17 and 23 normal source files, respectively. The completion entry records all 26 payload objects with exact modes, sizes and hashes. ROOT independently accepted both complete closures, actual parent deltas and executed checks; tracker preparation verified 56 per-gene closure objects representing 49 distinct paths at the approved heads, actual merges and qualified tracker base without rerunning accepted gene tests. Earlier histories and unchanged normal sources remain preserved.

All 235 dated queue objects, 148 prior completion updates, 2,876 catalogue identities and association text, 231 earlier project histories, dated source inventories and the exact 830,798-byte earlier progress prefix are preserved. Only FLNC and FLNB receive additional tracker credit. The FLNA follow-up #5715 adds no distinct gene; pending FLVCR1 work is not counted. Fresh ownership checks covered complete current and former paths of 269 open PRs, followed by ROOT's complete check of newly published FLVCR1 #5716, bringing the release cut to 270. PR #4518 still owns generated project pages, slide assets and an older project history, without overlap with this checkpoint's five-file delta. Completion records accepted merged work while retaining evidence limitations and DRAFT statuses. Acceptance is the coordinating AI agent's campaign audit, not human maintainer sign-off.

Curation session: history record.

Completion checkpoint 656 — 2026-10-31 04:41:30 UTC

656 complete; 2,220 remaining out of 2,876 catalogue genes.

This checkpoint records FLVCR1 and FLVCR2, advancing the published catalogue from 654 to 656 of 2,876 genes, with 2,220 remaining. FLVCR1 PR #5716 and FLVCR2 PR #5719 have independently accepted actual merges: FLVCR1 and FLVCR2. Their executed integration evidence and retained limitations support these two completion credits.

FLVCR1

The FLVCR1 review retains all 68 original contexts and both natural products: 17 ACCEPT, 23 KEEP_AS_NON_CORE, 10 MODIFY, 13 UNDECIDED, 3 TOO_GENERAL and 2 MARK_AS_OVER_ANNOTATED. Its status remains DRAFT. Two cores describe full-length FLVCR1a choline and ethanolamine transport at the plasma membrane. Purified choline reconstitution is distinguished from cellular ethanolamine assays, and kinase trapping from intrinsic transport energetics. These functions are not automatically assigned to the 279-residue mitochondrial product.

Cellular heme export, mitochondrial localization and erythroid findings remain contextual, with source-specific species and construct limits. Handling completed heme or altering feedback does not establish a catalytic role in heme synthesis; newer amine transport evidence does not by itself refute the older cellular findings. Eight quantified PDZ-domain/peptide interactions receive a specific binding term, while thirteen source-pair assertions remain unresolved because they fall below the study's quantifiable threshold. This does not establish biological nonbinding. The HPX association retains its rabbit-reagent, unresolved fragment-species and reported fragment-range limits. The exact FLVCR1 assay in PMID:40972734 remains unverified. The source guide preserves all original contexts, the three restored singleton extensions and these access boundaries.

FLVCR2

The FLVCR2 review preserves 30 original contexts, the singleton plasma-membrane extension and both natural products: 16 ACCEPT, 10 KEEP_AS_NON_CORE, 3 TOO_GENERAL and 1 REMOVE. Its computed status is COMPLETE with zero curation warnings. Two cores describe characterized full-length choline and ethanolamine transport; no unsupported function is transferred to the 321-residue product. The choline core now explicitly includes transport across the blood–brain barrier, matching the retained ACCEPT annotations.

Direct human transport assays, human brain endothelial staining and endogenous human iHBEC uptake are distinguished from mouse in-vivo tracer experiments, purified mouse-protein reconstitution and mouse constructs expressed in HEK293 cells. These results support a physiological choline-transport role without demonstrating the complete route across both endothelial faces: PMID:38693257 leaves abluminal export unresolved. Enhanced transport at lower pH does not establish obligate proton coupling.

Historical heme uptake/binding and organellar pools remain non-core. The review explicitly weighs PMID:38778100's nonconfirmation statement and small-amine pocket/uptake results against PMID:20823265's complementary human-protein accumulation and endogenous human-cell knockdown evidence. The inspected newer experiments do not directly test or exclude heme flux; the older positive assays do not establish purified full-length heme translocation or its physiological importance. Hemin-agarose and purified human N-terminal fragment binding are assessed separately from transport and are not transferred to the short natural product.

Removal of the heme-export IBA rests on original target-specific FLVCR1/FLVCR2 comparative washout evidence and an explicit identity link, after verification of the actual PAINT target path. PMID:15369674 remains VERIFIED because its original primary PDF, Figure 3C and accompanying Results was directly inspected; the unchanged abstract-only cache flag does not describe that reading. Cached PMID:20823265 independently identifies the human FLVCR2 comparator and corroborates its tested non-export result. Neither donor count nor newer amine transport alone supplies this conclusion. PMID:14729055 and PMID:40972734 retain unverified source-specific assays despite independent support for the existing terms. The source guide records these limits and exact reuse of the shared PMID:15369674 source from accepted FLVCR1.

Validation and checkpoint scope

FLVCR1's actual integration run executed the full suite: 4,431 unit tests and 283 doctests passed, with 86 deselections, 37 doctest skips and the recorded warnings. Its expected generic-binding advisory, module advisories, ignored SQLAlchemy destructor diagnostic and scoped skipped workflow steps remain disclosed in the completion record. FLVCR2's actual integration run executed 4,452 passing unit tests and 284 passing doctests, with 86 deselections, 37 doctest skips, nine unit-test warnings and eight doctest warnings. Its gene review had zero curation warnings; the 739-module validation retained 2,287 advisories. The ignored SQLAlchemy destructor diagnostic and three scoped skipped validation steps remain recorded separately from the executed full suite.

Neither review adds NEW annotations or publication quotations. This checkpoint changes only the two catalogue checkboxes, current status and mirrored completion records, appends this progress entry and adds a new project history record. The complete existing progress prefix, catalogue text/order, prior queue objects and histories must remain intact. The two completion entries preserve the distinct actual integration counts, source boundaries and scoped skips.

Completion checkpoint 658 — 2026-10-31 07:18:24 UTC

658 complete; 2,218 remaining out of 2,876 catalogue genes. This checkpoint records FMO3 and FMR1 after independent verification of their actual merges and executed integration suites. Completion preserves the scientific limits and computed status of each review.

FMO3 catalyzes NADPH-dependent oxidation of trimethylamine to trimethylamine N-oxide at the endoplasmic reticulum, with FAD as its prosthetic cofactor. The accepted review contains 23 source contexts: nine ACCEPT, nine KEEP_AS_NON_CORE and five MODIFY, with one trimethylamine-monooxygenase core. Alternative-substrate capacities remain contextual, including albendazole oxidation and hypotaurine assays with their experimental limits; neither shared enzyme nomenclature nor family membership is treated as a formal GO ancestry relationship. Five binding refinements retain the actual partner and assay scope, including the distinction between a human-ORF interaction assay and an established physiological encounter. The record has 19 references, no alternative products and no added annotations or quotations, and its accepted status is COMPLETE.

FMR1 encodes FMRP, which recognizes selected mRNAs, regulates translation in a target-dependent manner, and can scaffold RNA-containing condensates. The three cores distinguish mRNA recognition, translation regulation and condensate scaffolding. Repression and activation are both supported in their respective experimental settings; human fragment reconstitution, rodent neuronal assays and cellular localization do not establish identical activity for all natural products. The accepted review preserves 253 original and exported contexts in 250 stored rows through three source-key collisions, with all eight original extension contexts. Stored actions are 81 ACCEPT, 139 KEEP_AS_NON_CORE, eight MODIFY, 16 UNDECIDED and six TOO_GENERAL. It retains 11 natural products, 92 references, three cores and DRAFT status, with no NEW annotations or publication quotations. In particular, accepted RNA-binding and scaffold evidence is kept separate from unresolved signaling-specific causal assertions.

The actual merged evidence is FMO3 PR #5720, commit 203e15c0, integration run 41169395482, and FMR1 PR #5768, commit 436087e4, integration run 41177038493. The merged FMO3 source guide and FMR1 source guide document the source, species, construct and product boundaries.

Both actual integrations executed 12 example checks, 4,452 unit tests (86 deselected, nine warnings), 284 doctests (37 skipped, eight warnings), 444 automation tests, 19 JavaScript tests, 295-file type checking and 42 history tests. Their repository-wide validation totals differ:

Actual integration Gene-review schemas History records Modules / module warnings Family reviews Gene advisories
FMO3 9,899 19,557 739 / 2,287 749 0
FMR1 9,927 19,636 741 / 2,277 750 37

The accepted logs retain dependency deprecations and an ignored SQLAlchemy destructor error. History-coverage checking, saving downloaded UniProt sequences and full upstream PAINT verification were scoped skips. FMR1's advisories include retained generic binding and source-context action differences; they are disclosed with the accepted review. No accepted gene validators were rerun for this checkpoint.

Object verification covers 22 FMO3 and 93 FMR1 gene/history/source objects, including 14 and 85 normal sources. Their 86 payload paths are distinct, with no parent-identical no-ops. The tracker preserves all 2,876 catalogue identities and association text, 235 dated queue objects, 150 prior completion updates, 233 prior project histories and the complete 842,774-byte progress prefix. The two queue files remain exact mirrors. The nine existing PR #4518 history/generated/slides overlaps were reviewed at their exact unchanged head and base; none owns the four tracker files or accepted sources. Provenance is recorded in the new Codex project history.

Completion checkpoint 661 — 2026-10-31 17:03:31 UTC

661 complete; 2,215 remaining out of 2,876 catalogue genes. This checkpoint records the independently verified actual merges of FNIP1, FN1 and FOXC1. It publishes their existing completion credit; it does not create additional gene credit or change the scientific reviews. All three retain DRAFT status with their documented uncertainties.

FNIP1 has two defined activities: inhibition of the Hsp90 ATPase cycle as a cochaperone, and participation in the FLCN–FNIP1 complex that activates RagC/D GTP hydrolysis and connects lysosomal nutrient sensing to TORC1 signaling. Purified-complex activity does not establish FNIP1-alone catalysis. Three natural products are preserved, without assigning full-length activity to the shorter products; the historical 508-aa expression construct is not identical to the current short natural product. The review retains 58 original and exported contexts in 56 stored annotations, seven original extension atoms, 26 references and two cores. Its 17 ACCEPT, 22 KEEP_AS_NON_CORE, 12 MODIFY and five TOO_GENERAL decisions preserve source-specific client and donor limits. Three source-defect records document the B-cell apoptosis direction issue without claiming that an upstream report was filed. See the FNIP1 source guide, accepted PR #5774, actual merge and executed integration.

FN1 encodes fibronectin, a secreted matrix scaffold with distinct integrin, collagen, heparin and proteoglycan recognition activities. The five cores distinguish matrix assembly from defined ligand-binding assays, retain soluble plasma versus assembled-matrix contexts, and avoid transferring fragment behavior to all 17 natural products. Fusion-specific FN1–ALK localization is not treated as unqualified localization of native fibronectin. The review contains 235 stored annotations: 223 current typed contexts, 11 historical source-only contexts and one retained authored NEW annotation. The current 222 original QuickGO contexts produce 219 exporter rows; preserved OR alternatives account for one-to-many typed contexts, so there is no invented single raw-action total. The original 226-row sibling GOA file and additive 219-row snapshot remain separate. Final actions are 53 ACCEPT, 120 KEEP_AS_NON_CORE, 24 MODIFY, 12 MARK_AS_OVER_ANNOTATED, three TOO_GENERAL, 22 UNDECIDED and one retained NEW. The 149 original quotation associations are preserved as 134 active and 15 archived associations; no new quotations were added. There are 156 references. See the FN1 source guide, accepted PR #5772, actual merge and executed integration.

FOXC1 recognizes regulatory DNA and activates transcription. A second core captures its binding to GLI2 and enhancement of GLI2 DNA-binding activity in the tested human cancer-cell system; the proposed allosteric opening remains a model. The inhibitory region attenuates activation-domain-driven reporter output without establishing a separate full-length repressor mechanism. Its 143 original and exported contexts map to 141 stored annotations with all three original extension atoms preserved. Final actions are 38 ACCEPT, 44 KEEP_AS_NON_CORE, 38 TOO_GENERAL, six MODIFY and 15 UNDECIDED, with 45 references and two cores. The unresolved annotations retain their exact source-access or assay limitations. Three probable, unreported source queries distinguish corneal evidence from the ocular-lens transparency term. No alternative products, NEW annotations or quotations were introduced. See the FOXC1 source guide, accepted PR #5775, actual merge and executed integration.

All three actual merge-group runs completed their validation, suite and aggregate jobs successfully. The unit suites, doctests, examples, automation checks and type checks below actually executed.

Actual integration Unit tests / deselected / warnings Doctests / skipped / warnings Examples Python / JavaScript automation tests Type-checked files
FNIP1 4,452 / 86 / 9 284 / 37 / 8 12 444 / 19 295
FN1 4,506 / 86 / 9 284 / 37 / 8 12 454 / 19 295
FOXC1 4,506 / 86 / 9 284 / 37 / 8 12 454 / 19 295
Actual integration Gene-review schemas History records / history tests Modules / module warnings Family reviews Target advisories
FNIP1 9,928 19,641 / 42 741 / 2,277 750 10
FN1 9,928 19,645 / 42 741 / 2,277 750 53
FOXC1 9,929 19,648 / 42 741 / 2,277 750 7

The accepted logs retain dependency deprecations and an ignored SQLAlchemy destructor error. History-coverage checking, saving downloaded UniProt sequences and full upstream PAINT verification were scoped skips. FN1 used the complete validation route; its separate merge-queue-only schema step was skipped, not counted as another execution. Target advisories remain disclosed in the accepted reviews. Local preparation checks tracker preservation, history and rendering without rerunning gene reviews.

Object verification covers 30 FNIP1, 173 FN1 and 50 FOXC1 objects: 252 distinct objects comprising 209 normal sources, 37 gene/history files and six accepted FN1 infrastructure files. Their 81 published payload paths are distinct, with no parent-identical no-ops. The tracker preserves all 2,876 catalogue identities and association text, 235 dated queue objects, 151 prior completion updates, 234 prior project histories and the complete 847,624-byte progress prefix. The two queue files remain exact mirrors. Provenance is recorded in the new Codex project history.

Completion checkpoint 665 — 2026-10-31 21:21:06 UTC

665 complete; 2,211 remaining out of 2,876 catalogue genes. This checkpoint records the independently verified actual merges of FOXE1, FOXC2, FOXE3 and FOXG1. It publishes their existing completion credit and adds no new gene credit. FOXE1, FOXE3 and FOXG1 have COMPLETE review status; FOXC2 remains DRAFT with six disclosed advisories. Review status does not erase the source-specific uncertainties retained in the annotations.

FOXE1 recognizes regulatory DNA and regulates Pol II transcription in thyroid and craniofacial development. Human promoter binding, chromatin occupancy and reporter assays support this activity; regulatory effects depend on promoter, cofactors and abundance. Rat ortholog experiments provide a separate promoter-specific repression context. Its 56 original and exported contexts remain 56 stored annotations: 23 ACCEPT, 12 KEEP_AS_NON_CORE, 14 TOO_GENERAL, three MODIFY, three UNDECIDED and one MARK_AS_OVER_ANNOTATED. The review contains one core and 24 references. Gene-level support is distinguished from verification of inaccessible individual assays. See the FOXE1 source guide, accepted PR #5784, actual merge and executed integration.

FOXC2 has two defined transcriptional activities. Its DNA-binding activator activity includes human lymphatic endothelial chromatin and enhancer evidence. Separately, purified human domains and transfected-cell experiments support NFAT1/NFATC2-dependent corepression, with DNA-enhanced contact and an NFAT element requirement. The endogenous tissue and target range of that mechanism remain unresolved; cooperation with NFATC1 in lymphatic vessels is a distinct context. The 62 original and exported contexts remain 62 source-backed annotations, alongside one authored NEW annotation, giving 63 stored annotations. Final actions are 22 ACCEPT, 20 KEEP_AS_NON_CORE, 14 TOO_GENERAL, three MODIFY, three UNDECIDED and one NEW. The original extension conjunction retains both atoms. There are two cores and 28 references. See the FOXC2 source guide, accepted PR #5783, actual merge and executed integration.

FOXE3 regulates transcription and coordinates lens epithelial proliferation and the timing of lens-fiber differentiation. Human DNAJB1 chromatin, promoter and RNA experiments establish a tested positive regulatory context; they do not establish the sign of regulation at every target. Mouse studies support maintenance of epithelial proliferation and restraint of premature fiber differentiation, while later fiber maturation is also affected. Its 42 original and exported contexts remain 42 stored annotations: 15 ACCEPT, 12 KEEP_AS_NON_CORE, 11 TOO_GENERAL, two MODIFY and two UNDECIDED. The single core incorporates the specific lens-regulatory processes, with 14 references. Human and mouse evidence and the unresolved source-specific assays remain distinguished. See the FOXE3 source guide, accepted PR #5787, actual merge and executed integration.

FOXG1 recognizes regulatory DNA and regulates Pol II transcription through context-dependent partner interactions. Human evidence supports repression-associated regulation involving TLE and KDM5B; endogenous promoter association and perturbation results complement motif-selection and engineered reporter assays. Neural developmental roles and observations in human brain tumor-initiating cells retain their distinct model scopes. Its 19 original and exported contexts remain 19 stored annotations: eight ACCEPT, five TOO_GENERAL and six MODIFY, with one core and 14 references. Specific binding refinements preserve the tested partner and assay limits. See the FOXG1 source guide, accepted PR #5788, actual merge and executed integration.

All four reviews preserve their original source records and contain no alternative-product assertions or quotation associations. This tracker changes none of their scientific content. All four actual merge-group runs completed their validation, suite and aggregate jobs successfully. Each executed 4,566 unit tests (86 deselected; nine warnings), 287 doctests (37 skipped; eight warnings), 12 examples, 454 Python automation tests, 19 JavaScript tests and type checking of 299 files.

Actual integration Gene-review schemas History records / history tests Modules / module warnings Family reviews Target advisories
FOXE1 9,937 19,909 / 42 744 / 2,287 751 0
FOXC2 9,938 19,912 / 42 744 / 2,287 751 6
FOXE3 9,939 19,914 / 42 744 / 2,287 751 0
FOXG1 9,940 19,916 / 42 744 / 2,287 751 0

The accepted logs retain dependency deprecations and an ignored SQLAlchemy destructor error. History-coverage checking, saving downloaded UniProt sequences and full upstream PAINT verification were scoped skips. Local checkpoint checks cover tracker preservation, history and rendering without rerunning gene reviews.

Object verification covers 28 FOXE1, 32 FOXC2, 19 FOXE3 and 20 FOXG1 objects: 91 distinct objects comprising 58 normal sources and 33 gene/history files. Their 77 published payload paths are distinct, with no parent-identical no-ops. The tracker preserves all 2,876 catalogue identities and association text, 235 dated queue objects, 152 prior completion updates, 235 prior project histories and the complete 854,366-byte progress prefix. The two queue files remain exact mirrors. Provenance is recorded in the new Codex project history.

Completion checkpoint 669 — 2026-11-01 02:34:51 UTC

669 complete; 2,207 remaining out of 2,876 catalogue genes. This checkpoint publishes the independently verified actual merges of FOXJ1, FOXN1, FOXP1 and FOXRED1. Their completion credit was already accepted; this tracker adds no new gene credit and changes none of their scientific content.

FOXJ1 is a nuclear Pol II activator supporting motile-cilium assembly and lung ciliated-cell differentiation. Human airway basal-cell gene transfer and variant-cell experiments retain their distinct endpoints; gene transfer alone is not presented as proof of complete multiciliated-cell maturation. See the source guide, PR #5790, actual merge and integration run.

FOXN1 is a nuclear Pol II activator with characteristic roles in keratinocyte differentiation and thymic epithelial morphogenesis. Effects on developing T cells retain the epithelial-niche context and source-specific limits. See the source guide, PR #5804, actual merge and integration run.

FOXP1 regulates Pol II transcription through sequence-specific DNA recognition and partner recruitment, including SMRT-associated repression. Activation at particular targets, including FBXL7, remains a distinct experimental context. Seven declared natural products are preserved; tested protein fragments are not treated as natural isoforms. See the source guide, PR #5806, actual merge and integration run.

FOXRED1 supports middle-to-late mitochondrial complex I assembly, with inner-membrane association. Its flavoprotein fold and manual similarity annotations remain mechanistic clues; a specific catalytic reaction or FAD-binding activity has not been demonstrated. Three natural products and the complete inherited review remain preserved. See the source guide, PR #5807, actual merge and integration run.

Review Original / exported contexts Native seed Final stored Status / advisories References
FOXJ1 72 / 72 71 71 DRAFT / 1 22
FOXN1 40 / 40 40 40 DRAFT / 8 19
FOXP1 79 / 79 74 77 COMPLETE / 0 38
FOXRED1 10 / 10 No new seed 10 COMPLETE / 0 11

FOXJ1 preserves its original collision provenance and two extension atoms. FOXP1 separates three annotation-scope pairs from the native seed while retaining two provenance-only collisions and all 14 extension atoms. FOXRED1's archived twelve-row prior review retains two retired NEW assertions. All 16 original quote associations remain recoverable: 10 active and six historical, with their original reference and section associations. These four accepted reviews introduce no new quotations or current NEW annotations. Each has one core; DRAFT and COMPLETE status do not replace the recorded source-access limits.

All four actual merge-group runs completed their validation, full suite and aggregate jobs successfully. Each executed 287 doctests (37 skipped; eight warnings), 12 examples, 454 Python automation tests, 19 JavaScript tests and type checking of 299 files. Unit runs each deselected 86 tests and reported nine warnings.

Actual integration Unit tests Gene-review schemas Histories / history tests Modules / module warnings Family reviews
FOXJ1 4,566 9,942 19,920 / 42 744 / 2,287 751
FOXN1 4,566 9,943 19,923 / 42 744 / 2,287 751
FOXP1 4,572 9,961 19,955 / 42 744 / 2,287 751
FOXRED1 4,572 9,963 19,964 / 42 746 / 2,288 751

The accepted logs retain dependency warnings and an ignored SQLAlchemy destructor error. History-coverage checking, saving downloaded UniProt sequences and full upstream PAINT verification were scoped skips. Local checkpoint checks cover tracker preservation, the new history record and private rendering without rerunning gene reviews.

The four accepted closures contain 116 distinct objects: 81 normal sources and 35 gene/history files, with 87 distinct published payload paths and no parent-identical no-ops. This checkpoint preserves all 2,876 catalogue identities and association text, 235 dated queue objects, 153 prior completion updates, 236 prior project histories and the entire 861,304-byte progress prefix. The queue mirrors remain identical. Provenance is recorded in the new Codex project history.

Completion checkpoint 673 — 2026-11-01 06:29:20 UTC

673 complete; 2,203 remaining out of 2,876 catalogue genes. This publishes the four independently accepted completions after checkpoint 669; it adds no new gene credit.

Gene Actual merge and integration Original/exported → native → stored Status; annotation advisories
FOXP2 merge 697bac83; run 41264900872 72/72 → 70 → 72 DRAFT; 9
FRMPD4 merge d0211172; run 41267878385 76/76 → 76 → 76 DRAFT; 7
FRRS1L merge a5fe7128; run 41273013978 13/13 → 13 → 13 COMPLETE; 0
FTL merge a623939c; run 41277830293 73/73 → 73 → 73 DRAFT; 35

FOXP2 retains both scope-distinct source pairs as separate rows, including all 11 nucleus extension atoms. Its nine UniProt product declarations include eight verified sequences and one unresolved product sequence; declaration does not establish an isoform-specific function. FRMPD4 retains 22 UNDECIDED interaction contexts where censored or unquantified fragment data do not establish the exact binding claim. Its portable audit preserves all 713 target workbook rows and all 53 source-specific joins. FRRS1L retains four UNDECIDED contexts, including the sampled synapse-localization uncertainty. FTL retains two source-specific UNDECIDED contexts, the original urine atom and five exact cached quotations linked to their claims. Its 35 advisories comprise 34 generic-binding contexts and the structural core term absent from the existing annotation list; no NEW annotation was added to suppress that warning.

Gene Actions References / assessed Cores Verified objects / normal sources / PR payload
FOXP2 ACCEPT: 12, KEEP_AS_NON_CORE: 22, TOO_GENERAL: 16, MODIFY: 22 32 / 24 1 35 / 27 / 17
FRMPD4 MODIFY: 39, KEEP_AS_NON_CORE: 8, UNDECIDED: 22, ACCEPT: 6, TOO_GENERAL: 1 19 / 14 2 34 / 17 / 23
FRRS1L ACCEPT: 6, KEEP_AS_NON_CORE: 2, MODIFY: 1, UNDECIDED: 4 13 / 8 1 19 / 11 / 19
FTL TOO_GENERAL: 6, KEEP_AS_NON_CORE: 44, ACCEPT: 20, MARK_AS_OVER_ANNOTATED: 1, UNDECIDED: 2 58 / 57 3 63 / 55 / 26

The combined accepted closure contains 144 distinct objects, including 103 normal sources. The four PR payloads contain 85 distinct paths. Shared sources have identical object identities; no infrastructure change is credited to these gene payloads. Original source objects, native seed mappings and current reviewed annotations are checked separately.

All four actual merge-group runs completed the suite, validation and aggregate jobs successfully. Their executed counts are retained below and in the queue mirror.

Gene Unit tests Doctests Schemas Modules (warnings) History records + tests Families
FOXP2 4572 287 9964 746 (2288) 19966 + 42 751
FRMPD4 4577 295 9965 746 (2288) 19985 + 42 751
FRRS1L 4577 295 9966 747 (2409) 19992 + 42 751
FTL 4577 295 9967 747 (2291) 19997 + 42 751

Each actual run also passed 12 example checks, 454 automation tests and 19 JavaScript tests. FOXP2 checked 299 mypy source files; the later three checked 302. Each suite retained 86 deselections and nine unit-test warnings, plus 37 skipped doctests and eight doctest warnings. Dependency deprecations and the nonfatal SqlImplementation destructor diagnostic are retained in the raw-log evidence. The PR-only history-coverage step, saved-UniProt step and full-upstream PAINT step were skipped as explicitly recorded; this does not erase the executed history validation, family validation or full suite.

The 867,103-byte progress prefix, all 237 existing project histories, 235 original queue records and 154 earlier completion updates remain unchanged. Catalogue text/order is preserved apart from checking these four completed genes. The project policy now permits concise, verified source-backed snippets and reference-only entries when appropriate, replacing the obsolete blanket prohibition without altering the separate generic-binding instruction.

Local tracker checks cover the exact five-path delta, source/object preservation, queue equality, the new native history record and private rendered checkpoint links. They do not substitute for the actual integration results above. Project history.

Completion checkpoint 676 — 2026-11-01 09:43:00 UTC

676 complete; 2,200 remaining out of 2,876 catalogue genes. This publishes three independently accepted completions after checkpoint 673 and adds no new gene credit.

Gene Actual merge and integration Original/exported → native → current stored Status; annotation advisories
FUCA1 merge 02e13917; run 41281010527 25/25 → 26 → 26 DRAFT; 4
FTSJ1 merge d50aed9c; run 41282642404 40/40 → 40 → 40 DRAFT; 1
FUT8 merge d068d105; run 41286874138 29/29 → 29 → 29 DRAFT; 1

FUCA1 preserves 25 original GOA contexts and the urine extension atom. Its inherited review contained 26 records: the mouse IMP glycoprotein-catabolism assertion remains in the historical archive, while the current 26th row is a separately justified human IC assertion. These are distinct assertions with distinct evidence. All 29 inherited quote associations remain traceable: 26 active and three historical; no new quotation was added. The two lysosome annotations are retained as core locations.

FTSJ1 preserves 40 original contexts and two documented product sequences, 329 and 327 residues; the sequence difference does not establish a functional difference. Its three catalytic cores distinguish Cm32, Gm34 and Cm34. Three translation annotations are marked over-annotated because FTSJ1 modifies tRNA rather than executing ribosomal translation. The neurogenesis annotation is refined to neuron projection morphogenesis with the pharmacological attribution limits retained. Eight verified quotations belong to the whole PR; its final morphology amendment added none.

FUT8 preserves 29 original contexts, the parotid-gland atom and four documented product sequences. Its core is N-glycan core fucosylation. Three removed process assertions have reaction-level contradictions documented alongside their ontology or Reactome provenance; the developmental and broad oligosaccharide contexts remain non-core. Five brief verified quotations support the resolved review points. Product 2 (308 residues, Retinal) is distinguished from product 4 (169 residues, Retina-1/Retina-2); the latter's inactivity comment is not transferred to the former.

Gene Current actions References / assessed Cores Objects / normal sources / PR payload
FUCA1 ACCEPT: 15, KEEP_AS_NON_CORE: 8, TOO_GENERAL: 2, NEW: 1 18 / 18 1 27 / 15 / 7
FTSJ1 ACCEPT: 20, MARK_AS_OVER_ANNOTATED: 3, KEEP_AS_NON_CORE: 3, TOO_GENERAL: 13, MODIFY: 1 35 / 35 3 38 / 29 / 23
FUT8 ACCEPT: 14, KEEP_AS_NON_CORE: 4, TOO_GENERAL: 8, REMOVE: 3 25 / 25 1 31 / 23 / 22

The combined accepted closure contains 91 distinct objects, including 62 normal sources. The three PR payloads contain 52 distinct paths. Shared sources have identical object identities. The 94 original GOA contexts are separated from the one authored IC annotation; historical seed reviews and final reviews are joined by their actual stored indices. Full authored source evidence remains in each gene's accepted review and source archive.

All three actual merge-group runs completed the suite, validation and aggregate jobs successfully. The executed counts are preserved below and in the queue mirror.

Gene Unit tests Doctests Schemas Modules (warnings) History records + tests Families
FUCA1 4577 295 9967 747 (2291) 19999 + 42 751
FTSJ1 4577 295 9968 747 (2291) 20002 + 42 751
FUT8 4596 298 9976 747 (2291) 20036 + 42 751

Each run also passed 12 example checks, 454 automation tests and 19 JavaScript tests. FUCA1 and FTSJ1 checked 302 mypy source files and retained 86 unit-test deselections; FUT8 checked 303 files and retained 89 deselections. Each suite reported nine unit-test warnings, 37 skipped doctests and eight doctest warnings. Recorded dependency and destructor diagnostics remain in the actual logs. The explicitly skipped PR-only history-coverage, saved-UniProt and full-upstream PAINT steps are listed in the queue evidence; the suite, history, module and family checks above actually executed.

The 872,512-byte progress prefix, all 238 existing project histories, 235 original queue records and 155 earlier completion updates remain unchanged. Catalogue text and order are preserved apart from checking these three completed genes. The current quotation and generic-binding policies are unchanged.

Local tracker checks cover the exact five-path delta, accepted object preservation, queue equality, native history and private rendered checkpoint links. They do not substitute for the completed integration runs above. Project history.

Completion checkpoint 679 — 2026-11-01 13:02:35 UTC

679 complete; 2,197 remaining out of 2,876 catalogue genes. This publishes three independently accepted completions after checkpoint 676 and adds no new gene credit.

Gene Actual merge and integration Original/exported → native → current stored Status; annotation advisories
FXYD2 merge df3df230; run 41294795127 25/25 → 25 → 25 COMPLETE; 0
FXN merge 2d87d72a; run 41302726137 92/92 → 92 → 92 DRAFT; 20
FYB1 merge ce6b1910; run 41304269937 35/35 → 35 → 37 DRAFT; 10

FXYD2 preserves 25 original GOA contexts, 16 extension atoms and two documented product sequences. Its core is regulation of the sodium/potassium ATPase complex; this does not attribute ATP hydrolysis or independent ion translocation to FXYD2. Four source-specific UNDECIDED judgments remain in the accepted COMPLETE review. Five verified quotations are counted over the whole PR, including the initial excerpt and four additions. The generated GO cache companion is distinct from the 28 scientific sources; its accepted actual state includes eight upstream rows and the one approved GO:1903406 addition.

FXN preserves 92 original GOA contexts, five extension atoms and three documented products. Its core remains the iron-sulfur assembly machinery, with conditional biochemical results distinguished from a defining physiological iron-oxidation role. The entire inherited 79-record review remains archived. All 68 inherited quotation associations are traceable: 20 active and 48 historical, with six additional current gene quotations. The separate prediction review contains 17 predictions and 19 quote occurrences representing 16 distinct excerpts from 13 sources; those are not additional GOA annotations. Two accepted prediction-code companion files remain part of the immutable accepted closure.

FYB1 preserves 35 original contexts and adds two separately justified process annotations: protection of SKAP1 from degradation and positive regulation of integrin-mediated cell adhesion in T cells. The evidence retains the binding-dependent protection and engineered membrane-targeting limits. Its 37 current rows, three documented product sequences and nine verified quote associations remain distinct counts; the initial two quotations and seven follow-up additions belong to the same accepted PR. The core remains an intracellular signaling adaptor, with context-specific domain and lipid binding refinements preserved.

Gene Current actions References / assessed Cores Objects / normal sources / PR payload
FXYD2 UNDECIDED: 4, ACCEPT: 9, TOO_GENERAL: 4, KEEP_AS_NON_CORE: 4, MODIFY: 4 28 / 27 1 37 / 28 / 29
FXN MARK_AS_OVER_ANNOTATED: 2, MODIFY: 1, KEEP_AS_NON_CORE: 38, ACCEPT: 33, UNDECIDED: 10, TOO_GENERAL: 8 49 / 49 1 86 / 65 / 40
FYB1 MODIFY: 6, KEEP_AS_NON_CORE: 14, UNDECIDED: 3, TOO_GENERAL: 2, ACCEPT: 10, NEW: 2 50 / 50 1 55 / 47 / 30

The combined accepted closure contains 176 distinct objects, including 138 normal scientific sources and three explicit generated-cache/code companions. The three PR payloads contain 99 distinct paths. Shared sources have identical object identities. The 152 original GOA contexts are separated from FYB1's two authored annotations; FXN's prediction reviews remain separate. Historical seed judgments and current reviews are joined through the actual source mappings. The tracker does not alter any gene, source, prediction or companion object.

All three actual merge-group runs completed the suite, validation and aggregate jobs successfully. Executed counts are preserved below and in the queue mirror.

Gene Unit tests Doctests Schemas Modules (warnings) History records + tests Families
FXYD2 4602 298 9981 747 (2291) 20059 + 42 751
FXN 4613 298 9981 747 (2291) 20065 + 42 751
FYB1 4613 298 9982 747 (2291) 20067 + 42 751

Each run also passed 12 example checks, 454 automation tests and 19 JavaScript tests, and checked 303 mypy source files. Each retained 89 unit-test deselections, nine unit-test warnings, 37 skipped doctests and eight doctest warnings. Recorded dependency and destructor diagnostics remain in the actual logs. Explicit skipped-step records are preserved in the queue evidence; the suite, schema, history, module and family checks above actually executed.

The 878,077-byte progress prefix, all 239 existing project histories, 235 original queue records and 156 earlier completion updates remain unchanged. Catalogue text and order are preserved apart from checking these three completed genes. The current quotation and generic-binding policies are unchanged.

Local tracker checks cover the exact five-path delta, accepted object preservation, queue equality, native history and private rendered checkpoint links. They do not substitute for the completed integration runs above. Project history.

Completion checkpoint 684 — 2026-11-01 19:38:01 UTC

684 complete; 2,192 remaining out of 2,876 catalogue genes. This publishes five independently accepted completions after checkpoint 679 and adds no new gene credit.

Gene Actual merge and integration Original/exported → native → current stored Status; annotation advisories
G6PC1 merge f12e63ef; run 41315587697 40/40 → 40 → 40 DRAFT; 3
FZD4 merge ab56cfad; run 41316538776 134/134 → 134 → 134 DRAFT; 8
G6PC3 merge a93774f2; run 41325704845 17/17 → 17 → 18 COMPLETE; 0
G6PD merge 9067107a; run 41325713373 66/66 → 66 → 66 DRAFT; 4
GAA merge 3c6145f2; run 41328147496 45/45 → 45 → 45 COMPLETE; 0

G6PC1's core describes ER-luminal glucose-6-phosphate hydrolysis and the terminal glucose-production step. Its 40 current contexts, two product sequences and 28 reference assessments remain distinct from the inherited 39-record review and 42 quotation associations preserved in the archive. Two active core quotations are retained. One source-specific UNDECIDED judgment remains.

FZD4's two cores distinguish Wnt reception from Norrin-dependent retinal vascular signaling. Its 134 original contexts, six extension atoms, one canonical sequence, 60 reference assessments and eight active quotations are preserved. Seventeen source-specific UNDECIDED judgments remain, including the ATRA-response context; experimental species, constructs and interaction-participant limits remain explicit.

G6PC3 has 17 original contexts and one separately justified cellular-detoxification annotation. Its two cores distinguish physiological 1,5-anhydroglucitol-6-phosphate detoxification from the demonstrated glucose-6-phosphate catalytic capability. The physiological contribution of the latter remains unresolved; rat microsomal transport does not quantify human G6PC3-dependent glucose flux. Four current quotation associations and all 23 historical associations are retained separately.

G6PD's core is NADP+-dependent glucose-6-phosphate oxidation in the cytosolic pentose-phosphate pathway. All 66 original contexts, three documented products and 39 reference assessments remain intact. The urine extension is preserved in the original-context archive with its raw64/native62 join; it is not a restored structured field in the current annotation. Seven active quote occurrences remain distinct from 52 inherited associations, of which six remain associated with current claims and 46 are historical-only.

GAA's two cores describe complementary alpha-1,4 and alpha-1,6 glucan hydrolysis during lysosomal glycogen degradation. Its 45 original contexts, canonical 952-residue product and restored urine atom are preserved. The full prior 45-record review and all 55 inherited quotation associations remain archived. Two current core snippets and four selected-table file snippets have distinct source locators; none of these counts creates an extra annotation.

Gene Current actions References / assessed Cores Objects / scientific sources / PR payload
G6PC1 ACCEPT: 26, KEEP_AS_NON_CORE: 7, TOO_GENERAL: 5, MARK_AS_OVER_ANNOTATED: 1, UNDECIDED: 1 28 / 28 1 69 / 56 / 43
FZD4 KEEP_AS_NON_CORE: 36, UNDECIDED: 17, TOO_GENERAL: 8, ACCEPT: 57, MODIFY: 16 60 / 60 2 90 / 80 / 43
G6PC3 ACCEPT: 11, KEEP_AS_NON_CORE: 4, TOO_GENERAL: 2, NEW: 1 18 / 18 2 40 / 29 / 27
G6PD ACCEPT: 36, KEEP_AS_NON_CORE: 19, UNDECIDED: 6, TOO_GENERAL: 2, MODIFY: 2, MARK_AS_OVER_ANNOTATED: 1 39 / 39 1 115 / 104 / 74
GAA KEEP_AS_NON_CORE: 19, UNDECIDED: 1, MODIFY: 6, ACCEPT: 18, MARK_AS_OVER_ANNOTATED: 1 27 / 27 2 93 / 79 / 61

The combined accepted closure contains 387 distinct objects, including 328 normal scientific source paths. The five cumulative PR payloads contain 248 distinct paths. Shared sources have matching byte/hash/blob identities. The 302 original contexts remain distinct from 303 current annotations, including G6PC3's single NEW row. Eight original extension atoms are preserved: seven are represented structurally in current reviews and G6PD's one urine atom remains in its archive. No gene or source object is changed by this tracker update.

Gene Unit tests Doctests Modules History records + tests Families
G6PC1 4613 298 747 20070 + 42 751
FZD4 4613 298 747 20074 + 42 751
G6PC3 4658 305 748 20673 + 42 751
G6PD 4658 305 748 20675 + 42 751
GAA 4658 305 748 20677 + 42 751

These are actual executed integration results. Every run also passed 12 example checks and 454 automation tests. G6PC1 and FZD4 checked 303 mypy source files; G6PC3, G6PD and GAA checked 309 and validated all 605 prediction reviews. The source receipts retain unit/doctest warnings, deselections and skipped doctests. History-coverage, UniProt-save and full-upstream-PAINT workflow steps were skipped and receive no execution credit.

G6PD's suite executed successfully in attempt 1. After an OLS service timeout, validation and the aggregate job executed successfully in attempt 2; GitHub's copied suite record in attempt 2 is not a second suite execution. G6PC3 and GAA's retained gh logs lacked step labels. Their actual job-step metadata and complete original logs were read directly; the stopped parser attempts remain preserved and are not reported as collector passes.

The 883,943-byte progress prefix, all 240 prior project histories, 235 dated queue records and 157 earlier completion updates remain unchanged. Catalogue text and order are preserved apart from checking the five completed genes. The current quotation and generic-binding policies are unchanged.

Local checks cover the exact five-path tracker delta, queue equality, preserved accepted objects, native history and private rendered checkpoint links. Project history.

Completion checkpoint 688 — 2026-11-04 02:31:54 UTC

688 complete; 2,188 remaining out of 2,876 catalogue genes. This publishes four independently accepted completions after checkpoint 684 and adds no new gene credit.

Gene Actual merge Executed integration Original / native / stored contexts Review status
GABBR2 b89135d9 run 41363318390 49 / 49 / 49 DRAFT
GABRB2 fb5f6b99 run 41370719583 66 / 66 / 66 COMPLETE
GABRA1 67dfb006 run 41377341759 66 / 66 / 66 DRAFT
GABRG2 83d42fb1 run 41755090303 74 / 74 / 74 DRAFT

GABBR2 supplies the G-protein-coupling subunit of the GABA-B heterodimer; GABBR1 supplies orthosteric GABA recognition. GABRA1, GABRB2 and GABRG2 contribute to assembled GABA-A chloride channels. Gamma2 contributes the alpha/gamma benzodiazepine interface rather than the beta/alpha orthosteric GABA interface. These are accepted gene reviews, not claims that every source-specific uncertainty has been resolved.

Gene Current annotation actions Assessed references Natural products Extension atoms / contributes_to contexts Current quote occurrences
GABBR2 MODIFY: 14, ACCEPT: 29, KEEP_AS_NON_CORE: 3, UNDECIDED: 3 35 1 2 / 1 3
GABRB2 MODIFY: 9, ACCEPT: 42, UNDECIDED: 3, REMOVE: 1, MARK_AS_OVER_ANNOTATED: 4, KEEP_AS_NON_CORE: 7 40 4 1 / 4 11
GABRA1 MODIFY: 11, ACCEPT: 47, UNDECIDED: 3, KEEP_AS_NON_CORE: 5 36 1 3 / 3 13
GABRG2 MODIFY: 11, ACCEPT: 47, REMOVE: 4, UNDECIDED: 1, KEEP_AS_NON_CORE: 11 31 3 0 / 2 4

All 255 original contexts remain distinct and are represented by 255 stored annotations; this batch adds no NEW annotation. The six structured extension atoms, ten contributes_to relationships and 31 current quotation occurrences remain in the accepted reviews. Canonical-only GABBR2 and GABRA1 each count as one natural product despite having no alternative_products list. The four beta2 and three gamma2 product records remain distinct from engineered experimental constructs; counting a product does not establish every annotated activity for that product.

The accepted closures cover 144 distinct paths, including 110 scientific source paths with identical bytes wherever shared. Their cumulative published payloads and actual merge deltas each cover 118 distinct paths, although the per-gene deltas differ. GABRA1 and GABRG2's actual shared ontology cache equals their respective actual parent, retaining the intended term rows and earlier rows; the older whole-cache versions remain in the published commits. No gene, source or cache file is changed by this tracker update.

Gene Unit tests Doctests History records + tests
GABBR2 4680 308 21131 + 42
GABRB2 4680 308 21177 + 42
GABRA1 4681 308 21190 + 42
GABRG2 5356 320 21871 + 42

All four actual merge-group runs executed their suites, target validation and aggregate checks successfully. Each also passed 12 example checks, 454 automation tests and 19 JavaScript tests. Their retained receipts distinguish warnings, deselections and skipped doctests from executed results. Ordinary PR suite skips, history-coverage skips, UniProt-save skips and full-upstream-PAINT skips receive no execution credit. Gene review uncertainties and optional follow-ups remain in the linked reviews and source guides; checkpoint completion means the curation was accepted and merged.

The prior 891,197-byte progress journal, 235 dated queue records, 158 earlier completion updates and all prior project histories are preserved. Catalogue text and order change only by checking these four genes and updating the status count. GALE, GALNT3 and other pending reviews are excluded. Project history.

Completion checkpoint 692 — 2026-11-04 04:14:41 UTC

692 complete; 2,184 remaining out of 2,876 catalogue genes. This checkpoint publishes four independently accepted reviews after checkpoint 688 and adds no new gene credit.

Gene Actual merge Executed integration Original / seeded / stored contexts Review status
GABRB3 db5df360 run 41760048843 97 / 97 / 97 DRAFT
GALE 81b7e91b run 41760051237 18 / 18 / 19 COMPLETE
GALK1 9d3ff448 run 41760890259 26 / 26 / 26 DRAFT
GALC 9eaad1ba run 41762276962 20 / 19 / 20 COMPLETE

GABRB3 contributes to assembled GABA-A receptor channels. GALE interconverts UDP-linked galactose and glucose sugars, including their N-acetyl derivatives; the reversible UDP-galactose supply direction remains explicit. GALK1 phosphorylates galactose, and lysosomal GALC hydrolyzes galactosyl lipids including psychosine. Acceptance records completion of the reviews, while their source-specific uncertainties and experimental-construct limits remain visible in the linked gene files.

The 161 original contexts are represented by 162 stored annotations. GALC's 19-row seed omitted one genuine original context that was restored, bringing its current total to 20; that restoration is not NEW. GALE separately retains one inherited NAD-binding NEW alongside its 18 original contexts. GALK1's retired redundant inherited NEW remains preserved historically.

Gene Assessed references Natural products Extension atoms Current quote occurrences
GABRB3 41 4 2 13
GALE 16 2 0 4
GALK1 29 1 1 8
GALC 37 4 3 10

The reviews retain six structured extension atoms, one NOT context, one contributes_to context and 35 current quotation occurrences. The eleven natural products remain distinct from experimental constructs; product counting does not assign every function to every product. GALC's corrected acceptance records 37 references and 37 assessments. Historical quotations and superseded projections remain available through each review's retained provenance.

All four linked actual merge-group runs executed their suites and integration checks successfully. Their acceptance receipts distinguish executed results from skipped steps and unresolved diagnostics. The accepted gene closures span 179 distinct paths, including 138 immutable scientific source paths; cumulative published payloads cover 129 paths and actual merge deltas cover 109. GABRB3's actual ontology cache preserves its parent rows and adds the authorized GO:0160001 row. This tracker changes no gene, source or ontology-cache bytes.

The prior 896,068-byte progress journal, 235 dated queue records and 159 earlier completion updates are preserved. Catalogue order changes only by checking these four genes and updating the count. Later acceptances, including GAD1, GAMT and GALNS, are outside this fixed checkpoint. Project history.

Completion checkpoint 696 — 2026-11-04 05:29:09 UTC

696 complete; 2,180 remaining out of 2,876 catalogue genes. This checkpoint publishes four independently accepted reviews after checkpoint 692 and adds no new gene completion credit.

Gene Actual merge Executed integration Original / parsed / stored contexts Review status
GAD1 abd3b7a9 run 41763694369 50 / 50 / 50 COMPLETE
GAMT 88dcd9a8 run 41764895356 18 / 18 / 18 DRAFT
GALNS fac06dd3 run 41767491587 15 / 15 / 16 COMPLETE
GALNT3 fa0d0b8b run 41771214510 35 / 35 / 35 DRAFT

GAD1 produces GABA by decarboxylating glutamate; GAMT methylates guanidinoacetate to form creatine. Lysosomal GALNS removes sulfate groups during glycosaminoglycan breakdown. GALNT3 initiates protein O-glycosylation in the Golgi, including FGF23 glycosylation that limits proteolytic processing. Product-specific and experimental-construct limits remain in the accepted gene reviews.

The 118 original GOA contexts correspond to 119 stored annotations: GALNS retains one separate NEW annotation. All four inherited targets used genuine no-seed native acquisition and a private parser projection from the actual native TSV. The parsed counts are not a claim of a seeded target-fetch command.

Gene Assessed references Natural products Extension atoms Current quote occurrences
GAD1 32 4 0 7
GAMT 14 2 0 6
GALNS 17 1 1 9
GALNT3 23 2 3 11

The reviews retain four structured extension atoms, 33 current quotation occurrences and nine natural products. They contain no NOT or contributes_to qualifiers in this window. Natural products count the canonical product and explicitly verified natural alternatives retained in each gene's source-evidence file; an absent alternative_products array does not erase the canonical product. Engineered constructs are excluded, and counting a product does not assign all functions to it. The 128 historical quotation associations remain traceable in the retained gene provenance; historical and current counts are not silently combined.

The accepted closures cover 176 deduplicated paths, including 129 deduplicated scientific source paths. The cumulative published payloads and actual parent deltas each cover 95 deduplicated paths. These are unions, not sums of the per-gene counts. Shared scientific source bytes are identical across the accepted receipts. All four actual merge-group runs executed their integration checks successfully; skipped steps and unresolved diagnostic limits remain explicit in the linked acceptance records.

This fixed window includes only GAD1, GAMT, GALNS and GALNT3. GAN and later acceptances are excluded. The prior 900,108-byte progress journal, 235 dated queue records and 160 earlier completion updates are preserved. Catalogue order changes only by checking these four genes and updating the count. Scientific source files remain unchanged.

Project history.

Completion checkpoint 699 — 2026-11-04 18:53:34 UTC

699 complete; 2,177 remaining out of 2,876 catalogue genes. This checkpoint publishes three independently accepted reviews after checkpoint 696 and adds no new gene completion credit.

Gene Actual merge Executed integration Original / native seed / stored contexts Review status
GAN 74c548ae run 41772300448 32 / 32 / 32 COMPLETE
GARS1 ba7d6080 run 41781433328 51 / 51 / 51 DRAFT
GANAB 7c35d1b6 run 41786437034 39 / 38 / 39 COMPLETE

Gigaxonin recognizes substrates for CUL3 ubiquitin ligase complexes, supporting cytoskeletal protein turnover. GARS1 attaches glycine to tRNA for cytosolic and mitochondrial translation. GANAB supplies glucosidase II catalytic activity during ER glycoprotein maturation. Product and construct limits, unresolved annotations and optional advisories remain in the accepted reviews; project completion does not change their computed status.

The three genuine native seeds contained 121 rows. The reviews retain all 122 original contexts because GANAB's two distinct source assertions share one simplified parser key; restoring the omitted original is not NEW. There are no NEW annotations in this window.

Gene Assessed references Natural products Extension atoms Current quote occurrences
GAN 42 1 0 6
GARS1 55 2 0 7
GANAB 26 3 2 5

The reviews contain 123 reference assessments, four cores, six natural products, two literal extension atoms and 18 current quotation occurrences. No NOT or contributes_to qualifiers or inherited quotation associations occur in this window. Natural-product counts include the canonical sequence: GAN has no declared alternative-product list, GARS1 has two products from alternative initiation, and GANAB has three declared products. Engineered constructs are excluded, and a product count does not assign every function to every product.

The accepted closures cover 155 deduplicated paths, including 113 deduplicated scientific source paths. Cumulative published payloads and actual parent deltas each cover 101 deduplicated paths. These are unions, not sums. Shared scientific source bytes match across the accepted receipts. GARS1's actual delta omits PMID 24627108 because the identical source was already in its merge parent. All three actual merge-group suites and integration checks executed successfully; skipped routes and unresolved diagnostics remain explicit in their acceptance records.

This fixed window includes only GAN, GARS1 and GANAB. GATA-family reviews, GATM and later acceptances are excluded. The prior 904,229-byte progress journal, 235 dated queue records and 161 earlier completion updates are preserved. Catalogue order changes only by checking these three genes and updating the count. Scientific source files remain unchanged.

Project history.

Completion checkpoint 703 — 2026-11-04 21:05:29 UTC

703 complete; 2,173 remaining out of 2,876 catalogue genes. This checkpoint publishes four independently accepted reviews after checkpoint 699 and adds no new gene completion credit.

Gene Accepted ordinal Actual merge Executed integration Original / stored contexts Review status
GATA2 700 cb5d8224 run 41892284745 118 / 118 DRAFT
GATA1 701 50ac2889 run 41892444528 120 / 120 DRAFT
GATA3 702 16d5fc72 run 41892578431 197 / 198 DRAFT
GATA6 703 a59a136e run 41899592105 92 / 92 COMPLETE

These GATA-family transcription factors bind regulatory DNA and control cell-type-specific gene expression. Their accepted reviews distinguish the shared transcriptional mechanism from lineage and developmental effects; GATA3 also retains direct nucleosome binding. Natural products, engineered constructs and unresolved evidence remain distinguished. Project completion does not change the reviews' computed status.

All 527 current original contexts are conserved. GATA2, GATA1 and GATA6 contributed 330 genuine native seed rows. GATA3 underwent force/no-seed refresh: its 197 originals include two distinct source assertions sharing one simplified parser key, and its retained inherited NEW produces 198 stored rows. Thus the window has 526 parser keys, 527 original contexts and 528 stored rows. GATA3's 77 source-retired contexts and 181 historical quotation associations remain archived; retirement does not refute their biology.

Gene Assessed references Natural products Flat extension atoms Current review quote occurrences
GATA2 63 2 23 6
GATA1 54 3 8 7
GATA3 92 2 4 7
GATA6 52 2 3 7

The reviews contain 261 reference assessments, five cores, nine natural products, 38 flat extension atoms and 27 current review quotation occurrences. No NOT or contributes_to qualifiers occur in this window. GATA2 also preserves all 31 literal extension atoms within their original groups, including raw context 76's four OR alternatives; they are not split into invented annotations. Product counts include displayed natural sequences and exclude engineered constructs; they do not assign every function to every product.

The accepted closures cover 294 deduplicated paths, including 229 deduplicated scientific source paths. Cumulative published payloads and actual parent deltas each cover 156 deduplicated paths. These are unions, not sums. Shared scientific source bytes match across accepted receipts. Actual deltas omit identical sources already present in their respective parents: three for GATA1, one for GATA3 and one for GATA6. Derived ontology-cache convergence is recorded separately and preserves the actual parent content. All four actual merge-group suites and required integration checks executed successfully; skipped routes, warnings and unresolved diagnostics remain explicit in the acceptance records.

This fixed window includes only GATA2, GATA1, GATA3 and GATA6. GATM, GBE1 and later acceptances are excluded. The prior 908,026-byte progress journal, 235 dated queue records and 162 earlier completion updates are preserved. Catalogue order changes only by checking these four genes and updating the count. Scientific source files remain unchanged. The native history links the four accepted gene PRs and separates symbols from accepted ordinals.

Project history.

Completion checkpoint 709 — 2026-11-05 03:58:46 UTC

709 complete; 2,167 remaining out of 2,876 catalogue genes. This catch-up records six independently accepted reviews after checkpoint 703 and grants no additional completion credit.

Gene Accepted ordinal Actual merge Executed integration Original / stored contexts Status
GATAD2B 704 07b1560b run 41910098291 74 / 76 COMPLETE
GATM 705 4b7ce2de run 41914007905 37 / 37 COMPLETE
GBE1 706 cea5eb4b run 41923730354 27 / 28 COMPLETE
GBA2 707 aa59c86d run 41927365263 53 / 53 COMPLETE
GBA1 708 c94e28bd run 41940610293 96 / 96 COMPLETE
GCDH 709 ac55b7d2 run 41953219963 25 / 25 COMPLETE

The six reviews preserve 312 original contexts and contain 315 current rows, including three supported NEW molecular functions. GBA2 retains both pairs of source-ID/date assertions that its 51-row seed collapsed; they remain 53 original contexts. GATM used a force/no-seed refresh, so its 37 originals are not described as genuine seed rows.

The committed reviews contain 225 reference assessments, six cores, 15 natural products and 46 current review quotation occurrences. Product counts include displayed natural sequences and exclude engineered constructs; they do not imply equal activity across products. Eight flat extension atoms, two NOT contexts and one contributes_to qualifier are retained. GBA1 separately preserves seven literal atom occurrences and two OR groups; its four flat atoms include a shared consequence of an OR expression.

Accepted closures cover 398 deduplicated paths, including 306 scientific source paths. The cumulative published payloads cover 227 deduplicated paths, and actual parent deltas cover 226. Identical shared sources already present in the actual parent are explicitly retained: R-HSA-9976102 for GATAD2B and PMID33361282 for GBA1. These figures are unions rather than sums.

All six actual merge-group suites and required integration checks executed successfully. Their accepted receipts retain skipped routes, warnings and unresolved corpus diagnostics. Historical evidence and earlier project records remain unchanged. This checkpoint is fixed to accepted ordinals 704–709; GCH1 and later acceptances are outside its scope.

Project history.

Completion checkpoint 715 — 2026-11-05 08:58:45 UTC

715 complete; 2,161 remaining out of 2,876 catalogue genes. This catch-up records six independently accepted reviews after checkpoint 709 and grants no additional completion credit.

Gene Accepted ordinal Actual merge Executed integration Original / stored contexts Status
GCH1 710 bcead031 run 41957380148 71 / 71 DRAFT
GCK 711 37e83e3c run 41969819517 86 / 86 COMPLETE
GCSH 712 34bc185a run 41974409149 28 / 28 COMPLETE
GDF2 713 2fb8b13e run 41988851330 61 / 61 COMPLETE
GDAP1 714 e8b41e0c run 41990175310 61 / 61 COMPLETE
GEMIN5 715 61459f7d run 41992363005 73 / 73 DRAFT

The six reviews preserve all 380 original contexts in 380 current rows, with no NEW annotations. GCH1 retains both original contexts collapsed into one of its 70 native seed keys; GEMIN5 retains both pairs collapsed by its 71-key seed. These are 71 and 73 originals respectively, not added assertions.

The committed reviews contain 355 reference assessments, nine cores and 70 current quotation occurrences. Twelve natural sequences or precursors are counted, including displayed products; engineered constructs are excluded. GDF2 additionally records one mature BMP9 cleavage product, separately from its single precursor. GCSH's processed chain is not another splice isoform. The product counts do not imply equal activity across products. All 23 flat extension atoms and GCH1's one NOT context are retained.

Accepted closures cover 377 deduplicated paths, including 269 normal scientific source paths. Cumulative published payloads and actual parent deltas each cover 175 deduplicated paths; these figures are unions rather than sums. GCSH's 25 normal target sources remain distinct from its 53 dependency-reference paths: 52 immutable dependency references and the authored GCSH review. The full GCSH closure has 68 objects; the dependency paths are not 53 unchanged source caches. GEMIN5's 11 official UniProt JSON excerpt placements retain their source provenance separately from its 16 local source placements.

All six actual merge-group suites and required integration checks executed successfully. GCH1 and GEMIN5 retain computed DRAFT status and their reviewed advisories; acceptance does not erase unresolved scientific questions, skipped routes or corpus warnings. Historical evidence and earlier project records remain unchanged. This checkpoint is fixed to accepted ordinals 710–715; GFER and later acceptances are outside its scope.

Project history.

Completion checkpoint 720 — 2026-11-05 14:33:42 UTC

720 complete; 2,156 of 2,876 remain. This checkpoint records five independently accepted actual merges after checkpoint 715: GFER, GFI1B, GFAP, GFPT1 and GGCX. It publishes their existing credit and adds no new gene acceptance. GIGYF1 and later acceptances belong to a subsequent checkpoint.

Gene Accepted ordinal PR Actual merge Executed merge-group run Original / stored contexts References / assessments Core functions Natural products Current review quotes
GFER 716 #6010 7de769bf 41999350735 27 / 27 37 / 37 1 2 8
GFI1B 717 #6011 2b437ead 42003936094 21 / 21 33 / 33 1 2 13
GFAP 718 #6013 b1a4b490 42017473920 279 / 279 74 / 74 1 3 5
GFPT1 719 #6014 684b4fd4 42018676529 30 / 30 40 / 40 1 2 4
GGCX 720 #6015 3bec32ba 42037746017 39 / 39 42 / 42 1 2 5

The five accepted reviews preserve 396 original contexts in 396 stored rows, with zero NEW annotations, 226 reference assessments, five cores, 11 natural products and 35 current structured review quote occurrences. Nine flat extension atoms remain: three in GFAP, one in GFPT1 and five in GGCX. No NOT or contributes_to contexts occur in this window. Natural-product counts exclude engineered assay constructs and do not assign identical functions to every splice product. Quote counts concern the current review YAML, including repeated placements; companion evidence and historical quotations remain separate.

The accepted object closures contain 41/32/79/47/49 paths respectively, including 28/23/69/35/39 normal sources. Published and actual-parent payloads contain 19/25/55/16/36 paths. Their deduplicated unions are 232 closure paths, 181 normal-source paths and 151 published/actual-parent paths. These union counts are distinct from the per-gene sums; shared sources are counted once in a union. GGCX's final amendment child count does not replace its full 36-path actual merge scope.

GFER, GFPT1 and GGCX retain computed DRAFT status and accepted uncertainty. GFER keeps its unresolved extracellular and liver-development contexts, official-term/cache-label discrepancy and inherited research-source advisory. GFPT1 retains 30 original contexts restored from 29 seed keys: its unqualified extracellular-exosome context is non-core, while the separate literal CL:0000639 pituitary-basophil context remains UNDECIDED with its documented source mismatch. GGCX retains 39 originals restored from 38 seed keys, its five extension atoms and its source-sensitive annotation advisory. GFI1B and GFAP are COMPLETE. Acceptance does not remove these distinctions.

All five actual merge-group suites, required schema validation and aggregate gates executed successfully. Ordinary PR runs that skipped the suite were not used as integration evidence. Existing corpus warnings, declared test deselections/skips and source-access limitations remain recorded in the accepted receipts; this checkpoint does not re-adjudicate them. Earlier catalogue order, queue records, completion updates, journal bytes and scientific source objects remain unchanged.

Project history.

Completion checkpoint 725 — 2026-11-06 21:50:21 UTC

725 complete; 2,151 of 2,876 remain. This checkpoint publishes five independently accepted actual merges after checkpoint 720. It records existing acceptance credit and grants no additional gene acceptance.

Gene Accepted ordinal PR Actual merge Executed merge-group run Original / stored contexts Review status
GIGYF1 721 #6016 b6074c8b 42039801433 47 / 49 COMPLETE
GIPC3 722 #6017 2fe95a57 42042207155 2 / 3 COMPLETE
GJB1 723 #6018 f78a69fd 42058408119 61 / 61 COMPLETE
GJB3 724 #6023 096c9189 42293900770 26 / 26 COMPLETE
GJC2 725 #6025 5f8f3b5c 42294479600 14 / 14 COMPLETE

All five full merge commits are ancestors of the checked main revision, and the committed reviews match their accepted merge versions byte-for-byte. The table distinguishes original GOA contexts from stored rows: GIGYF1 retains two separate NEW annotations, and GIPC3 retains two original IPI contexts plus one separate conditional ISO proposal. GJB1, GJB3 and GJC2 add no NEW annotations.

GIPC3’s accepted review has computed status COMPLETE, while the proposed human myosin-VI-binding transfer still requires the mouse donor annotation to be curated before implementation. The human evidence limitation remains explicit. The earlier compact acceptance summary’s “three original” and “MF_DARK” shorthand is superseded here by the actual committed GOA, review and source guide; the original receipt is preserved. Completion does not remove this condition or resolve the other reviews’ retained scientific uncertainties.

Each linked merge-group run executed its integration suite and required checks successfully. Ordinary PR runs that skipped the suite are not credited as integration. Existing test skips, deselections, warnings and broader unresolved corpus diagnostics remain in the accepted evidence; this tracker update does not re-adjudicate them.

Only GIGYF1, GIPC3, GJB1, GJB3 and GJC2 are checked in this fixed window, accepted ordinals 721–725. All other pending genes remain unchecked. The ClinGen seed, catalogue identities and order, earlier progress journal, 235 dated queue records, 166 previous completion updates, scientific sources and prior histories are preserved.

Project history.

Completion checkpoint 730 — 2026-11-07 01:04:28 UTC

730 complete; 2,146 of 2,876 remain. This checkpoint publishes five independently accepted actual merges after checkpoint 725. It records existing acceptance credit and grants no additional gene acceptance.

Gene Accepted ordinal PR Actual merge Executed merge-group run Original / stored contexts Review status
GJB2 726 #6022 ca13d601 42298981344 72 / 72 COMPLETE
GK 727 #6026 577501df 42298987018 31 / 31 COMPLETE
GJB6 728 #6024 ee3a4835 42309180087 35 / 35 COMPLETE
GLDC 729 #6141 15905dca 42311308840 25 / 25 COMPLETE
GLB1 730 #6143 7c74c30d 42313947766 62 / 63 COMPLETE

All five full merge commits are ancestors of the checked main revision, and the committed reviews match their accepted merge versions byte-for-byte. GLB1 retains 62 original GOA contexts and one separate NEW annotation; GJB2, GK, GJB6 and GLDC add no NEW annotations. The accepted reviews retain 1, 2, 4, 4 and 5 UNDECIDED judgments respectively. Their computed COMPLETE status does not resolve those scientific uncertainties.

Each linked merge-group run executed its integration suite and required checks successfully. Ordinary PR runs that skipped the suite are not credited as integration. Existing test skips, deselections, warnings and broader unresolved corpus diagnostics remain in the accepted evidence; this tracker update does not re-adjudicate them.

Only GJB2, GK, GJB6, GLDC and GLB1 are checked in this fixed window, accepted ordinals 726–730. All other pending genes remain unchecked. The ClinGen seed, catalogue identities and order, earlier progress journal, 235 dated queue records, 167 previous completion updates, scientific sources and prior histories are preserved.

Project history.

Completion checkpoint 735 — 2026-11-07 04:49:34 UTC

735 complete; 2,141 of 2,876 remain. This checkpoint publishes five independently accepted actual merges after checkpoint 730. It records existing acceptance credit and grants no additional gene acceptance.

Gene Accepted ordinal PR Actual merge Executed merge-group run Original / stored contexts Review status
GLDN 731 #6145 4fa058f6 42320833455 13 / 14 COMPLETE
GLI3 732 #6151 fdb02a90 42324294450 125 / 125 DRAFT
GLA 733 #6139 2f72fda8 42324380133 58 / 58 DRAFT
GLT8D1 734 #6156 b9e302be 42336216455 6 / 6 COMPLETE
GLIS2 735 #6154 5f65fb60 42336825343 71 / 71 COMPLETE

All five full merge commits are ancestors of the checked main revision, and the committed reviews match their accepted merge versions byte-for-byte. GLDN retains 13 original GOA contexts and one separate NEW annotation; the other four add no NEW annotations. GLI3 retains six UNDECIDED judgments. GLI3 and GLA retain their actual computed DRAFT status; the other three are COMPLETE. Campaign acceptance records completed review and verified merge, without rewriting those statuses or resolving scientific uncertainties.

Each linked merge-group run executed its integration suite and required checks successfully. Ordinary PR runs that skipped the suite are not credited as integration. Existing test skips, deselections, warnings and broader unresolved corpus diagnostics remain in the accepted evidence; this tracker update does not re-adjudicate them.

Only GLDN, GLI3, GLA, GLT8D1 and GLIS2 are checked in this fixed window, accepted ordinals 731–735. GNB4, GNB2 and all other pending genes remain unchecked. The ClinGen seed, catalogue identities and order, earlier progress journal, 235 dated queue records, 168 previous completion updates, scientific sources and prior histories are preserved.

Project history.

Completion checkpoint 740 — 2026-11-07 09:35:37 UTC

740 complete; 2,136 of 2,876 remain. This checkpoint publishes five independently accepted actual merges after checkpoint 735. It records existing acceptance credit and grants no additional gene acceptance.

Gene Accepted ordinal PR Actual merge Executed merge-group run Literal raw / stored contexts Review status
GNB4 736 #6165 e9d50a8a 42338059015 22 / 22 COMPLETE
GNB2 737 #6163 f5b02387 42340221509 72 / 72 DRAFT
GPKOW 738 #6166 d022781f 42342368043 87 / 87 COMPLETE
GMNN 739 #6161 ce559357 42352318406 74 / 73 DRAFT
GRIA1 740 #6177 bb89a377 42357033229 198 / 192 DRAFT

All five actual merges are ancestors of the checked main revision, and each committed review matches its accepted merge and approved source version byte-for-byte. GNB4 and GPKOW are COMPLETE; GNB2, GMNN and GRIA1 retain their actual DRAFT status. GNB2 retains one UNDECIDED judgment and GRIA1 retains fourteen. None of these five adds a NEW annotation. Campaign acceptance records completed review and verified merge, without rewriting review status or resolving scientific uncertainties.

GNB2 preserves 72 literal incoming records and 72 reviewed contexts; its downloaded GOA TSV contains 71 rows, with the distinct extension context restored in the review and public provenance. GMNN preserves 74 literal records in 73 schema contexts, and GRIA1 preserves 198 literal records in 192 schema contexts. Their public evidence retains the individual original records and explicit projection mappings.

Each linked merge-group run executed its integration suite and required checks successfully. Ordinary PR runs that skipped the suite are not credited as integration. Test skips, deselections, warnings and broader unresolved corpus diagnostics remain in the accepted evidence; this tracker update does not re-adjudicate them.

Only GNB4, GNB2, GPKOW, GMNN and GRIA1 are checked in this fixed window, accepted ordinals 736–740. All other genes remain unchanged. The ClinGen seed, catalogue identities and order, earlier progress journal, 235 dated queue records, 169 previous completion updates, scientific sources and prior histories are preserved.

Project history.

Completion checkpoint 743 — 2026-11-08 14:45:16 UTC

743 complete; 2,133 of 2,876 remain. This checkpoint publishes three previously accepted actual merges after checkpoint 740; it grants no new gene acceptance.

Gene Accepted ordinal PR Actual merge Executed merge-group run Literal raw / stored contexts Review status
GRXCR2 741 #6183 4667b403 42366408865 11 / 12 COMPLETE
GRIA4 742 #6181 1ed9a994 42367054898 55 / 53 COMPLETE
GSX2 743 #6189 ed63914b 42371674797 18 / 18 COMPLETE

All three actual merges are ancestors of checked main 7066962c40d3e93a7c979b254bcc0d6690c0dda9, and their committed reviews match that main revision byte-for-byte. Each retains its genuine COMPLETE status. GRIA4 still has one UNDECIDED judgment and preserves 55 literal records in 53 schema contexts. GRXCR2 preserves 11 incoming records plus one previously accepted NEW annotation in 12 stored contexts. GSX2 retains 18 contexts without a NEW assertion. Campaign acceptance and the stored review status are distinct from whether every biological question has been resolved.

The three linked merge-group runs executed their full integration suites and required checks successfully. Their recorded warnings, skipped tests and unrelated corpus diagnostics remain in the accepted evidence; ordinary PR runs that skipped the suite are not substituted for integration. This checkpoint records ROOT's existing acceptance receipts for GRXCR2 and GRIA4 and its November 8 acceptance of the already merged GSX2 work.

Only GRXCR2, GRIA4 and GSX2 are newly checked in this window. All other catalogue identities and checkboxes, 235 dated queue records, 170 earlier completion updates, the complete prior journal, scientific files and earlier histories remain unchanged. The accompanying instruction change carries forward the approved six-workstream/storage limits, keeper protection, registered-checkout rule and explicit nested-uv runtime safeguards; it creates no additional workstream or environment.

Project history.

Completion checkpoint 747 (2026-11-08 16:06:16 UTC)

747 complete; 2,129 of 2,876 remain. This checkpoint publishes four previously accepted actual merges after checkpoint 743; it grants no new gene acceptance.

Gene Accepted ordinal PR Actual merge Executed merge-group run Literal raw / stored contexts Review status
H1-4 744 #6197 88991cd3 42492099265 52 / 51 DRAFT
GSDME 745 #6187 704ef96a 42492101186 35 / 35 DRAFT
GUCY2D 746 #6195 e276db44 42492424060 49 / 49 DRAFT
GUCA1A 747 #6192 60e9a8d9 42494116477 39 / 39 DRAFT

All four actual merges are ancestors of checked main 9404d53df530b1c13ffb853c7c86a0b80684eba7, and their committed reviews match that main revision byte-for-byte. Each retains its genuine DRAFT status. H1-4 retains three UNDECIDED judgments and preserves 52 literal input records in 51 stored contexts; GUCY2D retains five UNDECIDED judgments in 49 contexts. GSDME and GUCA1A retain 35 and 39 contexts respectively. None adds a NEW annotation. Campaign acceptance records completed review and verified delivery without erasing scientific uncertainty or changing computed review status.

The linked merge-group runs executed their full integration suites and required checks successfully. Their warnings, test skips, deselections and unrelated corpus diagnostics remain in the delivery evidence; ordinary runs that skipped the suite are not substituted for integration. ROOT acceptance is recorded separately in the local immutable clingen-acceptance-20261108-747.json (SHA256 c9bfb1d86febe5faf3f26f42479720491844bd855fef076ba72817ebc0bdd822, records 0–3). The queue identifies that acceptance receipt and the separately hashed local delivery audits; these artifact names are provenance identifiers, not public download links. The PR, merge and run links above provide durable public evidence.

Only H1-4, GSDME, GUCY2D and GUCA1A are newly checked in this fixed window. All other catalogue identities and checkboxes, 235 dated queue records, 171 previous completion updates, the complete prior journal, scientific files, instructions and earlier histories remain unchanged.

Project history.

Completion checkpoint 748 (2026-11-10 04:45:41 UTC)

748 complete; 2,128 of 2,876 remain. This publishes ROOT's prior acceptance of H3-3A and grants no new acceptance.

H3-3A: PR #6217, actual merge dc1892ff, executed merge-group run 42747632016. The merged review remains DRAFT with six UNDECIDED judgments and zero NEW annotations. All 147 literal input records, 146 downloaded TSV rows, 147 stored contexts and three extension atoms are retained.

ROOT acceptance: local immutable h3-root-acceptance-20261110T044541Z.json (SHA256 3aac8742127f2e9dc26c249db1fe9e7d51751618eccd16da2f10ace25cae8474, pointer /records/0). This provenance identifier is not a public download link. Only H3-3A is newly checked; 235 dated queue records, 172 earlier completion updates and the full earlier journal remain unchanged.

Project history.

Completion checkpoint 749 (2026-11-11 18:04:57 UTC)

749 complete; 2,127 of 2,876 remain. This publishes ROOT's prior acceptance of HAAO and grants no new acceptance.

HAAO: PR #6272, actual merge 3f52339d, executed merge-group run 43068188719. The merged review remains DRAFT with three UNDECIDED judgments and zero NEW annotations. The current input has 35 literal records and 35 downloaded TSV rows; all 38 stored contexts are preserved, including three explicitly retired historical contexts.

ROOT acceptance: local immutable HAAO-root-acceptance-749.json (SHA256 5334d4e245407026a7a537484472d952a589a8b4b8187598be4eaecb12b43ffd, pointer /records/0). Delivery proof: local haao-delivery-candidate-v2.json (SHA256 e2d3452432ae8371a6247ae96005059492925e54bb4f140d60dfc4489e81f805). These provenance identifiers are not public download links. Only HAAO is newly checked; 235 dated queue records, 173 earlier completion updates and the full earlier journal remain unchanged.

Project history.

Completion checkpoint 750 (2026-11-12 01:28:39 UTC)

750 complete; 2,126 of 2,876 remain. This publishes ROOT's prior acceptance of HADH and grants no new acceptance.

HADH: PR #6312, actual merge 24b5db4f, executed merge-group run 43130690079. The exact 12 reviewed files and head-specific approval were verified against the actual merge and fresh main. The review remains DRAFT: 41 GOA rows and 41 stored contexts, with 31 ACCEPT, 7 KEEP_AS_NON_CORE, 2 MODIFY and 1 MARK_AS_OVER_ANNOTATED; no retired, NEW or UNDECIDED contexts.

Integration tests executed: 6,156 tests, 386 doctests, 489 agentic checks, 19 JavaScript tests and 12 examples passed. Gene semantic/reference/ontology checks covered HADH, with two advisories; repository-wide gene checks were schema-only. Other repository checks passed with existing warnings, unresolved cases and unreadable-source quotes still explicit. The history-coverage advisory, conditional sequence-cache save and upstream PAINT verification steps were skipped by workflow conditions. Completion does not make these limitations disappear.

ROOT acceptance: local immutable HADH-root-acceptance-750.json (SHA256 3d803c671d890fc62c83e4378f9c4d1905c19e83d1447396956b82e18c90b03e). This identifier is provenance, not a public download link. Only HADH is newly checked; the 235 dated queue records, 174 earlier completion updates and full earlier journal remain unchanged. HACD1, HADHA, HADHB and the bounded HACD2 companion are not given completion credit here.

Project history.